data_2mpx_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mpx _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 35.1 ptt-85 . . . . . 0 C--O 1.236 0.352 0 CA-C-O 121.456 0.646 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 3.4 p -57.28 145.0 8.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.206 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.34 -20.69 47.53 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -83.67 159.5 21.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.861 0.363 . . . . 0.0 110.791 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 39.4 ptt180 -50.72 161.85 0.31 Allowed 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 33' ' ' VAL . . . . . 0.444 HG13 ' N ' ' C' ' 42' ' ' GLY . 9.4 p -128.21 150.13 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.858 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -146.72 91.8 2.07 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 94.1 t -67.63 130.88 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.93 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 36' ' ' ILE . . . . . 0.43 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 5.6 mm -76.17 74.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.508 0.67 . . . . 0.0 109.934 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.72 -119.77 0.5 Allowed Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.73 -17.94 27.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.121 -0.539 . . . . 0.0 109.966 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.21 41.72 3.66 Favored Glycine 0 N--CA 1.465 0.588 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 64.8 m170 -75.4 147.37 40.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 110.694 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.4 ptm180 -134.77 163.18 30.38 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.748 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 42' ' ' GLY . . . . . 0.444 ' N ' HG13 ' C' ' 33' ' ' VAL . . . 157.56 -127.25 1.88 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -178.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 98.6 m -131.89 142.85 49.79 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 120.912 0.386 . . . . 0.0 111.845 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 95.9 t -77.83 132.31 32.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.043 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 45' ' ' ALA . . . . . 0.41 ' CB ' ' O ' ' C' ' 59' ' ' GLY . . . -85.77 -158.72 0.41 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.486 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 81.8 t80 -64.41 143.48 57.87 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 89.9 t -119.64 131.75 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.613 -178.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.0 -176.09 19.45 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 49' ' ' ALA . . . . . 0.52 ' CB ' ' O ' ' C' ' 55' ' ' GLY . . . -70.3 142.92 52.18 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-O 120.937 0.399 . . . . 0.0 110.015 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 69.6 p -138.6 169.58 17.54 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.473 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 97.1 mt -60.86 -38.82 86.88 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.993 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.0 t80 -59.06 -46.14 89.01 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.523 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.18 143.98 29.63 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.1 p -85.14 166.95 16.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.538 179.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 55' ' ' GLY . . . . . 0.52 ' O ' ' CB ' ' C' ' 49' ' ' ALA . . . 94.17 -140.54 15.1 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -134.38 96.04 3.51 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.403 -0.469 . . . . 0.0 110.464 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -113.89 171.12 7.78 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.105 0.479 . . . . 0.0 109.785 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 58' ' ' VAL . . . . . 0.492 ' N ' ' O ' ' C' ' 89' ' ' VAL . 59.9 t -129.77 130.21 66.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.401 -179.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 59' ' ' GLY . . . . . 0.41 ' O ' ' CB ' ' C' ' 45' ' ' ALA . . . -92.11 134.57 12.3 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 178.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 59.5 t -122.19 132.96 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 CA-C-O 120.906 0.384 . . . . 0.0 111.162 -178.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 7.9 mm -81.39 96.22 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.954 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 62' ' ' LEU . . . . . 0.548 HD11 ' H ' ' C' ' 64' ' ' GLU . 0.2 OUTLIER -78.17 114.85 17.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.577 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -66.89 -18.07 65.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.66 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 64' ' ' GLU . . . . . 0.548 ' H ' HD11 ' C' ' 62' ' ' LEU . 79.3 mm-40 -60.55 -32.22 71.3 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.341 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 65' ' ' ALA . . . . . 0.498 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 84.53 46.63 0.02 OUTLIER 'General case' 0 N--CA 1.461 0.09 0 CA-C-O 120.796 0.331 . . . . 0.0 110.772 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 66' ' ' LYS . . . . . 0.538 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.6 ptpt -141.3 110.89 6.44 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.168 0.508 . . . . 0.0 110.238 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 151.31 -143.02 10.02 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 18.3 ptmt -99.4 -171.99 2.18 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 69' ' ' ASN . . . . . 0.455 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 23.0 p-10 -112.07 102.53 10.73 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.603 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -62.41 -15.98 52.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.313 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 71' ' ' GLY . . . . . 0.479 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.42 -45.52 94.27 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.065 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 72' ' ' THR . . . . . 0.479 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 20.1 p -162.18 120.83 2.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.843 0.354 . . . . 0.0 110.667 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 73' ' ' VAL . . . . . 0.487 ' N ' ' O ' ' C' ' 76' ' ' ARG . 12.7 t -138.69 122.06 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.617 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 74' ' ' GLN . . . . . 0.491 ' C ' ' H ' ' C' ' 76' ' ' ARG . 55.6 tt0 44.78 58.44 3.95 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.275 0.56 . . . . 0.0 110.963 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 60.02 3.88 2.96 Favored Glycine 0 CA--C 1.517 0.186 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 76' ' ' ARG . . . . . 0.491 ' H ' ' C ' ' C' ' 74' ' ' GLN . 17.2 tpp180 -124.75 129.59 50.77 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.862 0.363 . . . . 0.0 110.373 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -113.34 136.43 52.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.271 0.558 . . . . 0.0 111.078 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -88.78 -39.29 14.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.862 178.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -173.33 158.97 3.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.486 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -65.46 96.99 0.27 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.843 0.354 . . . . 0.0 111.001 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.3 t -169.2 144.82 3.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.522 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 49.8 p-10 -84.11 172.16 12.21 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.275 0.56 . . . . 0.0 110.82 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -47.68 151.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.165 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 84' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.03 -6.8 56.8 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 85' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -137.74 128.27 26.61 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 124.73 54.32 0.18 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.736 -0.546 . . . . 0.0 111.736 179.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 96.7 mt -80.43 129.36 37.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 178.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 88' ' ' PHE . . . . . 0.569 ' O ' ' CD2' ' C' ' 88' ' ' PHE . 48.6 p90 -74.94 119.35 19.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.087 0.47 . . . . 0.0 111.063 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 89' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' C' ' 58' ' ' VAL . 4.5 m -140.5 162.63 23.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 90' ' ' ARG . . . . . 0.526 ' NH1' ' OE1' ' C' ' 93' ' ' GLN . 0.0 OUTLIER -91.14 163.46 14.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.728 179.732 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' C' C ' 91' ' ' GLN . . . . . . . . . . . . . 55.6 mt-30 -59.31 -42.63 91.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.721 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 67.7 m -63.16 -33.84 76.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.245 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 93' ' ' GLN . . . . . 0.526 ' OE1' ' NH1' ' C' ' 90' ' ' ARG . 72.5 tp60 -64.29 -36.95 85.79 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.655 -178.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 94' ' ' ILE . . . . . . . . . . . . . 24.1 pt -99.44 139.3 21.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.051 0.453 . . . . 0.0 110.453 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 59.5 tt0 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.775 -179.655 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 62.7 ttp180 . . . . . 0 N--CA 1.452 -0.339 0 CA-C-O 120.975 0.417 . . . . 0.0 110.798 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 1.6 p -55.9 140.62 13.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.059 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.7 -9.94 62.4 Favored Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 67.5 m -92.67 163.76 13.65 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.942 0.401 . . . . 0.0 111.045 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 17.7 ptm180 -61.62 159.11 13.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.318 179.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 33' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' C' ' 42' ' ' GLY . 2.6 m -135.7 160.36 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 34' ' ' GLU . . . . . 0.514 ' N ' ' OXT' ' C' ' 95' ' ' GLN . 77.3 mm-40 -133.2 96.02 3.66 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 177.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 84.9 t -61.07 131.2 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.702 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 36' ' ' ILE . . . . . 0.493 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 6.5 mm -76.68 82.76 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-O 121.426 0.632 . . . . 0.0 110.027 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.28 -125.97 0.79 Allowed Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -64.02 -18.47 64.35 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.306 -0.447 . . . . 0.0 110.454 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.12 55.98 0.59 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 40' ' ' HIS . . . . . 0.475 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 61.0 t-80 -95.44 154.9 16.97 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.799 0.333 . . . . 0.0 110.404 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 41' ' ' ARG . . . . . 0.467 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 37.2 ptt-85 -128.52 157.54 40.89 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.337 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 42' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' C' ' 33' ' ' VAL . . . 176.33 -166.37 37.35 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.5 m -111.11 132.09 54.55 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-O 120.903 0.382 . . . . 0.0 110.667 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 44' ' ' VAL . . . . . 0.431 ' N ' ' CG1' ' C' ' 33' ' ' VAL . 1.5 p -72.26 135.21 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.83 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.21 -156.48 0.33 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.801 178.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 46' ' ' TYR . . . . . 0.402 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 91.0 t80 -63.42 140.68 58.9 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.065 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 47' ' ' VAL . . . . . 0.402 ' O ' ' CE2' ' C' ' 46' ' ' TYR . 30.4 m -110.47 153.94 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.063 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.49 -175.3 22.56 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 49' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' C' ' 55' ' ' GLY . . . -67.99 153.78 43.0 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.073 0.463 . . . . 0.0 109.971 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 50' ' ' THR . . . . . 0.467 HG23 ' H ' ' C' ' 53' ' ' ALA . 8.1 t -142.45 171.38 14.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.34 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 51' ' ' LEU . . . . . 0.483 ' N ' ' CD2' ' C' ' 51' ' ' LEU . 3.9 mm? -61.23 -39.27 89.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.471 -179.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 t80 -58.54 -45.72 88.32 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.368 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 53' ' ' ALA . . . . . 0.467 ' H ' HG23 ' C' ' 50' ' ' THR . . . -148.98 146.4 27.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.297 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 54' ' ' THR . . . . . 0.713 ' HG1' ' H ' ' C' ' 55' ' ' GLY . 11.0 t -87.92 171.94 9.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.283 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 55' ' ' GLY . . . . . 0.713 ' H ' ' HG1' ' C' ' 54' ' ' THR . . . 96.14 -156.8 21.38 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 -179.479 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -119.27 106.83 12.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.091 0.472 . . . . 0.0 110.607 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 57' ' ' TRP . . . . . 0.551 ' HE1' ' NE ' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -135.22 170.67 15.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.825 179.466 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' C' C ' 58' ' ' VAL . . . . . . . . . . . . . 57.4 t -131.37 132.36 62.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.56 -0.746 . . . . 0.0 111.343 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.46 132.94 11.37 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 72.9 t -127.35 134.28 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.556 0.693 . . . . 0.0 111.42 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.6 pt -85.06 119.93 34.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.964 178.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 62' ' ' LEU . . . . . 0.525 ' O ' ' CD2' ' C' ' 85' ' ' HIS . 3.8 tp -92.24 122.21 34.5 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.093 -178.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 63' ' ' ASP . . . . . 0.475 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.3 m-20 -67.46 -14.15 62.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.375 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 64' ' ' GLU . . . . . 0.505 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 77.7 mm-40 -62.66 -31.05 71.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.561 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 65' ' ' ALA . . . . . 0.505 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 85.8 42.28 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.142 0 CA-C-O 120.958 0.409 . . . . 0.0 110.556 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 66' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' C' ' 84' ' ' GLY . 18.9 ptmt -140.4 120.16 13.43 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.978 179.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 146.21 -148.25 19.8 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 68' ' ' LYS . . . . . 0.493 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 40.8 tttt -97.4 -166.55 1.4 Allowed 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 69' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' C' ' 69' ' ' ASN . 1.2 m-20 -104.18 95.94 6.31 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.227 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 70' ' ' ASP . . . . . 0.557 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 5.4 t70 -60.48 -23.07 64.2 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.681 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 71' ' ' GLY . . . . . 0.446 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -59.06 -40.28 95.38 Favored Glycine 0 C--O 1.224 -0.482 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.35 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 72' ' ' THR . . . . . 0.446 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 38.1 p -158.5 116.47 2.95 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.807 0.337 . . . . 0.0 110.52 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 73' ' ' VAL . . . . . 0.462 ' O ' ' N ' ' C' ' 76' ' ' ARG . 58.6 t -129.88 126.78 62.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.511 179.705 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 47.58 45.93 17.73 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.21 0.529 . . . . 0.0 110.704 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.64 3.13 39.77 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 76' ' ' ARG . . . . . 0.462 ' N ' ' O ' ' C' ' 73' ' ' VAL . 20.3 tpp85 -124.81 129.79 51.12 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.873 0.368 . . . . 0.0 110.371 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -109.44 138.92 45.08 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.883 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -105.35 -26.97 11.77 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.464 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 79' ' ' PHE . . . . . 0.557 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 31.3 t80 -169.84 142.21 2.39 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.232 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.27 106.3 1.07 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.054 0.454 . . . . 0.0 111.363 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.1 t -169.19 145.07 3.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.299 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -82.26 171.14 14.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.261 0.553 . . . . 0.0 110.686 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -44.81 155.28 0.11 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.292 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 84' ' ' GLY . . . . . 0.526 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 95.45 -3.73 66.22 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 85' ' ' HIS . . . . . 0.572 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.3 OUTLIER -139.58 140.29 37.02 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.339 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.38 60.0 0.32 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 87' ' ' ILE . . . . . 0.411 HD13 HG21 ' C' ' 87' ' ' ILE . 95.9 mt -94.25 130.32 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -75.6 120.47 21.05 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.506 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 89' ' ' VAL . . . . . . . . . . . . . 20.8 m -139.48 162.53 26.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.443 179.278 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 90' ' ' ARG . . . . . 0.551 ' NE ' ' HE1' ' C' ' 57' ' ' TRP . 5.5 mpt_? -93.89 150.71 20.13 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.024 0.44 . . . . 0.0 110.249 -179.256 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 91' ' ' GLN . . . . . 0.609 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 1.3 pm0 -51.57 -39.39 57.78 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.142 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 78.9 p -69.99 -28.33 65.43 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.053 0.454 . . . . 0.0 110.368 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 93' ' ' GLN . . . . . 0.493 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.6 tt0 -70.69 -20.19 62.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.501 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 94' ' ' ILE . . . . . 0.476 ' O ' ' O ' ' C' ' 91' ' ' GLN . 48.1 pt -128.38 163.09 33.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.074 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 95' ' ' GLN . . . . . 0.514 ' OXT' ' N ' ' C' ' 34' ' ' GLU . 59.8 tt0 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.453 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 86.0 mtp180 . . . . . 0 CA--C 1.52 -0.206 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.1 p -52.68 144.4 3.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.257 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.51 -9.71 75.43 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 74.2 m -86.5 165.07 16.55 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.458 . . . . 0.0 111.275 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -58.28 151.14 20.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.881 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 33' ' ' VAL . . . . . 0.429 HG12 ' N ' ' C' ' 42' ' ' GLY . 14.0 p -121.76 150.94 25.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.835 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -147.43 97.3 2.83 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -70.7 132.35 33.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.697 -178.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 36' ' ' ILE . . . . . 0.487 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 5.9 mm -71.95 80.3 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.509 179.674 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.29 -126.86 0.84 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -62.99 -21.12 65.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.355 -0.423 . . . . 0.0 110.77 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 107.87 55.49 0.61 Allowed Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 40' ' ' HIS . . . . . 0.602 ' HE2' ' H ' ' C' ' 63' ' ' ASP . 41.8 t-80 -84.93 140.17 31.3 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 121.158 0.504 . . . . 0.0 111.681 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 41' ' ' ARG . . . . . 0.544 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 11.6 ptm85 -119.73 169.73 9.84 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.285 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 42' ' ' GLY . . . . . 0.429 ' N ' HG12 ' C' ' 33' ' ' VAL . . . 150.48 -131.2 3.48 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -178.259 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 12.3 t -142.67 154.2 44.11 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 111.56 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 m -88.18 138.88 18.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.024 179.058 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.19 -158.79 0.49 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.962 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 75.1 t80 -64.8 142.53 58.4 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.122 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 8.7 p -113.17 131.98 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.688 -178.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.14 -173.81 24.03 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 49' ' ' ALA . . . . . 0.444 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -66.79 145.78 55.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.079 0.466 . . . . 0.0 110.222 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 50' ' ' THR . . . . . 0.453 ' OG1' ' OH ' ' C' ' 78' ' ' TYR . 19.5 m -126.64 159.37 33.81 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.862 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 88.8 mt -60.28 -39.54 87.23 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -59.16 -46.48 88.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 0.0 109.943 179.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 53' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -141.72 141.61 33.29 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 110.149 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 9.9 t -89.17 162.12 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.937 -179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 55' ' ' GLY . . . . . 0.444 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 108.78 -145.95 16.52 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 64.6 mttp -123.68 116.4 23.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.993 0.425 . . . . 0.0 110.359 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -141.55 164.2 30.86 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.326 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 58' ' ' VAL . . . . . . . . . . . . . 75.2 t -122.54 128.51 75.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.755 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.48 141.74 19.88 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 70.8 t -127.09 133.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 120.879 0.371 . . . . 0.0 110.531 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 11.7 mm -82.2 95.01 3.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 62' ' ' LEU . . . . . 0.564 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -74.57 104.86 5.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.132 -178.865 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' C' C ' 63' ' ' ASP . . . . . 0.602 ' H ' ' HE2' ' C' ' 40' ' ' HIS . 54.0 p30 -65.88 -9.88 33.27 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.992 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 64' ' ' GLU . . . . . 0.501 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 75.9 mm-40 -63.21 -32.15 73.47 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.475 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 65' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 91.08 39.44 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.042 0.449 . . . . 0.0 110.555 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 66' ' ' LYS . . . . . 0.543 ' N ' ' O ' ' C' ' 84' ' ' GLY . 23.1 pttp -140.75 140.87 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.18 178.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 121.89 -150.15 17.07 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 9.4 mmtt -95.81 -171.51 2.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.39 0.614 . . . . 0.0 111.149 -179.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 69' ' ' ASN . . . . . 0.541 ' ND2' ' O ' ' C' ' 72' ' ' THR . 46.9 p-10 -106.09 102.01 11.46 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.543 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 70' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 7.3 t0 -62.06 -23.73 66.66 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.461 -0.791 . . . . 0.0 108.969 179.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 71' ' ' GLY . . . . . 0.43 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.07 -41.83 94.76 Favored Glycine 0 C--O 1.226 -0.38 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 72' ' ' THR . . . . . 0.541 ' O ' ' ND2' ' C' ' 69' ' ' ASN . 32.7 p -158.55 118.31 3.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.922 0.392 . . . . 0.0 110.838 179.289 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 73' ' ' VAL . . . . . 0.488 ' N ' ' O ' ' C' ' 76' ' ' ARG . 39.6 t -126.43 122.96 62.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.685 179.225 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 68.7 tp60 45.05 49.99 9.36 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.074 0.464 . . . . 0.0 111.544 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.56 1.79 31.8 Favored Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 76' ' ' ARG . . . . . 0.488 ' O ' ' N ' ' C' ' 73' ' ' VAL . 76.3 ttt180 -124.78 126.09 45.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.374 -0.413 . . . . 0.0 110.325 -179.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -107.34 137.92 44.5 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-O 121.363 0.601 . . . . 0.0 111.19 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 78' ' ' TYR . . . . . 0.453 ' OH ' ' OG1' ' C' ' 50' ' ' THR . 1.7 m-85 -98.57 -32.94 11.18 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.371 178.343 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 79' ' ' PHE . . . . . 0.539 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 86.0 t80 -169.55 151.73 4.48 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.373 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 44.0 p -64.9 108.87 1.9 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.745 0.307 . . . . 0.0 111.349 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -172.63 148.32 1.92 Allowed 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.329 179.032 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -86.0 169.87 12.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.153 0.501 . . . . 0.0 111.179 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -50.57 145.05 7.06 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.002 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 84' ' ' GLY . . . . . 0.543 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 104.05 -4.34 45.2 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 85' ' ' HIS . . . . . 0.564 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 4.0 m-70 -140.97 136.2 31.93 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.145 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.95 49.79 0.32 Allowed Glycine 0 N--CA 1.47 0.907 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.331 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 97.4 mt -83.78 135.18 25.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -84.16 119.11 24.62 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.528 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 89' ' ' VAL . . . . . . . . . . . . . 16.2 m -136.51 162.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 178.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 90' ' ' ARG . . . . . 0.514 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -90.78 155.04 19.09 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.599 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' C' C ' 91' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' C' ' 94' ' ' ILE . 29.2 pt20 -53.22 -38.97 63.4 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.733 -179.545 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 66.6 m -63.18 -37.19 86.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.223 0.535 . . . . 0.0 110.172 178.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 93' ' ' GLN . . . . . 0.487 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.9 tt0 -65.02 -30.05 71.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.109 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 94' ' ' ILE . . . . . 0.434 ' O ' ' O ' ' C' ' 91' ' ' GLN . 17.1 pt -108.93 145.43 15.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.975 0.417 . . . . 0.0 110.461 179.637 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.745 179.98 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 78.0 mtp85 . . . . . 0 N--CA 1.465 0.287 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 6.1 m -50.66 143.21 2.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 91.92 -8.27 78.27 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 45.7 t -89.05 163.73 15.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.982 0.42 . . . . 0.0 111.426 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -59.23 149.15 29.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.156 179.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 2.5 m -126.81 159.78 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.013 0.435 . . . . 0.0 110.035 -179.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -140.52 93.64 2.64 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 35' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' C' ' 37' ' ' GLY . 84.2 t -56.54 126.54 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 36' ' ' ILE . . . . . 0.495 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 4.6 mm -67.18 77.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 CA-C-O 121.582 0.706 . . . . 0.0 109.333 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' C' ' 35' ' ' VAL . . . -163.17 -126.61 0.83 Allowed Glycine 0 CA--C 1.519 0.311 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -64.48 -17.31 63.74 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.274 179.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.11 58.07 0.89 Allowed Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 40' ' ' HIS . . . . . 0.669 ' HE2' ' H ' ' C' ' 63' ' ' ASP . 75.7 t60 -89.82 138.95 31.05 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 111.124 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 41' ' ' ARG . . . . . 0.517 ' O ' ' CD2' ' C' ' 40' ' ' HIS . 87.6 mtm-85 -89.87 162.71 15.33 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.675 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 171.64 -172.4 44.58 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -179.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 85.4 m -124.71 131.95 53.42 Favored 'General case' 0 C--O 1.24 0.569 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -72.58 121.14 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.07 -157.5 0.12 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.934 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -63.61 142.0 58.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.569 -179.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 7.2 p -117.59 135.93 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.176 -179.055 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.99 -177.73 19.5 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 49' ' ' ALA . . . . . 0.488 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -70.45 141.44 52.06 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.974 0.416 . . . . 0.0 110.245 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 50' ' ' THR . . . . . 0.471 ' CB ' ' HH ' ' C' ' 78' ' ' TYR . 47.7 p -139.43 168.58 19.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.293 179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 83.3 mt -60.78 -39.35 88.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.974 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 82.8 t80 -59.42 -46.28 89.17 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.215 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -145.94 142.38 28.66 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.012 0.434 . . . . 0.0 110.526 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 60.3 p -85.44 169.12 13.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.914 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 55' ' ' GLY . . . . . 0.488 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 89.66 -146.06 18.67 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -125.77 101.62 6.94 Favored 'General case' 0 N--CA 1.464 0.262 0 O-C-N 122.603 -0.351 . . . . 0.0 110.237 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -121.32 166.45 14.04 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 58' ' ' VAL . . . . . . . . . . . . . 51.2 t -127.03 129.41 71.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.298 -179.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.61 129.72 9.9 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.6 t -123.81 131.63 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 121.244 0.545 . . . . 0.0 110.805 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 10.1 pt -82.19 126.08 39.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.907 179.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 62' ' ' LEU . . . . . 0.6 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 3.5 tp -102.33 111.48 23.8 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 63' ' ' ASP . . . . . 0.669 ' H ' ' HE2' ' C' ' 40' ' ' HIS . 42.8 t0 -59.71 -11.1 4.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.127 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 64' ' ' GLU . . . . . 0.499 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 80.6 mm-40 -62.01 -34.01 75.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.286 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 65' ' ' ALA . . . . . 0.499 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 85.67 46.28 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.858 0.361 . . . . 0.0 110.546 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 66' ' ' LYS . . . . . 0.546 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.7 ptpt -149.79 104.09 3.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.355 0.597 . . . . 0.0 110.105 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.43 -143.19 8.64 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -179.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -96.62 -167.48 1.57 Allowed 'General case' 0 C--O 1.241 0.624 0 CA-C-O 121.104 0.478 . . . . 0.0 109.933 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -117.48 98.72 6.55 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.412 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 76.2 m-20 -62.7 -14.96 50.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.76 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 71' ' ' GLY . . . . . 0.486 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.69 -42.75 96.45 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.069 -1.063 . . . . 0.0 110.63 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 72' ' ' THR . . . . . 0.486 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 18.9 p -163.22 117.75 1.66 Allowed 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.978 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 73' ' ' VAL . . . . . 0.427 ' O ' ' N ' ' C' ' 76' ' ' ARG . 26.1 t -134.72 122.75 39.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.583 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 51.11 36.37 15.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.743 0.306 . . . . 0.0 111.309 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.58 -2.66 66.64 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 76' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' C' ' 73' ' ' VAL . 16.8 tpp180 -116.11 120.68 39.82 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.351 -0.425 . . . . 0.0 109.937 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -103.14 126.26 50.23 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.375 0.607 . . . . 0.0 110.633 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 78' ' ' TYR . . . . . 0.471 ' HH ' ' CB ' ' C' ' 50' ' ' THR . 83.3 m-85 -79.89 -37.61 34.4 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.861 178.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 56.8 t80 -171.04 151.74 3.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.392 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.5 p -64.92 98.48 0.28 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.955 0.407 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 6.1 t -167.56 146.86 4.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -81.72 170.67 15.48 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.264 0.555 . . . . 0.0 110.983 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -49.57 155.33 0.8 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.174 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 84' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.8 -7.22 62.92 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 85' ' ' HIS . . . . . 0.6 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 18.5 m-70 -138.39 130.49 28.5 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 123.88 59.49 0.19 Allowed Glycine 0 C--N 1.341 0.856 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.236 179.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 97.9 mt -90.62 125.5 43.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 88' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' C' ' 88' ' ' PHE . 49.4 p90 -70.79 120.34 16.24 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 120.973 0.416 . . . . 0.0 110.587 -179.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 89' ' ' VAL . . . . . . . . . . . . . 20.5 m -139.01 160.58 29.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 90' ' ' ARG . . . . . 0.43 ' H ' ' HD3' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -92.91 155.15 17.77 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -179.701 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 91' ' ' GLN . . . . . 0.525 ' NE2' ' OG ' ' C' ' 92' ' ' SER . 2.9 pp0? -52.74 -39.83 62.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.081 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 92' ' ' SER . . . . . 0.525 ' OG ' ' NE2' ' C' ' 91' ' ' GLN . 57.7 m -64.71 -37.14 86.59 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.996 0.427 . . . . 0.0 110.403 178.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 93' ' ' GLN . . . . . 0.495 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.2 tt0 -64.75 -19.23 65.68 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.912 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 94' ' ' ILE . . . . . 0.471 ' O ' ' O ' ' C' ' 91' ' ' GLN . 47.1 pt -123.46 153.79 29.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.668 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 95' ' ' GLN . . . . . 0.447 ' OXT' ' O ' ' C' ' 94' ' ' ILE . 69.2 tp60 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.06 -0.971 . . . . 0.0 110.907 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 . . . . . 0 C--O 1.233 0.23 0 CA-C-O 120.976 0.417 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 p -62.12 138.07 23.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.014 0.435 . . . . 0.0 110.115 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.27 63.68 Favored Glycine 0 CA--C 1.533 1.202 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 70.9 m -89.76 163.1 15.21 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.7 0.286 . . . . 0.0 111.16 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -62.18 150.41 38.88 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.087 0.47 . . . . 0.0 111.19 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m -131.14 155.51 41.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.07 100.44 4.28 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 88.0 t -64.94 130.1 29.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.876 -178.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 36' ' ' ILE . . . . . 0.453 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 8.4 mm -82.97 75.43 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 179.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.72 -121.37 0.57 Allowed Glycine 0 CA--C 1.522 0.478 0 N-CA-C 110.696 -0.961 . . . . 0.0 110.696 -178.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -58.17 -29.4 65.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.041 -0.58 . . . . 0.0 109.951 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.68 59.78 0.51 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 40' ' ' HIS . . . . . 0.419 ' CE1' ' CG ' ' C' ' 64' ' ' GLU . 94.4 m-70 -103.5 150.55 23.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.038 0.447 . . . . 0.0 110.635 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 53.1 ptt85 -137.76 154.78 49.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.744 -179.155 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.94 -122.7 0.94 Allowed Glycine 0 C--O 1.226 -0.351 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 5.3 t -141.02 154.62 46.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.843 179.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 1.2 p -91.72 141.57 14.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.997 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.85 -154.31 0.29 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.549 179.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -62.69 141.95 58.32 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.115 0.483 . . . . 0.0 110.645 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 72.9 t -112.59 129.84 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.688 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 127.37 -172.97 18.66 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 49' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' C' ' 55' ' ' GLY . . . -68.16 146.98 52.91 Favored 'General case' 0 C--N 1.334 -0.071 0 CA-C-O 120.914 0.387 . . . . 0.0 110.019 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 50' ' ' THR . . . . . 0.412 ' O ' ' O ' ' C' ' 53' ' ' ALA . 69.7 p -133.26 167.12 20.95 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.121 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.84 -40.78 89.68 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -57.87 -46.6 84.62 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.359 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 53' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -143.76 144.4 31.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.819 0.342 . . . . 0.0 110.285 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 10.0 t -90.12 165.29 14.07 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.385 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 55' ' ' GLY . . . . . 0.5 ' O ' ' CB ' ' C' ' 49' ' ' ALA . . . 101.22 -152.81 18.96 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 60.6 mtpt -119.94 112.07 18.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.551 -179.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -139.12 171.51 14.19 Favored 'General case' 0 CA--C 1.517 -0.296 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 58' ' ' VAL . . . . . 0.405 ' N ' ' O ' ' C' ' 89' ' ' VAL . 50.4 t -131.3 133.16 62.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.637 -178.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -91.4 139.16 14.64 Favored Glycine 0 CA--C 1.532 1.134 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.69 136.85 59.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-O 121.085 0.469 . . . . 0.0 111.287 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 41.5 mt -88.45 99.87 9.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.1 118.78 20.69 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -67.53 -13.05 61.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.239 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 64' ' ' GLU . . . . . 0.501 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 79.3 mm-40 -62.28 -36.16 81.23 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.42 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 65' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 85.79 44.05 0.01 OUTLIER 'General case' 0 C--N 1.342 0.269 0 CA-C-O 120.911 0.386 . . . . 0.0 110.748 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 66' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' C' ' 84' ' ' GLY . 14.4 ptpt -139.58 119.12 13.04 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.771 178.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 144.73 -146.0 15.97 Favored Glycine 0 CA--C 1.518 0.232 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 68' ' ' LYS . . . . . 0.447 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 36.6 tttt -98.01 -168.75 1.71 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.992 0.425 . . . . 0.0 109.973 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 69' ' ' ASN . . . . . 0.447 ' H ' ' HG2' ' C' ' 68' ' ' LYS . 10.9 p30 -112.65 95.74 5.59 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.157 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 70' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' C' ' 70' ' ' ASP . 3.9 p-10 -65.26 -10.21 30.29 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.469 -0.493 . . . . 0.0 110.245 178.57 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 71' ' ' GLY . . . . . 0.481 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -60.34 -41.78 98.58 Favored Glycine 0 C--O 1.224 -0.489 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 72' ' ' THR . . . . . 0.481 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 20.6 p -162.36 109.7 1.32 Allowed 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.879 0.371 . . . . 0.0 110.662 179.621 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 73' ' ' VAL . . . . . 0.43 ' O ' ' N ' ' C' ' 76' ' ' ARG . 43.7 t -125.94 122.36 61.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.3 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 51.69 35.74 15.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.124 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.88 -1.67 72.71 Favored Glycine 0 CA--C 1.52 0.399 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 76' ' ' ARG . . . . . 0.43 ' N ' ' O ' ' C' ' 73' ' ' VAL . 60.2 ttm-85 -116.01 125.51 52.57 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.096 -0.552 . . . . 0.0 109.768 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.7 pttp -112.29 137.47 50.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.658 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -96.52 -36.11 10.88 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -164.68 145.76 7.92 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.299 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 30.6 p -64.29 104.45 0.76 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.922 0.391 . . . . 0.0 111.306 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 10.7 t -171.3 144.95 2.09 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.527 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -79.93 169.19 18.24 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.342 0.591 . . . . 0.0 111.143 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -45.67 153.71 0.25 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.864 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 84' ' ' GLY . . . . . 0.535 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 99.03 -5.24 59.32 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 85' ' ' HIS . . . . . 0.543 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -138.27 143.36 40.0 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.36 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.09 58.19 0.36 Allowed Glycine 0 C--N 1.337 0.615 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -88.96 134.55 28.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -82.64 119.71 24.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.087 0.47 . . . . 0.0 110.413 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 89' ' ' VAL . . . . . 0.405 ' O ' ' N ' ' C' ' 58' ' ' VAL . 20.5 m -139.46 165.31 23.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 90' ' ' ARG . . . . . 0.408 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -97.36 159.25 15.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.839 0.352 . . . . 0.0 110.436 -179.688 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' C' C ' 91' ' ' GLN . . . . . 0.49 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.7 pt20 -55.9 -40.7 73.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.929 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 88.0 p -70.73 -28.37 64.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.98 0.419 . . . . 0.0 110.4 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 93' ' ' GLN . . . . . 0.453 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 73.2 tp60 -66.9 -29.0 68.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.576 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 94' ' ' ILE . . . . . 0.49 ' O ' ' O ' ' C' ' 91' ' ' GLN . 49.4 pt -125.98 164.15 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.245 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 89.2 mt-30 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.399 179.755 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 85.9 mtp180 . . . . . 0 C--O 1.237 0.426 0 CA-C-O 121.361 0.6 . . . . 0.0 110.335 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.22 146.45 13.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.354 179.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.75 -17.74 57.88 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.26 -0.736 . . . . 0.0 111.26 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 85.0 p -78.28 165.13 24.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.008 0.432 . . . . 0.0 111.553 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -54.48 155.56 3.91 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.65 149.52 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.032 0.444 . . . . 0.0 110.804 -179.386 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -151.45 94.47 2.02 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.388 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 85.5 t -70.36 131.23 34.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.581 -179.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 88.3 mt -72.91 74.06 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-O 121.311 0.577 . . . . 0.0 109.671 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.24 -121.9 0.59 Allowed Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -59.13 -29.93 67.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.596 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.18 46.65 0.92 Allowed Glycine 0 N--CA 1.466 0.691 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -71.72 136.22 47.11 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.877 0.37 . . . . 0.0 110.409 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -114.51 175.91 5.28 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.196 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 134.43 -137.95 9.68 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -179.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 99.0 m -134.25 142.34 47.3 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 120.978 0.418 . . . . 0.0 111.47 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 16.0 m -75.29 144.89 11.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.612 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -91.3 -157.2 0.48 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.334 -179.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -62.69 140.01 58.69 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.306 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 70.1 t -110.77 129.61 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.717 -178.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 126.47 -171.16 18.21 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 49' ' ' ALA . . . . . 0.452 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -68.6 147.11 52.39 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.062 0.458 . . . . 0.0 109.928 179.278 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 50' ' ' THR . . . . . 0.434 ' O ' ' O ' ' C' ' 53' ' ' ALA . 82.3 p -132.02 165.17 24.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.232 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.5 tp -60.27 -40.95 92.2 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -58.28 -46.18 86.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.451 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 53' ' ' ALA . . . . . 0.434 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -144.81 147.38 32.81 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.853 0.359 . . . . 0.0 110.447 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -88.38 173.16 8.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 55' ' ' GLY . . . . . 0.452 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 97.01 -151.2 19.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 16.5 ptmt -128.28 102.93 6.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.137 0.494 . . . . 0.0 110.064 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -131.68 161.79 31.94 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 58' ' ' VAL . . . . . 0.412 ' N ' ' O ' ' C' ' 89' ' ' VAL . 57.4 t -121.36 128.68 75.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.904 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.8 134.52 12.51 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 85.1 t -126.7 130.38 71.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.431 0 O-C-N 122.507 -0.408 . . . . 0.0 111.214 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 4.8 pt -80.23 96.13 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.357 -0.537 . . . . 0.0 110.469 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 62' ' ' LEU . . . . . 0.629 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -73.14 118.06 15.63 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.862 179.907 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.5 p-10 -65.53 -9.22 24.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.51 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 64' ' ' GLU . . . . . 0.492 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 80.9 mm-40 -62.12 -33.64 74.85 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.212 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 65' ' ' ALA . . . . . 0.492 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 85.83 46.47 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.679 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 66' ' ' LYS . . . . . 0.56 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.2 ptmt -147.22 114.5 6.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.296 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 147.12 -142.74 10.57 Favored Glycine 0 CA--C 1.516 0.149 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 16.6 mmtt -97.18 -172.69 2.49 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 110.275 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 69' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.7 p-10 -114.07 98.22 6.84 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.979 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -60.17 -17.28 39.77 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.104 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 71' ' ' GLY . . . . . 0.478 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.59 -41.85 95.79 Favored Glycine 0 C--O 1.225 -0.44 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 72' ' ' THR . . . . . 0.522 ' O ' ' ND2' ' C' ' 69' ' ' ASN . 21.4 p -162.21 111.74 1.49 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.761 0.315 . . . . 0.0 110.591 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 73' ' ' VAL . . . . . 0.476 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.3 t -126.32 124.76 66.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.305 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 53.8 tt0 46.24 47.87 13.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.38 0.61 . . . . 0.0 111.029 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.69 3.61 42.55 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.174 -1.17 . . . . 0.0 110.174 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 76' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' C' ' 73' ' ' VAL . 29.2 tpt180 -125.23 125.93 44.37 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.971 0.415 . . . . 0.0 110.416 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -106.94 138.2 43.57 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.516 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -102.84 -29.98 11.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -170.54 147.41 2.91 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.349 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 80' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' C' ' 80' ' ' THR . 9.7 p -63.93 97.06 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.979 0.419 . . . . 0.0 110.955 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 2.2 t -165.02 145.19 7.14 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.312 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -83.14 171.42 13.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.104 0.478 . . . . 0.0 110.695 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -50.18 151.88 1.91 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.341 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 84' ' ' GLY . . . . . 0.56 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 98.91 -6.16 60.05 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 -179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 85' ' ' HIS . . . . . 0.629 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 19.3 m-70 -136.5 131.34 33.83 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.14 59.42 0.17 Allowed Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.4 mm -86.6 132.79 31.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -82.83 118.5 23.46 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 89' ' ' VAL . . . . . 0.412 ' O ' ' N ' ' C' ' 58' ' ' VAL . 17.8 m -139.62 159.52 27.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 90' ' ' ARG . . . . . 0.514 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.1 mpt_? -82.5 154.22 25.19 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.251 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 91' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' C' ' 94' ' ' ILE . 16.0 pt20 -54.3 -39.71 67.24 Favored 'General case' 0 C--N 1.33 -0.255 0 O-C-N 123.299 0.374 . . . . 0.0 111.106 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 74.2 m -63.22 -37.34 86.86 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.983 0.421 . . . . 0.0 110.299 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 73.6 tp60 -63.86 -34.79 78.73 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.029 -178.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 94' ' ' ILE . . . . . 0.414 ' O ' ' O ' ' C' ' 91' ' ' GLN . 15.9 pt -100.92 140.14 20.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.655 -179.65 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 . . . . . 0 C--O 1.235 0.295 0 CA-C-O 121.376 0.608 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 71.6 t -66.19 135.83 27.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.439 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.21 -18.83 47.81 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.0 t -73.1 154.04 40.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 117.044 0.422 . . . . 0.0 110.528 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 48.0 ptt85 -46.54 161.62 0.06 Allowed 'General case' 0 N--CA 1.461 0.114 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 11.3 p -128.99 151.56 35.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.72 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -149.81 95.42 2.31 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 87.1 t -72.11 131.3 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.403 -179.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 90.2 mt -75.12 76.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-O 121.28 0.562 . . . . 0.0 109.543 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.14 -122.5 0.63 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -59.35 -25.7 64.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.212 -0.494 . . . . 0.0 109.966 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.8 42.77 1.29 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -73.79 145.74 44.8 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.275 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 52.6 ptt85 -141.75 165.1 28.4 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.963 0.411 . . . . 0.0 110.564 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 155.73 -109.39 0.4 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 43' ' ' THR . . . . . 0.478 ' HG1' ' N ' ' C' ' 44' ' ' VAL . 6.8 t -145.4 154.27 42.1 Favored 'General case' 0 C--O 1.243 0.726 0 CA-C-O 120.828 0.347 . . . . 0.0 111.257 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 44' ' ' VAL . . . . . 0.478 ' N ' ' HG1' ' C' ' 43' ' ' THR . 92.8 t -90.93 122.44 42.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.196 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.21 -159.12 0.2 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.953 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -64.35 145.05 56.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.346 0.593 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 47' ' ' VAL . . . . . 0.632 ' CG2' HE21 ' C' ' 91' ' ' GLN . 9.3 p -124.17 141.2 45.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.485 -178.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 120.66 -171.01 14.57 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 49' ' ' ALA . . . . . 0.451 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -68.01 141.89 56.09 Favored 'General case' 0 C--O 1.23 0.066 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 71.1 p -134.81 164.63 27.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.235 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.6 tp -59.16 -39.27 81.95 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.51 -45.66 84.68 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.871 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -149.27 145.69 27.2 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 110.865 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 63.6 p -83.13 168.04 17.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.682 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 55' ' ' GLY . . . . . 0.451 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 98.65 -143.4 16.62 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 40.5 pttt -136.59 106.79 6.37 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.47 0.652 . . . . 0.0 110.624 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 85.5 m95 -130.73 168.26 17.48 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.808 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 58' ' ' VAL . . . . . 0.461 ' N ' ' O ' ' C' ' 89' ' ' VAL . 64.6 t -125.57 130.61 72.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.574 -178.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -89.82 129.09 9.53 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 66.9 t -122.47 132.56 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.135 0.493 . . . . 0.0 110.921 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 45.7 mt -85.22 104.16 12.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.361 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 62' ' ' LEU . . . . . 0.442 ' O ' ' CD2' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -84.83 115.67 22.87 Favored 'General case' 0 C--O 1.232 0.174 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.923 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -67.08 -9.08 35.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.289 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 64' ' ' GLU . . . . . 0.503 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.76 -37.54 87.04 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.296 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 65' ' ' ALA . . . . . 0.503 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 86.59 44.34 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 110.672 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 66' ' ' LYS . . . . . 0.568 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.4 ptmt -146.68 106.95 4.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.076 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.96 -140.57 7.36 Favored Glycine 0 CA--C 1.52 0.352 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 68' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' C' ' 85' ' ' HIS . 7.9 mmtm -95.88 -174.74 3.21 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.277 0.56 . . . . 0.0 110.447 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -112.02 96.72 6.21 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 114.688 -1.142 . . . . 0.0 110.68 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -60.78 -15.05 25.55 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.986 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 71' ' ' GLY . . . . . 0.486 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.4 -45.09 94.81 Favored Glycine 0 N--CA 1.449 -0.5 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 72' ' ' THR . . . . . 0.486 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 21.2 p -163.25 115.19 1.49 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.012 0.435 . . . . 0.0 110.711 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 73' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' C' ' 76' ' ' ARG . 38.8 t -129.53 123.73 58.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.355 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 74' ' ' GLN . . . . . 0.452 ' C ' ' H ' ' C' ' 76' ' ' ARG . 56.4 tt0 42.86 56.61 3.92 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.214 0.531 . . . . 0.0 111.336 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.3 4.76 6.85 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 76' ' ' ARG . . . . . 0.526 ' N ' ' O ' ' C' ' 73' ' ' VAL . 26.0 tpt180 -125.41 127.44 46.56 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.248 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 26.7 pttm -112.56 137.97 50.02 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.213 0.53 . . . . 0.0 111.158 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -93.13 -37.18 12.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.814 178.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 79' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' C' ' 80' ' ' THR . 50.5 t80 -172.6 153.39 2.8 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.323 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 80' ' ' THR . . . . . 0.45 ' N ' ' CD1' ' C' ' 79' ' ' PHE . 28.7 p -64.58 95.57 0.15 Allowed 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.48 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 81' ' ' CYS . . . . . 0.456 ' SG ' ' CG ' ' C' ' 85' ' ' HIS . 9.9 t -163.43 142.26 8.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.561 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -79.14 168.22 19.92 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.334 0.588 . . . . 0.0 110.819 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -46.36 150.47 0.63 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.879 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 84' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 105.06 -8.54 45.57 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 85' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -136.06 136.04 39.89 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.8 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.75 59.61 0.2 Allowed Glycine 0 C--N 1.337 0.596 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.0 mm -85.74 133.0 30.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -82.28 119.06 23.63 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.156 0.503 . . . . 0.0 110.064 -179.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 89' ' ' VAL . . . . . 0.461 ' O ' ' N ' ' C' ' 58' ' ' VAL . 5.0 m -139.73 164.86 23.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.104 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 90' ' ' ARG . . . . . 0.503 ' H ' ' HD3' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -97.12 166.71 11.45 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.939 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' C' C ' 91' ' ' GLN . . . . . 0.632 HE21 ' CG2' ' C' ' 47' ' ' VAL . 26.1 mp0 -59.61 -42.88 93.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.764 0.316 . . . . 0.0 110.735 -178.653 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 64.2 m -62.79 -36.03 81.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.379 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 16.8 tt0 -63.96 -35.93 82.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.444 -178.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 94' ' ' ILE . . . . . 0.403 HD13 HG22 ' C' ' 94' ' ' ILE . 35.4 pt -101.27 144.41 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.881 0.372 . . . . 0.0 110.59 179.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.946 -1.026 . . . . 0.0 111.113 -179.61 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 80.1 mtp85 . . . . . 0 N--CA 1.464 0.257 0 CA-C-O 121.239 0.542 . . . . 0.0 110.354 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -57.01 141.92 13.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.217 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.75 -18.04 55.58 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 83.8 p -81.54 163.13 22.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.964 0.411 . . . . 0.0 110.923 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -50.66 153.36 1.7 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.935 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 33' ' ' VAL . . . . . 0.422 HG12 ' N ' ' C' ' 42' ' ' GLY . 12.3 p -125.39 149.77 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.939 0.399 . . . . 0.0 111.047 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -150.43 92.79 1.9 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 80.2 t -67.47 131.28 33.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.06 -179.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 42.5 mm -75.62 74.57 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.293 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -120.47 0.54 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.819 -0.913 . . . . 0.0 110.819 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.61 -27.19 66.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.021 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.14 44.98 1.04 Allowed Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -75.34 141.73 43.29 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 40.0 ptt180 -129.3 165.78 20.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.174 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 42' ' ' GLY . . . . . 0.422 ' N ' HG12 ' C' ' 33' ' ' VAL . . . 151.37 -130.28 3.11 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.129 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.4 m -131.91 140.98 49.22 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.119 0.485 . . . . 0.0 111.56 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 97.2 t -75.78 133.16 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.839 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 45' ' ' ALA . . . . . 0.428 ' CB ' ' O ' ' C' ' 59' ' ' GLY . . . -85.59 -159.6 0.46 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.967 0.413 . . . . 0.0 110.519 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 46' ' ' TYR . . . . . 0.426 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 84.6 t80 -65.34 144.89 56.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.171 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 47' ' ' VAL . . . . . 0.426 ' O ' ' CE2' ' C' ' 46' ' ' TYR . 19.2 m -118.42 154.15 20.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.969 -179.253 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.93 179.4 20.88 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 49' ' ' ALA . . . . . 0.479 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -68.53 149.36 49.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.089 0.471 . . . . 0.0 110.366 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 50' ' ' THR . . . . . 0.406 HG22 ' H ' ' C' ' 53' ' ' ALA . 7.6 t -149.22 174.98 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.698 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 86.3 mt -60.96 -39.45 89.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.603 -179.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 52' ' ' PHE . . . . . 0.495 ' CD2' ' CZ ' ' C' ' 88' ' ' PHE . 91.9 t80 -59.22 -46.59 88.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.612 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 53' ' ' ALA . . . . . 0.406 ' H ' HG22 ' C' ' 50' ' ' THR . . . -149.28 140.16 22.82 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.789 0.328 . . . . 0.0 110.412 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 72.7 p -83.74 168.91 15.78 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.405 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 55' ' ' GLY . . . . . 0.479 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 89.14 -153.51 23.63 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 56.6 mtmt -110.88 108.78 18.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.881 0.372 . . . . 0.0 110.478 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 83.8 m95 -134.0 161.38 34.97 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.021 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 58' ' ' VAL . . . . . 0.475 ' N ' ' O ' ' C' ' 89' ' ' VAL . 87.6 t -128.82 130.57 68.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.311 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 59' ' ' GLY . . . . . 0.428 ' O ' ' CB ' ' C' ' 45' ' ' ALA . . . -90.43 136.15 13.27 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 92.3 t -130.42 134.47 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.269 0.557 . . . . 0.0 111.334 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 6.3 pt -85.22 114.59 25.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.603 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 62' ' ' LEU . . . . . 0.614 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.7 OUTLIER -92.23 125.56 36.95 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.936 0.398 . . . . 0.0 110.666 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -67.53 -11.56 58.29 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.618 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 64' ' ' GLU . . . . . 0.49 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 79.8 mm-40 -61.16 -32.7 72.42 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.436 179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 65' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 86.9 35.85 0.02 OUTLIER 'General case' 0 C--N 1.34 0.185 0 O-C-N 123.504 0.503 . . . . 0.0 110.658 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 66' ' ' LYS . . . . . 0.537 ' N ' ' O ' ' C' ' 84' ' ' GLY . 65.0 pttt -134.98 136.46 42.21 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.12 -146.54 17.15 Favored Glycine 0 N--CA 1.461 0.313 0 N-CA-C 110.689 -0.965 . . . . 0.0 110.689 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 4.3 mmtm -97.5 -170.16 1.96 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.186 0.517 . . . . 0.0 110.351 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 69' ' ' ASN . . . . . 0.462 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.2 p-10 -114.46 99.47 7.58 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.749 -179.501 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -60.31 -16.99 39.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 71' ' ' GLY . . . . . 0.472 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.7 -43.14 96.52 Favored Glycine 0 C--O 1.226 -0.359 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 72' ' ' THR . . . . . 0.472 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 18.8 p -161.9 112.62 1.62 Allowed 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.713 0.292 . . . . 0.0 110.765 179.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 73' ' ' VAL . . . . . 0.509 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.6 t -127.53 123.26 61.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.233 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 74' ' ' GLN . . . . . 0.436 ' C ' ' H ' ' C' ' 76' ' ' ARG . 71.2 tp60 43.5 57.01 4.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.365 0.602 . . . . 0.0 110.601 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 61.78 4.81 6.08 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 76' ' ' ARG . . . . . 0.509 ' N ' ' O ' ' C' ' 73' ' ' VAL . 46.7 tpt85 -125.16 126.8 45.83 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 110.172 -0.306 . . . . 0.0 110.172 -179.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 77' ' ' LYS . . . . . 0.491 ' O ' ' NH1' ' C' ' 76' ' ' ARG . 63.2 pttt -108.93 137.98 46.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.879 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 51.8 m-85 -99.91 -31.24 11.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.8 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -171.58 151.0 2.85 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.388 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.0 p -64.19 98.16 0.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.942 0.401 . . . . 0.0 110.822 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 81' ' ' CYS . . . . . 0.412 ' O ' ' N ' ' C' ' 71' ' ' GLY . 4.1 t -168.91 142.92 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.432 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -84.07 170.56 13.75 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.525 0.679 . . . . 0.0 110.591 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -44.82 152.64 0.22 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.989 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 84' ' ' GLY . . . . . 0.537 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.18 -7.76 56.95 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 85' ' ' HIS . . . . . 0.614 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 7.0 m-70 -140.02 134.23 31.13 Favored 'General case' 0 C--O 1.24 0.564 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.7 58.47 0.16 Allowed Glycine 0 C--N 1.337 0.633 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -83.27 131.23 34.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 88' ' ' PHE . . . . . 0.495 ' CZ ' ' CD2' ' C' ' 52' ' ' PHE . 97.4 m-85 -79.42 118.99 21.81 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.79 -178.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 89' ' ' VAL . . . . . 0.475 ' O ' ' N ' ' C' ' 58' ' ' VAL . 12.1 m -141.52 163.47 20.34 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.262 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 90' ' ' ARG . . . . . 0.501 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -90.29 154.33 19.79 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.116 0.484 . . . . 0.0 110.841 179.788 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' C' C ' 91' ' ' GLN . . . . . 0.407 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.1 pt20 -52.54 -38.65 60.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.467 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 89.2 p -67.7 -33.32 74.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.096 0.474 . . . . 0.0 110.657 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -66.66 -21.21 66.11 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.594 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 94' ' ' ILE . . . . . 0.463 HD13 HG23 ' C' ' 94' ' ' ILE . 39.0 pt -117.24 146.65 21.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.642 -179.814 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 . . . . . 0 C--O 1.235 0.329 0 CA-C-O 121.418 0.627 . . . . 0.0 110.57 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.9 p -57.63 142.5 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.257 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.2 -18.78 47.99 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.114 -0.794 . . . . 0.0 111.114 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 31' ' ' SER . . . . . 0.402 ' O ' ' CG2' ' C' ' 44' ' ' VAL . 37.0 t -90.36 164.63 14.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.475 0.179 . . . . 0.0 110.523 179.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -60.75 161.03 8.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.207 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -133.67 151.09 32.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.806 -179.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -141.98 91.39 2.34 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.302 177.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.7 t -61.82 131.8 27.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 CA-C-O 121.116 0.484 . . . . 0.0 110.633 -179.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -77.61 88.65 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.416 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.95 -126.1 0.8 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -67.03 -12.58 60.31 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.927 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.04 60.34 0.53 Allowed Glycine 0 CA--C 1.52 0.395 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -105.68 143.68 33.49 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.982 0.42 . . . . 0.0 110.6 179.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -145.78 165.94 27.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.755 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 175.11 -125.76 1.11 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 96.4 m -127.8 136.39 51.4 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 120.715 0.293 . . . . 0.0 111.057 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 44' ' ' VAL . . . . . 0.402 ' CG2' ' O ' ' C' ' 31' ' ' SER . 43.1 t -72.51 128.89 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -94.82 -159.04 0.68 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.314 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -65.49 141.34 58.52 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.133 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 6.2 p -121.03 133.32 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.394 -179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.05 -174.05 21.6 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 49' ' ' ALA . . . . . 0.436 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -71.21 152.23 43.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.874 0.369 . . . . 0.0 110.272 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 50' ' ' THR . . . . . 0.501 HG23 ' H ' ' C' ' 53' ' ' ALA . 1.7 t -146.19 166.56 25.84 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.827 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 51' ' ' LEU . . . . . 0.43 ' N ' ' CD1' ' C' ' 51' ' ' LEU . 10.5 mp -60.67 -38.58 85.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.167 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 52' ' ' PHE . . . . . 0.529 ' N ' ' OE1' ' C' ' 74' ' ' GLN . 92.4 t80 -59.89 -44.76 94.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.206 179.148 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 53' ' ' ALA . . . . . 0.501 ' H ' HG23 ' C' ' 50' ' ' THR . . . -145.5 144.28 30.47 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.511 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 99.1 m -98.44 132.83 43.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.546 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 55' ' ' GLY . . . . . 0.436 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 136.98 -147.69 19.37 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -124.26 96.17 4.82 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 36.6 m95 -122.94 162.98 21.25 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.986 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 58' ' ' VAL . . . . . 0.482 ' N ' ' O ' ' C' ' 89' ' ' VAL . 59.2 t -125.15 128.27 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.773 -179.252 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.54 136.85 15.08 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 109.691 -1.363 . . . . 0.0 109.691 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.4 t -123.39 133.9 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.037 0.446 . . . . 0.0 111.038 -178.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 61' ' ' ILE . . . . . 0.431 HG23 HD11 ' C' ' 61' ' ' ILE . 16.4 mm -87.06 93.28 4.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.811 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 62' ' ' LEU . . . . . 0.617 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.6 OUTLIER -76.03 120.14 20.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.546 -179.409 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -67.85 -11.94 59.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.837 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 64' ' ' GLU . . . . . 0.481 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 80.7 mm-40 -63.37 -34.25 77.32 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.476 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 65' ' ' ALA . . . . . 0.481 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 83.42 47.18 0.02 OUTLIER 'General case' 0 C--N 1.338 0.105 0 O-C-N 123.322 0.389 . . . . 0.0 110.748 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 66' ' ' LYS . . . . . 0.552 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.4 ptpt -146.84 109.21 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.387 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.53 -140.5 7.25 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.449 -1.061 . . . . 0.0 110.449 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -97.19 -173.36 2.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.919 0.39 . . . . 0.0 110.125 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 42.3 p-10 -113.95 98.01 6.73 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.576 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 -61.65 -17.37 55.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.375 179.246 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 71' ' ' GLY . . . . . 0.475 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.93 -43.1 97.0 Favored Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 72' ' ' THR . . . . . 0.475 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 19.1 p -161.41 118.09 2.2 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 120.513 0.197 . . . . 0.0 110.636 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 73' ' ' VAL . . . . . 0.623 ' O ' ' N ' ' C' ' 76' ' ' ARG . 12.7 t -128.31 125.68 64.53 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 74' ' ' GLN . . . . . 0.529 ' OE1' ' N ' ' C' ' 52' ' ' PHE . 3.4 pt20 39.55 36.79 0.25 Allowed 'General case' 0 C--N 1.328 -0.364 0 O-C-N 123.148 0.28 . . . . 0.0 111.323 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 89.03 -19.56 37.78 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 76' ' ' ARG . . . . . 0.623 ' N ' ' O ' ' C' ' 73' ' ' VAL . 59.9 ttt85 -101.96 126.25 48.83 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 pttt -106.83 132.32 52.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.491 0.662 . . . . 0.0 111.209 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 78' ' ' TYR . . . . . 0.472 ' OH ' ' CG2' ' C' ' 50' ' ' THR . 3.1 m-85 -84.26 -40.65 17.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.063 178.268 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 79' ' ' PHE . . . . . 0.409 ' CG ' ' N ' ' C' ' 80' ' ' THR . 86.8 t80 -170.87 158.19 5.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.467 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 80' ' ' THR . . . . . 0.409 ' N ' ' CG ' ' C' ' 79' ' ' PHE . 82.7 p -64.12 96.95 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.975 0.417 . . . . 0.0 111.029 -179.499 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.31 144.9 4.65 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.305 179.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -86.57 169.45 12.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.191 0.519 . . . . 0.0 110.887 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -46.71 149.93 0.77 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.185 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 84' ' ' GLY . . . . . 0.552 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.36 -7.11 56.14 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -178.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 85' ' ' HIS . . . . . 0.617 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 6.3 m-70 -139.15 132.82 30.56 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.093 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.9 58.57 0.16 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.9 mm -82.34 132.39 31.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -83.66 116.68 22.76 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.482 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 89' ' ' VAL . . . . . 0.482 ' O ' ' N ' ' C' ' 58' ' ' VAL . 4.3 m -140.21 160.01 25.76 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.911 178.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 90' ' ' ARG . . . . . 0.585 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -85.97 162.62 18.44 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 120.791 0.329 . . . . 0.0 110.758 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 91' ' ' GLN . . . . . 0.455 ' O ' ' O ' ' C' ' 94' ' ' ILE . 96.0 mt-30 -59.31 -41.2 88.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.597 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 40.0 t -61.53 -37.99 85.78 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.432 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -63.2 -33.88 76.44 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.565 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 94' ' ' ILE . . . . . 0.455 ' O ' ' O ' ' C' ' 91' ' ' GLN . 34.1 pt -105.01 149.13 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 121.082 0.468 . . . . 0.0 110.799 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.596 179.826 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 96.1 mtm-85 . . . . . 0 C--O 1.234 0.251 0 CA-C-O 120.969 0.414 . . . . 0.0 110.369 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -67.14 140.32 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 CA-C-O 121.361 0.601 . . . . 0.0 111.058 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.07 -16.38 57.23 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.032 -178.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 81.5 p -80.36 165.38 22.32 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.918 0.39 . . . . 0.0 111.606 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 32' ' ' ARG . . . . . 0.67 ' NE ' HH21 ' C' ' 41' ' ' ARG . 99.7 mtt180 -68.67 156.21 38.61 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.473 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 33' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' C' ' 44' ' ' VAL . 2.2 m -130.82 156.3 42.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.321 0 CA-C-O 121.216 0.531 . . . . 0.0 110.445 -179.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -139.39 99.41 3.73 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 177.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 74.1 t -62.37 130.3 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.419 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.943 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 96.9 mt -75.0 76.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.804 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -125.36 0.77 Allowed Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 65.4 pttt -60.01 -20.02 55.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.592 -0.304 . . . . 0.0 110.579 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.44 54.99 0.81 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 40' ' ' HIS . . . . . 0.416 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 66.7 t-80 -87.32 137.4 32.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.218 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 41' ' ' ARG . . . . . 0.67 HH21 ' NE ' ' C' ' 32' ' ' ARG . 78.0 ttt-85 -110.09 139.43 45.22 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.13 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . -172.14 -170.8 36.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 95.1 m -114.18 131.55 56.41 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 44' ' ' VAL . . . . . 0.431 ' N ' ' CG1' ' C' ' 33' ' ' VAL . 1.3 p -69.49 139.6 20.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.294 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -96.17 -156.88 0.55 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.375 -0.829 . . . . 0.0 109.274 178.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -63.66 142.37 58.42 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.201 0.524 . . . . 0.0 110.221 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 19.7 m -118.8 153.58 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.285 -178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 116.96 -175.83 15.91 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 49' ' ' ALA . . . . . 0.495 ' CB ' ' O ' ' C' ' 55' ' ' GLY . . . -68.13 141.2 56.14 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 50' ' ' THR . . . . . 0.428 ' OG1' ' OH ' ' C' ' 78' ' ' TYR . 60.3 p -137.69 167.7 21.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.289 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.5 tp -59.86 -41.16 90.84 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 52' ' ' PHE . . . . . 0.462 ' CE1' ' NZ ' ' C' ' 68' ' ' LYS . 88.8 t80 -58.74 -46.0 88.41 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.274 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.39 140.94 32.2 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.964 0.412 . . . . 0.0 110.677 179.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.3 p -84.44 167.63 16.25 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.745 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 55' ' ' GLY . . . . . 0.495 ' O ' ' CB ' ' C' ' 49' ' ' ALA . . . 87.1 -133.35 11.74 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -131.18 114.68 15.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.524 0.678 . . . . 0.0 110.513 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -137.52 156.04 48.57 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.45 179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 58' ' ' VAL . . . . . 0.401 ' HB ' ' O ' ' C' ' 89' ' ' VAL . 82.1 t -119.36 130.06 74.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.441 -179.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.37 135.49 12.91 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 75.1 t -125.94 132.69 70.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.07 0.462 . . . . 0.0 111.374 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.5 pt -83.5 95.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.561 0.696 . . . . 0.0 110.196 178.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 62' ' ' LEU . . . . . 0.579 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -70.12 120.82 16.38 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.335 -179.321 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 63' ' ' ASP . . . . . 0.416 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.0 m-20 -67.61 -11.1 57.39 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.4 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 64' ' ' GLU . . . . . 0.508 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.19 -35.79 79.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.179 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 65' ' ' ALA . . . . . 0.508 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 87.05 39.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.962 0.41 . . . . 0.0 110.397 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 66' ' ' LYS . . . . . 0.512 ' N ' ' O ' ' C' ' 84' ' ' GLY . 21.3 ptmt -135.6 135.56 40.34 Favored 'General case' 0 CA--C 1.521 -0.155 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.59 179.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.21 -146.79 16.45 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 68' ' ' LYS . . . . . 0.462 ' NZ ' ' CE1' ' C' ' 52' ' ' PHE . 17.5 ptpt -98.47 -168.0 1.58 Allowed 'General case' 0 C--O 1.238 0.452 0 CA-C-O 120.941 0.4 . . . . 0.0 110.736 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 69' ' ' ASN . . . . . 0.422 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 40.6 p-10 -111.8 105.42 13.89 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.56 -179.468 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 70' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' C' ' 70' ' ' ASP . 0.9 OUTLIER -63.93 -11.46 28.44 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.899 178.515 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 71' ' ' GLY . . . . . 0.494 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -60.29 -42.92 98.97 Favored Glycine 0 N--CA 1.45 -0.383 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 72' ' ' THR . . . . . 0.494 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 20.4 p -163.91 115.38 1.36 Allowed 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 123.838 0.376 . . . . 0.0 110.683 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 73' ' ' VAL . . . . . 0.422 ' CG2' ' O ' ' C' ' 69' ' ' ASN . 16.8 t -131.12 119.02 43.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.8 mm-40 52.35 35.16 16.52 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.558 0.218 . . . . 0.0 111.441 179.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.62 -1.7 81.71 Favored Glycine 0 CA--C 1.517 0.195 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 76' ' ' ARG . . . . . 0.405 ' O ' ' N ' ' C' ' 73' ' ' VAL . 28.1 tpt180 -115.98 123.85 49.04 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.244 -0.478 . . . . 0.0 109.75 179.494 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -109.7 136.33 49.22 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-O 121.272 0.558 . . . . 0.0 110.645 -179.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 78' ' ' TYR . . . . . 0.428 ' OH ' ' OG1' ' C' ' 50' ' ' THR . 58.9 m-85 -93.66 -37.23 11.95 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.597 178.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -170.56 149.18 3.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.279 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 31.0 p -64.3 101.48 0.43 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.888 0.375 . . . . 0.0 111.615 -178.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.0 t -171.19 146.97 2.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.307 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -78.65 168.63 19.47 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.432 0.634 . . . . 0.0 110.717 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -43.57 157.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.307 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 84' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.86 -8.15 63.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 85' ' ' HIS . . . . . 0.579 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 30.7 m-70 -137.61 144.49 41.97 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.6 60.4 0.49 Allowed Glycine 0 N--CA 1.467 0.718 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 50.7 mm -93.77 127.37 45.86 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 88' ' ' PHE . . . . . 0.537 ' O ' ' CD2' ' C' ' 88' ' ' PHE . 49.0 p90 -77.34 119.7 21.33 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.276 0.56 . . . . 0.0 110.091 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 89' ' ' VAL . . . . . 0.401 ' O ' ' HB ' ' C' ' 58' ' ' VAL . 4.0 p -143.44 140.41 26.24 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.728 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 90' ' ' ARG . . . . . 0.56 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -65.59 151.52 46.28 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.954 -0.298 . . . . 0.0 110.925 -177.774 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 91' ' ' GLN . . . . . 0.528 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 3.8 pm0 -57.87 -33.75 69.02 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.836 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 81.7 p -64.95 -36.81 85.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.349 . . . . 0.0 110.849 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -67.59 -20.68 65.4 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.021 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 94' ' ' ILE . . . . . 0.455 ' O ' ' O ' ' C' ' 91' ' ' GLN . 24.3 pt -117.65 148.72 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.88 0.371 . . . . 0.0 110.142 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.583 -179.608 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo . . . . . 0 N--CA 1.483 0.885 0 N-CA-C 109.062 -1.168 . . . . 0.0 109.062 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -85.24 170.37 12.9 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.877 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 35.1 ptt-85 -122.25 149.2 44.02 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 121.456 0.646 . . . . 0.0 110.839 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 3.4 p -57.28 145.0 8.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.206 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.34 -20.69 47.53 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -83.67 159.5 21.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.861 0.363 . . . . 0.0 110.791 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 39.4 ptt180 -50.72 161.85 0.31 Allowed 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' VAL . . . . . 0.444 HG13 ' N ' ' C' ' 42' ' ' GLY . 9.4 p -128.21 150.13 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.858 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -146.72 91.8 2.07 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 94.1 t -67.63 130.88 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.93 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' ILE . . . . . 0.43 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 5.6 mm -76.17 74.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.508 0.67 . . . . 0.0 109.934 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.72 -119.77 0.5 Allowed Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.73 -17.94 27.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.121 -0.539 . . . . 0.0 109.966 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.21 41.72 3.66 Favored Glycine 0 N--CA 1.465 0.588 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 64.8 m170 -75.4 147.37 40.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 110.694 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.4 ptm180 -134.77 163.18 30.38 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.748 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 42' ' ' GLY . . . . . 0.444 ' N ' HG13 ' C' ' 33' ' ' VAL . . . 157.56 -127.25 1.88 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -178.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 98.6 m -131.89 142.85 49.79 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 120.912 0.386 . . . . 0.0 111.845 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 95.9 t -77.83 132.31 32.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.043 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 45' ' ' ALA . . . . . 0.41 ' CB ' ' O ' ' C' ' 59' ' ' GLY . . . -85.77 -158.72 0.41 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.486 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 81.8 t80 -64.41 143.48 57.87 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 89.9 t -119.64 131.75 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.613 -178.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.0 -176.09 19.45 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 49' ' ' ALA . . . . . 0.52 ' CB ' ' O ' ' C' ' 55' ' ' GLY . . . -70.3 142.92 52.18 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-O 120.937 0.399 . . . . 0.0 110.015 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 69.6 p -138.6 169.58 17.54 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.473 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 97.1 mt -60.86 -38.82 86.88 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.993 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.0 t80 -59.06 -46.14 89.01 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.523 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.18 143.98 29.63 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.1 p -85.14 166.95 16.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.538 179.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 55' ' ' GLY . . . . . 0.52 ' O ' ' CB ' ' C' ' 49' ' ' ALA . . . 94.17 -140.54 15.1 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -134.38 96.04 3.51 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.403 -0.469 . . . . 0.0 110.464 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -113.89 171.12 7.78 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.105 0.479 . . . . 0.0 109.785 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 58' ' ' VAL . . . . . 0.492 ' N ' ' O ' ' C' ' 89' ' ' VAL . 59.9 t -129.77 130.21 66.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.401 -179.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 59' ' ' GLY . . . . . 0.41 ' O ' ' CB ' ' C' ' 45' ' ' ALA . . . -92.11 134.57 12.3 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 178.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 59.5 t -122.19 132.96 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 CA-C-O 120.906 0.384 . . . . 0.0 111.162 -178.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 7.9 mm -81.39 96.22 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.954 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 62' ' ' LEU . . . . . 0.548 HD11 ' H ' ' C' ' 64' ' ' GLU . 0.2 OUTLIER -78.17 114.85 17.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.577 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -66.89 -18.07 65.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.66 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 64' ' ' GLU . . . . . 0.548 ' H ' HD11 ' C' ' 62' ' ' LEU . 79.3 mm-40 -60.55 -32.22 71.3 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.341 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 65' ' ' ALA . . . . . 0.498 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 84.53 46.63 0.02 OUTLIER 'General case' 0 N--CA 1.461 0.09 0 CA-C-O 120.796 0.331 . . . . 0.0 110.772 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 66' ' ' LYS . . . . . 0.538 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.6 ptpt -141.3 110.89 6.44 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.168 0.508 . . . . 0.0 110.238 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 151.31 -143.02 10.02 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 18.3 ptmt -99.4 -171.99 2.18 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 69' ' ' ASN . . . . . 0.455 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 23.0 p-10 -112.07 102.53 10.73 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.603 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -62.41 -15.98 52.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.313 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 71' ' ' GLY . . . . . 0.479 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.42 -45.52 94.27 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.065 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 72' ' ' THR . . . . . 0.479 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 20.1 p -162.18 120.83 2.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.843 0.354 . . . . 0.0 110.667 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 73' ' ' VAL . . . . . 0.487 ' N ' ' O ' ' C' ' 76' ' ' ARG . 12.7 t -138.69 122.06 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.617 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 74' ' ' GLN . . . . . 0.491 ' C ' ' H ' ' C' ' 76' ' ' ARG . 55.6 tt0 44.78 58.44 3.95 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.275 0.56 . . . . 0.0 110.963 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 60.02 3.88 2.96 Favored Glycine 0 CA--C 1.517 0.186 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 76' ' ' ARG . . . . . 0.491 ' H ' ' C ' ' C' ' 74' ' ' GLN . 17.2 tpp180 -124.75 129.59 50.77 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.862 0.363 . . . . 0.0 110.373 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -113.34 136.43 52.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.271 0.558 . . . . 0.0 111.078 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -88.78 -39.29 14.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.862 178.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -173.33 158.97 3.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.486 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -65.46 96.99 0.27 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.843 0.354 . . . . 0.0 111.001 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.3 t -169.2 144.82 3.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.522 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 49.8 p-10 -84.11 172.16 12.21 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.275 0.56 . . . . 0.0 110.82 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -47.68 151.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.165 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 84' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.03 -6.8 56.8 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 85' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -137.74 128.27 26.61 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 124.73 54.32 0.18 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.736 -0.546 . . . . 0.0 111.736 179.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 96.7 mt -80.43 129.36 37.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 178.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 88' ' ' PHE . . . . . 0.569 ' O ' ' CD2' ' C' ' 88' ' ' PHE . 48.6 p90 -74.94 119.35 19.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.087 0.47 . . . . 0.0 111.063 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 89' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' C' ' 58' ' ' VAL . 4.5 m -140.5 162.63 23.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 90' ' ' ARG . . . . . 0.526 ' NH1' ' OE1' ' C' ' 93' ' ' GLN . 0.0 OUTLIER -91.14 163.46 14.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.728 179.732 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 91' ' ' GLN . . . . . . . . . . . . . 55.6 mt-30 -59.31 -42.63 91.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.721 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 67.7 m -63.16 -33.84 76.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.245 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 93' ' ' GLN . . . . . 0.526 ' OE1' ' NH1' ' C' ' 90' ' ' ARG . 72.5 tp60 -64.29 -36.95 85.79 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.655 -178.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 94' ' ' ILE . . . . . . . . . . . . . 24.1 pt -99.44 139.3 21.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.051 0.453 . . . . 0.0 110.453 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 59.5 tt0 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.775 -179.655 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo . . . . . 0 N--CA 1.481 0.759 0 N-CA-C 108.735 -1.294 . . . . 0.0 108.735 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.85 122.81 20.16 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.566 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 62.7 ttp180 -73.36 139.59 46.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.798 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 1.6 p -55.9 140.62 13.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.059 179.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.7 -9.94 62.4 Favored Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 67.5 m -92.67 163.76 13.65 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.942 0.401 . . . . 0.0 111.045 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 17.7 ptm180 -61.62 159.11 13.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.318 179.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 33' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' C' ' 42' ' ' GLY . 2.6 m -135.7 160.36 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 34' ' ' GLU . . . . . 0.514 ' N ' ' OXT' ' C' ' 95' ' ' GLN . 77.3 mm-40 -133.2 96.02 3.66 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 177.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 84.9 t -61.07 131.2 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.702 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 36' ' ' ILE . . . . . 0.493 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 6.5 mm -76.68 82.76 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-O 121.426 0.632 . . . . 0.0 110.027 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.28 -125.97 0.79 Allowed Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -64.02 -18.47 64.35 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.306 -0.447 . . . . 0.0 110.454 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.12 55.98 0.59 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 40' ' ' HIS . . . . . 0.475 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 61.0 t-80 -95.44 154.9 16.97 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.799 0.333 . . . . 0.0 110.404 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 41' ' ' ARG . . . . . 0.467 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 37.2 ptt-85 -128.52 157.54 40.89 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.337 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 42' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' C' ' 33' ' ' VAL . . . 176.33 -166.37 37.35 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.5 m -111.11 132.09 54.55 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-O 120.903 0.382 . . . . 0.0 110.667 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 44' ' ' VAL . . . . . 0.431 ' N ' ' CG1' ' C' ' 33' ' ' VAL . 1.5 p -72.26 135.21 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.83 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.21 -156.48 0.33 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.801 178.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 46' ' ' TYR . . . . . 0.402 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 91.0 t80 -63.42 140.68 58.9 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.065 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 47' ' ' VAL . . . . . 0.402 ' O ' ' CE2' ' C' ' 46' ' ' TYR . 30.4 m -110.47 153.94 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.063 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.49 -175.3 22.56 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 49' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' C' ' 55' ' ' GLY . . . -67.99 153.78 43.0 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.073 0.463 . . . . 0.0 109.971 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 50' ' ' THR . . . . . 0.467 HG23 ' H ' ' C' ' 53' ' ' ALA . 8.1 t -142.45 171.38 14.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.34 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 51' ' ' LEU . . . . . 0.483 ' N ' ' CD2' ' C' ' 51' ' ' LEU . 3.9 mm? -61.23 -39.27 89.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.471 -179.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 t80 -58.54 -45.72 88.32 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.368 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 53' ' ' ALA . . . . . 0.467 ' H ' HG23 ' C' ' 50' ' ' THR . . . -148.98 146.4 27.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.297 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 54' ' ' THR . . . . . 0.713 ' HG1' ' H ' ' C' ' 55' ' ' GLY . 11.0 t -87.92 171.94 9.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.283 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 55' ' ' GLY . . . . . 0.713 ' H ' ' HG1' ' C' ' 54' ' ' THR . . . 96.14 -156.8 21.38 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 -179.479 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -119.27 106.83 12.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.091 0.472 . . . . 0.0 110.607 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 57' ' ' TRP . . . . . 0.551 ' HE1' ' NE ' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -135.22 170.67 15.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.825 179.466 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' C' C ' 58' ' ' VAL . . . . . . . . . . . . . 57.4 t -131.37 132.36 62.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.56 -0.746 . . . . 0.0 111.343 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.46 132.94 11.37 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 72.9 t -127.35 134.28 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.556 0.693 . . . . 0.0 111.42 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.6 pt -85.06 119.93 34.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.964 178.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 62' ' ' LEU . . . . . 0.525 ' O ' ' CD2' ' C' ' 85' ' ' HIS . 3.8 tp -92.24 122.21 34.5 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.093 -178.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 63' ' ' ASP . . . . . 0.475 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.3 m-20 -67.46 -14.15 62.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.375 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 64' ' ' GLU . . . . . 0.505 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 77.7 mm-40 -62.66 -31.05 71.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.561 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 65' ' ' ALA . . . . . 0.505 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 85.8 42.28 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.142 0 CA-C-O 120.958 0.409 . . . . 0.0 110.556 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 66' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' C' ' 84' ' ' GLY . 18.9 ptmt -140.4 120.16 13.43 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.978 179.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 146.21 -148.25 19.8 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 68' ' ' LYS . . . . . 0.493 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 40.8 tttt -97.4 -166.55 1.4 Allowed 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 69' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' C' ' 69' ' ' ASN . 1.2 m-20 -104.18 95.94 6.31 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.227 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 70' ' ' ASP . . . . . 0.557 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 5.4 t70 -60.48 -23.07 64.2 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.681 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 71' ' ' GLY . . . . . 0.446 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -59.06 -40.28 95.38 Favored Glycine 0 C--O 1.224 -0.482 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.35 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 72' ' ' THR . . . . . 0.446 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 38.1 p -158.5 116.47 2.95 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.807 0.337 . . . . 0.0 110.52 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 73' ' ' VAL . . . . . 0.462 ' O ' ' N ' ' C' ' 76' ' ' ARG . 58.6 t -129.88 126.78 62.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.511 179.705 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 47.58 45.93 17.73 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.21 0.529 . . . . 0.0 110.704 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.64 3.13 39.77 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 76' ' ' ARG . . . . . 0.462 ' N ' ' O ' ' C' ' 73' ' ' VAL . 20.3 tpp85 -124.81 129.79 51.12 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.873 0.368 . . . . 0.0 110.371 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -109.44 138.92 45.08 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.883 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -105.35 -26.97 11.77 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.464 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 79' ' ' PHE . . . . . 0.557 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 31.3 t80 -169.84 142.21 2.39 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.232 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.27 106.3 1.07 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.054 0.454 . . . . 0.0 111.363 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.1 t -169.19 145.07 3.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.299 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -82.26 171.14 14.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.261 0.553 . . . . 0.0 110.686 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -44.81 155.28 0.11 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.292 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 84' ' ' GLY . . . . . 0.526 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 95.45 -3.73 66.22 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 85' ' ' HIS . . . . . 0.572 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.3 OUTLIER -139.58 140.29 37.02 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.339 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.38 60.0 0.32 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 87' ' ' ILE . . . . . 0.411 HD13 HG21 ' C' ' 87' ' ' ILE . 95.9 mt -94.25 130.32 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -75.6 120.47 21.05 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.506 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 89' ' ' VAL . . . . . . . . . . . . . 20.8 m -139.48 162.53 26.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.443 179.278 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 90' ' ' ARG . . . . . 0.551 ' NE ' ' HE1' ' C' ' 57' ' ' TRP . 5.5 mpt_? -93.89 150.71 20.13 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.024 0.44 . . . . 0.0 110.249 -179.256 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 91' ' ' GLN . . . . . 0.609 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 1.3 pm0 -51.57 -39.39 57.78 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.142 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 78.9 p -69.99 -28.33 65.43 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.053 0.454 . . . . 0.0 110.368 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 93' ' ' GLN . . . . . 0.493 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.6 tt0 -70.69 -20.19 62.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.501 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 94' ' ' ILE . . . . . 0.476 ' O ' ' O ' ' C' ' 91' ' ' GLN . 48.1 pt -128.38 163.09 33.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.074 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 95' ' ' GLN . . . . . 0.514 ' OXT' ' N ' ' C' ' 34' ' ' GLU . 59.8 tt0 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.453 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo . . . . . 0 N--CA 1.482 0.812 0 N-CA-C 108.86 -1.246 . . . . 0.0 108.86 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.28 163.65 29.91 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.377 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 86.0 mtp180 -125.27 148.44 48.68 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.742 179.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.1 p -52.68 144.4 3.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.257 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.51 -9.71 75.43 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 74.2 m -86.5 165.07 16.55 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.458 . . . . 0.0 111.275 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -58.28 151.14 20.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.881 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 33' ' ' VAL . . . . . 0.429 HG12 ' N ' ' C' ' 42' ' ' GLY . 14.0 p -121.76 150.94 25.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.835 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -147.43 97.3 2.83 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -70.7 132.35 33.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.697 -178.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 36' ' ' ILE . . . . . 0.487 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 5.9 mm -71.95 80.3 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.509 179.674 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.29 -126.86 0.84 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -62.99 -21.12 65.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.355 -0.423 . . . . 0.0 110.77 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 107.87 55.49 0.61 Allowed Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 40' ' ' HIS . . . . . 0.602 ' HE2' ' H ' ' C' ' 63' ' ' ASP . 41.8 t-80 -84.93 140.17 31.3 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 121.158 0.504 . . . . 0.0 111.681 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 41' ' ' ARG . . . . . 0.544 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 11.6 ptm85 -119.73 169.73 9.84 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.285 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 42' ' ' GLY . . . . . 0.429 ' N ' HG12 ' C' ' 33' ' ' VAL . . . 150.48 -131.2 3.48 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -178.259 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 12.3 t -142.67 154.2 44.11 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 111.56 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 m -88.18 138.88 18.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.024 179.058 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.19 -158.79 0.49 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.962 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 75.1 t80 -64.8 142.53 58.4 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.122 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 8.7 p -113.17 131.98 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.688 -178.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.14 -173.81 24.03 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 49' ' ' ALA . . . . . 0.444 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -66.79 145.78 55.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.079 0.466 . . . . 0.0 110.222 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 50' ' ' THR . . . . . 0.453 ' OG1' ' OH ' ' C' ' 78' ' ' TYR . 19.5 m -126.64 159.37 33.81 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.862 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 88.8 mt -60.28 -39.54 87.23 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -59.16 -46.48 88.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 0.0 109.943 179.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 53' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -141.72 141.61 33.29 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 110.149 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 9.9 t -89.17 162.12 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.937 -179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 55' ' ' GLY . . . . . 0.444 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 108.78 -145.95 16.52 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 64.6 mttp -123.68 116.4 23.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.993 0.425 . . . . 0.0 110.359 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -141.55 164.2 30.86 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.326 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 58' ' ' VAL . . . . . . . . . . . . . 75.2 t -122.54 128.51 75.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.755 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.48 141.74 19.88 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 70.8 t -127.09 133.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 120.879 0.371 . . . . 0.0 110.531 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 11.7 mm -82.2 95.01 3.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 62' ' ' LEU . . . . . 0.564 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -74.57 104.86 5.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.132 -178.865 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 63' ' ' ASP . . . . . 0.602 ' H ' ' HE2' ' C' ' 40' ' ' HIS . 54.0 p30 -65.88 -9.88 33.27 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.992 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 64' ' ' GLU . . . . . 0.501 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 75.9 mm-40 -63.21 -32.15 73.47 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.475 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 65' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 91.08 39.44 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.042 0.449 . . . . 0.0 110.555 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 66' ' ' LYS . . . . . 0.543 ' N ' ' O ' ' C' ' 84' ' ' GLY . 23.1 pttp -140.75 140.87 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.18 178.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 121.89 -150.15 17.07 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 9.4 mmtt -95.81 -171.51 2.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.39 0.614 . . . . 0.0 111.149 -179.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 69' ' ' ASN . . . . . 0.541 ' ND2' ' O ' ' C' ' 72' ' ' THR . 46.9 p-10 -106.09 102.01 11.46 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.543 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 70' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 7.3 t0 -62.06 -23.73 66.66 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.461 -0.791 . . . . 0.0 108.969 179.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 71' ' ' GLY . . . . . 0.43 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.07 -41.83 94.76 Favored Glycine 0 C--O 1.226 -0.38 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 72' ' ' THR . . . . . 0.541 ' O ' ' ND2' ' C' ' 69' ' ' ASN . 32.7 p -158.55 118.31 3.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.922 0.392 . . . . 0.0 110.838 179.289 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 73' ' ' VAL . . . . . 0.488 ' N ' ' O ' ' C' ' 76' ' ' ARG . 39.6 t -126.43 122.96 62.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.685 179.225 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 68.7 tp60 45.05 49.99 9.36 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.074 0.464 . . . . 0.0 111.544 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.56 1.79 31.8 Favored Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 76' ' ' ARG . . . . . 0.488 ' O ' ' N ' ' C' ' 73' ' ' VAL . 76.3 ttt180 -124.78 126.09 45.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.374 -0.413 . . . . 0.0 110.325 -179.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -107.34 137.92 44.5 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-O 121.363 0.601 . . . . 0.0 111.19 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 78' ' ' TYR . . . . . 0.453 ' OH ' ' OG1' ' C' ' 50' ' ' THR . 1.7 m-85 -98.57 -32.94 11.18 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.371 178.343 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 79' ' ' PHE . . . . . 0.539 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 86.0 t80 -169.55 151.73 4.48 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.373 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 44.0 p -64.9 108.87 1.9 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.745 0.307 . . . . 0.0 111.349 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -172.63 148.32 1.92 Allowed 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.329 179.032 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -86.0 169.87 12.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.153 0.501 . . . . 0.0 111.179 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -50.57 145.05 7.06 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.002 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 84' ' ' GLY . . . . . 0.543 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 104.05 -4.34 45.2 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 85' ' ' HIS . . . . . 0.564 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 4.0 m-70 -140.97 136.2 31.93 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.145 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.95 49.79 0.32 Allowed Glycine 0 N--CA 1.47 0.907 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.331 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 97.4 mt -83.78 135.18 25.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -84.16 119.11 24.62 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.528 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 89' ' ' VAL . . . . . . . . . . . . . 16.2 m -136.51 162.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 178.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 90' ' ' ARG . . . . . 0.514 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -90.78 155.04 19.09 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.599 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 91' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' C' ' 94' ' ' ILE . 29.2 pt20 -53.22 -38.97 63.4 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.733 -179.545 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 66.6 m -63.18 -37.19 86.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.223 0.535 . . . . 0.0 110.172 178.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 93' ' ' GLN . . . . . 0.487 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.9 tt0 -65.02 -30.05 71.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.109 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 94' ' ' ILE . . . . . 0.434 ' O ' ' O ' ' C' ' 91' ' ' GLN . 17.1 pt -108.93 145.43 15.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.975 0.417 . . . . 0.0 110.461 179.637 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.745 179.98 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo . . . . . 0 N--CA 1.48 0.703 0 N-CA-C 109.051 -1.173 . . . . 0.0 109.051 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -78.3 168.39 19.9 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.949 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 78.0 mtp85 -117.51 139.35 51.05 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.964 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 6.1 m -50.66 143.21 2.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 91.92 -8.27 78.27 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 45.7 t -89.05 163.73 15.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.982 0.42 . . . . 0.0 111.426 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -59.23 149.15 29.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.156 179.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 2.5 m -126.81 159.78 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.013 0.435 . . . . 0.0 110.035 -179.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -140.52 93.64 2.64 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 35' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' C' ' 37' ' ' GLY . 84.2 t -56.54 126.54 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 36' ' ' ILE . . . . . 0.495 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 4.6 mm -67.18 77.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 CA-C-O 121.582 0.706 . . . . 0.0 109.333 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' C' ' 35' ' ' VAL . . . -163.17 -126.61 0.83 Allowed Glycine 0 CA--C 1.519 0.311 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -64.48 -17.31 63.74 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.274 179.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.11 58.07 0.89 Allowed Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 40' ' ' HIS . . . . . 0.669 ' HE2' ' H ' ' C' ' 63' ' ' ASP . 75.7 t60 -89.82 138.95 31.05 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 111.124 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 41' ' ' ARG . . . . . 0.517 ' O ' ' CD2' ' C' ' 40' ' ' HIS . 87.6 mtm-85 -89.87 162.71 15.33 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.675 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 171.64 -172.4 44.58 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -179.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 85.4 m -124.71 131.95 53.42 Favored 'General case' 0 C--O 1.24 0.569 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -72.58 121.14 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.07 -157.5 0.12 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.934 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -63.61 142.0 58.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.569 -179.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 7.2 p -117.59 135.93 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.176 -179.055 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.99 -177.73 19.5 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 49' ' ' ALA . . . . . 0.488 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -70.45 141.44 52.06 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.974 0.416 . . . . 0.0 110.245 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 50' ' ' THR . . . . . 0.471 ' CB ' ' HH ' ' C' ' 78' ' ' TYR . 47.7 p -139.43 168.58 19.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.293 179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 83.3 mt -60.78 -39.35 88.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.974 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 82.8 t80 -59.42 -46.28 89.17 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.215 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -145.94 142.38 28.66 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.012 0.434 . . . . 0.0 110.526 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 60.3 p -85.44 169.12 13.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.914 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 55' ' ' GLY . . . . . 0.488 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 89.66 -146.06 18.67 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -125.77 101.62 6.94 Favored 'General case' 0 N--CA 1.464 0.262 0 O-C-N 122.603 -0.351 . . . . 0.0 110.237 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -121.32 166.45 14.04 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 58' ' ' VAL . . . . . . . . . . . . . 51.2 t -127.03 129.41 71.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.298 -179.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.61 129.72 9.9 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.6 t -123.81 131.63 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 121.244 0.545 . . . . 0.0 110.805 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 10.1 pt -82.19 126.08 39.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.907 179.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 62' ' ' LEU . . . . . 0.6 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 3.5 tp -102.33 111.48 23.8 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 63' ' ' ASP . . . . . 0.669 ' H ' ' HE2' ' C' ' 40' ' ' HIS . 42.8 t0 -59.71 -11.1 4.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.127 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 64' ' ' GLU . . . . . 0.499 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 80.6 mm-40 -62.01 -34.01 75.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.286 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 65' ' ' ALA . . . . . 0.499 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 85.67 46.28 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.858 0.361 . . . . 0.0 110.546 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 66' ' ' LYS . . . . . 0.546 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.7 ptpt -149.79 104.09 3.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.355 0.597 . . . . 0.0 110.105 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.43 -143.19 8.64 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -179.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -96.62 -167.48 1.57 Allowed 'General case' 0 C--O 1.241 0.624 0 CA-C-O 121.104 0.478 . . . . 0.0 109.933 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -117.48 98.72 6.55 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.412 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 76.2 m-20 -62.7 -14.96 50.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.76 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 71' ' ' GLY . . . . . 0.486 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.69 -42.75 96.45 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.069 -1.063 . . . . 0.0 110.63 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 72' ' ' THR . . . . . 0.486 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 18.9 p -163.22 117.75 1.66 Allowed 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.978 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 73' ' ' VAL . . . . . 0.427 ' O ' ' N ' ' C' ' 76' ' ' ARG . 26.1 t -134.72 122.75 39.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.583 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 51.11 36.37 15.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.743 0.306 . . . . 0.0 111.309 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.58 -2.66 66.64 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 76' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' C' ' 73' ' ' VAL . 16.8 tpp180 -116.11 120.68 39.82 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.351 -0.425 . . . . 0.0 109.937 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -103.14 126.26 50.23 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.375 0.607 . . . . 0.0 110.633 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 78' ' ' TYR . . . . . 0.471 ' HH ' ' CB ' ' C' ' 50' ' ' THR . 83.3 m-85 -79.89 -37.61 34.4 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.861 178.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 56.8 t80 -171.04 151.74 3.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.392 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.5 p -64.92 98.48 0.28 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.955 0.407 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 6.1 t -167.56 146.86 4.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -81.72 170.67 15.48 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.264 0.555 . . . . 0.0 110.983 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -49.57 155.33 0.8 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.174 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 84' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.8 -7.22 62.92 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 85' ' ' HIS . . . . . 0.6 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 18.5 m-70 -138.39 130.49 28.5 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 123.88 59.49 0.19 Allowed Glycine 0 C--N 1.341 0.856 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.236 179.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 97.9 mt -90.62 125.5 43.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 88' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' C' ' 88' ' ' PHE . 49.4 p90 -70.79 120.34 16.24 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 120.973 0.416 . . . . 0.0 110.587 -179.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 89' ' ' VAL . . . . . . . . . . . . . 20.5 m -139.01 160.58 29.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 90' ' ' ARG . . . . . 0.43 ' H ' ' HD3' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -92.91 155.15 17.77 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -179.701 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 91' ' ' GLN . . . . . 0.525 ' NE2' ' OG ' ' C' ' 92' ' ' SER . 2.9 pp0? -52.74 -39.83 62.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.081 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 92' ' ' SER . . . . . 0.525 ' OG ' ' NE2' ' C' ' 91' ' ' GLN . 57.7 m -64.71 -37.14 86.59 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.996 0.427 . . . . 0.0 110.403 178.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 93' ' ' GLN . . . . . 0.495 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.2 tt0 -64.75 -19.23 65.68 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.912 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 94' ' ' ILE . . . . . 0.471 ' O ' ' O ' ' C' ' 91' ' ' GLN . 47.1 pt -123.46 153.79 29.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.668 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 95' ' ' GLN . . . . . 0.447 ' OXT' ' O ' ' C' ' 94' ' ' ILE . 69.2 tp60 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.06 -0.971 . . . . 0.0 110.907 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 N--CA 1.485 1.012 0 N-CA-C 109.291 -1.08 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -81.29 130.13 34.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.11 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -76.18 147.72 38.24 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.976 0.417 . . . . 0.0 110.636 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.6 p -62.12 138.07 23.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.014 0.435 . . . . 0.0 110.115 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.27 63.68 Favored Glycine 0 CA--C 1.533 1.202 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.093 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 70.9 m -89.76 163.1 15.21 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.7 0.286 . . . . 0.0 111.16 179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -62.18 150.41 38.88 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.087 0.47 . . . . 0.0 111.19 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m -131.14 155.51 41.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.07 100.44 4.28 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 88.0 t -64.94 130.1 29.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.876 -178.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 36' ' ' ILE . . . . . 0.453 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 8.4 mm -82.97 75.43 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 179.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.72 -121.37 0.57 Allowed Glycine 0 CA--C 1.522 0.478 0 N-CA-C 110.696 -0.961 . . . . 0.0 110.696 -178.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -58.17 -29.4 65.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.041 -0.58 . . . . 0.0 109.951 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.68 59.78 0.51 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 40' ' ' HIS . . . . . 0.419 ' CE1' ' CG ' ' C' ' 64' ' ' GLU . 94.4 m-70 -103.5 150.55 23.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.038 0.447 . . . . 0.0 110.635 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 53.1 ptt85 -137.76 154.78 49.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.744 -179.155 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.94 -122.7 0.94 Allowed Glycine 0 C--O 1.226 -0.351 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 5.3 t -141.02 154.62 46.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.843 179.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 1.2 p -91.72 141.57 14.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.997 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.85 -154.31 0.29 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.549 179.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -62.69 141.95 58.32 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.115 0.483 . . . . 0.0 110.645 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 72.9 t -112.59 129.84 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.688 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 127.37 -172.97 18.66 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 49' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' C' ' 55' ' ' GLY . . . -68.16 146.98 52.91 Favored 'General case' 0 C--N 1.334 -0.071 0 CA-C-O 120.914 0.387 . . . . 0.0 110.019 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 50' ' ' THR . . . . . 0.412 ' O ' ' O ' ' C' ' 53' ' ' ALA . 69.7 p -133.26 167.12 20.95 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.121 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.84 -40.78 89.68 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -57.87 -46.6 84.62 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.359 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 53' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -143.76 144.4 31.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.819 0.342 . . . . 0.0 110.285 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 10.0 t -90.12 165.29 14.07 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.385 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 55' ' ' GLY . . . . . 0.5 ' O ' ' CB ' ' C' ' 49' ' ' ALA . . . 101.22 -152.81 18.96 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 60.6 mtpt -119.94 112.07 18.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.551 -179.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -139.12 171.51 14.19 Favored 'General case' 0 CA--C 1.517 -0.296 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 58' ' ' VAL . . . . . 0.405 ' N ' ' O ' ' C' ' 89' ' ' VAL . 50.4 t -131.3 133.16 62.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.637 -178.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -91.4 139.16 14.64 Favored Glycine 0 CA--C 1.532 1.134 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.69 136.85 59.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-O 121.085 0.469 . . . . 0.0 111.287 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 41.5 mt -88.45 99.87 9.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.1 118.78 20.69 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -67.53 -13.05 61.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.239 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 64' ' ' GLU . . . . . 0.501 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 79.3 mm-40 -62.28 -36.16 81.23 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.42 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 65' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 85.79 44.05 0.01 OUTLIER 'General case' 0 C--N 1.342 0.269 0 CA-C-O 120.911 0.386 . . . . 0.0 110.748 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 66' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' C' ' 84' ' ' GLY . 14.4 ptpt -139.58 119.12 13.04 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.771 178.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 144.73 -146.0 15.97 Favored Glycine 0 CA--C 1.518 0.232 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 68' ' ' LYS . . . . . 0.447 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 36.6 tttt -98.01 -168.75 1.71 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.992 0.425 . . . . 0.0 109.973 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 69' ' ' ASN . . . . . 0.447 ' H ' ' HG2' ' C' ' 68' ' ' LYS . 10.9 p30 -112.65 95.74 5.59 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.157 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 70' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' C' ' 70' ' ' ASP . 3.9 p-10 -65.26 -10.21 30.29 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.469 -0.493 . . . . 0.0 110.245 178.57 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 71' ' ' GLY . . . . . 0.481 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -60.34 -41.78 98.58 Favored Glycine 0 C--O 1.224 -0.489 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 72' ' ' THR . . . . . 0.481 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 20.6 p -162.36 109.7 1.32 Allowed 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.879 0.371 . . . . 0.0 110.662 179.621 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 73' ' ' VAL . . . . . 0.43 ' O ' ' N ' ' C' ' 76' ' ' ARG . 43.7 t -125.94 122.36 61.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.3 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 51.69 35.74 15.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.124 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.88 -1.67 72.71 Favored Glycine 0 CA--C 1.52 0.399 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 76' ' ' ARG . . . . . 0.43 ' N ' ' O ' ' C' ' 73' ' ' VAL . 60.2 ttm-85 -116.01 125.51 52.57 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.096 -0.552 . . . . 0.0 109.768 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.7 pttp -112.29 137.47 50.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.658 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -96.52 -36.11 10.88 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -164.68 145.76 7.92 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.299 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 30.6 p -64.29 104.45 0.76 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.922 0.391 . . . . 0.0 111.306 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 10.7 t -171.3 144.95 2.09 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.527 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -79.93 169.19 18.24 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.342 0.591 . . . . 0.0 111.143 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -45.67 153.71 0.25 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.864 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 84' ' ' GLY . . . . . 0.535 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 99.03 -5.24 59.32 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 85' ' ' HIS . . . . . 0.543 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -138.27 143.36 40.0 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.36 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.09 58.19 0.36 Allowed Glycine 0 C--N 1.337 0.615 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -88.96 134.55 28.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -82.64 119.71 24.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.087 0.47 . . . . 0.0 110.413 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 89' ' ' VAL . . . . . 0.405 ' O ' ' N ' ' C' ' 58' ' ' VAL . 20.5 m -139.46 165.31 23.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 90' ' ' ARG . . . . . 0.408 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -97.36 159.25 15.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.839 0.352 . . . . 0.0 110.436 -179.688 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' C' C ' 91' ' ' GLN . . . . . 0.49 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.7 pt20 -55.9 -40.7 73.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.929 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 88.0 p -70.73 -28.37 64.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.98 0.419 . . . . 0.0 110.4 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 93' ' ' GLN . . . . . 0.453 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 73.2 tp60 -66.9 -29.0 68.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.576 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 94' ' ' ILE . . . . . 0.49 ' O ' ' O ' ' C' ' 91' ' ' GLN . 49.4 pt -125.98 164.15 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.245 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 89.2 mt-30 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.399 179.755 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo . . . . . 0 N--CA 1.481 0.788 0 N-CA-C 109.066 -1.167 . . . . 0.0 109.066 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 1.5 tt -117.01 119.33 34.97 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 85.9 mtp180 -83.89 132.58 34.77 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-O 121.361 0.6 . . . . 0.0 110.335 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.22 146.45 13.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.354 179.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.75 -17.74 57.88 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.26 -0.736 . . . . 0.0 111.26 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 85.0 p -78.28 165.13 24.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.008 0.432 . . . . 0.0 111.553 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -54.48 155.56 3.91 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.65 149.52 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.032 0.444 . . . . 0.0 110.804 -179.386 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -151.45 94.47 2.02 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.388 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 85.5 t -70.36 131.23 34.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.581 -179.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 88.3 mt -72.91 74.06 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-O 121.311 0.577 . . . . 0.0 109.671 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.24 -121.9 0.59 Allowed Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -59.13 -29.93 67.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.596 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.18 46.65 0.92 Allowed Glycine 0 N--CA 1.466 0.691 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -71.72 136.22 47.11 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.877 0.37 . . . . 0.0 110.409 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -114.51 175.91 5.28 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.196 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 134.43 -137.95 9.68 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -179.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 99.0 m -134.25 142.34 47.3 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 120.978 0.418 . . . . 0.0 111.47 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 16.0 m -75.29 144.89 11.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.612 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -91.3 -157.2 0.48 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.334 -179.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -62.69 140.01 58.69 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.306 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 70.1 t -110.77 129.61 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.717 -178.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 126.47 -171.16 18.21 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 49' ' ' ALA . . . . . 0.452 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -68.6 147.11 52.39 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.062 0.458 . . . . 0.0 109.928 179.278 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 50' ' ' THR . . . . . 0.434 ' O ' ' O ' ' C' ' 53' ' ' ALA . 82.3 p -132.02 165.17 24.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.232 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.5 tp -60.27 -40.95 92.2 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -58.28 -46.18 86.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.451 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 53' ' ' ALA . . . . . 0.434 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -144.81 147.38 32.81 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.853 0.359 . . . . 0.0 110.447 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -88.38 173.16 8.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 55' ' ' GLY . . . . . 0.452 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 97.01 -151.2 19.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 16.5 ptmt -128.28 102.93 6.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.137 0.494 . . . . 0.0 110.064 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -131.68 161.79 31.94 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 58' ' ' VAL . . . . . 0.412 ' N ' ' O ' ' C' ' 89' ' ' VAL . 57.4 t -121.36 128.68 75.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.904 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.8 134.52 12.51 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 85.1 t -126.7 130.38 71.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.431 0 O-C-N 122.507 -0.408 . . . . 0.0 111.214 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 4.8 pt -80.23 96.13 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.357 -0.537 . . . . 0.0 110.469 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 62' ' ' LEU . . . . . 0.629 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -73.14 118.06 15.63 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.862 179.907 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.5 p-10 -65.53 -9.22 24.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.51 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 64' ' ' GLU . . . . . 0.492 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 80.9 mm-40 -62.12 -33.64 74.85 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.212 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 65' ' ' ALA . . . . . 0.492 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 85.83 46.47 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.679 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 66' ' ' LYS . . . . . 0.56 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.2 ptmt -147.22 114.5 6.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.296 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 147.12 -142.74 10.57 Favored Glycine 0 CA--C 1.516 0.149 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 16.6 mmtt -97.18 -172.69 2.49 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 110.275 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 69' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.7 p-10 -114.07 98.22 6.84 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.979 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -60.17 -17.28 39.77 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.104 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 71' ' ' GLY . . . . . 0.478 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.59 -41.85 95.79 Favored Glycine 0 C--O 1.225 -0.44 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 72' ' ' THR . . . . . 0.522 ' O ' ' ND2' ' C' ' 69' ' ' ASN . 21.4 p -162.21 111.74 1.49 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.761 0.315 . . . . 0.0 110.591 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 73' ' ' VAL . . . . . 0.476 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.3 t -126.32 124.76 66.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.305 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 53.8 tt0 46.24 47.87 13.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.38 0.61 . . . . 0.0 111.029 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.69 3.61 42.55 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.174 -1.17 . . . . 0.0 110.174 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 76' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' C' ' 73' ' ' VAL . 29.2 tpt180 -125.23 125.93 44.37 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.971 0.415 . . . . 0.0 110.416 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -106.94 138.2 43.57 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.516 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -102.84 -29.98 11.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -170.54 147.41 2.91 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.349 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 80' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' C' ' 80' ' ' THR . 9.7 p -63.93 97.06 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.979 0.419 . . . . 0.0 110.955 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 2.2 t -165.02 145.19 7.14 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.312 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -83.14 171.42 13.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.104 0.478 . . . . 0.0 110.695 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -50.18 151.88 1.91 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.341 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 84' ' ' GLY . . . . . 0.56 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 98.91 -6.16 60.05 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 -179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 85' ' ' HIS . . . . . 0.629 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 19.3 m-70 -136.5 131.34 33.83 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.14 59.42 0.17 Allowed Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.4 mm -86.6 132.79 31.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -82.83 118.5 23.46 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 89' ' ' VAL . . . . . 0.412 ' O ' ' N ' ' C' ' 58' ' ' VAL . 17.8 m -139.62 159.52 27.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 90' ' ' ARG . . . . . 0.514 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.1 mpt_? -82.5 154.22 25.19 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.251 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 91' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' C' ' 94' ' ' ILE . 16.0 pt20 -54.3 -39.71 67.24 Favored 'General case' 0 C--N 1.33 -0.255 0 O-C-N 123.299 0.374 . . . . 0.0 111.106 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 74.2 m -63.22 -37.34 86.86 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.983 0.421 . . . . 0.0 110.299 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 73.6 tp60 -63.86 -34.79 78.73 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.029 -178.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 94' ' ' ILE . . . . . 0.414 ' O ' ' O ' ' C' ' 91' ' ' GLN . 15.9 pt -100.92 140.14 20.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.655 -179.65 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo . . . . . 0 N--CA 1.485 0.998 0 N-CA-C 109.328 -1.066 . . . . 0.0 109.328 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 27' ' ' LEU . . . . . 0.521 ' CD2' ' H ' ' C' ' 27' ' ' LEU . 0.1 OUTLIER -71.45 148.87 46.43 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.323 -179.574 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 -81.07 148.39 29.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.861 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 71.6 t -66.19 135.83 27.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.439 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.21 -18.83 47.81 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.0 t -73.1 154.04 40.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 117.044 0.422 . . . . 0.0 110.528 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 48.0 ptt85 -46.54 161.62 0.06 Allowed 'General case' 0 N--CA 1.461 0.114 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 11.3 p -128.99 151.56 35.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.72 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -149.81 95.42 2.31 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 87.1 t -72.11 131.3 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.403 -179.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 90.2 mt -75.12 76.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-O 121.28 0.562 . . . . 0.0 109.543 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.14 -122.5 0.63 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -59.35 -25.7 64.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.212 -0.494 . . . . 0.0 109.966 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.8 42.77 1.29 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -73.79 145.74 44.8 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.275 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 52.6 ptt85 -141.75 165.1 28.4 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.963 0.411 . . . . 0.0 110.564 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 155.73 -109.39 0.4 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 43' ' ' THR . . . . . 0.478 ' HG1' ' N ' ' C' ' 44' ' ' VAL . 6.8 t -145.4 154.27 42.1 Favored 'General case' 0 C--O 1.243 0.726 0 CA-C-O 120.828 0.347 . . . . 0.0 111.257 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 44' ' ' VAL . . . . . 0.478 ' N ' ' HG1' ' C' ' 43' ' ' THR . 92.8 t -90.93 122.44 42.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.196 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.21 -159.12 0.2 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.953 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -64.35 145.05 56.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.346 0.593 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 47' ' ' VAL . . . . . 0.632 ' CG2' HE21 ' C' ' 91' ' ' GLN . 9.3 p -124.17 141.2 45.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.485 -178.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 120.66 -171.01 14.57 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 49' ' ' ALA . . . . . 0.451 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -68.01 141.89 56.09 Favored 'General case' 0 C--O 1.23 0.066 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 71.1 p -134.81 164.63 27.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.235 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.6 tp -59.16 -39.27 81.95 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.51 -45.66 84.68 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.871 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -149.27 145.69 27.2 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 110.865 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 63.6 p -83.13 168.04 17.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.682 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 55' ' ' GLY . . . . . 0.451 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 98.65 -143.4 16.62 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 40.5 pttt -136.59 106.79 6.37 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.47 0.652 . . . . 0.0 110.624 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 85.5 m95 -130.73 168.26 17.48 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.808 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 58' ' ' VAL . . . . . 0.461 ' N ' ' O ' ' C' ' 89' ' ' VAL . 64.6 t -125.57 130.61 72.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.574 -178.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -89.82 129.09 9.53 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 66.9 t -122.47 132.56 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.135 0.493 . . . . 0.0 110.921 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 45.7 mt -85.22 104.16 12.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.361 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 62' ' ' LEU . . . . . 0.442 ' O ' ' CD2' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -84.83 115.67 22.87 Favored 'General case' 0 C--O 1.232 0.174 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.923 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -67.08 -9.08 35.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.289 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 64' ' ' GLU . . . . . 0.503 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.76 -37.54 87.04 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.296 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 65' ' ' ALA . . . . . 0.503 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 86.59 44.34 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 110.672 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 66' ' ' LYS . . . . . 0.568 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.4 ptmt -146.68 106.95 4.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.076 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.96 -140.57 7.36 Favored Glycine 0 CA--C 1.52 0.352 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 68' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' C' ' 85' ' ' HIS . 7.9 mmtm -95.88 -174.74 3.21 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.277 0.56 . . . . 0.0 110.447 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -112.02 96.72 6.21 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 114.688 -1.142 . . . . 0.0 110.68 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -60.78 -15.05 25.55 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.986 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 71' ' ' GLY . . . . . 0.486 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.4 -45.09 94.81 Favored Glycine 0 N--CA 1.449 -0.5 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 72' ' ' THR . . . . . 0.486 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 21.2 p -163.25 115.19 1.49 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.012 0.435 . . . . 0.0 110.711 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 73' ' ' VAL . . . . . 0.526 ' O ' ' N ' ' C' ' 76' ' ' ARG . 38.8 t -129.53 123.73 58.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.355 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 74' ' ' GLN . . . . . 0.452 ' C ' ' H ' ' C' ' 76' ' ' ARG . 56.4 tt0 42.86 56.61 3.92 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.214 0.531 . . . . 0.0 111.336 179.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.3 4.76 6.85 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 76' ' ' ARG . . . . . 0.526 ' N ' ' O ' ' C' ' 73' ' ' VAL . 26.0 tpt180 -125.41 127.44 46.56 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.248 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 26.7 pttm -112.56 137.97 50.02 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.213 0.53 . . . . 0.0 111.158 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -93.13 -37.18 12.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.814 178.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 79' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' C' ' 80' ' ' THR . 50.5 t80 -172.6 153.39 2.8 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.323 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 80' ' ' THR . . . . . 0.45 ' N ' ' CD1' ' C' ' 79' ' ' PHE . 28.7 p -64.58 95.57 0.15 Allowed 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.48 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 81' ' ' CYS . . . . . 0.456 ' SG ' ' CG ' ' C' ' 85' ' ' HIS . 9.9 t -163.43 142.26 8.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.561 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -79.14 168.22 19.92 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.334 0.588 . . . . 0.0 110.819 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -46.36 150.47 0.63 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.879 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 84' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 105.06 -8.54 45.57 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 85' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -136.06 136.04 39.89 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.8 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.75 59.61 0.2 Allowed Glycine 0 C--N 1.337 0.596 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.0 mm -85.74 133.0 30.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -82.28 119.06 23.63 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.156 0.503 . . . . 0.0 110.064 -179.204 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 89' ' ' VAL . . . . . 0.461 ' O ' ' N ' ' C' ' 58' ' ' VAL . 5.0 m -139.73 164.86 23.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.104 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 90' ' ' ARG . . . . . 0.503 ' H ' ' HD3' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -97.12 166.71 11.45 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.939 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' C' C ' 91' ' ' GLN . . . . . 0.632 HE21 ' CG2' ' C' ' 47' ' ' VAL . 26.1 mp0 -59.61 -42.88 93.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.764 0.316 . . . . 0.0 110.735 -178.653 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 64.2 m -62.79 -36.03 81.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.379 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 16.8 tt0 -63.96 -35.93 82.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.444 -178.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 94' ' ' ILE . . . . . 0.403 HD13 HG22 ' C' ' 94' ' ' ILE . 35.4 pt -101.27 144.41 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.881 0.372 . . . . 0.0 110.59 179.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.946 -1.026 . . . . 0.0 111.113 -179.61 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo . . . . . 0 N--CA 1.485 1.02 0 N-CA-C 109.094 -1.156 . . . . 0.0 109.094 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 27' ' ' LEU . . . . . 0.43 ' CD2' ' H ' ' C' ' 27' ' ' LEU . 0.2 OUTLIER -81.92 168.25 18.1 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.771 179.857 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 80.1 mtp85 -120.85 147.34 45.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.354 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -57.01 141.92 13.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.217 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.75 -18.04 55.58 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 83.8 p -81.54 163.13 22.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.964 0.411 . . . . 0.0 110.923 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -50.66 153.36 1.7 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.935 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 33' ' ' VAL . . . . . 0.422 HG12 ' N ' ' C' ' 42' ' ' GLY . 12.3 p -125.39 149.77 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.939 0.399 . . . . 0.0 111.047 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -150.43 92.79 1.9 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 80.2 t -67.47 131.28 33.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.06 -179.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 42.5 mm -75.62 74.57 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.293 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -120.47 0.54 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.819 -0.913 . . . . 0.0 110.819 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.61 -27.19 66.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.021 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.14 44.98 1.04 Allowed Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -75.34 141.73 43.29 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 40.0 ptt180 -129.3 165.78 20.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.174 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 42' ' ' GLY . . . . . 0.422 ' N ' HG12 ' C' ' 33' ' ' VAL . . . 151.37 -130.28 3.11 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.129 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.4 m -131.91 140.98 49.22 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.119 0.485 . . . . 0.0 111.56 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 97.2 t -75.78 133.16 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.839 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 45' ' ' ALA . . . . . 0.428 ' CB ' ' O ' ' C' ' 59' ' ' GLY . . . -85.59 -159.6 0.46 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.967 0.413 . . . . 0.0 110.519 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 46' ' ' TYR . . . . . 0.426 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 84.6 t80 -65.34 144.89 56.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.171 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 47' ' ' VAL . . . . . 0.426 ' O ' ' CE2' ' C' ' 46' ' ' TYR . 19.2 m -118.42 154.15 20.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.969 -179.253 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.93 179.4 20.88 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 49' ' ' ALA . . . . . 0.479 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -68.53 149.36 49.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.089 0.471 . . . . 0.0 110.366 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 50' ' ' THR . . . . . 0.406 HG22 ' H ' ' C' ' 53' ' ' ALA . 7.6 t -149.22 174.98 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.698 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 86.3 mt -60.96 -39.45 89.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.603 -179.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 52' ' ' PHE . . . . . 0.495 ' CD2' ' CZ ' ' C' ' 88' ' ' PHE . 91.9 t80 -59.22 -46.59 88.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.612 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 53' ' ' ALA . . . . . 0.406 ' H ' HG22 ' C' ' 50' ' ' THR . . . -149.28 140.16 22.82 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.789 0.328 . . . . 0.0 110.412 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 72.7 p -83.74 168.91 15.78 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.405 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 55' ' ' GLY . . . . . 0.479 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 89.14 -153.51 23.63 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 56.6 mtmt -110.88 108.78 18.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.881 0.372 . . . . 0.0 110.478 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 83.8 m95 -134.0 161.38 34.97 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.021 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 58' ' ' VAL . . . . . 0.475 ' N ' ' O ' ' C' ' 89' ' ' VAL . 87.6 t -128.82 130.57 68.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.311 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 59' ' ' GLY . . . . . 0.428 ' O ' ' CB ' ' C' ' 45' ' ' ALA . . . -90.43 136.15 13.27 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 92.3 t -130.42 134.47 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.269 0.557 . . . . 0.0 111.334 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 6.3 pt -85.22 114.59 25.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.603 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 62' ' ' LEU . . . . . 0.614 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.7 OUTLIER -92.23 125.56 36.95 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.936 0.398 . . . . 0.0 110.666 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -67.53 -11.56 58.29 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.618 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 64' ' ' GLU . . . . . 0.49 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 79.8 mm-40 -61.16 -32.7 72.42 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.436 179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 65' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 86.9 35.85 0.02 OUTLIER 'General case' 0 C--N 1.34 0.185 0 O-C-N 123.504 0.503 . . . . 0.0 110.658 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 66' ' ' LYS . . . . . 0.537 ' N ' ' O ' ' C' ' 84' ' ' GLY . 65.0 pttt -134.98 136.46 42.21 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.12 -146.54 17.15 Favored Glycine 0 N--CA 1.461 0.313 0 N-CA-C 110.689 -0.965 . . . . 0.0 110.689 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 4.3 mmtm -97.5 -170.16 1.96 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.186 0.517 . . . . 0.0 110.351 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 69' ' ' ASN . . . . . 0.462 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.2 p-10 -114.46 99.47 7.58 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.749 -179.501 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -60.31 -16.99 39.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 71' ' ' GLY . . . . . 0.472 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.7 -43.14 96.52 Favored Glycine 0 C--O 1.226 -0.359 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 72' ' ' THR . . . . . 0.472 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 18.8 p -161.9 112.62 1.62 Allowed 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.713 0.292 . . . . 0.0 110.765 179.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 73' ' ' VAL . . . . . 0.509 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.6 t -127.53 123.26 61.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.233 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 74' ' ' GLN . . . . . 0.436 ' C ' ' H ' ' C' ' 76' ' ' ARG . 71.2 tp60 43.5 57.01 4.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.365 0.602 . . . . 0.0 110.601 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 61.78 4.81 6.08 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 76' ' ' ARG . . . . . 0.509 ' N ' ' O ' ' C' ' 73' ' ' VAL . 46.7 tpt85 -125.16 126.8 45.83 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 110.172 -0.306 . . . . 0.0 110.172 -179.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 77' ' ' LYS . . . . . 0.491 ' O ' ' NH1' ' C' ' 76' ' ' ARG . 63.2 pttt -108.93 137.98 46.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.879 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 51.8 m-85 -99.91 -31.24 11.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.8 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -171.58 151.0 2.85 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.388 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.0 p -64.19 98.16 0.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.942 0.401 . . . . 0.0 110.822 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 81' ' ' CYS . . . . . 0.412 ' O ' ' N ' ' C' ' 71' ' ' GLY . 4.1 t -168.91 142.92 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.432 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -84.07 170.56 13.75 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.525 0.679 . . . . 0.0 110.591 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -44.82 152.64 0.22 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.989 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 84' ' ' GLY . . . . . 0.537 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.18 -7.76 56.95 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 85' ' ' HIS . . . . . 0.614 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 7.0 m-70 -140.02 134.23 31.13 Favored 'General case' 0 C--O 1.24 0.564 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.7 58.47 0.16 Allowed Glycine 0 C--N 1.337 0.633 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -83.27 131.23 34.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 88' ' ' PHE . . . . . 0.495 ' CZ ' ' CD2' ' C' ' 52' ' ' PHE . 97.4 m-85 -79.42 118.99 21.81 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.79 -178.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 89' ' ' VAL . . . . . 0.475 ' O ' ' N ' ' C' ' 58' ' ' VAL . 12.1 m -141.52 163.47 20.34 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.262 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 90' ' ' ARG . . . . . 0.501 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -90.29 154.33 19.79 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.116 0.484 . . . . 0.0 110.841 179.788 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 91' ' ' GLN . . . . . 0.407 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.1 pt20 -52.54 -38.65 60.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.467 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 89.2 p -67.7 -33.32 74.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.096 0.474 . . . . 0.0 110.657 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -66.66 -21.21 66.11 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.594 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 94' ' ' ILE . . . . . 0.463 HD13 HG23 ' C' ' 94' ' ' ILE . 39.0 pt -117.24 146.65 21.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.642 -179.814 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo . . . . . 0 N--CA 1.483 0.859 0 N-CA-C 109.03 -1.181 . . . . 0.0 109.03 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 27' ' ' LEU . . . . . 0.609 ' CD2' ' H ' ' C' ' 27' ' ' LEU . 2.2 pt? -85.8 170.57 12.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.334 179.501 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 -125.73 147.93 49.22 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.418 0.627 . . . . 0.0 110.57 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.9 p -57.63 142.5 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.257 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.2 -18.78 47.99 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.114 -0.794 . . . . 0.0 111.114 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 31' ' ' SER . . . . . 0.402 ' O ' ' CG2' ' C' ' 44' ' ' VAL . 37.0 t -90.36 164.63 14.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.475 0.179 . . . . 0.0 110.523 179.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -60.75 161.03 8.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.207 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -133.67 151.09 32.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.806 -179.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -141.98 91.39 2.34 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.302 177.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.7 t -61.82 131.8 27.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 CA-C-O 121.116 0.484 . . . . 0.0 110.633 -179.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -77.61 88.65 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.416 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.95 -126.1 0.8 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -67.03 -12.58 60.31 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.927 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.04 60.34 0.53 Allowed Glycine 0 CA--C 1.52 0.395 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -105.68 143.68 33.49 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.982 0.42 . . . . 0.0 110.6 179.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -145.78 165.94 27.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.755 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 175.11 -125.76 1.11 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 96.4 m -127.8 136.39 51.4 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 120.715 0.293 . . . . 0.0 111.057 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 44' ' ' VAL . . . . . 0.402 ' CG2' ' O ' ' C' ' 31' ' ' SER . 43.1 t -72.51 128.89 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -94.82 -159.04 0.68 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.314 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -65.49 141.34 58.52 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.133 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 6.2 p -121.03 133.32 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.394 -179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.05 -174.05 21.6 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 49' ' ' ALA . . . . . 0.436 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -71.21 152.23 43.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.874 0.369 . . . . 0.0 110.272 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 50' ' ' THR . . . . . 0.501 HG23 ' H ' ' C' ' 53' ' ' ALA . 1.7 t -146.19 166.56 25.84 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.827 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 51' ' ' LEU . . . . . 0.43 ' N ' ' CD1' ' C' ' 51' ' ' LEU . 10.5 mp -60.67 -38.58 85.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.167 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 52' ' ' PHE . . . . . 0.529 ' N ' ' OE1' ' C' ' 74' ' ' GLN . 92.4 t80 -59.89 -44.76 94.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.206 179.148 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 53' ' ' ALA . . . . . 0.501 ' H ' HG23 ' C' ' 50' ' ' THR . . . -145.5 144.28 30.47 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.511 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 99.1 m -98.44 132.83 43.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.546 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 55' ' ' GLY . . . . . 0.436 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 136.98 -147.69 19.37 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -124.26 96.17 4.82 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 36.6 m95 -122.94 162.98 21.25 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.986 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 58' ' ' VAL . . . . . 0.482 ' N ' ' O ' ' C' ' 89' ' ' VAL . 59.2 t -125.15 128.27 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.773 -179.252 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.54 136.85 15.08 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 109.691 -1.363 . . . . 0.0 109.691 179.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.4 t -123.39 133.9 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.037 0.446 . . . . 0.0 111.038 -178.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 61' ' ' ILE . . . . . 0.431 HG23 HD11 ' C' ' 61' ' ' ILE . 16.4 mm -87.06 93.28 4.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.811 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 62' ' ' LEU . . . . . 0.617 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.6 OUTLIER -76.03 120.14 20.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.546 -179.409 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -67.85 -11.94 59.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.837 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 64' ' ' GLU . . . . . 0.481 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 80.7 mm-40 -63.37 -34.25 77.32 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.476 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 65' ' ' ALA . . . . . 0.481 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 83.42 47.18 0.02 OUTLIER 'General case' 0 C--N 1.338 0.105 0 O-C-N 123.322 0.389 . . . . 0.0 110.748 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 66' ' ' LYS . . . . . 0.552 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.4 ptpt -146.84 109.21 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.387 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.53 -140.5 7.25 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.449 -1.061 . . . . 0.0 110.449 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -97.19 -173.36 2.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.919 0.39 . . . . 0.0 110.125 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 42.3 p-10 -113.95 98.01 6.73 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.576 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 -61.65 -17.37 55.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.375 179.246 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 71' ' ' GLY . . . . . 0.475 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -58.93 -43.1 97.0 Favored Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 72' ' ' THR . . . . . 0.475 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 19.1 p -161.41 118.09 2.2 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 120.513 0.197 . . . . 0.0 110.636 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 73' ' ' VAL . . . . . 0.623 ' O ' ' N ' ' C' ' 76' ' ' ARG . 12.7 t -128.31 125.68 64.53 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 74' ' ' GLN . . . . . 0.529 ' OE1' ' N ' ' C' ' 52' ' ' PHE . 3.4 pt20 39.55 36.79 0.25 Allowed 'General case' 0 C--N 1.328 -0.364 0 O-C-N 123.148 0.28 . . . . 0.0 111.323 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 89.03 -19.56 37.78 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 76' ' ' ARG . . . . . 0.623 ' N ' ' O ' ' C' ' 73' ' ' VAL . 59.9 ttt85 -101.96 126.25 48.83 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 pttt -106.83 132.32 52.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.491 0.662 . . . . 0.0 111.209 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 78' ' ' TYR . . . . . 0.472 ' OH ' ' CG2' ' C' ' 50' ' ' THR . 3.1 m-85 -84.26 -40.65 17.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.063 178.268 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 79' ' ' PHE . . . . . 0.409 ' CG ' ' N ' ' C' ' 80' ' ' THR . 86.8 t80 -170.87 158.19 5.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.467 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 80' ' ' THR . . . . . 0.409 ' N ' ' CG ' ' C' ' 79' ' ' PHE . 82.7 p -64.12 96.95 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.975 0.417 . . . . 0.0 111.029 -179.499 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.31 144.9 4.65 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.305 179.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -86.57 169.45 12.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.191 0.519 . . . . 0.0 110.887 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -46.71 149.93 0.77 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.185 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 84' ' ' GLY . . . . . 0.552 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.36 -7.11 56.14 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -178.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 85' ' ' HIS . . . . . 0.617 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 6.3 m-70 -139.15 132.82 30.56 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.093 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.9 58.57 0.16 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.9 mm -82.34 132.39 31.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -83.66 116.68 22.76 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.482 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 89' ' ' VAL . . . . . 0.482 ' O ' ' N ' ' C' ' 58' ' ' VAL . 4.3 m -140.21 160.01 25.76 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.911 178.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 90' ' ' ARG . . . . . 0.585 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -85.97 162.62 18.44 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 120.791 0.329 . . . . 0.0 110.758 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 91' ' ' GLN . . . . . 0.455 ' O ' ' O ' ' C' ' 94' ' ' ILE . 96.0 mt-30 -59.31 -41.2 88.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.597 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 40.0 t -61.53 -37.99 85.78 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.432 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -63.2 -33.88 76.44 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.565 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 94' ' ' ILE . . . . . 0.455 ' O ' ' O ' ' C' ' 91' ' ' GLN . 34.1 pt -105.01 149.13 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 121.082 0.468 . . . . 0.0 110.799 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.596 179.826 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 N--CA 1.485 0.976 0 N-CA-C 109.287 -1.082 . . . . 0.0 109.287 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 1.3 tt -112.41 120.57 42.14 Favored 'General case' 0 CA--C 1.534 0.353 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 96.1 mtm-85 -73.79 127.01 31.68 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.969 0.414 . . . . 0.0 110.369 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -67.14 140.32 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 CA-C-O 121.361 0.601 . . . . 0.0 111.058 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.07 -16.38 57.23 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.032 -178.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 81.5 p -80.36 165.38 22.32 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.918 0.39 . . . . 0.0 111.606 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 32' ' ' ARG . . . . . 0.67 ' NE ' HH21 ' C' ' 41' ' ' ARG . 99.7 mtt180 -68.67 156.21 38.61 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.473 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 33' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' C' ' 44' ' ' VAL . 2.2 m -130.82 156.3 42.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.321 0 CA-C-O 121.216 0.531 . . . . 0.0 110.445 -179.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -139.39 99.41 3.73 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 177.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 74.1 t -62.37 130.3 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.419 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.943 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 96.9 mt -75.0 76.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.804 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -125.36 0.77 Allowed Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 65.4 pttt -60.01 -20.02 55.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.592 -0.304 . . . . 0.0 110.579 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.44 54.99 0.81 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 40' ' ' HIS . . . . . 0.416 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 66.7 t-80 -87.32 137.4 32.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.218 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 41' ' ' ARG . . . . . 0.67 HH21 ' NE ' ' C' ' 32' ' ' ARG . 78.0 ttt-85 -110.09 139.43 45.22 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.13 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . -172.14 -170.8 36.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 95.1 m -114.18 131.55 56.41 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 44' ' ' VAL . . . . . 0.431 ' N ' ' CG1' ' C' ' 33' ' ' VAL . 1.3 p -69.49 139.6 20.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.294 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -96.17 -156.88 0.55 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.375 -0.829 . . . . 0.0 109.274 178.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -63.66 142.37 58.42 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.201 0.524 . . . . 0.0 110.221 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 19.7 m -118.8 153.58 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.285 -178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 116.96 -175.83 15.91 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 49' ' ' ALA . . . . . 0.495 ' CB ' ' O ' ' C' ' 55' ' ' GLY . . . -68.13 141.2 56.14 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 50' ' ' THR . . . . . 0.428 ' OG1' ' OH ' ' C' ' 78' ' ' TYR . 60.3 p -137.69 167.7 21.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.289 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.5 tp -59.86 -41.16 90.84 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 52' ' ' PHE . . . . . 0.462 ' CE1' ' NZ ' ' C' ' 68' ' ' LYS . 88.8 t80 -58.74 -46.0 88.41 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.274 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.39 140.94 32.2 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.964 0.412 . . . . 0.0 110.677 179.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.3 p -84.44 167.63 16.25 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.745 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 55' ' ' GLY . . . . . 0.495 ' O ' ' CB ' ' C' ' 49' ' ' ALA . . . 87.1 -133.35 11.74 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -131.18 114.68 15.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.524 0.678 . . . . 0.0 110.513 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -137.52 156.04 48.57 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.45 179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 58' ' ' VAL . . . . . 0.401 ' HB ' ' O ' ' C' ' 89' ' ' VAL . 82.1 t -119.36 130.06 74.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.441 -179.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.37 135.49 12.91 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 75.1 t -125.94 132.69 70.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.07 0.462 . . . . 0.0 111.374 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.5 pt -83.5 95.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.561 0.696 . . . . 0.0 110.196 178.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 62' ' ' LEU . . . . . 0.579 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -70.12 120.82 16.38 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.335 -179.321 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 63' ' ' ASP . . . . . 0.416 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.0 m-20 -67.61 -11.1 57.39 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.4 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 64' ' ' GLU . . . . . 0.508 ' O ' ' CB ' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.19 -35.79 79.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.179 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 65' ' ' ALA . . . . . 0.508 ' CB ' ' O ' ' C' ' 64' ' ' GLU . . . 87.05 39.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.962 0.41 . . . . 0.0 110.397 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 66' ' ' LYS . . . . . 0.512 ' N ' ' O ' ' C' ' 84' ' ' GLY . 21.3 ptmt -135.6 135.56 40.34 Favored 'General case' 0 CA--C 1.521 -0.155 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.59 179.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.21 -146.79 16.45 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 68' ' ' LYS . . . . . 0.462 ' NZ ' ' CE1' ' C' ' 52' ' ' PHE . 17.5 ptpt -98.47 -168.0 1.58 Allowed 'General case' 0 C--O 1.238 0.452 0 CA-C-O 120.941 0.4 . . . . 0.0 110.736 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 69' ' ' ASN . . . . . 0.422 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 40.6 p-10 -111.8 105.42 13.89 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.56 -179.468 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 70' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' C' ' 70' ' ' ASP . 0.9 OUTLIER -63.93 -11.46 28.44 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.899 178.515 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 71' ' ' GLY . . . . . 0.494 ' O ' ' CG2' ' C' ' 72' ' ' THR . . . -60.29 -42.92 98.97 Favored Glycine 0 N--CA 1.45 -0.383 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 72' ' ' THR . . . . . 0.494 ' CG2' ' O ' ' C' ' 71' ' ' GLY . 20.4 p -163.91 115.38 1.36 Allowed 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 123.838 0.376 . . . . 0.0 110.683 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 73' ' ' VAL . . . . . 0.422 ' CG2' ' O ' ' C' ' 69' ' ' ASN . 16.8 t -131.12 119.02 43.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.8 mm-40 52.35 35.16 16.52 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.558 0.218 . . . . 0.0 111.441 179.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.62 -1.7 81.71 Favored Glycine 0 CA--C 1.517 0.195 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 76' ' ' ARG . . . . . 0.405 ' O ' ' N ' ' C' ' 73' ' ' VAL . 28.1 tpt180 -115.98 123.85 49.04 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.244 -0.478 . . . . 0.0 109.75 179.494 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -109.7 136.33 49.22 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-O 121.272 0.558 . . . . 0.0 110.645 -179.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 78' ' ' TYR . . . . . 0.428 ' OH ' ' OG1' ' C' ' 50' ' ' THR . 58.9 m-85 -93.66 -37.23 11.95 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.597 178.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -170.56 149.18 3.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.279 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 31.0 p -64.3 101.48 0.43 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.888 0.375 . . . . 0.0 111.615 -178.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.0 t -171.19 146.97 2.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.307 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -78.65 168.63 19.47 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.432 0.634 . . . . 0.0 110.717 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -43.57 157.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.307 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 84' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.86 -8.15 63.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 85' ' ' HIS . . . . . 0.579 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 30.7 m-70 -137.61 144.49 41.97 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.6 60.4 0.49 Allowed Glycine 0 N--CA 1.467 0.718 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 50.7 mm -93.77 127.37 45.86 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 88' ' ' PHE . . . . . 0.537 ' O ' ' CD2' ' C' ' 88' ' ' PHE . 49.0 p90 -77.34 119.7 21.33 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.276 0.56 . . . . 0.0 110.091 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 89' ' ' VAL . . . . . 0.401 ' O ' ' HB ' ' C' ' 58' ' ' VAL . 4.0 p -143.44 140.41 26.24 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.728 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 90' ' ' ARG . . . . . 0.56 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -65.59 151.52 46.28 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.954 -0.298 . . . . 0.0 110.925 -177.774 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 91' ' ' GLN . . . . . 0.528 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 3.8 pm0 -57.87 -33.75 69.02 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.836 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 81.7 p -64.95 -36.81 85.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.349 . . . . 0.0 110.849 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -67.59 -20.68 65.4 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.021 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 94' ' ' ILE . . . . . 0.455 ' O ' ' O ' ' C' ' 91' ' ' GLN . 24.3 pt -117.65 148.72 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.88 0.371 . . . . 0.0 110.142 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.583 -179.608 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 35.1 ptt-85 . . . . . 0 C--O 1.236 0.352 0 CA-C-O 121.456 0.646 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 29' ' ' VAL . . . . . 0.475 HG23 ' O ' ' C' ' 45' ' ' ALA . 3.4 p -57.28 145.0 8.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.206 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.34 -20.69 47.53 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -83.67 159.5 21.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.861 0.363 . . . . 0.0 110.791 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 39.4 ptt180 -50.72 161.85 0.31 Allowed 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 33' ' ' VAL . . . . . 0.715 HG12 ' C ' ' C' ' 42' ' ' GLY . 9.4 p -128.21 150.13 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.858 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -146.72 91.8 2.07 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.207 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 94.1 t -67.63 130.88 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.93 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 36' ' ' ILE . . . . . 0.444 ' O ' HG22 ' C' ' 36' ' ' ILE . 5.6 mm -76.17 74.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.508 0.67 . . . . 0.0 109.934 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.72 -119.77 0.5 Allowed Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.73 -17.94 27.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.121 -0.539 . . . . 0.0 109.966 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.21 41.72 3.66 Favored Glycine 0 N--CA 1.465 0.588 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 40' ' ' HIS . . . . . 0.622 ' ND1' HD11 ' C' ' 62' ' ' LEU . 64.8 m170 -75.4 147.37 40.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 110.694 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.4 ptm180 -134.77 163.18 30.38 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.748 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 42' ' ' GLY . . . . . 0.715 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 157.56 -127.25 1.88 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -178.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 98.6 m -131.89 142.85 49.79 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 120.912 0.386 . . . . 0.0 111.845 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 95.9 t -77.83 132.31 32.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.043 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 45' ' ' ALA . . . . . 0.507 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -85.77 -158.72 0.41 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.486 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 81.8 t80 -64.41 143.48 57.87 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 47' ' ' VAL . . . . . 0.559 HG22 HG22 ' C' ' 58' ' ' VAL . 89.9 t -119.64 131.75 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.613 -178.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.0 -176.09 19.45 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 49' ' ' ALA . . . . . 0.746 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -70.3 142.92 52.18 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-O 120.937 0.399 . . . . 0.0 110.015 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 69.6 p -138.6 169.58 17.54 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.473 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 97.1 mt -60.86 -38.82 86.88 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.993 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.0 t80 -59.06 -46.14 89.01 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.523 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.18 143.98 29.63 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.1 p -85.14 166.95 16.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.538 179.728 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 55' ' ' GLY . . . . . 0.746 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 94.17 -140.54 15.1 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -134.38 96.04 3.51 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.403 -0.469 . . . . 0.0 110.464 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -113.89 171.12 7.78 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.105 0.479 . . . . 0.0 109.785 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 58' ' ' VAL . . . . . 0.559 HG22 HG22 ' C' ' 47' ' ' VAL . 59.9 t -129.77 130.21 66.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.401 -179.425 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 59' ' ' GLY . . . . . 0.507 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -92.11 134.57 12.3 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 178.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 60' ' ' VAL . . . . . 0.475 HG13 HG21 ' C' ' 33' ' ' VAL . 59.5 t -122.19 132.96 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 CA-C-O 120.906 0.384 . . . . 0.0 111.162 -178.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 7.9 mm -81.39 96.22 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.954 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 62' ' ' LEU . . . . . 0.622 HD11 ' ND1' ' C' ' 40' ' ' HIS . 0.2 OUTLIER -78.17 114.85 17.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.577 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -66.89 -18.07 65.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.66 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 64' ' ' GLU . . . . . 0.655 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.3 mm-40 -60.55 -32.22 71.3 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.341 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 65' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 84.53 46.63 0.02 OUTLIER 'General case' 0 N--CA 1.461 0.09 0 CA-C-O 120.796 0.331 . . . . 0.0 110.772 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 66' ' ' LYS . . . . . 0.538 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.6 ptpt -141.3 110.89 6.44 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.168 0.508 . . . . 0.0 110.238 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 151.31 -143.02 10.02 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 68' ' ' LYS . . . . . 0.428 ' HG2' ' H ' ' C' ' 68' ' ' LYS . 18.3 ptmt -99.4 -171.99 2.18 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 69' ' ' ASN . . . . . 0.455 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 23.0 p-10 -112.07 102.53 10.73 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.603 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -62.41 -15.98 52.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.313 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 71' ' ' GLY . . . . . 0.647 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.42 -45.52 94.27 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.065 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 72' ' ' THR . . . . . 0.647 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.1 p -162.18 120.83 2.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.843 0.354 . . . . 0.0 110.667 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 73' ' ' VAL . . . . . 0.487 ' N ' ' O ' ' C' ' 76' ' ' ARG . 12.7 t -138.69 122.06 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.617 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 74' ' ' GLN . . . . . 0.441 ' C ' ' H ' ' C' ' 76' ' ' ARG . 55.6 tt0 44.78 58.44 3.95 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.275 0.56 . . . . 0.0 110.963 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 60.02 3.88 2.96 Favored Glycine 0 CA--C 1.517 0.186 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 76' ' ' ARG . . . . . 0.487 ' O ' ' N ' ' C' ' 73' ' ' VAL . 17.2 tpp180 -124.75 129.59 50.77 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.862 0.363 . . . . 0.0 110.373 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -113.34 136.43 52.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.271 0.558 . . . . 0.0 111.078 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -88.78 -39.29 14.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.862 178.753 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -173.33 158.97 3.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.486 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -65.46 96.99 0.27 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.843 0.354 . . . . 0.0 111.001 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.3 t -169.2 144.82 3.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.522 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 49.8 p-10 -84.11 172.16 12.21 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.275 0.56 . . . . 0.0 110.82 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -47.68 151.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.165 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 84' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.03 -6.8 56.8 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 85' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -137.74 128.27 26.61 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 124.73 54.32 0.18 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.736 -0.546 . . . . 0.0 111.736 179.695 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 87' ' ' ILE . . . . . 0.457 HD12 HD23 ' C' ' 62' ' ' LEU . 96.7 mt -80.43 129.36 37.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 88' ' ' PHE . . . . . 0.569 ' CD2' ' O ' ' C' ' 88' ' ' PHE . 48.6 p90 -74.94 119.35 19.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.087 0.47 . . . . 0.0 111.063 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 89' ' ' VAL . . . . . 0.496 HG21 ' CG2' ' C' ' 94' ' ' ILE . 4.5 m -140.5 162.63 23.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 90' ' ' ARG . . . . . 0.581 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -91.14 163.46 14.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.728 179.732 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' C' C ' 91' ' ' GLN . . . . . . . . . . . . . 55.6 mt-30 -59.31 -42.63 91.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.721 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 67.7 m -63.16 -33.84 76.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.245 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 93' ' ' GLN . . . . . 0.526 ' OE1' ' NH1' ' C' ' 90' ' ' ARG . 72.5 tp60 -64.29 -36.95 85.79 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.655 -178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 94' ' ' ILE . . . . . 0.496 ' CG2' HG21 ' C' ' 89' ' ' VAL . 24.1 pt -99.44 139.3 21.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.051 0.453 . . . . 0.0 110.453 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 59.5 tt0 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.775 -179.655 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 62.7 ttp180 . . . . . 0 N--CA 1.452 -0.339 0 CA-C-O 120.975 0.417 . . . . 0.0 110.798 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 29' ' ' VAL . . . . . 0.467 ' HA ' HG13 ' C' ' 44' ' ' VAL . 1.6 p -55.9 140.62 13.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.059 179.647 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.7 -9.94 62.4 Favored Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 31' ' ' SER . . . . . 0.534 ' O ' HG12 ' C' ' 44' ' ' VAL . 67.5 m -92.67 163.76 13.65 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.942 0.401 . . . . 0.0 111.045 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 17.7 ptm180 -61.62 159.11 13.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.318 179.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 33' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' C' ' 42' ' ' GLY . 2.6 m -135.7 160.36 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 34' ' ' GLU . . . . . 0.508 ' N ' ' OXT' ' C' ' 95' ' ' GLN . 77.3 mm-40 -133.2 96.02 3.66 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 177.55 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 84.9 t -61.07 131.2 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.702 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 36' ' ' ILE . . . . . 0.493 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 6.5 mm -76.68 82.76 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-O 121.426 0.632 . . . . 0.0 110.027 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.28 -125.97 0.79 Allowed Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -64.02 -18.47 64.35 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.306 -0.447 . . . . 0.0 110.454 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.12 55.98 0.59 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 40' ' ' HIS . . . . . 0.526 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 61.0 t-80 -95.44 154.9 16.97 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.799 0.333 . . . . 0.0 110.404 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 41' ' ' ARG . . . . . 0.467 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 37.2 ptt-85 -128.52 157.54 40.89 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.337 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 42' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' C' ' 33' ' ' VAL . . . 176.33 -166.37 37.35 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.5 m -111.11 132.09 54.55 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-O 120.903 0.382 . . . . 0.0 110.667 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 44' ' ' VAL . . . . . 0.534 HG12 ' O ' ' C' ' 31' ' ' SER . 1.5 p -72.26 135.21 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.83 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 45' ' ' ALA . . . . . 0.409 ' O ' HG22 ' C' ' 44' ' ' VAL . . . -87.21 -156.48 0.33 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.801 178.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 46' ' ' TYR . . . . . 0.402 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 91.0 t80 -63.42 140.68 58.9 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.065 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 47' ' ' VAL . . . . . 0.402 ' O ' ' CE2' ' C' ' 46' ' ' TYR . 30.4 m -110.47 153.94 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.063 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.49 -175.3 22.56 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.248 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 49' ' ' ALA . . . . . 0.784 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -67.99 153.78 43.0 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.073 0.463 . . . . 0.0 109.971 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 50' ' ' THR . . . . . 0.536 HG23 ' H ' ' C' ' 53' ' ' ALA . 8.1 t -142.45 171.38 14.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.34 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 51' ' ' LEU . . . . . 0.529 HD22 ' N ' ' C' ' 51' ' ' LEU . 3.9 mm? -61.23 -39.27 89.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.471 -179.146 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 t80 -58.54 -45.72 88.32 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.368 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 53' ' ' ALA . . . . . 0.536 ' H ' HG23 ' C' ' 50' ' ' THR . . . -148.98 146.4 27.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.297 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 11.0 t -87.92 171.94 9.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 55' ' ' GLY . . . . . 0.784 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 96.14 -156.8 21.38 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 -179.479 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -119.27 106.83 12.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.091 0.472 . . . . 0.0 110.607 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 57' ' ' TRP . . . . . 0.58 ' HE1' ' NE ' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -135.22 170.67 15.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.825 179.466 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' C' C ' 58' ' ' VAL . . . . . 0.522 ' CG1' HG23 ' C' ' 44' ' ' VAL . 57.4 t -131.37 132.36 62.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.56 -0.746 . . . . 0.0 111.343 -179.305 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.46 132.94 11.37 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 72.9 t -127.35 134.28 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.556 0.693 . . . . 0.0 111.42 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.6 pt -85.06 119.93 34.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.964 178.527 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 62' ' ' LEU . . . . . 0.565 HD22 ' CD1' ' C' ' 87' ' ' ILE . 3.8 tp -92.24 122.21 34.5 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.093 -178.706 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 63' ' ' ASP . . . . . 0.526 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.3 m-20 -67.46 -14.15 62.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.375 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 64' ' ' GLU . . . . . 0.658 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 77.7 mm-40 -62.66 -31.05 71.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.561 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 65' ' ' ALA . . . . . 0.658 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.8 42.28 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.142 0 CA-C-O 120.958 0.409 . . . . 0.0 110.556 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 66' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' C' ' 84' ' ' GLY . 18.9 ptmt -140.4 120.16 13.43 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.978 179.265 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 146.21 -148.25 19.8 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.521 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 68' ' ' LYS . . . . . 0.501 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 40.8 tttt -97.4 -166.55 1.4 Allowed 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 69' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' C' ' 69' ' ' ASN . 1.2 m-20 -104.18 95.94 6.31 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.227 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 70' ' ' ASP . . . . . 0.557 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 5.4 t70 -60.48 -23.07 64.2 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.681 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 71' ' ' GLY . . . . . 0.53 ' O ' HG23 ' C' ' 72' ' ' THR . . . -59.06 -40.28 95.38 Favored Glycine 0 C--O 1.224 -0.482 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.35 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 72' ' ' THR . . . . . 0.53 HG23 ' O ' ' C' ' 71' ' ' GLY . 38.1 p -158.5 116.47 2.95 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.807 0.337 . . . . 0.0 110.52 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 73' ' ' VAL . . . . . 0.448 HG23 ' O ' ' C' ' 69' ' ' ASN . 58.6 t -129.88 126.78 62.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.511 179.705 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 47.58 45.93 17.73 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.21 0.529 . . . . 0.0 110.704 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.64 3.13 39.77 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 76' ' ' ARG . . . . . 0.419 ' N ' ' O ' ' C' ' 73' ' ' VAL . 20.3 tpp85 -124.81 129.79 51.12 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.873 0.368 . . . . 0.0 110.371 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -109.44 138.92 45.08 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.883 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -105.35 -26.97 11.77 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.464 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 79' ' ' PHE . . . . . 0.557 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 31.3 t80 -169.84 142.21 2.39 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.232 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 80' ' ' THR . . . . . 0.451 ' H ' HG22 ' C' ' 80' ' ' THR . 0.0 OUTLIER -64.27 106.3 1.07 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.054 0.454 . . . . 0.0 111.363 -179.731 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.1 t -169.19 145.07 3.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.299 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -82.26 171.14 14.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.261 0.553 . . . . 0.0 110.686 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -44.81 155.28 0.11 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.292 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 84' ' ' GLY . . . . . 0.526 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 95.45 -3.73 66.22 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 85' ' ' HIS . . . . . 0.572 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.3 OUTLIER -139.58 140.29 37.02 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.339 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.38 60.0 0.32 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 87' ' ' ILE . . . . . 0.565 ' CD1' HD22 ' C' ' 62' ' ' LEU . 95.9 mt -94.25 130.32 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -75.6 120.47 21.05 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.506 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 89' ' ' VAL . . . . . 0.52 HG21 HG21 ' C' ' 94' ' ' ILE . 20.8 m -139.48 162.53 26.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.443 179.278 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 90' ' ' ARG . . . . . 0.58 ' NE ' ' HE1' ' C' ' 57' ' ' TRP . 5.5 mpt_? -93.89 150.71 20.13 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.024 0.44 . . . . 0.0 110.249 -179.256 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 91' ' ' GLN . . . . . 0.693 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 1.3 pm0 -51.57 -39.39 57.78 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.142 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 78.9 p -69.99 -28.33 65.43 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.053 0.454 . . . . 0.0 110.368 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 93' ' ' GLN . . . . . 0.493 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.6 tt0 -70.69 -20.19 62.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.501 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 94' ' ' ILE . . . . . 0.52 HG21 HG21 ' C' ' 89' ' ' VAL . 48.1 pt -128.38 163.09 33.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.074 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 95' ' ' GLN . . . . . 0.508 ' OXT' ' N ' ' C' ' 34' ' ' GLU . 59.8 tt0 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.453 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 86.0 mtp180 . . . . . 0 CA--C 1.52 -0.206 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 29' ' ' VAL . . . . . 0.442 ' HA ' HG23 ' C' ' 44' ' ' VAL . 2.1 p -52.68 144.4 3.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.257 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.51 -9.71 75.43 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 31' ' ' SER . . . . . 0.501 ' O ' HG22 ' C' ' 44' ' ' VAL . 74.2 m -86.5 165.07 16.55 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.458 . . . . 0.0 111.275 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -58.28 151.14 20.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.881 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 33' ' ' VAL . . . . . 0.706 HG12 ' C ' ' C' ' 42' ' ' GLY . 14.0 p -121.76 150.94 25.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.835 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 34' ' ' GLU . . . . . 0.402 ' N ' HG22 ' C' ' 33' ' ' VAL . 85.2 tt0 -147.43 97.3 2.83 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.29 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -70.7 132.35 33.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.697 -178.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 36' ' ' ILE . . . . . 0.487 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 5.9 mm -71.95 80.3 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.509 179.674 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.29 -126.86 0.84 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -62.99 -21.12 65.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.355 -0.423 . . . . 0.0 110.77 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 107.87 55.49 0.61 Allowed Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 40' ' ' HIS . . . . . 0.544 ' CE1' ' O ' ' C' ' 41' ' ' ARG . 41.8 t-80 -84.93 140.17 31.3 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 121.158 0.504 . . . . 0.0 111.681 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 41' ' ' ARG . . . . . 0.544 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 11.6 ptm85 -119.73 169.73 9.84 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.285 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 42' ' ' GLY . . . . . 0.706 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 150.48 -131.2 3.48 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -178.259 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 12.3 t -142.67 154.2 44.11 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 111.56 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 44' ' ' VAL . . . . . 0.501 HG22 ' O ' ' C' ' 31' ' ' SER . 3.2 m -88.18 138.88 18.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.024 179.058 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.19 -158.79 0.49 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.962 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 75.1 t80 -64.8 142.53 58.4 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.122 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 47' ' ' VAL . . . . . 0.496 HG23 HG22 ' C' ' 58' ' ' VAL . 8.7 p -113.17 131.98 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.688 -178.715 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.14 -173.81 24.03 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 49' ' ' ALA . . . . . 0.566 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -66.79 145.78 55.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.079 0.466 . . . . 0.0 110.222 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 50' ' ' THR . . . . . 0.452 ' O ' ' O ' ' C' ' 53' ' ' ALA . 19.5 m -126.64 159.37 33.81 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.862 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 51' ' ' LEU . . . . . 0.44 ' N ' HG22 ' C' ' 50' ' ' THR . 88.8 mt -60.28 -39.54 87.23 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -59.16 -46.48 88.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 0.0 109.943 179.401 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 53' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -141.72 141.61 33.29 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 110.149 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 9.9 t -89.17 162.12 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.937 -179.651 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 55' ' ' GLY . . . . . 0.566 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 108.78 -145.95 16.52 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 64.6 mttp -123.68 116.4 23.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.993 0.425 . . . . 0.0 110.359 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -141.55 164.2 30.86 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.326 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 58' ' ' VAL . . . . . 0.496 HG22 HG23 ' C' ' 47' ' ' VAL . 75.2 t -122.54 128.51 75.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.755 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.48 141.74 19.88 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 70.8 t -127.09 133.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 120.879 0.371 . . . . 0.0 110.531 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 11.7 mm -82.2 95.01 3.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 62' ' ' LEU . . . . . 0.564 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -74.57 104.86 5.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.132 -178.865 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 63' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' C' ' 64' ' ' GLU . 54.0 p30 -65.88 -9.88 33.27 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.992 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 64' ' ' GLU . . . . . 0.649 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 75.9 mm-40 -63.21 -32.15 73.47 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.475 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 65' ' ' ALA . . . . . 0.649 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 91.08 39.44 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.042 0.449 . . . . 0.0 110.555 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 66' ' ' LYS . . . . . 0.543 ' N ' ' O ' ' C' ' 84' ' ' GLY . 23.1 pttp -140.75 140.87 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.18 178.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 121.89 -150.15 17.07 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.789 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 9.4 mmtt -95.81 -171.51 2.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.39 0.614 . . . . 0.0 111.149 -179.03 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 69' ' ' ASN . . . . . 0.541 ' ND2' ' O ' ' C' ' 72' ' ' THR . 46.9 p-10 -106.09 102.01 11.46 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.543 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 70' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 7.3 t0 -62.06 -23.73 66.66 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.461 -0.791 . . . . 0.0 108.969 179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 71' ' ' GLY . . . . . 0.531 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.07 -41.83 94.76 Favored Glycine 0 C--O 1.226 -0.38 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 72' ' ' THR . . . . . 0.541 ' O ' ' ND2' ' C' ' 69' ' ' ASN . 32.7 p -158.55 118.31 3.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.922 0.392 . . . . 0.0 110.838 179.289 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 73' ' ' VAL . . . . . 0.466 ' O ' ' N ' ' C' ' 76' ' ' ARG . 39.6 t -126.43 122.96 62.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.685 179.225 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 68.7 tp60 45.05 49.99 9.36 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.074 0.464 . . . . 0.0 111.544 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.56 1.79 31.8 Favored Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.259 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 76' ' ' ARG . . . . . 0.466 ' N ' ' O ' ' C' ' 73' ' ' VAL . 76.3 ttt180 -124.78 126.09 45.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.374 -0.413 . . . . 0.0 110.325 -179.449 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -107.34 137.92 44.5 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-O 121.363 0.601 . . . . 0.0 111.19 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 78' ' ' TYR . . . . . 0.425 ' OH ' ' OG1' ' C' ' 50' ' ' THR . 1.7 m-85 -98.57 -32.94 11.18 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.371 178.343 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 79' ' ' PHE . . . . . 0.539 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 86.0 t80 -169.55 151.73 4.48 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.373 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 44.0 p -64.9 108.87 1.9 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.745 0.307 . . . . 0.0 111.349 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -172.63 148.32 1.92 Allowed 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.329 179.032 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -86.0 169.87 12.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.153 0.501 . . . . 0.0 111.179 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -50.57 145.05 7.06 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.002 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 84' ' ' GLY . . . . . 0.543 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 104.05 -4.34 45.2 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 85' ' ' HIS . . . . . 0.564 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 4.0 m-70 -140.97 136.2 31.93 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.145 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.95 49.79 0.32 Allowed Glycine 0 N--CA 1.47 0.907 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.331 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 97.4 mt -83.78 135.18 25.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -84.16 119.11 24.62 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.528 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 89' ' ' VAL . . . . . 0.455 HG21 HG23 ' C' ' 94' ' ' ILE . 16.2 m -136.51 162.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 178.515 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 90' ' ' ARG . . . . . 0.586 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -90.78 155.04 19.09 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.599 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 91' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' C' ' 94' ' ' ILE . 29.2 pt20 -53.22 -38.97 63.4 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.733 -179.545 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 66.6 m -63.18 -37.19 86.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.223 0.535 . . . . 0.0 110.172 178.574 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 93' ' ' GLN . . . . . 0.487 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.9 tt0 -65.02 -30.05 71.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.109 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 94' ' ' ILE . . . . . 0.455 HG23 HG21 ' C' ' 89' ' ' VAL . 17.1 pt -108.93 145.43 15.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.975 0.417 . . . . 0.0 110.461 179.637 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.745 179.98 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 78.0 mtp85 . . . . . 0 N--CA 1.465 0.287 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 29' ' ' VAL . . . . . 0.44 ' H ' HG13 ' C' ' 29' ' ' VAL . 6.1 m -50.66 143.21 2.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 30' ' ' GLY . . . . . 0.447 ' N ' HG23 ' C' ' 44' ' ' VAL . . . 91.92 -8.27 78.27 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 31' ' ' SER . . . . . 0.527 ' O ' HG22 ' C' ' 44' ' ' VAL . 45.7 t -89.05 163.73 15.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.982 0.42 . . . . 0.0 111.426 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -59.23 149.15 29.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.156 179.231 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 33' ' ' VAL . . . . . 0.791 HG12 HG13 ' C' ' 44' ' ' VAL . 2.5 m -126.81 159.78 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.013 0.435 . . . . 0.0 110.035 -179.261 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -140.52 93.64 2.64 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 35' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' C' ' 37' ' ' GLY . 84.2 t -56.54 126.54 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.739 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 36' ' ' ILE . . . . . 0.618 ' O ' HG22 ' C' ' 36' ' ' ILE . 4.6 mm -67.18 77.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 CA-C-O 121.582 0.706 . . . . 0.0 109.333 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' C' ' 35' ' ' VAL . . . -163.17 -126.61 0.83 Allowed Glycine 0 CA--C 1.519 0.311 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -64.48 -17.31 63.74 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.274 179.396 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.11 58.07 0.89 Allowed Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 40' ' ' HIS . . . . . 0.73 ' HE2' ' H ' ' C' ' 63' ' ' ASP . 75.7 t60 -89.82 138.95 31.05 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 111.124 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 41' ' ' ARG . . . . . 0.517 ' O ' ' CD2' ' C' ' 40' ' ' HIS . 87.6 mtm-85 -89.87 162.71 15.33 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.675 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 42' ' ' GLY . . . . . 0.47 ' C ' HG22 ' C' ' 33' ' ' VAL . . . 171.64 -172.4 44.58 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 85.4 m -124.71 131.95 53.42 Favored 'General case' 0 C--O 1.24 0.569 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 44' ' ' VAL . . . . . 0.791 HG13 HG12 ' C' ' 33' ' ' VAL . 0.2 OUTLIER -72.58 121.14 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.671 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.07 -157.5 0.12 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.934 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -63.61 142.0 58.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.569 -179.614 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 47' ' ' VAL . . . . . 0.511 HG23 HG22 ' C' ' 58' ' ' VAL . 7.2 p -117.59 135.93 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.176 -179.055 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.99 -177.73 19.5 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 49' ' ' ALA . . . . . 0.567 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -70.45 141.44 52.06 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.974 0.416 . . . . 0.0 110.245 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 47.7 p -139.43 168.58 19.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.293 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 83.3 mt -60.78 -39.35 88.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.974 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 82.8 t80 -59.42 -46.28 89.17 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.215 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -145.94 142.38 28.66 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.012 0.434 . . . . 0.0 110.526 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 60.3 p -85.44 169.12 13.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.914 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 55' ' ' GLY . . . . . 0.567 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 89.66 -146.06 18.67 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -125.77 101.62 6.94 Favored 'General case' 0 N--CA 1.464 0.262 0 O-C-N 122.603 -0.351 . . . . 0.0 110.237 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -121.32 166.45 14.04 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 58' ' ' VAL . . . . . 0.511 HG22 HG23 ' C' ' 47' ' ' VAL . 51.2 t -127.03 129.41 71.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.298 -179.338 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.61 129.72 9.9 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.6 t -123.81 131.63 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 121.244 0.545 . . . . 0.0 110.805 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 10.1 pt -82.19 126.08 39.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.907 179.084 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 62' ' ' LEU . . . . . 0.6 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 3.5 tp -102.33 111.48 23.8 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 63' ' ' ASP . . . . . 0.73 ' H ' ' HE2' ' C' ' 40' ' ' HIS . 42.8 t0 -59.71 -11.1 4.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.127 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 64' ' ' GLU . . . . . 0.64 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.6 mm-40 -62.01 -34.01 75.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.286 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 65' ' ' ALA . . . . . 0.64 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.67 46.28 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.858 0.361 . . . . 0.0 110.546 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 66' ' ' LYS . . . . . 0.546 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.7 ptpt -149.79 104.09 3.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.355 0.597 . . . . 0.0 110.105 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.43 -143.19 8.64 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -179.417 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -96.62 -167.48 1.57 Allowed 'General case' 0 C--O 1.241 0.624 0 CA-C-O 121.104 0.478 . . . . 0.0 109.933 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -117.48 98.72 6.55 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.412 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 76.2 m-20 -62.7 -14.96 50.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.76 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 71' ' ' GLY . . . . . 0.671 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.69 -42.75 96.45 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.069 -1.063 . . . . 0.0 110.63 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 72' ' ' THR . . . . . 0.671 HG23 ' O ' ' C' ' 71' ' ' GLY . 18.9 p -163.22 117.75 1.66 Allowed 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.978 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 73' ' ' VAL . . . . . . . . . . . . . 26.1 t -134.72 122.75 39.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.583 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 51.11 36.37 15.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.743 0.306 . . . . 0.0 111.309 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.58 -2.66 66.64 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 76' ' ' ARG . . . . . . . . . . . . . 16.8 tpp180 -116.11 120.68 39.82 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.351 -0.425 . . . . 0.0 109.937 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -103.14 126.26 50.23 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.375 0.607 . . . . 0.0 110.633 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 83.3 m-85 -79.89 -37.61 34.4 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.861 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 56.8 t80 -171.04 151.74 3.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.392 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.5 p -64.92 98.48 0.28 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.955 0.407 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 6.1 t -167.56 146.86 4.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.519 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -81.72 170.67 15.48 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.264 0.555 . . . . 0.0 110.983 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -49.57 155.33 0.8 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.174 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 84' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.8 -7.22 62.92 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 85' ' ' HIS . . . . . 0.6 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 18.5 m-70 -138.39 130.49 28.5 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.266 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 123.88 59.49 0.19 Allowed Glycine 0 C--N 1.341 0.856 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.236 179.705 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 87' ' ' ILE . . . . . 0.427 ' CD1' HD22 ' C' ' 62' ' ' LEU . 97.9 mt -90.62 125.5 43.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.609 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 88' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' C' ' 88' ' ' PHE . 49.4 p90 -70.79 120.34 16.24 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 120.973 0.416 . . . . 0.0 110.587 -179.13 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 89' ' ' VAL . . . . . . . . . . . . . 20.5 m -139.01 160.58 29.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 90' ' ' ARG . . . . . 0.495 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -92.91 155.15 17.77 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -179.701 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 91' ' ' GLN . . . . . 0.471 ' O ' ' O ' ' C' ' 94' ' ' ILE . 0.0 OUTLIER -52.74 -39.83 62.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.081 -179.685 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 92' ' ' SER . . . . . 0.434 ' N ' ' CD ' ' C' ' 91' ' ' GLN . 57.7 m -64.71 -37.14 86.59 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.996 0.427 . . . . 0.0 110.403 178.379 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 93' ' ' GLN . . . . . 0.495 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.2 tt0 -64.75 -19.23 65.68 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.912 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 94' ' ' ILE . . . . . 0.471 ' O ' ' O ' ' C' ' 91' ' ' GLN . 47.1 pt -123.46 153.79 29.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.668 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 95' ' ' GLN . . . . . 0.447 ' OXT' ' O ' ' C' ' 94' ' ' ILE . 69.2 tp60 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.06 -0.971 . . . . 0.0 110.907 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 . . . . . 0 C--O 1.233 0.23 0 CA-C-O 120.976 0.417 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 29' ' ' VAL . . . . . 0.432 ' HA ' HG13 ' C' ' 44' ' ' VAL . 2.6 p -62.12 138.07 23.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.014 0.435 . . . . 0.0 110.115 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.27 63.68 Favored Glycine 0 CA--C 1.533 1.202 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.093 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 31' ' ' SER . . . . . 0.442 ' O ' HG12 ' C' ' 44' ' ' VAL . 70.9 m -89.76 163.1 15.21 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.7 0.286 . . . . 0.0 111.16 179.737 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -62.18 150.41 38.88 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.087 0.47 . . . . 0.0 111.19 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m -131.14 155.51 41.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.07 100.44 4.28 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.148 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 35' ' ' VAL . . . . . 0.471 ' HA ' HG22 ' C' ' 94' ' ' ILE . 88.0 t -64.94 130.1 29.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.876 -178.511 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 36' ' ' ILE . . . . . 0.453 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 8.4 mm -82.97 75.43 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.72 -121.37 0.57 Allowed Glycine 0 CA--C 1.522 0.478 0 N-CA-C 110.696 -0.961 . . . . 0.0 110.696 -178.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -58.17 -29.4 65.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.041 -0.58 . . . . 0.0 109.951 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.68 59.78 0.51 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 40' ' ' HIS . . . . . 0.419 ' CE1' ' CG ' ' C' ' 64' ' ' GLU . 94.4 m-70 -103.5 150.55 23.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.038 0.447 . . . . 0.0 110.635 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 53.1 ptt85 -137.76 154.78 49.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.744 -179.155 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.94 -122.7 0.94 Allowed Glycine 0 C--O 1.226 -0.351 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 43' ' ' THR . . . . . 0.605 ' CG2' HD12 ' C' ' 61' ' ' ILE . 5.3 t -141.02 154.62 46.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.843 179.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 44' ' ' VAL . . . . . 0.506 HG23 ' CG1' ' C' ' 58' ' ' VAL . 1.2 p -91.72 141.57 14.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.997 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 45' ' ' ALA . . . . . 0.46 ' O ' HG22 ' C' ' 44' ' ' VAL . . . -88.85 -154.31 0.29 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.549 179.062 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -62.69 141.95 58.32 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.115 0.483 . . . . 0.0 110.645 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 72.9 t -112.59 129.84 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.688 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 127.37 -172.97 18.66 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 49' ' ' ALA . . . . . 0.713 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.16 146.98 52.91 Favored 'General case' 0 C--N 1.334 -0.071 0 CA-C-O 120.914 0.387 . . . . 0.0 110.019 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 50' ' ' THR . . . . . 0.412 ' O ' ' O ' ' C' ' 53' ' ' ALA . 69.7 p -133.26 167.12 20.95 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.121 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.84 -40.78 89.68 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -57.87 -46.6 84.62 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.359 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 53' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -143.76 144.4 31.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.819 0.342 . . . . 0.0 110.285 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 10.0 t -90.12 165.29 14.07 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.385 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 55' ' ' GLY . . . . . 0.713 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 101.22 -152.81 18.96 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 60.6 mtpt -119.94 112.07 18.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.551 -179.371 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -139.12 171.51 14.19 Favored 'General case' 0 CA--C 1.517 -0.296 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 58' ' ' VAL . . . . . 0.506 ' CG1' HG23 ' C' ' 44' ' ' VAL . 50.4 t -131.3 133.16 62.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.637 -178.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -91.4 139.16 14.64 Favored Glycine 0 CA--C 1.532 1.134 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.329 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.69 136.85 59.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-O 121.085 0.469 . . . . 0.0 111.287 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 61' ' ' ILE . . . . . 0.605 HD12 ' CG2' ' C' ' 43' ' ' THR . 41.5 mt -88.45 99.87 9.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.182 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.1 118.78 20.69 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -67.53 -13.05 61.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.239 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 64' ' ' GLU . . . . . 0.653 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.3 mm-40 -62.28 -36.16 81.23 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.42 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 65' ' ' ALA . . . . . 0.653 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.79 44.05 0.01 OUTLIER 'General case' 0 C--N 1.342 0.269 0 CA-C-O 120.911 0.386 . . . . 0.0 110.748 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 66' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' C' ' 84' ' ' GLY . 14.4 ptpt -139.58 119.12 13.04 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.771 178.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 144.73 -146.0 15.97 Favored Glycine 0 CA--C 1.518 0.232 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.457 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 68' ' ' LYS . . . . . 0.444 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 36.6 tttt -98.01 -168.75 1.71 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.992 0.425 . . . . 0.0 109.973 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 69' ' ' ASN . . . . . 0.444 ' H ' ' HG2' ' C' ' 68' ' ' LYS . 10.9 p30 -112.65 95.74 5.59 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.157 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 70' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' C' ' 70' ' ' ASP . 3.9 p-10 -65.26 -10.21 30.29 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.469 -0.493 . . . . 0.0 110.245 178.57 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 71' ' ' GLY . . . . . 0.663 ' O ' HG23 ' C' ' 72' ' ' THR . . . -60.34 -41.78 98.58 Favored Glycine 0 C--O 1.224 -0.489 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.225 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 72' ' ' THR . . . . . 0.663 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.6 p -162.36 109.7 1.32 Allowed 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.879 0.371 . . . . 0.0 110.662 179.621 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 73' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' C' ' 76' ' ' ARG . 43.7 t -125.94 122.36 61.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.3 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 51.69 35.74 15.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.124 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.88 -1.67 72.71 Favored Glycine 0 CA--C 1.52 0.399 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 76' ' ' ARG . . . . . 0.425 ' N ' ' O ' ' C' ' 73' ' ' VAL . 60.2 ttm-85 -116.01 125.51 52.57 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.096 -0.552 . . . . 0.0 109.768 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.7 pttp -112.29 137.47 50.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.658 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -96.52 -36.11 10.88 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 79' ' ' PHE . . . . . 0.56 ' CD1' HD11 ' C' ' 61' ' ' ILE . 22.4 t80 -164.68 145.76 7.92 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.299 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 30.6 p -64.29 104.45 0.76 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.922 0.391 . . . . 0.0 111.306 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 10.7 t -171.3 144.95 2.09 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.527 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -79.93 169.19 18.24 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.342 0.591 . . . . 0.0 111.143 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -45.67 153.71 0.25 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.864 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 84' ' ' GLY . . . . . 0.535 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 99.03 -5.24 59.32 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 85' ' ' HIS . . . . . 0.543 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -138.27 143.36 40.0 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.36 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.09 58.19 0.36 Allowed Glycine 0 C--N 1.337 0.615 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -88.96 134.55 28.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -82.64 119.71 24.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.087 0.47 . . . . 0.0 110.413 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 89' ' ' VAL . . . . . 0.589 HG21 HG21 ' C' ' 94' ' ' ILE . 20.5 m -139.46 165.31 23.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 90' ' ' ARG . . . . . 0.463 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -97.36 159.25 15.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.839 0.352 . . . . 0.0 110.436 -179.688 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 91' ' ' GLN . . . . . 0.49 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.7 pt20 -55.9 -40.7 73.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.929 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 88.0 p -70.73 -28.37 64.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.98 0.419 . . . . 0.0 110.4 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 93' ' ' GLN . . . . . 0.453 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 73.2 tp60 -66.9 -29.0 68.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.576 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 94' ' ' ILE . . . . . 0.589 HG21 HG21 ' C' ' 89' ' ' VAL . 49.4 pt -125.98 164.15 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.245 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 89.2 mt-30 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.399 179.755 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 85.9 mtp180 . . . . . 0 C--O 1.237 0.426 0 CA-C-O 121.361 0.6 . . . . 0.0 110.335 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 29' ' ' VAL . . . . . 0.498 HG23 ' O ' ' C' ' 45' ' ' ALA . 3.6 p -64.22 146.45 13.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.354 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.75 -17.74 57.88 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.26 -0.736 . . . . 0.0 111.26 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 31' ' ' SER . . . . . 0.453 ' O ' HG22 ' C' ' 44' ' ' VAL . 85.0 p -78.28 165.13 24.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.008 0.432 . . . . 0.0 111.553 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -54.48 155.56 3.91 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 33' ' ' VAL . . . . . 0.634 HG12 ' C ' ' C' ' 42' ' ' GLY . 7.6 p -123.65 149.52 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.032 0.444 . . . . 0.0 110.804 -179.386 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -151.45 94.47 2.02 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.388 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 85.5 t -70.36 131.23 34.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.581 -179.335 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 36' ' ' ILE . . . . . 0.563 ' O ' HG22 ' C' ' 36' ' ' ILE . 88.3 mt -72.91 74.06 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-O 121.311 0.577 . . . . 0.0 109.671 179.707 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.24 -121.9 0.59 Allowed Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -59.13 -29.93 67.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.596 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.18 46.65 0.92 Allowed Glycine 0 N--CA 1.466 0.691 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -71.72 136.22 47.11 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.877 0.37 . . . . 0.0 110.409 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -114.51 175.91 5.28 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.196 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 42' ' ' GLY . . . . . 0.634 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 134.43 -137.95 9.68 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -179.136 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 99.0 m -134.25 142.34 47.3 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 120.978 0.418 . . . . 0.0 111.47 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 44' ' ' VAL . . . . . 0.453 HG22 ' O ' ' C' ' 31' ' ' SER . 16.0 m -75.29 144.89 11.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.612 179.174 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 45' ' ' ALA . . . . . 0.498 ' O ' HG23 ' C' ' 29' ' ' VAL . . . -91.3 -157.2 0.48 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.334 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -62.69 140.01 58.69 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.306 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 47' ' ' VAL . . . . . 0.518 HG22 HG22 ' C' ' 58' ' ' VAL . 70.1 t -110.77 129.61 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.717 -178.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 126.47 -171.16 18.21 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 49' ' ' ALA . . . . . 0.635 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.6 147.11 52.39 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.062 0.458 . . . . 0.0 109.928 179.278 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 50' ' ' THR . . . . . 0.434 ' O ' ' O ' ' C' ' 53' ' ' ALA . 82.3 p -132.02 165.17 24.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.232 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.5 tp -60.27 -40.95 92.2 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -58.28 -46.18 86.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.451 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 53' ' ' ALA . . . . . 0.434 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -144.81 147.38 32.81 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.853 0.359 . . . . 0.0 110.447 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -88.38 173.16 8.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 55' ' ' GLY . . . . . 0.635 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 97.01 -151.2 19.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 16.5 ptmt -128.28 102.93 6.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.137 0.494 . . . . 0.0 110.064 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -131.68 161.79 31.94 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 58' ' ' VAL . . . . . 0.518 HG22 HG22 ' C' ' 47' ' ' VAL . 57.4 t -121.36 128.68 75.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.904 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.8 134.52 12.51 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 60' ' ' VAL . . . . . 0.562 HG13 HG21 ' C' ' 33' ' ' VAL . 85.1 t -126.7 130.38 71.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.431 0 O-C-N 122.507 -0.408 . . . . 0.0 111.214 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 4.8 pt -80.23 96.13 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.357 -0.537 . . . . 0.0 110.469 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 62' ' ' LEU . . . . . 0.629 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -73.14 118.06 15.63 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.862 179.907 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.5 p-10 -65.53 -9.22 24.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.51 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 64' ' ' GLU . . . . . 0.648 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.9 mm-40 -62.12 -33.64 74.85 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.212 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 65' ' ' ALA . . . . . 0.648 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.83 46.47 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.679 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 66' ' ' LYS . . . . . 0.56 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.2 ptmt -147.22 114.5 6.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.296 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 147.12 -142.74 10.57 Favored Glycine 0 CA--C 1.516 0.149 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 16.6 mmtt -97.18 -172.69 2.49 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 110.275 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 69' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.7 p-10 -114.07 98.22 6.84 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.979 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -60.17 -17.28 39.77 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.104 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 71' ' ' GLY . . . . . 0.653 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.59 -41.85 95.79 Favored Glycine 0 C--O 1.225 -0.44 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 72' ' ' THR . . . . . 0.653 HG23 ' O ' ' C' ' 71' ' ' GLY . 21.4 p -162.21 111.74 1.49 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.761 0.315 . . . . 0.0 110.591 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 73' ' ' VAL . . . . . 0.476 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.3 t -126.32 124.76 66.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.305 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 53.8 tt0 46.24 47.87 13.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.38 0.61 . . . . 0.0 111.029 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.69 3.61 42.55 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.174 -1.17 . . . . 0.0 110.174 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 76' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' C' ' 73' ' ' VAL . 29.2 tpt180 -125.23 125.93 44.37 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.971 0.415 . . . . 0.0 110.416 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -106.94 138.2 43.57 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.516 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -102.84 -29.98 11.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -170.54 147.41 2.91 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.349 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 80' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' C' ' 80' ' ' THR . 9.7 p -63.93 97.06 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.979 0.419 . . . . 0.0 110.955 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 2.2 t -165.02 145.19 7.14 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.312 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -83.14 171.42 13.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.104 0.478 . . . . 0.0 110.695 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -50.18 151.88 1.91 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.341 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 84' ' ' GLY . . . . . 0.56 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 98.91 -6.16 60.05 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 -179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 85' ' ' HIS . . . . . 0.629 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 19.3 m-70 -136.5 131.34 33.83 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.14 59.42 0.17 Allowed Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.4 mm -86.6 132.79 31.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -82.83 118.5 23.46 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 89' ' ' VAL . . . . . 0.48 HG21 HG23 ' C' ' 94' ' ' ILE . 17.8 m -139.62 159.52 27.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.703 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 90' ' ' ARG . . . . . 0.585 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.1 mpt_? -82.5 154.22 25.19 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.251 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 91' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' C' ' 94' ' ' ILE . 16.0 pt20 -54.3 -39.71 67.24 Favored 'General case' 0 C--N 1.33 -0.255 0 O-C-N 123.299 0.374 . . . . 0.0 111.106 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 74.2 m -63.22 -37.34 86.86 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.983 0.421 . . . . 0.0 110.299 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 12.2 tp-100 -63.86 -34.79 78.73 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.029 -178.561 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 94' ' ' ILE . . . . . 0.48 HG23 HG21 ' C' ' 89' ' ' VAL . 15.9 pt -100.92 140.14 20.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.655 -179.65 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 . . . . . 0 C--O 1.235 0.295 0 CA-C-O 121.376 0.608 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 29' ' ' VAL . . . . . 0.51 ' CG2' HG12 ' C' ' 47' ' ' VAL . 71.6 t -66.19 135.83 27.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.439 179.837 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.21 -18.83 47.81 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.0 t -73.1 154.04 40.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 117.044 0.422 . . . . 0.0 110.528 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 48.0 ptt85 -46.54 161.62 0.06 Allowed 'General case' 0 N--CA 1.461 0.114 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 33' ' ' VAL . . . . . 0.517 HG12 ' C ' ' C' ' 42' ' ' GLY . 11.3 p -128.99 151.56 35.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.72 -179.451 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -149.81 95.42 2.31 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 87.1 t -72.11 131.3 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.403 -179.021 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 36' ' ' ILE . . . . . 0.516 ' O ' HG22 ' C' ' 36' ' ' ILE . 90.2 mt -75.12 76.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-O 121.28 0.562 . . . . 0.0 109.543 179.453 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.14 -122.5 0.63 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -59.35 -25.7 64.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.212 -0.494 . . . . 0.0 109.966 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.8 42.77 1.29 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -73.79 145.74 44.8 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.275 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 52.6 ptt85 -141.75 165.1 28.4 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.963 0.411 . . . . 0.0 110.564 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 42' ' ' GLY . . . . . 0.517 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 155.73 -109.39 0.4 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 43' ' ' THR . . . . . 0.485 ' CG2' HD12 ' C' ' 61' ' ' ILE . 6.8 t -145.4 154.27 42.1 Favored 'General case' 0 C--O 1.243 0.726 0 CA-C-O 120.828 0.347 . . . . 0.0 111.257 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 92.8 t -90.93 122.44 42.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.196 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 45' ' ' ALA . . . . . 0.457 ' O ' HG13 ' C' ' 29' ' ' VAL . . . -80.21 -159.12 0.2 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.953 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -64.35 145.05 56.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.346 0.593 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 47' ' ' VAL . . . . . 0.67 ' CG2' HE21 ' C' ' 91' ' ' GLN . 9.3 p -124.17 141.2 45.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.485 -178.735 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 120.66 -171.01 14.57 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 49' ' ' ALA . . . . . 0.564 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.01 141.89 56.09 Favored 'General case' 0 C--O 1.23 0.066 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.641 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 71.1 p -134.81 164.63 27.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.235 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.6 tp -59.16 -39.27 81.95 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.51 -45.66 84.68 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.871 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -149.27 145.69 27.2 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 110.865 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 63.6 p -83.13 168.04 17.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.682 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 55' ' ' GLY . . . . . 0.564 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 98.65 -143.4 16.62 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 40.5 pttt -136.59 106.79 6.37 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.47 0.652 . . . . 0.0 110.624 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 85.5 m95 -130.73 168.26 17.48 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.808 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 58' ' ' VAL . . . . . 0.609 HG22 HG23 ' C' ' 47' ' ' VAL . 64.6 t -125.57 130.61 72.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.574 -178.632 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 59' ' ' GLY . . . . . 0.436 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -89.82 129.09 9.53 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 178.526 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 60' ' ' VAL . . . . . 0.418 HG13 HG21 ' C' ' 33' ' ' VAL . 66.9 t -122.47 132.56 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.135 0.493 . . . . 0.0 110.921 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 61' ' ' ILE . . . . . 0.514 HD11 ' CG ' ' C' ' 79' ' ' PHE . 45.7 mt -85.22 104.16 12.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.361 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 62' ' ' LEU . . . . . 0.442 ' O ' ' CD2' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -84.83 115.67 22.87 Favored 'General case' 0 C--O 1.232 0.174 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.923 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -67.08 -9.08 35.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.289 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 64' ' ' GLU . . . . . 0.646 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.76 -37.54 87.04 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.296 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 65' ' ' ALA . . . . . 0.646 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 86.59 44.34 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 110.672 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 66' ' ' LYS . . . . . 0.568 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.4 ptmt -146.68 106.95 4.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.076 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.96 -140.57 7.36 Favored Glycine 0 CA--C 1.52 0.352 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.121 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 68' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' C' ' 85' ' ' HIS . 7.9 mmtm -95.88 -174.74 3.21 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.277 0.56 . . . . 0.0 110.447 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -112.02 96.72 6.21 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 114.688 -1.142 . . . . 0.0 110.68 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -60.78 -15.05 25.55 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.986 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 71' ' ' GLY . . . . . 0.659 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.4 -45.09 94.81 Favored Glycine 0 N--CA 1.449 -0.5 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 72' ' ' THR . . . . . 0.659 HG23 ' O ' ' C' ' 71' ' ' GLY . 21.2 p -163.25 115.19 1.49 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.012 0.435 . . . . 0.0 110.711 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 73' ' ' VAL . . . . . 0.5 ' N ' ' O ' ' C' ' 76' ' ' ARG . 38.8 t -129.53 123.73 58.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.355 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 56.4 tt0 42.86 56.61 3.92 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.214 0.531 . . . . 0.0 111.336 179.232 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.3 4.76 6.85 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 76' ' ' ARG . . . . . 0.5 ' O ' ' N ' ' C' ' 73' ' ' VAL . 26.0 tpt180 -125.41 127.44 46.56 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.248 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 26.7 pttm -112.56 137.97 50.02 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.213 0.53 . . . . 0.0 111.158 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -93.13 -37.18 12.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.814 178.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 79' ' ' PHE . . . . . 0.514 ' CG ' HD11 ' C' ' 61' ' ' ILE . 50.5 t80 -172.6 153.39 2.8 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.323 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 80' ' ' THR . . . . . 0.45 ' N ' ' CD1' ' C' ' 79' ' ' PHE . 28.7 p -64.58 95.57 0.15 Allowed 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.48 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 81' ' ' CYS . . . . . 0.456 ' SG ' ' CG ' ' C' ' 85' ' ' HIS . 9.9 t -163.43 142.26 8.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.561 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -79.14 168.22 19.92 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.334 0.588 . . . . 0.0 110.819 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -46.36 150.47 0.63 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.879 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 84' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 105.06 -8.54 45.57 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.266 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 85' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -136.06 136.04 39.89 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.8 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.75 59.61 0.2 Allowed Glycine 0 C--N 1.337 0.596 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.0 mm -85.74 133.0 30.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.561 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -82.28 119.06 23.63 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.156 0.503 . . . . 0.0 110.064 -179.204 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 89' ' ' VAL . . . . . 0.496 HG21 ' CG2' ' C' ' 94' ' ' ILE . 5.0 m -139.73 164.86 23.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.104 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 90' ' ' ARG . . . . . 0.568 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -97.12 166.71 11.45 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.939 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 91' ' ' GLN . . . . . 0.67 HE21 ' CG2' ' C' ' 47' ' ' VAL . 26.1 mp0 -59.61 -42.88 93.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.764 0.316 . . . . 0.0 110.735 -178.653 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 64.2 m -62.79 -36.03 81.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.379 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 16.8 tt0 -63.96 -35.93 82.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.444 -178.84 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 94' ' ' ILE . . . . . 0.496 ' CG2' HG21 ' C' ' 89' ' ' VAL . 35.4 pt -101.27 144.41 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.881 0.372 . . . . 0.0 110.59 179.178 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 24.0 mt-30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.946 -1.026 . . . . 0.0 111.113 -179.61 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 80.1 mtp85 . . . . . 0 N--CA 1.464 0.257 0 CA-C-O 121.239 0.542 . . . . 0.0 110.354 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -57.01 141.92 13.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.217 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.75 -18.04 55.58 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 83.8 p -81.54 163.13 22.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.964 0.411 . . . . 0.0 110.923 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -50.66 153.36 1.7 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.935 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 33' ' ' VAL . . . . . 0.722 HG12 ' C ' ' C' ' 42' ' ' GLY . 12.3 p -125.39 149.77 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.939 0.399 . . . . 0.0 111.047 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -150.43 92.79 1.9 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 80.2 t -67.47 131.28 33.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.06 -179.237 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 36' ' ' ILE . . . . . 0.47 ' O ' HG22 ' C' ' 36' ' ' ILE . 42.5 mm -75.62 74.57 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.293 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -120.47 0.54 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.819 -0.913 . . . . 0.0 110.819 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.61 -27.19 66.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.021 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.14 44.98 1.04 Allowed Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -75.34 141.73 43.29 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 40.0 ptt180 -129.3 165.78 20.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.174 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 42' ' ' GLY . . . . . 0.722 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 151.37 -130.28 3.11 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.129 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.4 m -131.91 140.98 49.22 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.119 0.485 . . . . 0.0 111.56 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 44' ' ' VAL . . . . . 0.441 HG13 ' CG1' ' C' ' 58' ' ' VAL . 97.2 t -75.78 133.16 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.839 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 45' ' ' ALA . . . . . 0.596 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -85.59 -159.6 0.46 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.967 0.413 . . . . 0.0 110.519 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 46' ' ' TYR . . . . . 0.426 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 84.6 t80 -65.34 144.89 56.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.171 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 47' ' ' VAL . . . . . 0.534 HG12 HG22 ' C' ' 58' ' ' VAL . 19.2 m -118.42 154.15 20.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.969 -179.253 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.93 179.4 20.88 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 49' ' ' ALA . . . . . 0.613 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.53 149.36 49.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.089 0.471 . . . . 0.0 110.366 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 50' ' ' THR . . . . . 0.463 HG23 ' H ' ' C' ' 53' ' ' ALA . 7.6 t -149.22 174.98 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.698 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 86.3 mt -60.96 -39.45 89.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.603 -179.287 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 52' ' ' PHE . . . . . 0.495 ' CD2' ' CZ ' ' C' ' 88' ' ' PHE . 91.9 t80 -59.22 -46.59 88.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.612 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 53' ' ' ALA . . . . . 0.463 ' H ' HG23 ' C' ' 50' ' ' THR . . . -149.28 140.16 22.82 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.789 0.328 . . . . 0.0 110.412 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 72.7 p -83.74 168.91 15.78 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.405 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 55' ' ' GLY . . . . . 0.613 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 89.14 -153.51 23.63 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 56.6 mtmt -110.88 108.78 18.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.881 0.372 . . . . 0.0 110.478 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 83.8 m95 -134.0 161.38 34.97 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.021 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 58' ' ' VAL . . . . . 0.534 HG22 HG12 ' C' ' 47' ' ' VAL . 87.6 t -128.82 130.57 68.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.311 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 59' ' ' GLY . . . . . 0.596 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -90.43 136.15 13.27 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 60' ' ' VAL . . . . . 0.413 ' CG1' HG21 ' C' ' 33' ' ' VAL . 92.3 t -130.42 134.47 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.269 0.557 . . . . 0.0 111.334 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 6.3 pt -85.22 114.59 25.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.603 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 62' ' ' LEU . . . . . 0.614 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.7 OUTLIER -92.23 125.56 36.95 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.936 0.398 . . . . 0.0 110.666 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -67.53 -11.56 58.29 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.618 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 64' ' ' GLU . . . . . 0.651 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.8 mm-40 -61.16 -32.7 72.42 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.436 179.776 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 65' ' ' ALA . . . . . 0.651 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 86.9 35.85 0.02 OUTLIER 'General case' 0 C--N 1.34 0.185 0 O-C-N 123.504 0.503 . . . . 0.0 110.658 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 66' ' ' LYS . . . . . 0.537 ' N ' ' O ' ' C' ' 84' ' ' GLY . 65.0 pttt -134.98 136.46 42.21 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.12 -146.54 17.15 Favored Glycine 0 N--CA 1.461 0.313 0 N-CA-C 110.689 -0.965 . . . . 0.0 110.689 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 4.3 mmtm -97.5 -170.16 1.96 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.186 0.517 . . . . 0.0 110.351 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 69' ' ' ASN . . . . . 0.462 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.2 p-10 -114.46 99.47 7.58 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.749 -179.501 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -60.31 -16.99 39.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 71' ' ' GLY . . . . . 0.655 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.7 -43.14 96.52 Favored Glycine 0 C--O 1.226 -0.359 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 72' ' ' THR . . . . . 0.655 HG23 ' O ' ' C' ' 71' ' ' GLY . 18.8 p -161.9 112.62 1.62 Allowed 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.713 0.292 . . . . 0.0 110.765 179.326 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 73' ' ' VAL . . . . . 0.509 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.6 t -127.53 123.26 61.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.233 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 74' ' ' GLN . . . . . 0.404 ' C ' ' H ' ' C' ' 76' ' ' ARG . 71.2 tp60 43.5 57.01 4.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.365 0.602 . . . . 0.0 110.601 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 61.78 4.81 6.08 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 76' ' ' ARG . . . . . 0.509 ' N ' ' O ' ' C' ' 73' ' ' VAL . 46.7 tpt85 -125.16 126.8 45.83 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 110.172 -0.306 . . . . 0.0 110.172 -179.793 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 77' ' ' LYS . . . . . 0.491 ' O ' ' NH1' ' C' ' 76' ' ' ARG . 63.2 pttt -108.93 137.98 46.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.879 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 51.8 m-85 -99.91 -31.24 11.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.8 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -171.58 151.0 2.85 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.388 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.0 p -64.19 98.16 0.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.942 0.401 . . . . 0.0 110.822 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 81' ' ' CYS . . . . . 0.412 ' O ' ' N ' ' C' ' 71' ' ' GLY . 4.1 t -168.91 142.92 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.432 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -84.07 170.56 13.75 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.525 0.679 . . . . 0.0 110.591 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -44.82 152.64 0.22 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.989 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 84' ' ' GLY . . . . . 0.537 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.18 -7.76 56.95 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 85' ' ' HIS . . . . . 0.614 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 7.0 m-70 -140.02 134.23 31.13 Favored 'General case' 0 C--O 1.24 0.564 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.094 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.7 58.47 0.16 Allowed Glycine 0 C--N 1.337 0.633 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -83.27 131.23 34.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 88' ' ' PHE . . . . . 0.495 ' CZ ' ' CD2' ' C' ' 52' ' ' PHE . 97.4 m-85 -79.42 118.99 21.81 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.79 -178.897 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 89' ' ' VAL . . . . . 0.475 ' O ' ' N ' ' C' ' 58' ' ' VAL . 12.1 m -141.52 163.47 20.34 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.262 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 90' ' ' ARG . . . . . 0.572 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -90.29 154.33 19.79 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.116 0.484 . . . . 0.0 110.841 179.788 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 91' ' ' GLN . . . . . 0.407 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.1 pt20 -52.54 -38.65 60.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.467 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 89.2 p -67.7 -33.32 74.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.096 0.474 . . . . 0.0 110.657 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -66.66 -21.21 66.11 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.594 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 94' ' ' ILE . . . . . 0.432 ' CG2' HG21 ' C' ' 89' ' ' VAL . 39.0 pt -117.24 146.65 21.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.642 -179.814 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 . . . . . 0 C--O 1.235 0.329 0 CA-C-O 121.418 0.627 . . . . 0.0 110.57 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 29' ' ' VAL . . . . . 0.423 HG23 ' O ' ' C' ' 45' ' ' ALA . 2.9 p -57.63 142.5 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.257 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.2 -18.78 47.99 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.114 -0.794 . . . . 0.0 111.114 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 31' ' ' SER . . . . . 0.742 ' O ' HG23 ' C' ' 44' ' ' VAL . 37.0 t -90.36 164.63 14.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.475 0.179 . . . . 0.0 110.523 179.548 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -60.75 161.03 8.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.207 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 33' ' ' VAL . . . . . 0.541 ' HB ' HG22 ' C' ' 44' ' ' VAL . 0.2 OUTLIER -133.67 151.09 32.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.806 -179.419 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -141.98 91.39 2.34 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.302 177.388 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.7 t -61.82 131.8 27.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 CA-C-O 121.116 0.484 . . . . 0.0 110.633 -179.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -77.61 88.65 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.416 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.95 -126.1 0.8 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -67.03 -12.58 60.31 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.927 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.04 60.34 0.53 Allowed Glycine 0 CA--C 1.52 0.395 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -105.68 143.68 33.49 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.982 0.42 . . . . 0.0 110.6 179.239 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -145.78 165.94 27.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.755 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 175.11 -125.76 1.11 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 96.4 m -127.8 136.39 51.4 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 120.715 0.293 . . . . 0.0 111.057 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 44' ' ' VAL . . . . . 0.742 HG23 ' O ' ' C' ' 31' ' ' SER . 43.1 t -72.51 128.89 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 45' ' ' ALA . . . . . 0.462 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -94.82 -159.04 0.68 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.314 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -65.49 141.34 58.52 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.133 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 47' ' ' VAL . . . . . 0.519 HG23 HG22 ' C' ' 58' ' ' VAL . 6.2 p -121.03 133.32 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.394 -179.383 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.05 -174.05 21.6 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 49' ' ' ALA . . . . . 0.436 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -71.21 152.23 43.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.874 0.369 . . . . 0.0 110.272 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 50' ' ' THR . . . . . 0.669 HG23 ' H ' ' C' ' 53' ' ' ALA . 1.7 t -146.19 166.56 25.84 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.827 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 51' ' ' LEU . . . . . 0.518 ' N ' HD12 ' C' ' 51' ' ' LEU . 10.5 mp -60.67 -38.58 85.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.167 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 52' ' ' PHE . . . . . 0.529 ' N ' ' OE1' ' C' ' 74' ' ' GLN . 92.4 t80 -59.89 -44.76 94.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.206 179.148 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 53' ' ' ALA . . . . . 0.669 ' H ' HG23 ' C' ' 50' ' ' THR . . . -145.5 144.28 30.47 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.511 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 99.1 m -98.44 132.83 43.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.546 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 55' ' ' GLY . . . . . 0.436 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 136.98 -147.69 19.37 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -124.26 96.17 4.82 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 36.6 m95 -122.94 162.98 21.25 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.986 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 58' ' ' VAL . . . . . 0.519 HG22 HG23 ' C' ' 47' ' ' VAL . 59.2 t -125.15 128.27 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.773 -179.252 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 59' ' ' GLY . . . . . 0.462 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -84.54 136.85 15.08 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 109.691 -1.363 . . . . 0.0 109.691 179.003 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.4 t -123.39 133.9 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.037 0.446 . . . . 0.0 111.038 -178.811 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 16.4 mm -87.06 93.28 4.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.811 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 62' ' ' LEU . . . . . 0.617 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.6 OUTLIER -76.03 120.14 20.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.546 -179.409 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -67.85 -11.94 59.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.837 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 64' ' ' GLU . . . . . 0.657 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.7 mm-40 -63.37 -34.25 77.32 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.476 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 65' ' ' ALA . . . . . 0.657 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 83.42 47.18 0.02 OUTLIER 'General case' 0 C--N 1.338 0.105 0 O-C-N 123.322 0.389 . . . . 0.0 110.748 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 66' ' ' LYS . . . . . 0.552 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.4 ptpt -146.84 109.21 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.387 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.53 -140.5 7.25 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.449 -1.061 . . . . 0.0 110.449 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -97.19 -173.36 2.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.919 0.39 . . . . 0.0 110.125 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 42.3 p-10 -113.95 98.01 6.73 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.576 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 -61.65 -17.37 55.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.375 179.246 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 71' ' ' GLY . . . . . 0.66 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.93 -43.1 97.0 Favored Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 72' ' ' THR . . . . . 0.66 HG23 ' O ' ' C' ' 71' ' ' GLY . 19.1 p -161.41 118.09 2.2 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 120.513 0.197 . . . . 0.0 110.636 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 73' ' ' VAL . . . . . 0.623 ' O ' ' N ' ' C' ' 76' ' ' ARG . 12.7 t -128.31 125.68 64.53 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 74' ' ' GLN . . . . . 0.529 ' OE1' ' N ' ' C' ' 52' ' ' PHE . 3.4 pt20 39.55 36.79 0.25 Allowed 'General case' 0 C--N 1.328 -0.364 0 O-C-N 123.148 0.28 . . . . 0.0 111.323 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 89.03 -19.56 37.78 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 76' ' ' ARG . . . . . 0.623 ' N ' ' O ' ' C' ' 73' ' ' VAL . 59.9 ttt85 -101.96 126.25 48.83 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 pttt -106.83 132.32 52.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.491 0.662 . . . . 0.0 111.209 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 78' ' ' TYR . . . . . 0.546 ' OH ' HG21 ' C' ' 50' ' ' THR . 3.1 m-85 -84.26 -40.65 17.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.063 178.268 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 79' ' ' PHE . . . . . 0.409 ' CG ' ' N ' ' C' ' 80' ' ' THR . 86.8 t80 -170.87 158.19 5.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.467 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 80' ' ' THR . . . . . 0.409 ' N ' ' CG ' ' C' ' 79' ' ' PHE . 82.7 p -64.12 96.95 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.975 0.417 . . . . 0.0 111.029 -179.499 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.31 144.9 4.65 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.305 179.465 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -86.57 169.45 12.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.191 0.519 . . . . 0.0 110.887 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -46.71 149.93 0.77 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.185 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 84' ' ' GLY . . . . . 0.552 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.36 -7.11 56.14 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -178.89 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 85' ' ' HIS . . . . . 0.617 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 6.3 m-70 -139.15 132.82 30.56 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.093 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.9 58.57 0.16 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.9 mm -82.34 132.39 31.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -83.66 116.68 22.76 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.482 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 89' ' ' VAL . . . . . 0.482 HG21 ' CG2' ' C' ' 94' ' ' ILE . 4.3 m -140.21 160.01 25.76 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.911 178.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 90' ' ' ARG . . . . . 0.658 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -85.97 162.62 18.44 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 120.791 0.329 . . . . 0.0 110.758 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 91' ' ' GLN . . . . . 0.455 ' O ' ' O ' ' C' ' 94' ' ' ILE . 96.0 mt-30 -59.31 -41.2 88.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.597 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 40.0 t -61.53 -37.99 85.78 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.432 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -63.2 -33.88 76.44 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.565 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 94' ' ' ILE . . . . . 0.482 ' CG2' HG21 ' C' ' 89' ' ' VAL . 34.1 pt -105.01 149.13 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 121.082 0.468 . . . . 0.0 110.799 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.596 179.826 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 96.1 mtm-85 . . . . . 0 C--O 1.234 0.251 0 CA-C-O 120.969 0.414 . . . . 0.0 110.369 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -67.14 140.32 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 CA-C-O 121.361 0.601 . . . . 0.0 111.058 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.07 -16.38 57.23 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.032 -178.782 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 31' ' ' SER . . . . . 0.778 ' O ' HG12 ' C' ' 44' ' ' VAL . 81.5 p -80.36 165.38 22.32 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.918 0.39 . . . . 0.0 111.606 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 32' ' ' ARG . . . . . 0.684 ' NE ' HH21 ' C' ' 41' ' ' ARG . 99.7 mtt180 -68.67 156.21 38.61 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.473 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 33' ' ' VAL . . . . . 0.451 HG22 ' C ' ' C' ' 42' ' ' GLY . 2.2 m -130.82 156.3 42.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.321 0 CA-C-O 121.216 0.531 . . . . 0.0 110.445 -179.707 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -139.39 99.41 3.73 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 177.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 35' ' ' VAL . . . . . 0.412 ' HA ' HG22 ' C' ' 94' ' ' ILE . 74.1 t -62.37 130.3 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.419 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.943 -178.575 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 36' ' ' ILE . . . . . 0.471 ' O ' HG22 ' C' ' 36' ' ' ILE . 96.9 mt -75.0 76.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.804 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -125.36 0.77 Allowed Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 65.4 pttt -60.01 -20.02 55.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.592 -0.304 . . . . 0.0 110.579 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.44 54.99 0.81 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 40' ' ' HIS . . . . . 0.431 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 66.7 t-80 -87.32 137.4 32.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.218 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 41' ' ' ARG . . . . . 0.684 HH21 ' NE ' ' C' ' 32' ' ' ARG . 78.0 ttt-85 -110.09 139.43 45.22 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.13 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 42' ' ' GLY . . . . . 0.451 ' C ' HG22 ' C' ' 33' ' ' VAL . . . -172.14 -170.8 36.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.412 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 95.1 m -114.18 131.55 56.41 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 44' ' ' VAL . . . . . 0.778 HG12 ' O ' ' C' ' 31' ' ' SER . 1.3 p -69.49 139.6 20.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.294 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -96.17 -156.88 0.55 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.375 -0.829 . . . . 0.0 109.274 178.662 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -63.66 142.37 58.42 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.201 0.524 . . . . 0.0 110.221 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 47' ' ' VAL . . . . . 0.625 HG12 HG22 ' C' ' 58' ' ' VAL . 19.7 m -118.8 153.58 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.285 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 116.96 -175.83 15.91 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 49' ' ' ALA . . . . . 0.715 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.13 141.2 56.14 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 60.3 p -137.69 167.7 21.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.289 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.5 tp -59.86 -41.16 90.84 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 52' ' ' PHE . . . . . 0.462 ' CE1' ' NZ ' ' C' ' 68' ' ' LYS . 88.8 t80 -58.74 -46.0 88.41 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.274 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.39 140.94 32.2 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.964 0.412 . . . . 0.0 110.677 179.782 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.3 p -84.44 167.63 16.25 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.745 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 55' ' ' GLY . . . . . 0.715 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 87.1 -133.35 11.74 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -131.18 114.68 15.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.524 0.678 . . . . 0.0 110.513 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -137.52 156.04 48.57 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.45 179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 58' ' ' VAL . . . . . 0.625 HG22 HG12 ' C' ' 47' ' ' VAL . 82.1 t -119.36 130.06 74.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.441 -179.182 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.37 135.49 12.91 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 75.1 t -125.94 132.69 70.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.07 0.462 . . . . 0.0 111.374 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.5 pt -83.5 95.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.561 0.696 . . . . 0.0 110.196 178.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 62' ' ' LEU . . . . . 0.579 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -70.12 120.82 16.38 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.335 -179.321 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 63' ' ' ASP . . . . . 0.431 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.0 m-20 -67.61 -11.1 57.39 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.4 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 64' ' ' GLU . . . . . 0.657 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.19 -35.79 79.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.179 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 65' ' ' ALA . . . . . 0.657 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 87.05 39.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.962 0.41 . . . . 0.0 110.397 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 66' ' ' LYS . . . . . 0.512 ' N ' ' O ' ' C' ' 84' ' ' GLY . 21.3 ptmt -135.6 135.56 40.34 Favored 'General case' 0 CA--C 1.521 -0.155 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.59 179.353 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.21 -146.79 16.45 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 68' ' ' LYS . . . . . 0.462 ' NZ ' ' CE1' ' C' ' 52' ' ' PHE . 17.5 ptpt -98.47 -168.0 1.58 Allowed 'General case' 0 C--O 1.238 0.452 0 CA-C-O 120.941 0.4 . . . . 0.0 110.736 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 69' ' ' ASN . . . . . 0.422 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 40.6 p-10 -111.8 105.42 13.89 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.56 -179.468 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 70' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' C' ' 85' ' ' HIS . 0.9 OUTLIER -63.93 -11.46 28.44 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.899 178.515 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 71' ' ' GLY . . . . . 0.667 ' O ' HG23 ' C' ' 72' ' ' THR . . . -60.29 -42.92 98.97 Favored Glycine 0 N--CA 1.45 -0.383 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 72' ' ' THR . . . . . 0.667 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.4 p -163.91 115.38 1.36 Allowed 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 123.838 0.376 . . . . 0.0 110.683 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 73' ' ' VAL . . . . . 0.422 ' CG2' ' O ' ' C' ' 69' ' ' ASN . 16.8 t -131.12 119.02 43.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.8 mm-40 52.35 35.16 16.52 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.558 0.218 . . . . 0.0 111.441 179.146 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.62 -1.7 81.71 Favored Glycine 0 CA--C 1.517 0.195 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 76' ' ' ARG . . . . . 0.405 ' O ' ' N ' ' C' ' 73' ' ' VAL . 28.1 tpt180 -115.98 123.85 49.04 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.244 -0.478 . . . . 0.0 109.75 179.494 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -109.7 136.33 49.22 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-O 121.272 0.558 . . . . 0.0 110.645 -179.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -93.66 -37.23 11.95 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.597 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -170.56 149.18 3.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.279 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 31.0 p -64.3 101.48 0.43 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.888 0.375 . . . . 0.0 111.615 -178.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.0 t -171.19 146.97 2.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.307 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -78.65 168.63 19.47 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.432 0.634 . . . . 0.0 110.717 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -43.57 157.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.307 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 84' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.86 -8.15 63.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 85' ' ' HIS . . . . . 0.579 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 30.7 m-70 -137.61 144.49 41.97 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.6 60.4 0.49 Allowed Glycine 0 N--CA 1.467 0.718 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 50.7 mm -93.77 127.37 45.86 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 88' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' C' ' 88' ' ' PHE . 49.0 p90 -77.34 119.7 21.33 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.276 0.56 . . . . 0.0 110.091 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 89' ' ' VAL . . . . . 0.412 ' O ' ' HB ' ' C' ' 58' ' ' VAL . 4.0 p -143.44 140.41 26.24 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.728 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 90' ' ' ARG . . . . . 0.651 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -65.59 151.52 46.28 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.954 -0.298 . . . . 0.0 110.925 -177.774 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 91' ' ' GLN . . . . . 0.599 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 3.8 pm0 -57.87 -33.75 69.02 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.836 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 81.7 p -64.95 -36.81 85.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.349 . . . . 0.0 110.849 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -67.59 -20.68 65.4 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.021 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 94' ' ' ILE . . . . . 0.455 ' O ' ' O ' ' C' ' 91' ' ' GLN . 24.3 pt -117.65 148.72 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.88 0.371 . . . . 0.0 110.142 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.583 -179.608 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo . . . . . 0 N--CA 1.483 0.885 0 N-CA-C 109.062 -1.168 . . . . 0.0 109.062 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 27' ' ' LEU . . . . . 0.523 ' H ' HD23 ' C' ' 27' ' ' LEU . 0.1 OUTLIER -85.24 170.37 12.9 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.877 179.85 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 35.1 ptt-85 -122.25 149.2 44.02 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 121.456 0.646 . . . . 0.0 110.839 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 29' ' ' VAL . . . . . 0.475 HG23 ' O ' ' C' ' 45' ' ' ALA . 3.4 p -57.28 145.0 8.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.206 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.34 -20.69 47.53 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -83.67 159.5 21.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.861 0.363 . . . . 0.0 110.791 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 39.4 ptt180 -50.72 161.85 0.31 Allowed 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 33' ' ' VAL . . . . . 0.715 HG12 ' C ' ' C' ' 42' ' ' GLY . 9.4 p -128.21 150.13 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.858 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -146.72 91.8 2.07 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 94.1 t -67.63 130.88 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.93 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 36' ' ' ILE . . . . . 0.444 ' O ' HG22 ' C' ' 36' ' ' ILE . 5.6 mm -76.17 74.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.508 0.67 . . . . 0.0 109.934 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.72 -119.77 0.5 Allowed Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.73 -17.94 27.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.121 -0.539 . . . . 0.0 109.966 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.21 41.72 3.66 Favored Glycine 0 N--CA 1.465 0.588 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 40' ' ' HIS . . . . . 0.622 ' ND1' HD11 ' C' ' 62' ' ' LEU . 64.8 m170 -75.4 147.37 40.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 110.694 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.4 ptm180 -134.77 163.18 30.38 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.748 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 42' ' ' GLY . . . . . 0.715 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 157.56 -127.25 1.88 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -178.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 98.6 m -131.89 142.85 49.79 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 120.912 0.386 . . . . 0.0 111.845 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 95.9 t -77.83 132.31 32.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.043 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 45' ' ' ALA . . . . . 0.507 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -85.77 -158.72 0.41 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.486 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 81.8 t80 -64.41 143.48 57.87 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 47' ' ' VAL . . . . . 0.559 HG22 HG22 ' C' ' 58' ' ' VAL . 89.9 t -119.64 131.75 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.613 -178.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.0 -176.09 19.45 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 49' ' ' ALA . . . . . 0.746 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -70.3 142.92 52.18 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-O 120.937 0.399 . . . . 0.0 110.015 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 69.6 p -138.6 169.58 17.54 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.473 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 97.1 mt -60.86 -38.82 86.88 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.993 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.0 t80 -59.06 -46.14 89.01 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.523 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.18 143.98 29.63 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.1 p -85.14 166.95 16.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.538 179.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 55' ' ' GLY . . . . . 0.746 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 94.17 -140.54 15.1 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -134.38 96.04 3.51 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.403 -0.469 . . . . 0.0 110.464 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -113.89 171.12 7.78 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.105 0.479 . . . . 0.0 109.785 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 58' ' ' VAL . . . . . 0.559 HG22 HG22 ' C' ' 47' ' ' VAL . 59.9 t -129.77 130.21 66.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.401 -179.425 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 59' ' ' GLY . . . . . 0.507 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -92.11 134.57 12.3 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 178.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 60' ' ' VAL . . . . . 0.475 HG13 HG21 ' C' ' 33' ' ' VAL . 59.5 t -122.19 132.96 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 CA-C-O 120.906 0.384 . . . . 0.0 111.162 -178.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 7.9 mm -81.39 96.22 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.954 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 62' ' ' LEU . . . . . 0.622 HD11 ' ND1' ' C' ' 40' ' ' HIS . 0.2 OUTLIER -78.17 114.85 17.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.577 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -66.89 -18.07 65.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.66 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 64' ' ' GLU . . . . . 0.655 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.3 mm-40 -60.55 -32.22 71.3 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.341 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 65' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 84.53 46.63 0.02 OUTLIER 'General case' 0 N--CA 1.461 0.09 0 CA-C-O 120.796 0.331 . . . . 0.0 110.772 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 66' ' ' LYS . . . . . 0.538 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.6 ptpt -141.3 110.89 6.44 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.168 0.508 . . . . 0.0 110.238 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 151.31 -143.02 10.02 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 68' ' ' LYS . . . . . 0.428 ' HG2' ' H ' ' C' ' 68' ' ' LYS . 18.3 ptmt -99.4 -171.99 2.18 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 69' ' ' ASN . . . . . 0.455 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 23.0 p-10 -112.07 102.53 10.73 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.603 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -62.41 -15.98 52.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.313 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 71' ' ' GLY . . . . . 0.647 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.42 -45.52 94.27 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.065 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 72' ' ' THR . . . . . 0.647 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.1 p -162.18 120.83 2.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.843 0.354 . . . . 0.0 110.667 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 73' ' ' VAL . . . . . 0.487 ' N ' ' O ' ' C' ' 76' ' ' ARG . 12.7 t -138.69 122.06 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.617 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 74' ' ' GLN . . . . . 0.441 ' C ' ' H ' ' C' ' 76' ' ' ARG . 55.6 tt0 44.78 58.44 3.95 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.275 0.56 . . . . 0.0 110.963 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 60.02 3.88 2.96 Favored Glycine 0 CA--C 1.517 0.186 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 76' ' ' ARG . . . . . 0.487 ' O ' ' N ' ' C' ' 73' ' ' VAL . 17.2 tpp180 -124.75 129.59 50.77 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.862 0.363 . . . . 0.0 110.373 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -113.34 136.43 52.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.271 0.558 . . . . 0.0 111.078 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -88.78 -39.29 14.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.862 178.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -173.33 158.97 3.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.486 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -65.46 96.99 0.27 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.843 0.354 . . . . 0.0 111.001 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.3 t -169.2 144.82 3.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.522 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 49.8 p-10 -84.11 172.16 12.21 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.275 0.56 . . . . 0.0 110.82 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -47.68 151.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.165 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 84' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.03 -6.8 56.8 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 85' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -137.74 128.27 26.61 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 124.73 54.32 0.18 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.736 -0.546 . . . . 0.0 111.736 179.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 87' ' ' ILE . . . . . 0.457 HD12 HD23 ' C' ' 62' ' ' LEU . 96.7 mt -80.43 129.36 37.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 88' ' ' PHE . . . . . 0.569 ' CD2' ' O ' ' C' ' 88' ' ' PHE . 48.6 p90 -74.94 119.35 19.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.087 0.47 . . . . 0.0 111.063 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 89' ' ' VAL . . . . . 0.496 HG21 ' CG2' ' C' ' 94' ' ' ILE . 4.5 m -140.5 162.63 23.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 90' ' ' ARG . . . . . 0.581 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -91.14 163.46 14.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.728 179.732 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 91' ' ' GLN . . . . . . . . . . . . . 55.6 mt-30 -59.31 -42.63 91.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.721 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 67.7 m -63.16 -33.84 76.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.245 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 93' ' ' GLN . . . . . 0.526 ' OE1' ' NH1' ' C' ' 90' ' ' ARG . 72.5 tp60 -64.29 -36.95 85.79 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.655 -178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 94' ' ' ILE . . . . . 0.496 ' CG2' HG21 ' C' ' 89' ' ' VAL . 24.1 pt -99.44 139.3 21.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.051 0.453 . . . . 0.0 110.453 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 59.5 tt0 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.775 -179.655 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo . . . . . 0 N--CA 1.481 0.759 0 N-CA-C 108.735 -1.294 . . . . 0.0 108.735 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.85 122.81 20.16 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.566 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 62.7 ttp180 -73.36 139.59 46.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.798 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 29' ' ' VAL . . . . . 0.467 ' HA ' HG13 ' C' ' 44' ' ' VAL . 1.6 p -55.9 140.62 13.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.059 179.647 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.7 -9.94 62.4 Favored Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 31' ' ' SER . . . . . 0.534 ' O ' HG12 ' C' ' 44' ' ' VAL . 67.5 m -92.67 163.76 13.65 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.942 0.401 . . . . 0.0 111.045 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 17.7 ptm180 -61.62 159.11 13.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.318 179.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 33' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' C' ' 42' ' ' GLY . 2.6 m -135.7 160.36 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 34' ' ' GLU . . . . . 0.508 ' N ' ' OXT' ' C' ' 95' ' ' GLN . 77.3 mm-40 -133.2 96.02 3.66 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 177.55 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 84.9 t -61.07 131.2 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.702 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 36' ' ' ILE . . . . . 0.493 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 6.5 mm -76.68 82.76 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-O 121.426 0.632 . . . . 0.0 110.027 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.28 -125.97 0.79 Allowed Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -64.02 -18.47 64.35 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.306 -0.447 . . . . 0.0 110.454 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.12 55.98 0.59 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 40' ' ' HIS . . . . . 0.526 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 61.0 t-80 -95.44 154.9 16.97 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.799 0.333 . . . . 0.0 110.404 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 41' ' ' ARG . . . . . 0.467 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 37.2 ptt-85 -128.52 157.54 40.89 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.337 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 42' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' C' ' 33' ' ' VAL . . . 176.33 -166.37 37.35 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.5 m -111.11 132.09 54.55 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-O 120.903 0.382 . . . . 0.0 110.667 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 44' ' ' VAL . . . . . 0.534 HG12 ' O ' ' C' ' 31' ' ' SER . 1.5 p -72.26 135.21 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.83 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 45' ' ' ALA . . . . . 0.409 ' O ' HG22 ' C' ' 44' ' ' VAL . . . -87.21 -156.48 0.33 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.801 178.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 46' ' ' TYR . . . . . 0.402 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 91.0 t80 -63.42 140.68 58.9 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.065 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 47' ' ' VAL . . . . . 0.402 ' O ' ' CE2' ' C' ' 46' ' ' TYR . 30.4 m -110.47 153.94 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.063 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.49 -175.3 22.56 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.248 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 49' ' ' ALA . . . . . 0.784 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -67.99 153.78 43.0 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.073 0.463 . . . . 0.0 109.971 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 50' ' ' THR . . . . . 0.536 HG23 ' H ' ' C' ' 53' ' ' ALA . 8.1 t -142.45 171.38 14.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.34 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 51' ' ' LEU . . . . . 0.529 HD22 ' N ' ' C' ' 51' ' ' LEU . 3.9 mm? -61.23 -39.27 89.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.471 -179.146 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 t80 -58.54 -45.72 88.32 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.368 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 53' ' ' ALA . . . . . 0.536 ' H ' HG23 ' C' ' 50' ' ' THR . . . -148.98 146.4 27.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.297 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 11.0 t -87.92 171.94 9.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 55' ' ' GLY . . . . . 0.784 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 96.14 -156.8 21.38 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 -179.479 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -119.27 106.83 12.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.091 0.472 . . . . 0.0 110.607 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 57' ' ' TRP . . . . . 0.58 ' HE1' ' NE ' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -135.22 170.67 15.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.825 179.466 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 58' ' ' VAL . . . . . 0.522 ' CG1' HG23 ' C' ' 44' ' ' VAL . 57.4 t -131.37 132.36 62.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.56 -0.746 . . . . 0.0 111.343 -179.305 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.46 132.94 11.37 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 72.9 t -127.35 134.28 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.556 0.693 . . . . 0.0 111.42 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.6 pt -85.06 119.93 34.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.964 178.527 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 62' ' ' LEU . . . . . 0.565 HD22 ' CD1' ' C' ' 87' ' ' ILE . 3.8 tp -92.24 122.21 34.5 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.093 -178.706 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 63' ' ' ASP . . . . . 0.526 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.3 m-20 -67.46 -14.15 62.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.375 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 64' ' ' GLU . . . . . 0.658 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 77.7 mm-40 -62.66 -31.05 71.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.561 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 65' ' ' ALA . . . . . 0.658 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.8 42.28 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.142 0 CA-C-O 120.958 0.409 . . . . 0.0 110.556 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 66' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' C' ' 84' ' ' GLY . 18.9 ptmt -140.4 120.16 13.43 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.978 179.265 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 146.21 -148.25 19.8 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.521 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 68' ' ' LYS . . . . . 0.501 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 40.8 tttt -97.4 -166.55 1.4 Allowed 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 69' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' C' ' 69' ' ' ASN . 1.2 m-20 -104.18 95.94 6.31 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.227 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 70' ' ' ASP . . . . . 0.557 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 5.4 t70 -60.48 -23.07 64.2 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.681 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 71' ' ' GLY . . . . . 0.53 ' O ' HG23 ' C' ' 72' ' ' THR . . . -59.06 -40.28 95.38 Favored Glycine 0 C--O 1.224 -0.482 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.35 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 72' ' ' THR . . . . . 0.53 HG23 ' O ' ' C' ' 71' ' ' GLY . 38.1 p -158.5 116.47 2.95 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.807 0.337 . . . . 0.0 110.52 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 73' ' ' VAL . . . . . 0.448 HG23 ' O ' ' C' ' 69' ' ' ASN . 58.6 t -129.88 126.78 62.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.511 179.705 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 47.58 45.93 17.73 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.21 0.529 . . . . 0.0 110.704 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.64 3.13 39.77 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 76' ' ' ARG . . . . . 0.419 ' N ' ' O ' ' C' ' 73' ' ' VAL . 20.3 tpp85 -124.81 129.79 51.12 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.873 0.368 . . . . 0.0 110.371 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -109.44 138.92 45.08 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.883 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -105.35 -26.97 11.77 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.464 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 79' ' ' PHE . . . . . 0.557 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 31.3 t80 -169.84 142.21 2.39 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.232 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 80' ' ' THR . . . . . 0.451 ' H ' HG22 ' C' ' 80' ' ' THR . 0.0 OUTLIER -64.27 106.3 1.07 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.054 0.454 . . . . 0.0 111.363 -179.731 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.1 t -169.19 145.07 3.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.299 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -82.26 171.14 14.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.261 0.553 . . . . 0.0 110.686 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -44.81 155.28 0.11 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.292 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 84' ' ' GLY . . . . . 0.526 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 95.45 -3.73 66.22 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 85' ' ' HIS . . . . . 0.572 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.3 OUTLIER -139.58 140.29 37.02 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.339 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.38 60.0 0.32 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 87' ' ' ILE . . . . . 0.565 ' CD1' HD22 ' C' ' 62' ' ' LEU . 95.9 mt -94.25 130.32 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -75.6 120.47 21.05 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.506 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 89' ' ' VAL . . . . . 0.52 HG21 HG21 ' C' ' 94' ' ' ILE . 20.8 m -139.48 162.53 26.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.443 179.278 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 90' ' ' ARG . . . . . 0.58 ' NE ' ' HE1' ' C' ' 57' ' ' TRP . 5.5 mpt_? -93.89 150.71 20.13 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.024 0.44 . . . . 0.0 110.249 -179.256 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 91' ' ' GLN . . . . . 0.693 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 1.3 pm0 -51.57 -39.39 57.78 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.142 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 78.9 p -69.99 -28.33 65.43 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.053 0.454 . . . . 0.0 110.368 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 93' ' ' GLN . . . . . 0.493 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.6 tt0 -70.69 -20.19 62.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.501 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 94' ' ' ILE . . . . . 0.52 HG21 HG21 ' C' ' 89' ' ' VAL . 48.1 pt -128.38 163.09 33.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.074 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 95' ' ' GLN . . . . . 0.508 ' OXT' ' N ' ' C' ' 34' ' ' GLU . 59.8 tt0 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.453 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo . . . . . 0 N--CA 1.482 0.812 0 N-CA-C 108.86 -1.246 . . . . 0.0 108.86 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.28 163.65 29.91 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.377 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 86.0 mtp180 -125.27 148.44 48.68 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.742 179.739 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 29' ' ' VAL . . . . . 0.442 ' HA ' HG23 ' C' ' 44' ' ' VAL . 2.1 p -52.68 144.4 3.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.257 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.51 -9.71 75.43 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 31' ' ' SER . . . . . 0.501 ' O ' HG22 ' C' ' 44' ' ' VAL . 74.2 m -86.5 165.07 16.55 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.458 . . . . 0.0 111.275 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -58.28 151.14 20.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.881 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 33' ' ' VAL . . . . . 0.706 HG12 ' C ' ' C' ' 42' ' ' GLY . 14.0 p -121.76 150.94 25.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.835 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 34' ' ' GLU . . . . . 0.402 ' N ' HG22 ' C' ' 33' ' ' VAL . 85.2 tt0 -147.43 97.3 2.83 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.29 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -70.7 132.35 33.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.697 -178.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 36' ' ' ILE . . . . . 0.487 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 5.9 mm -71.95 80.3 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.509 179.674 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.29 -126.86 0.84 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -62.99 -21.12 65.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.355 -0.423 . . . . 0.0 110.77 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 107.87 55.49 0.61 Allowed Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 40' ' ' HIS . . . . . 0.544 ' CE1' ' O ' ' C' ' 41' ' ' ARG . 41.8 t-80 -84.93 140.17 31.3 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 121.158 0.504 . . . . 0.0 111.681 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 41' ' ' ARG . . . . . 0.544 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 11.6 ptm85 -119.73 169.73 9.84 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.285 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 42' ' ' GLY . . . . . 0.706 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 150.48 -131.2 3.48 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -178.259 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 12.3 t -142.67 154.2 44.11 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 111.56 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 44' ' ' VAL . . . . . 0.501 HG22 ' O ' ' C' ' 31' ' ' SER . 3.2 m -88.18 138.88 18.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.024 179.058 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.19 -158.79 0.49 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.962 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 75.1 t80 -64.8 142.53 58.4 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.122 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 47' ' ' VAL . . . . . 0.496 HG23 HG22 ' C' ' 58' ' ' VAL . 8.7 p -113.17 131.98 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.688 -178.715 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.14 -173.81 24.03 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 49' ' ' ALA . . . . . 0.566 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -66.79 145.78 55.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.079 0.466 . . . . 0.0 110.222 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 50' ' ' THR . . . . . 0.452 ' O ' ' O ' ' C' ' 53' ' ' ALA . 19.5 m -126.64 159.37 33.81 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.862 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 51' ' ' LEU . . . . . 0.44 ' N ' HG22 ' C' ' 50' ' ' THR . 88.8 mt -60.28 -39.54 87.23 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -59.16 -46.48 88.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 0.0 109.943 179.401 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 53' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -141.72 141.61 33.29 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 110.149 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 9.9 t -89.17 162.12 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.937 -179.651 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 55' ' ' GLY . . . . . 0.566 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 108.78 -145.95 16.52 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 64.6 mttp -123.68 116.4 23.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.993 0.425 . . . . 0.0 110.359 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -141.55 164.2 30.86 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.326 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 58' ' ' VAL . . . . . 0.496 HG22 HG23 ' C' ' 47' ' ' VAL . 75.2 t -122.54 128.51 75.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.755 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.48 141.74 19.88 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 70.8 t -127.09 133.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 120.879 0.371 . . . . 0.0 110.531 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 11.7 mm -82.2 95.01 3.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 62' ' ' LEU . . . . . 0.564 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -74.57 104.86 5.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.132 -178.865 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 63' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' C' ' 64' ' ' GLU . 54.0 p30 -65.88 -9.88 33.27 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.992 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 64' ' ' GLU . . . . . 0.649 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 75.9 mm-40 -63.21 -32.15 73.47 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.475 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 65' ' ' ALA . . . . . 0.649 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 91.08 39.44 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.042 0.449 . . . . 0.0 110.555 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 66' ' ' LYS . . . . . 0.543 ' N ' ' O ' ' C' ' 84' ' ' GLY . 23.1 pttp -140.75 140.87 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.18 178.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 121.89 -150.15 17.07 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 9.4 mmtt -95.81 -171.51 2.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.39 0.614 . . . . 0.0 111.149 -179.03 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 69' ' ' ASN . . . . . 0.541 ' ND2' ' O ' ' C' ' 72' ' ' THR . 46.9 p-10 -106.09 102.01 11.46 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.543 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 70' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 7.3 t0 -62.06 -23.73 66.66 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.461 -0.791 . . . . 0.0 108.969 179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 71' ' ' GLY . . . . . 0.531 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.07 -41.83 94.76 Favored Glycine 0 C--O 1.226 -0.38 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 72' ' ' THR . . . . . 0.541 ' O ' ' ND2' ' C' ' 69' ' ' ASN . 32.7 p -158.55 118.31 3.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.922 0.392 . . . . 0.0 110.838 179.289 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 73' ' ' VAL . . . . . 0.466 ' O ' ' N ' ' C' ' 76' ' ' ARG . 39.6 t -126.43 122.96 62.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.685 179.225 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 68.7 tp60 45.05 49.99 9.36 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.074 0.464 . . . . 0.0 111.544 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.56 1.79 31.8 Favored Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.259 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 76' ' ' ARG . . . . . 0.466 ' N ' ' O ' ' C' ' 73' ' ' VAL . 76.3 ttt180 -124.78 126.09 45.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.374 -0.413 . . . . 0.0 110.325 -179.449 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -107.34 137.92 44.5 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-O 121.363 0.601 . . . . 0.0 111.19 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 78' ' ' TYR . . . . . 0.425 ' OH ' ' OG1' ' C' ' 50' ' ' THR . 1.7 m-85 -98.57 -32.94 11.18 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.371 178.343 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 79' ' ' PHE . . . . . 0.539 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 86.0 t80 -169.55 151.73 4.48 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.373 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 44.0 p -64.9 108.87 1.9 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.745 0.307 . . . . 0.0 111.349 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -172.63 148.32 1.92 Allowed 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.329 179.032 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -86.0 169.87 12.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.153 0.501 . . . . 0.0 111.179 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -50.57 145.05 7.06 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.002 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 84' ' ' GLY . . . . . 0.543 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 104.05 -4.34 45.2 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 85' ' ' HIS . . . . . 0.564 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 4.0 m-70 -140.97 136.2 31.93 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.145 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.95 49.79 0.32 Allowed Glycine 0 N--CA 1.47 0.907 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.331 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 97.4 mt -83.78 135.18 25.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -84.16 119.11 24.62 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.528 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 89' ' ' VAL . . . . . 0.455 HG21 HG23 ' C' ' 94' ' ' ILE . 16.2 m -136.51 162.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 178.515 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 90' ' ' ARG . . . . . 0.586 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -90.78 155.04 19.09 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.599 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 91' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' C' ' 94' ' ' ILE . 29.2 pt20 -53.22 -38.97 63.4 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.733 -179.545 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 66.6 m -63.18 -37.19 86.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.223 0.535 . . . . 0.0 110.172 178.574 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 93' ' ' GLN . . . . . 0.487 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.9 tt0 -65.02 -30.05 71.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.109 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 94' ' ' ILE . . . . . 0.455 HG23 HG21 ' C' ' 89' ' ' VAL . 17.1 pt -108.93 145.43 15.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.975 0.417 . . . . 0.0 110.461 179.637 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.745 179.98 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo . . . . . 0 N--CA 1.48 0.703 0 N-CA-C 109.051 -1.173 . . . . 0.0 109.051 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 27' ' ' LEU . . . . . 0.688 ' CD1' HG11 ' C' ' 44' ' ' VAL . 0.1 OUTLIER -78.3 168.39 19.9 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.949 179.987 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 78.0 mtp85 -117.51 139.35 51.05 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.964 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 29' ' ' VAL . . . . . 0.44 ' H ' HG13 ' C' ' 29' ' ' VAL . 6.1 m -50.66 143.21 2.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 30' ' ' GLY . . . . . 0.447 ' N ' HG23 ' C' ' 44' ' ' VAL . . . 91.92 -8.27 78.27 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 31' ' ' SER . . . . . 0.527 ' O ' HG22 ' C' ' 44' ' ' VAL . 45.7 t -89.05 163.73 15.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.982 0.42 . . . . 0.0 111.426 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -59.23 149.15 29.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.156 179.231 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 33' ' ' VAL . . . . . 0.791 HG12 HG13 ' C' ' 44' ' ' VAL . 2.5 m -126.81 159.78 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.013 0.435 . . . . 0.0 110.035 -179.261 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -140.52 93.64 2.64 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 35' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' C' ' 37' ' ' GLY . 84.2 t -56.54 126.54 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.739 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 36' ' ' ILE . . . . . 0.618 ' O ' HG22 ' C' ' 36' ' ' ILE . 4.6 mm -67.18 77.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 CA-C-O 121.582 0.706 . . . . 0.0 109.333 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' C' ' 35' ' ' VAL . . . -163.17 -126.61 0.83 Allowed Glycine 0 CA--C 1.519 0.311 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -64.48 -17.31 63.74 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.274 179.396 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.11 58.07 0.89 Allowed Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 40' ' ' HIS . . . . . 0.73 ' HE2' ' H ' ' C' ' 63' ' ' ASP . 75.7 t60 -89.82 138.95 31.05 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 111.124 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 41' ' ' ARG . . . . . 0.517 ' O ' ' CD2' ' C' ' 40' ' ' HIS . 87.6 mtm-85 -89.87 162.71 15.33 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.675 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 42' ' ' GLY . . . . . 0.47 ' C ' HG22 ' C' ' 33' ' ' VAL . . . 171.64 -172.4 44.58 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 85.4 m -124.71 131.95 53.42 Favored 'General case' 0 C--O 1.24 0.569 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 44' ' ' VAL . . . . . 0.791 HG13 HG12 ' C' ' 33' ' ' VAL . 0.2 OUTLIER -72.58 121.14 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.671 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.07 -157.5 0.12 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.934 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -63.61 142.0 58.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.569 -179.614 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 47' ' ' VAL . . . . . 0.511 HG23 HG22 ' C' ' 58' ' ' VAL . 7.2 p -117.59 135.93 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.176 -179.055 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.99 -177.73 19.5 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 49' ' ' ALA . . . . . 0.567 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -70.45 141.44 52.06 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.974 0.416 . . . . 0.0 110.245 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 47.7 p -139.43 168.58 19.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.293 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 83.3 mt -60.78 -39.35 88.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.974 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 82.8 t80 -59.42 -46.28 89.17 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.215 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -145.94 142.38 28.66 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.012 0.434 . . . . 0.0 110.526 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 60.3 p -85.44 169.12 13.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.914 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 55' ' ' GLY . . . . . 0.567 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 89.66 -146.06 18.67 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -125.77 101.62 6.94 Favored 'General case' 0 N--CA 1.464 0.262 0 O-C-N 122.603 -0.351 . . . . 0.0 110.237 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -121.32 166.45 14.04 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 58' ' ' VAL . . . . . 0.511 HG22 HG23 ' C' ' 47' ' ' VAL . 51.2 t -127.03 129.41 71.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.298 -179.338 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.61 129.72 9.9 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.6 t -123.81 131.63 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 121.244 0.545 . . . . 0.0 110.805 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 10.1 pt -82.19 126.08 39.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.907 179.084 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 62' ' ' LEU . . . . . 0.6 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 3.5 tp -102.33 111.48 23.8 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 63' ' ' ASP . . . . . 0.73 ' H ' ' HE2' ' C' ' 40' ' ' HIS . 42.8 t0 -59.71 -11.1 4.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.127 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 64' ' ' GLU . . . . . 0.64 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.6 mm-40 -62.01 -34.01 75.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.286 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 65' ' ' ALA . . . . . 0.64 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.67 46.28 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.858 0.361 . . . . 0.0 110.546 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 66' ' ' LYS . . . . . 0.546 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.7 ptpt -149.79 104.09 3.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.355 0.597 . . . . 0.0 110.105 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.43 -143.19 8.64 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -179.417 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -96.62 -167.48 1.57 Allowed 'General case' 0 C--O 1.241 0.624 0 CA-C-O 121.104 0.478 . . . . 0.0 109.933 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -117.48 98.72 6.55 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.412 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 76.2 m-20 -62.7 -14.96 50.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.76 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 71' ' ' GLY . . . . . 0.671 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.69 -42.75 96.45 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.069 -1.063 . . . . 0.0 110.63 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 72' ' ' THR . . . . . 0.671 HG23 ' O ' ' C' ' 71' ' ' GLY . 18.9 p -163.22 117.75 1.66 Allowed 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.978 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 73' ' ' VAL . . . . . . . . . . . . . 26.1 t -134.72 122.75 39.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.583 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 51.11 36.37 15.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.743 0.306 . . . . 0.0 111.309 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.58 -2.66 66.64 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 76' ' ' ARG . . . . . . . . . . . . . 16.8 tpp180 -116.11 120.68 39.82 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.351 -0.425 . . . . 0.0 109.937 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -103.14 126.26 50.23 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.375 0.607 . . . . 0.0 110.633 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 83.3 m-85 -79.89 -37.61 34.4 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.861 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 56.8 t80 -171.04 151.74 3.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.392 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.5 p -64.92 98.48 0.28 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.955 0.407 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 6.1 t -167.56 146.86 4.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.519 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -81.72 170.67 15.48 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.264 0.555 . . . . 0.0 110.983 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -49.57 155.33 0.8 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.174 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 84' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.8 -7.22 62.92 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 85' ' ' HIS . . . . . 0.6 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 18.5 m-70 -138.39 130.49 28.5 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 123.88 59.49 0.19 Allowed Glycine 0 C--N 1.341 0.856 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.236 179.705 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 87' ' ' ILE . . . . . 0.427 ' CD1' HD22 ' C' ' 62' ' ' LEU . 97.9 mt -90.62 125.5 43.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.609 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 88' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' C' ' 88' ' ' PHE . 49.4 p90 -70.79 120.34 16.24 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 120.973 0.416 . . . . 0.0 110.587 -179.13 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 89' ' ' VAL . . . . . . . . . . . . . 20.5 m -139.01 160.58 29.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 90' ' ' ARG . . . . . 0.495 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -92.91 155.15 17.77 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -179.701 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 91' ' ' GLN . . . . . 0.471 ' O ' ' O ' ' C' ' 94' ' ' ILE . 0.0 OUTLIER -52.74 -39.83 62.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.081 -179.685 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 92' ' ' SER . . . . . 0.434 ' N ' ' CD ' ' C' ' 91' ' ' GLN . 57.7 m -64.71 -37.14 86.59 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.996 0.427 . . . . 0.0 110.403 178.379 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 93' ' ' GLN . . . . . 0.495 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.2 tt0 -64.75 -19.23 65.68 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.912 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 94' ' ' ILE . . . . . 0.471 ' O ' ' O ' ' C' ' 91' ' ' GLN . 47.1 pt -123.46 153.79 29.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.668 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 95' ' ' GLN . . . . . 0.447 ' OXT' ' O ' ' C' ' 94' ' ' ILE . 69.2 tp60 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.06 -0.971 . . . . 0.0 110.907 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 N--CA 1.485 1.012 0 N-CA-C 109.291 -1.08 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 27' ' ' LEU . . . . . 0.487 ' H ' HD23 ' C' ' 27' ' ' LEU . 0.1 OUTLIER -81.29 130.13 34.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.11 -179.868 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -76.18 147.72 38.24 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.976 0.417 . . . . 0.0 110.636 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 29' ' ' VAL . . . . . 0.432 ' HA ' HG13 ' C' ' 44' ' ' VAL . 2.6 p -62.12 138.07 23.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.014 0.435 . . . . 0.0 110.115 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.27 63.68 Favored Glycine 0 CA--C 1.533 1.202 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.093 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 31' ' ' SER . . . . . 0.442 ' O ' HG12 ' C' ' 44' ' ' VAL . 70.9 m -89.76 163.1 15.21 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.7 0.286 . . . . 0.0 111.16 179.737 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -62.18 150.41 38.88 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.087 0.47 . . . . 0.0 111.19 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m -131.14 155.51 41.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.07 100.44 4.28 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.148 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 35' ' ' VAL . . . . . 0.471 ' HA ' HG22 ' C' ' 94' ' ' ILE . 88.0 t -64.94 130.1 29.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.876 -178.511 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 36' ' ' ILE . . . . . 0.453 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 8.4 mm -82.97 75.43 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.72 -121.37 0.57 Allowed Glycine 0 CA--C 1.522 0.478 0 N-CA-C 110.696 -0.961 . . . . 0.0 110.696 -178.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -58.17 -29.4 65.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.041 -0.58 . . . . 0.0 109.951 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.68 59.78 0.51 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 40' ' ' HIS . . . . . 0.419 ' CE1' ' CG ' ' C' ' 64' ' ' GLU . 94.4 m-70 -103.5 150.55 23.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.038 0.447 . . . . 0.0 110.635 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 53.1 ptt85 -137.76 154.78 49.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.744 -179.155 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.94 -122.7 0.94 Allowed Glycine 0 C--O 1.226 -0.351 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 43' ' ' THR . . . . . 0.605 ' CG2' HD12 ' C' ' 61' ' ' ILE . 5.3 t -141.02 154.62 46.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.843 179.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 44' ' ' VAL . . . . . 0.506 HG23 ' CG1' ' C' ' 58' ' ' VAL . 1.2 p -91.72 141.57 14.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.997 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 45' ' ' ALA . . . . . 0.46 ' O ' HG22 ' C' ' 44' ' ' VAL . . . -88.85 -154.31 0.29 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.549 179.062 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -62.69 141.95 58.32 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.115 0.483 . . . . 0.0 110.645 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 72.9 t -112.59 129.84 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.688 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 127.37 -172.97 18.66 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 49' ' ' ALA . . . . . 0.713 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.16 146.98 52.91 Favored 'General case' 0 C--N 1.334 -0.071 0 CA-C-O 120.914 0.387 . . . . 0.0 110.019 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 50' ' ' THR . . . . . 0.412 ' O ' ' O ' ' C' ' 53' ' ' ALA . 69.7 p -133.26 167.12 20.95 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.121 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.84 -40.78 89.68 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -57.87 -46.6 84.62 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.359 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 53' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -143.76 144.4 31.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.819 0.342 . . . . 0.0 110.285 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 10.0 t -90.12 165.29 14.07 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.385 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 55' ' ' GLY . . . . . 0.713 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 101.22 -152.81 18.96 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 60.6 mtpt -119.94 112.07 18.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.551 -179.371 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -139.12 171.51 14.19 Favored 'General case' 0 CA--C 1.517 -0.296 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 58' ' ' VAL . . . . . 0.506 ' CG1' HG23 ' C' ' 44' ' ' VAL . 50.4 t -131.3 133.16 62.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.637 -178.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -91.4 139.16 14.64 Favored Glycine 0 CA--C 1.532 1.134 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.329 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.69 136.85 59.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-O 121.085 0.469 . . . . 0.0 111.287 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 61' ' ' ILE . . . . . 0.605 HD12 ' CG2' ' C' ' 43' ' ' THR . 41.5 mt -88.45 99.87 9.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.182 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.1 118.78 20.69 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -67.53 -13.05 61.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.239 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 64' ' ' GLU . . . . . 0.653 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.3 mm-40 -62.28 -36.16 81.23 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.42 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 65' ' ' ALA . . . . . 0.653 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.79 44.05 0.01 OUTLIER 'General case' 0 C--N 1.342 0.269 0 CA-C-O 120.911 0.386 . . . . 0.0 110.748 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 66' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' C' ' 84' ' ' GLY . 14.4 ptpt -139.58 119.12 13.04 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.771 178.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 144.73 -146.0 15.97 Favored Glycine 0 CA--C 1.518 0.232 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.457 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 68' ' ' LYS . . . . . 0.444 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 36.6 tttt -98.01 -168.75 1.71 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.992 0.425 . . . . 0.0 109.973 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 69' ' ' ASN . . . . . 0.444 ' H ' ' HG2' ' C' ' 68' ' ' LYS . 10.9 p30 -112.65 95.74 5.59 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.157 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 70' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' C' ' 70' ' ' ASP . 3.9 p-10 -65.26 -10.21 30.29 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.469 -0.493 . . . . 0.0 110.245 178.57 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 71' ' ' GLY . . . . . 0.663 ' O ' HG23 ' C' ' 72' ' ' THR . . . -60.34 -41.78 98.58 Favored Glycine 0 C--O 1.224 -0.489 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.225 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 72' ' ' THR . . . . . 0.663 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.6 p -162.36 109.7 1.32 Allowed 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.879 0.371 . . . . 0.0 110.662 179.621 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 73' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' C' ' 76' ' ' ARG . 43.7 t -125.94 122.36 61.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.3 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 51.69 35.74 15.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.124 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.88 -1.67 72.71 Favored Glycine 0 CA--C 1.52 0.399 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 76' ' ' ARG . . . . . 0.425 ' N ' ' O ' ' C' ' 73' ' ' VAL . 60.2 ttm-85 -116.01 125.51 52.57 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.096 -0.552 . . . . 0.0 109.768 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.7 pttp -112.29 137.47 50.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.658 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -96.52 -36.11 10.88 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 79' ' ' PHE . . . . . 0.56 ' CD1' HD11 ' C' ' 61' ' ' ILE . 22.4 t80 -164.68 145.76 7.92 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.299 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 30.6 p -64.29 104.45 0.76 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.922 0.391 . . . . 0.0 111.306 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 10.7 t -171.3 144.95 2.09 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.527 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -79.93 169.19 18.24 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.342 0.591 . . . . 0.0 111.143 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -45.67 153.71 0.25 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.864 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 84' ' ' GLY . . . . . 0.535 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 99.03 -5.24 59.32 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 85' ' ' HIS . . . . . 0.543 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -138.27 143.36 40.0 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.36 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.09 58.19 0.36 Allowed Glycine 0 C--N 1.337 0.615 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -88.96 134.55 28.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -82.64 119.71 24.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.087 0.47 . . . . 0.0 110.413 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 89' ' ' VAL . . . . . 0.589 HG21 HG21 ' C' ' 94' ' ' ILE . 20.5 m -139.46 165.31 23.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 90' ' ' ARG . . . . . 0.463 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -97.36 159.25 15.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.839 0.352 . . . . 0.0 110.436 -179.688 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 91' ' ' GLN . . . . . 0.49 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.7 pt20 -55.9 -40.7 73.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.929 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 88.0 p -70.73 -28.37 64.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.98 0.419 . . . . 0.0 110.4 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 93' ' ' GLN . . . . . 0.453 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 73.2 tp60 -66.9 -29.0 68.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.576 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 94' ' ' ILE . . . . . 0.589 HG21 HG21 ' C' ' 89' ' ' VAL . 49.4 pt -125.98 164.15 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.245 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 89.2 mt-30 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.399 179.755 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo . . . . . 0 N--CA 1.481 0.788 0 N-CA-C 109.066 -1.167 . . . . 0.0 109.066 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 27' ' ' LEU . . . . . 0.624 HD23 ' N ' ' C' ' 28' ' ' ARG . 1.5 tt -117.01 119.33 34.97 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 28' ' ' ARG . . . . . 0.624 ' N ' HD23 ' C' ' 27' ' ' LEU . 85.9 mtp180 -83.89 132.58 34.77 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-O 121.361 0.6 . . . . 0.0 110.335 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 29' ' ' VAL . . . . . 0.498 HG23 ' O ' ' C' ' 45' ' ' ALA . 3.6 p -64.22 146.45 13.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.354 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.75 -17.74 57.88 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.26 -0.736 . . . . 0.0 111.26 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 31' ' ' SER . . . . . 0.453 ' O ' HG22 ' C' ' 44' ' ' VAL . 85.0 p -78.28 165.13 24.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.008 0.432 . . . . 0.0 111.553 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -54.48 155.56 3.91 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 33' ' ' VAL . . . . . 0.634 HG12 ' C ' ' C' ' 42' ' ' GLY . 7.6 p -123.65 149.52 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.032 0.444 . . . . 0.0 110.804 -179.386 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -151.45 94.47 2.02 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.388 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 85.5 t -70.36 131.23 34.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.581 -179.335 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 36' ' ' ILE . . . . . 0.563 ' O ' HG22 ' C' ' 36' ' ' ILE . 88.3 mt -72.91 74.06 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-O 121.311 0.577 . . . . 0.0 109.671 179.707 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.24 -121.9 0.59 Allowed Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -59.13 -29.93 67.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.596 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.18 46.65 0.92 Allowed Glycine 0 N--CA 1.466 0.691 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -71.72 136.22 47.11 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.877 0.37 . . . . 0.0 110.409 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -114.51 175.91 5.28 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.196 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 42' ' ' GLY . . . . . 0.634 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 134.43 -137.95 9.68 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -179.136 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 99.0 m -134.25 142.34 47.3 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 120.978 0.418 . . . . 0.0 111.47 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 44' ' ' VAL . . . . . 0.453 HG22 ' O ' ' C' ' 31' ' ' SER . 16.0 m -75.29 144.89 11.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.612 179.174 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 45' ' ' ALA . . . . . 0.498 ' O ' HG23 ' C' ' 29' ' ' VAL . . . -91.3 -157.2 0.48 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.334 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -62.69 140.01 58.69 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.306 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 47' ' ' VAL . . . . . 0.518 HG22 HG22 ' C' ' 58' ' ' VAL . 70.1 t -110.77 129.61 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.717 -178.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 126.47 -171.16 18.21 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 49' ' ' ALA . . . . . 0.635 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.6 147.11 52.39 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.062 0.458 . . . . 0.0 109.928 179.278 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 50' ' ' THR . . . . . 0.434 ' O ' ' O ' ' C' ' 53' ' ' ALA . 82.3 p -132.02 165.17 24.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.232 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.5 tp -60.27 -40.95 92.2 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -58.28 -46.18 86.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.451 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 53' ' ' ALA . . . . . 0.434 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -144.81 147.38 32.81 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.853 0.359 . . . . 0.0 110.447 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -88.38 173.16 8.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 55' ' ' GLY . . . . . 0.635 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 97.01 -151.2 19.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 16.5 ptmt -128.28 102.93 6.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.137 0.494 . . . . 0.0 110.064 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -131.68 161.79 31.94 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 58' ' ' VAL . . . . . 0.518 HG22 HG22 ' C' ' 47' ' ' VAL . 57.4 t -121.36 128.68 75.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.904 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.8 134.52 12.51 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 60' ' ' VAL . . . . . 0.562 HG13 HG21 ' C' ' 33' ' ' VAL . 85.1 t -126.7 130.38 71.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.431 0 O-C-N 122.507 -0.408 . . . . 0.0 111.214 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 4.8 pt -80.23 96.13 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.357 -0.537 . . . . 0.0 110.469 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 62' ' ' LEU . . . . . 0.629 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -73.14 118.06 15.63 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.862 179.907 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.5 p-10 -65.53 -9.22 24.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.51 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 64' ' ' GLU . . . . . 0.648 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.9 mm-40 -62.12 -33.64 74.85 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.212 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 65' ' ' ALA . . . . . 0.648 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.83 46.47 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.679 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 66' ' ' LYS . . . . . 0.56 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.2 ptmt -147.22 114.5 6.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.296 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 147.12 -142.74 10.57 Favored Glycine 0 CA--C 1.516 0.149 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 16.6 mmtt -97.18 -172.69 2.49 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 110.275 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 69' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.7 p-10 -114.07 98.22 6.84 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.979 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -60.17 -17.28 39.77 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.104 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 71' ' ' GLY . . . . . 0.653 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.59 -41.85 95.79 Favored Glycine 0 C--O 1.225 -0.44 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 72' ' ' THR . . . . . 0.653 HG23 ' O ' ' C' ' 71' ' ' GLY . 21.4 p -162.21 111.74 1.49 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.761 0.315 . . . . 0.0 110.591 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 73' ' ' VAL . . . . . 0.476 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.3 t -126.32 124.76 66.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.305 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 53.8 tt0 46.24 47.87 13.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.38 0.61 . . . . 0.0 111.029 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.69 3.61 42.55 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.174 -1.17 . . . . 0.0 110.174 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 76' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' C' ' 73' ' ' VAL . 29.2 tpt180 -125.23 125.93 44.37 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.971 0.415 . . . . 0.0 110.416 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -106.94 138.2 43.57 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.516 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -102.84 -29.98 11.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -170.54 147.41 2.91 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.349 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 80' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' C' ' 80' ' ' THR . 9.7 p -63.93 97.06 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.979 0.419 . . . . 0.0 110.955 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 2.2 t -165.02 145.19 7.14 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.312 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -83.14 171.42 13.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.104 0.478 . . . . 0.0 110.695 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -50.18 151.88 1.91 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.341 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 84' ' ' GLY . . . . . 0.56 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 98.91 -6.16 60.05 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 -179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 85' ' ' HIS . . . . . 0.629 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 19.3 m-70 -136.5 131.34 33.83 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.14 59.42 0.17 Allowed Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.4 mm -86.6 132.79 31.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -82.83 118.5 23.46 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 89' ' ' VAL . . . . . 0.48 HG21 HG23 ' C' ' 94' ' ' ILE . 17.8 m -139.62 159.52 27.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.703 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 90' ' ' ARG . . . . . 0.585 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.1 mpt_? -82.5 154.22 25.19 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.251 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 91' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' C' ' 94' ' ' ILE . 16.0 pt20 -54.3 -39.71 67.24 Favored 'General case' 0 C--N 1.33 -0.255 0 O-C-N 123.299 0.374 . . . . 0.0 111.106 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 74.2 m -63.22 -37.34 86.86 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.983 0.421 . . . . 0.0 110.299 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 12.2 tp-100 -63.86 -34.79 78.73 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.029 -178.561 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 94' ' ' ILE . . . . . 0.48 HG23 HG21 ' C' ' 89' ' ' VAL . 15.9 pt -100.92 140.14 20.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.655 -179.65 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo . . . . . 0 N--CA 1.485 0.998 0 N-CA-C 109.328 -1.066 . . . . 0.0 109.328 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 27' ' ' LEU . . . . . 0.598 ' CD2' ' H ' ' C' ' 27' ' ' LEU . 0.1 OUTLIER -71.45 148.87 46.43 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.323 -179.574 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 -81.07 148.39 29.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.861 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 29' ' ' VAL . . . . . 0.51 ' CG2' HG12 ' C' ' 47' ' ' VAL . 71.6 t -66.19 135.83 27.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.439 179.837 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.21 -18.83 47.81 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.0 t -73.1 154.04 40.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 117.044 0.422 . . . . 0.0 110.528 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 48.0 ptt85 -46.54 161.62 0.06 Allowed 'General case' 0 N--CA 1.461 0.114 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 33' ' ' VAL . . . . . 0.517 HG12 ' C ' ' C' ' 42' ' ' GLY . 11.3 p -128.99 151.56 35.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.72 -179.451 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -149.81 95.42 2.31 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 87.1 t -72.11 131.3 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.403 -179.021 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 36' ' ' ILE . . . . . 0.516 ' O ' HG22 ' C' ' 36' ' ' ILE . 90.2 mt -75.12 76.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-O 121.28 0.562 . . . . 0.0 109.543 179.453 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.14 -122.5 0.63 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -59.35 -25.7 64.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.212 -0.494 . . . . 0.0 109.966 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.8 42.77 1.29 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -73.79 145.74 44.8 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.275 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 52.6 ptt85 -141.75 165.1 28.4 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.963 0.411 . . . . 0.0 110.564 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 42' ' ' GLY . . . . . 0.517 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 155.73 -109.39 0.4 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 43' ' ' THR . . . . . 0.485 ' CG2' HD12 ' C' ' 61' ' ' ILE . 6.8 t -145.4 154.27 42.1 Favored 'General case' 0 C--O 1.243 0.726 0 CA-C-O 120.828 0.347 . . . . 0.0 111.257 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 92.8 t -90.93 122.44 42.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.196 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 45' ' ' ALA . . . . . 0.457 ' O ' HG13 ' C' ' 29' ' ' VAL . . . -80.21 -159.12 0.2 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.953 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -64.35 145.05 56.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.346 0.593 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 47' ' ' VAL . . . . . 0.67 ' CG2' HE21 ' C' ' 91' ' ' GLN . 9.3 p -124.17 141.2 45.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.485 -178.735 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 120.66 -171.01 14.57 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 49' ' ' ALA . . . . . 0.564 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.01 141.89 56.09 Favored 'General case' 0 C--O 1.23 0.066 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.641 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 71.1 p -134.81 164.63 27.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.235 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.6 tp -59.16 -39.27 81.95 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.51 -45.66 84.68 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.871 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -149.27 145.69 27.2 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 110.865 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 63.6 p -83.13 168.04 17.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.682 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 55' ' ' GLY . . . . . 0.564 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 98.65 -143.4 16.62 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 40.5 pttt -136.59 106.79 6.37 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.47 0.652 . . . . 0.0 110.624 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 85.5 m95 -130.73 168.26 17.48 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.808 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 58' ' ' VAL . . . . . 0.609 HG22 HG23 ' C' ' 47' ' ' VAL . 64.6 t -125.57 130.61 72.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.574 -178.632 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 59' ' ' GLY . . . . . 0.436 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -89.82 129.09 9.53 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 178.526 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 60' ' ' VAL . . . . . 0.418 HG13 HG21 ' C' ' 33' ' ' VAL . 66.9 t -122.47 132.56 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.135 0.493 . . . . 0.0 110.921 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 61' ' ' ILE . . . . . 0.514 HD11 ' CG ' ' C' ' 79' ' ' PHE . 45.7 mt -85.22 104.16 12.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.361 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 62' ' ' LEU . . . . . 0.442 ' O ' ' CD2' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -84.83 115.67 22.87 Favored 'General case' 0 C--O 1.232 0.174 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.923 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -67.08 -9.08 35.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.289 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 64' ' ' GLU . . . . . 0.646 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.76 -37.54 87.04 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.296 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 65' ' ' ALA . . . . . 0.646 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 86.59 44.34 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 110.672 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 66' ' ' LYS . . . . . 0.568 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.4 ptmt -146.68 106.95 4.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.076 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.96 -140.57 7.36 Favored Glycine 0 CA--C 1.52 0.352 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.121 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 68' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' C' ' 85' ' ' HIS . 7.9 mmtm -95.88 -174.74 3.21 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.277 0.56 . . . . 0.0 110.447 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -112.02 96.72 6.21 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 114.688 -1.142 . . . . 0.0 110.68 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -60.78 -15.05 25.55 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.986 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 71' ' ' GLY . . . . . 0.659 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.4 -45.09 94.81 Favored Glycine 0 N--CA 1.449 -0.5 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 72' ' ' THR . . . . . 0.659 HG23 ' O ' ' C' ' 71' ' ' GLY . 21.2 p -163.25 115.19 1.49 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.012 0.435 . . . . 0.0 110.711 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 73' ' ' VAL . . . . . 0.5 ' N ' ' O ' ' C' ' 76' ' ' ARG . 38.8 t -129.53 123.73 58.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.355 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 56.4 tt0 42.86 56.61 3.92 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.214 0.531 . . . . 0.0 111.336 179.232 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.3 4.76 6.85 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 76' ' ' ARG . . . . . 0.5 ' O ' ' N ' ' C' ' 73' ' ' VAL . 26.0 tpt180 -125.41 127.44 46.56 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.248 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 26.7 pttm -112.56 137.97 50.02 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.213 0.53 . . . . 0.0 111.158 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -93.13 -37.18 12.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.814 178.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 79' ' ' PHE . . . . . 0.514 ' CG ' HD11 ' C' ' 61' ' ' ILE . 50.5 t80 -172.6 153.39 2.8 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.323 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 80' ' ' THR . . . . . 0.45 ' N ' ' CD1' ' C' ' 79' ' ' PHE . 28.7 p -64.58 95.57 0.15 Allowed 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.48 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 81' ' ' CYS . . . . . 0.456 ' SG ' ' CG ' ' C' ' 85' ' ' HIS . 9.9 t -163.43 142.26 8.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.561 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -79.14 168.22 19.92 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.334 0.588 . . . . 0.0 110.819 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -46.36 150.47 0.63 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.879 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 84' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 105.06 -8.54 45.57 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.266 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 85' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -136.06 136.04 39.89 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.8 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.75 59.61 0.2 Allowed Glycine 0 C--N 1.337 0.596 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.0 mm -85.74 133.0 30.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.561 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -82.28 119.06 23.63 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.156 0.503 . . . . 0.0 110.064 -179.204 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 89' ' ' VAL . . . . . 0.496 HG21 ' CG2' ' C' ' 94' ' ' ILE . 5.0 m -139.73 164.86 23.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.104 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 90' ' ' ARG . . . . . 0.568 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -97.12 166.71 11.45 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.939 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 91' ' ' GLN . . . . . 0.67 HE21 ' CG2' ' C' ' 47' ' ' VAL . 26.1 mp0 -59.61 -42.88 93.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.764 0.316 . . . . 0.0 110.735 -178.653 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 64.2 m -62.79 -36.03 81.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.379 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 16.8 tt0 -63.96 -35.93 82.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.444 -178.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 94' ' ' ILE . . . . . 0.544 ' CD1' HD11 ' C' ' 27' ' ' LEU . 35.4 pt -101.27 144.41 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.881 0.372 . . . . 0.0 110.59 179.178 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 95' ' ' GLN . . . . . 0.458 ' OE1' HD13 ' C' ' 27' ' ' LEU . 96.9 mt-30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.946 -1.026 . . . . 0.0 111.113 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo . . . . . 0 N--CA 1.485 1.02 0 N-CA-C 109.094 -1.156 . . . . 0.0 109.094 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 27' ' ' LEU . . . . . 0.635 ' H ' HD23 ' C' ' 27' ' ' LEU . 0.2 OUTLIER -81.92 168.25 18.1 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.771 179.857 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 80.1 mtp85 -120.85 147.34 45.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.354 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -57.01 141.92 13.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.217 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.75 -18.04 55.58 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 83.8 p -81.54 163.13 22.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.964 0.411 . . . . 0.0 110.923 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -50.66 153.36 1.7 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.935 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 33' ' ' VAL . . . . . 0.722 HG12 ' C ' ' C' ' 42' ' ' GLY . 12.3 p -125.39 149.77 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.939 0.399 . . . . 0.0 111.047 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -150.43 92.79 1.9 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 80.2 t -67.47 131.28 33.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.06 -179.237 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 36' ' ' ILE . . . . . 0.47 ' O ' HG22 ' C' ' 36' ' ' ILE . 42.5 mm -75.62 74.57 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.293 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -120.47 0.54 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.819 -0.913 . . . . 0.0 110.819 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.61 -27.19 66.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.021 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.14 44.98 1.04 Allowed Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -75.34 141.73 43.29 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 40.0 ptt180 -129.3 165.78 20.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.174 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 42' ' ' GLY . . . . . 0.722 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 151.37 -130.28 3.11 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.129 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.4 m -131.91 140.98 49.22 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.119 0.485 . . . . 0.0 111.56 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 44' ' ' VAL . . . . . 0.441 HG13 ' CG1' ' C' ' 58' ' ' VAL . 97.2 t -75.78 133.16 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.839 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 45' ' ' ALA . . . . . 0.596 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -85.59 -159.6 0.46 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.967 0.413 . . . . 0.0 110.519 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 46' ' ' TYR . . . . . 0.426 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 84.6 t80 -65.34 144.89 56.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.171 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 47' ' ' VAL . . . . . 0.534 HG12 HG22 ' C' ' 58' ' ' VAL . 19.2 m -118.42 154.15 20.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.969 -179.253 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.93 179.4 20.88 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 49' ' ' ALA . . . . . 0.613 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.53 149.36 49.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.089 0.471 . . . . 0.0 110.366 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 50' ' ' THR . . . . . 0.463 HG23 ' H ' ' C' ' 53' ' ' ALA . 7.6 t -149.22 174.98 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.698 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 86.3 mt -60.96 -39.45 89.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.603 -179.287 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 52' ' ' PHE . . . . . 0.495 ' CD2' ' CZ ' ' C' ' 88' ' ' PHE . 91.9 t80 -59.22 -46.59 88.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.612 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 53' ' ' ALA . . . . . 0.463 ' H ' HG23 ' C' ' 50' ' ' THR . . . -149.28 140.16 22.82 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.789 0.328 . . . . 0.0 110.412 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 72.7 p -83.74 168.91 15.78 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.405 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 55' ' ' GLY . . . . . 0.613 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 89.14 -153.51 23.63 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 56.6 mtmt -110.88 108.78 18.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.881 0.372 . . . . 0.0 110.478 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 83.8 m95 -134.0 161.38 34.97 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.021 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 58' ' ' VAL . . . . . 0.534 HG22 HG12 ' C' ' 47' ' ' VAL . 87.6 t -128.82 130.57 68.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.311 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 59' ' ' GLY . . . . . 0.596 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -90.43 136.15 13.27 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 60' ' ' VAL . . . . . 0.413 ' CG1' HG21 ' C' ' 33' ' ' VAL . 92.3 t -130.42 134.47 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.269 0.557 . . . . 0.0 111.334 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 6.3 pt -85.22 114.59 25.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.603 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 62' ' ' LEU . . . . . 0.614 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.7 OUTLIER -92.23 125.56 36.95 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.936 0.398 . . . . 0.0 110.666 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -67.53 -11.56 58.29 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.618 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 64' ' ' GLU . . . . . 0.651 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.8 mm-40 -61.16 -32.7 72.42 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.436 179.776 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 65' ' ' ALA . . . . . 0.651 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 86.9 35.85 0.02 OUTLIER 'General case' 0 C--N 1.34 0.185 0 O-C-N 123.504 0.503 . . . . 0.0 110.658 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 66' ' ' LYS . . . . . 0.537 ' N ' ' O ' ' C' ' 84' ' ' GLY . 65.0 pttt -134.98 136.46 42.21 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.12 -146.54 17.15 Favored Glycine 0 N--CA 1.461 0.313 0 N-CA-C 110.689 -0.965 . . . . 0.0 110.689 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 4.3 mmtm -97.5 -170.16 1.96 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.186 0.517 . . . . 0.0 110.351 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 69' ' ' ASN . . . . . 0.462 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.2 p-10 -114.46 99.47 7.58 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.749 -179.501 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -60.31 -16.99 39.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 71' ' ' GLY . . . . . 0.655 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.7 -43.14 96.52 Favored Glycine 0 C--O 1.226 -0.359 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 72' ' ' THR . . . . . 0.655 HG23 ' O ' ' C' ' 71' ' ' GLY . 18.8 p -161.9 112.62 1.62 Allowed 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.713 0.292 . . . . 0.0 110.765 179.326 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 73' ' ' VAL . . . . . 0.509 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.6 t -127.53 123.26 61.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.233 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 74' ' ' GLN . . . . . 0.404 ' C ' ' H ' ' C' ' 76' ' ' ARG . 71.2 tp60 43.5 57.01 4.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.365 0.602 . . . . 0.0 110.601 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 61.78 4.81 6.08 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 76' ' ' ARG . . . . . 0.509 ' N ' ' O ' ' C' ' 73' ' ' VAL . 46.7 tpt85 -125.16 126.8 45.83 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 110.172 -0.306 . . . . 0.0 110.172 -179.793 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 77' ' ' LYS . . . . . 0.491 ' O ' ' NH1' ' C' ' 76' ' ' ARG . 63.2 pttt -108.93 137.98 46.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.879 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 51.8 m-85 -99.91 -31.24 11.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.8 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -171.58 151.0 2.85 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.388 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.0 p -64.19 98.16 0.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.942 0.401 . . . . 0.0 110.822 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 81' ' ' CYS . . . . . 0.412 ' O ' ' N ' ' C' ' 71' ' ' GLY . 4.1 t -168.91 142.92 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.432 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -84.07 170.56 13.75 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.525 0.679 . . . . 0.0 110.591 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -44.82 152.64 0.22 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.989 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 84' ' ' GLY . . . . . 0.537 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.18 -7.76 56.95 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 85' ' ' HIS . . . . . 0.614 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 7.0 m-70 -140.02 134.23 31.13 Favored 'General case' 0 C--O 1.24 0.564 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.094 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.7 58.47 0.16 Allowed Glycine 0 C--N 1.337 0.633 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -83.27 131.23 34.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 88' ' ' PHE . . . . . 0.495 ' CZ ' ' CD2' ' C' ' 52' ' ' PHE . 97.4 m-85 -79.42 118.99 21.81 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.79 -178.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 89' ' ' VAL . . . . . 0.475 ' O ' ' N ' ' C' ' 58' ' ' VAL . 12.1 m -141.52 163.47 20.34 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.262 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 90' ' ' ARG . . . . . 0.572 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -90.29 154.33 19.79 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.116 0.484 . . . . 0.0 110.841 179.788 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 91' ' ' GLN . . . . . 0.407 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.1 pt20 -52.54 -38.65 60.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.467 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 89.2 p -67.7 -33.32 74.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.096 0.474 . . . . 0.0 110.657 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -66.66 -21.21 66.11 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.594 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 94' ' ' ILE . . . . . 0.432 ' CG2' HG21 ' C' ' 89' ' ' VAL . 39.0 pt -117.24 146.65 21.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.642 -179.814 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo . . . . . 0 N--CA 1.483 0.859 0 N-CA-C 109.03 -1.181 . . . . 0.0 109.03 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 27' ' ' LEU . . . . . 0.797 ' H ' HD23 ' C' ' 27' ' ' LEU . 2.2 pt? -85.8 170.57 12.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.334 179.501 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 -125.73 147.93 49.22 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.418 0.627 . . . . 0.0 110.57 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 29' ' ' VAL . . . . . 0.423 HG23 ' O ' ' C' ' 45' ' ' ALA . 2.9 p -57.63 142.5 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.257 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.2 -18.78 47.99 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.114 -0.794 . . . . 0.0 111.114 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 31' ' ' SER . . . . . 0.742 ' O ' HG23 ' C' ' 44' ' ' VAL . 37.0 t -90.36 164.63 14.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.475 0.179 . . . . 0.0 110.523 179.548 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -60.75 161.03 8.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.207 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 33' ' ' VAL . . . . . 0.541 ' HB ' HG22 ' C' ' 44' ' ' VAL . 0.2 OUTLIER -133.67 151.09 32.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.806 -179.419 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -141.98 91.39 2.34 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.302 177.388 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.7 t -61.82 131.8 27.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 CA-C-O 121.116 0.484 . . . . 0.0 110.633 -179.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -77.61 88.65 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.416 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.95 -126.1 0.8 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -67.03 -12.58 60.31 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.927 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.04 60.34 0.53 Allowed Glycine 0 CA--C 1.52 0.395 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -105.68 143.68 33.49 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.982 0.42 . . . . 0.0 110.6 179.239 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -145.78 165.94 27.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.755 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 175.11 -125.76 1.11 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 96.4 m -127.8 136.39 51.4 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 120.715 0.293 . . . . 0.0 111.057 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 44' ' ' VAL . . . . . 0.742 HG23 ' O ' ' C' ' 31' ' ' SER . 43.1 t -72.51 128.89 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 45' ' ' ALA . . . . . 0.462 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -94.82 -159.04 0.68 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.314 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -65.49 141.34 58.52 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.133 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 47' ' ' VAL . . . . . 0.519 HG23 HG22 ' C' ' 58' ' ' VAL . 6.2 p -121.03 133.32 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.394 -179.383 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.05 -174.05 21.6 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 49' ' ' ALA . . . . . 0.436 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -71.21 152.23 43.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.874 0.369 . . . . 0.0 110.272 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 50' ' ' THR . . . . . 0.669 HG23 ' H ' ' C' ' 53' ' ' ALA . 1.7 t -146.19 166.56 25.84 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.827 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 51' ' ' LEU . . . . . 0.518 ' N ' HD12 ' C' ' 51' ' ' LEU . 10.5 mp -60.67 -38.58 85.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.167 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 52' ' ' PHE . . . . . 0.529 ' N ' ' OE1' ' C' ' 74' ' ' GLN . 92.4 t80 -59.89 -44.76 94.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.206 179.148 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 53' ' ' ALA . . . . . 0.669 ' H ' HG23 ' C' ' 50' ' ' THR . . . -145.5 144.28 30.47 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.511 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 99.1 m -98.44 132.83 43.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.546 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 55' ' ' GLY . . . . . 0.436 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 136.98 -147.69 19.37 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -124.26 96.17 4.82 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 36.6 m95 -122.94 162.98 21.25 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.986 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 58' ' ' VAL . . . . . 0.519 HG22 HG23 ' C' ' 47' ' ' VAL . 59.2 t -125.15 128.27 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.773 -179.252 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 59' ' ' GLY . . . . . 0.462 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -84.54 136.85 15.08 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 109.691 -1.363 . . . . 0.0 109.691 179.003 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.4 t -123.39 133.9 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.037 0.446 . . . . 0.0 111.038 -178.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 16.4 mm -87.06 93.28 4.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.811 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 62' ' ' LEU . . . . . 0.617 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.6 OUTLIER -76.03 120.14 20.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.546 -179.409 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -67.85 -11.94 59.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.837 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 64' ' ' GLU . . . . . 0.657 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.7 mm-40 -63.37 -34.25 77.32 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.476 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 65' ' ' ALA . . . . . 0.657 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 83.42 47.18 0.02 OUTLIER 'General case' 0 C--N 1.338 0.105 0 O-C-N 123.322 0.389 . . . . 0.0 110.748 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 66' ' ' LYS . . . . . 0.552 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.4 ptpt -146.84 109.21 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.387 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.53 -140.5 7.25 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.449 -1.061 . . . . 0.0 110.449 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -97.19 -173.36 2.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.919 0.39 . . . . 0.0 110.125 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 42.3 p-10 -113.95 98.01 6.73 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.576 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 -61.65 -17.37 55.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.375 179.246 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 71' ' ' GLY . . . . . 0.66 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.93 -43.1 97.0 Favored Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 72' ' ' THR . . . . . 0.66 HG23 ' O ' ' C' ' 71' ' ' GLY . 19.1 p -161.41 118.09 2.2 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 120.513 0.197 . . . . 0.0 110.636 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 73' ' ' VAL . . . . . 0.623 ' O ' ' N ' ' C' ' 76' ' ' ARG . 12.7 t -128.31 125.68 64.53 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 74' ' ' GLN . . . . . 0.529 ' OE1' ' N ' ' C' ' 52' ' ' PHE . 3.4 pt20 39.55 36.79 0.25 Allowed 'General case' 0 C--N 1.328 -0.364 0 O-C-N 123.148 0.28 . . . . 0.0 111.323 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 89.03 -19.56 37.78 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 76' ' ' ARG . . . . . 0.623 ' N ' ' O ' ' C' ' 73' ' ' VAL . 59.9 ttt85 -101.96 126.25 48.83 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 pttt -106.83 132.32 52.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.491 0.662 . . . . 0.0 111.209 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 78' ' ' TYR . . . . . 0.546 ' OH ' HG21 ' C' ' 50' ' ' THR . 3.1 m-85 -84.26 -40.65 17.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.063 178.268 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 79' ' ' PHE . . . . . 0.409 ' CG ' ' N ' ' C' ' 80' ' ' THR . 86.8 t80 -170.87 158.19 5.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.467 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 80' ' ' THR . . . . . 0.409 ' N ' ' CG ' ' C' ' 79' ' ' PHE . 82.7 p -64.12 96.95 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.975 0.417 . . . . 0.0 111.029 -179.499 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.31 144.9 4.65 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.305 179.465 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -86.57 169.45 12.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.191 0.519 . . . . 0.0 110.887 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -46.71 149.93 0.77 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.185 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 84' ' ' GLY . . . . . 0.552 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.36 -7.11 56.14 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -178.89 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 85' ' ' HIS . . . . . 0.617 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 6.3 m-70 -139.15 132.82 30.56 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.093 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.9 58.57 0.16 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.9 mm -82.34 132.39 31.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -83.66 116.68 22.76 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.482 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 89' ' ' VAL . . . . . 0.482 HG21 ' CG2' ' C' ' 94' ' ' ILE . 4.3 m -140.21 160.01 25.76 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.911 178.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 90' ' ' ARG . . . . . 0.658 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -85.97 162.62 18.44 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 120.791 0.329 . . . . 0.0 110.758 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 91' ' ' GLN . . . . . 0.455 ' O ' ' O ' ' C' ' 94' ' ' ILE . 96.0 mt-30 -59.31 -41.2 88.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.597 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 40.0 t -61.53 -37.99 85.78 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.432 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -63.2 -33.88 76.44 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.565 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 94' ' ' ILE . . . . . 0.627 ' CD1' HD11 ' C' ' 27' ' ' LEU . 34.1 pt -105.01 149.13 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 121.082 0.468 . . . . 0.0 110.799 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.596 179.826 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 N--CA 1.485 0.976 0 N-CA-C 109.287 -1.082 . . . . 0.0 109.287 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 27' ' ' LEU . . . . . 0.616 HD23 ' N ' ' C' ' 28' ' ' ARG . 1.3 tt -112.41 120.57 42.14 Favored 'General case' 0 CA--C 1.534 0.353 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 28' ' ' ARG . . . . . 0.616 ' N ' HD23 ' C' ' 27' ' ' LEU . 96.1 mtm-85 -73.79 127.01 31.68 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.969 0.414 . . . . 0.0 110.369 -179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -67.14 140.32 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 CA-C-O 121.361 0.601 . . . . 0.0 111.058 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.07 -16.38 57.23 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.032 -178.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 31' ' ' SER . . . . . 0.778 ' O ' HG12 ' C' ' 44' ' ' VAL . 81.5 p -80.36 165.38 22.32 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.918 0.39 . . . . 0.0 111.606 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 32' ' ' ARG . . . . . 0.684 ' NE ' HH21 ' C' ' 41' ' ' ARG . 99.7 mtt180 -68.67 156.21 38.61 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.473 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 33' ' ' VAL . . . . . 0.451 HG22 ' C ' ' C' ' 42' ' ' GLY . 2.2 m -130.82 156.3 42.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.321 0 CA-C-O 121.216 0.531 . . . . 0.0 110.445 -179.707 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -139.39 99.41 3.73 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 177.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 35' ' ' VAL . . . . . 0.412 ' HA ' HG22 ' C' ' 94' ' ' ILE . 74.1 t -62.37 130.3 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.419 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.943 -178.575 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 36' ' ' ILE . . . . . 0.471 ' O ' HG22 ' C' ' 36' ' ' ILE . 96.9 mt -75.0 76.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.804 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -125.36 0.77 Allowed Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 65.4 pttt -60.01 -20.02 55.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.592 -0.304 . . . . 0.0 110.579 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.44 54.99 0.81 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 40' ' ' HIS . . . . . 0.431 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 66.7 t-80 -87.32 137.4 32.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.218 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 41' ' ' ARG . . . . . 0.684 HH21 ' NE ' ' C' ' 32' ' ' ARG . 78.0 ttt-85 -110.09 139.43 45.22 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.13 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 42' ' ' GLY . . . . . 0.451 ' C ' HG22 ' C' ' 33' ' ' VAL . . . -172.14 -170.8 36.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.412 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 95.1 m -114.18 131.55 56.41 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 44' ' ' VAL . . . . . 0.778 HG12 ' O ' ' C' ' 31' ' ' SER . 1.3 p -69.49 139.6 20.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.294 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -96.17 -156.88 0.55 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.375 -0.829 . . . . 0.0 109.274 178.662 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -63.66 142.37 58.42 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.201 0.524 . . . . 0.0 110.221 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 47' ' ' VAL . . . . . 0.625 HG12 HG22 ' C' ' 58' ' ' VAL . 19.7 m -118.8 153.58 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.285 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 116.96 -175.83 15.91 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 49' ' ' ALA . . . . . 0.715 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.13 141.2 56.14 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 60.3 p -137.69 167.7 21.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.289 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.5 tp -59.86 -41.16 90.84 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 52' ' ' PHE . . . . . 0.462 ' CE1' ' NZ ' ' C' ' 68' ' ' LYS . 88.8 t80 -58.74 -46.0 88.41 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.274 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.39 140.94 32.2 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.964 0.412 . . . . 0.0 110.677 179.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.3 p -84.44 167.63 16.25 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.745 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 55' ' ' GLY . . . . . 0.715 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 87.1 -133.35 11.74 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -131.18 114.68 15.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.524 0.678 . . . . 0.0 110.513 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -137.52 156.04 48.57 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.45 179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 58' ' ' VAL . . . . . 0.625 HG22 HG12 ' C' ' 47' ' ' VAL . 82.1 t -119.36 130.06 74.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.441 -179.182 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.37 135.49 12.91 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 75.1 t -125.94 132.69 70.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.07 0.462 . . . . 0.0 111.374 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.5 pt -83.5 95.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.561 0.696 . . . . 0.0 110.196 178.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 62' ' ' LEU . . . . . 0.579 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -70.12 120.82 16.38 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.335 -179.321 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 63' ' ' ASP . . . . . 0.431 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.0 m-20 -67.61 -11.1 57.39 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.4 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 64' ' ' GLU . . . . . 0.657 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.19 -35.79 79.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.179 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 65' ' ' ALA . . . . . 0.657 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 87.05 39.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.962 0.41 . . . . 0.0 110.397 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 66' ' ' LYS . . . . . 0.512 ' N ' ' O ' ' C' ' 84' ' ' GLY . 21.3 ptmt -135.6 135.56 40.34 Favored 'General case' 0 CA--C 1.521 -0.155 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.59 179.353 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.21 -146.79 16.45 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 68' ' ' LYS . . . . . 0.462 ' NZ ' ' CE1' ' C' ' 52' ' ' PHE . 17.5 ptpt -98.47 -168.0 1.58 Allowed 'General case' 0 C--O 1.238 0.452 0 CA-C-O 120.941 0.4 . . . . 0.0 110.736 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 69' ' ' ASN . . . . . 0.422 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 40.6 p-10 -111.8 105.42 13.89 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.56 -179.468 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 70' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' C' ' 85' ' ' HIS . 0.9 OUTLIER -63.93 -11.46 28.44 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.899 178.515 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 71' ' ' GLY . . . . . 0.667 ' O ' HG23 ' C' ' 72' ' ' THR . . . -60.29 -42.92 98.97 Favored Glycine 0 N--CA 1.45 -0.383 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 72' ' ' THR . . . . . 0.667 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.4 p -163.91 115.38 1.36 Allowed 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 123.838 0.376 . . . . 0.0 110.683 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 73' ' ' VAL . . . . . 0.422 ' CG2' ' O ' ' C' ' 69' ' ' ASN . 16.8 t -131.12 119.02 43.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.8 mm-40 52.35 35.16 16.52 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.558 0.218 . . . . 0.0 111.441 179.146 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.62 -1.7 81.71 Favored Glycine 0 CA--C 1.517 0.195 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 76' ' ' ARG . . . . . 0.405 ' O ' ' N ' ' C' ' 73' ' ' VAL . 28.1 tpt180 -115.98 123.85 49.04 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.244 -0.478 . . . . 0.0 109.75 179.494 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -109.7 136.33 49.22 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-O 121.272 0.558 . . . . 0.0 110.645 -179.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -93.66 -37.23 11.95 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.597 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -170.56 149.18 3.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.279 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 31.0 p -64.3 101.48 0.43 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.888 0.375 . . . . 0.0 111.615 -178.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.0 t -171.19 146.97 2.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.307 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -78.65 168.63 19.47 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.432 0.634 . . . . 0.0 110.717 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -43.57 157.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.307 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 84' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.86 -8.15 63.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 85' ' ' HIS . . . . . 0.579 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 30.7 m-70 -137.61 144.49 41.97 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.6 60.4 0.49 Allowed Glycine 0 N--CA 1.467 0.718 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 50.7 mm -93.77 127.37 45.86 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 88' ' ' PHE . . . . . 0.537 ' CD2' ' O ' ' C' ' 88' ' ' PHE . 49.0 p90 -77.34 119.7 21.33 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.276 0.56 . . . . 0.0 110.091 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 89' ' ' VAL . . . . . 0.412 ' O ' ' HB ' ' C' ' 58' ' ' VAL . 4.0 p -143.44 140.41 26.24 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.728 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 90' ' ' ARG . . . . . 0.651 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -65.59 151.52 46.28 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.954 -0.298 . . . . 0.0 110.925 -177.774 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 91' ' ' GLN . . . . . 0.599 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 3.8 pm0 -57.87 -33.75 69.02 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.836 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 81.7 p -64.95 -36.81 85.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.349 . . . . 0.0 110.849 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -67.59 -20.68 65.4 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.021 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 94' ' ' ILE . . . . . 0.455 ' O ' ' O ' ' C' ' 91' ' ' GLN . 24.3 pt -117.65 148.72 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.88 0.371 . . . . 0.0 110.142 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.583 -179.608 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 35.1 ptt-85 . . . . . 0 C--O 1.236 0.352 0 CA-C-O 121.456 0.646 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 29' ' ' VAL . . . . . 0.475 HG23 ' O ' ' C' ' 45' ' ' ALA . 3.4 p -57.28 145.0 8.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.206 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.34 -20.69 47.53 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -83.67 159.5 21.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.861 0.363 . . . . 0.0 110.791 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 39.4 ptt180 -50.72 161.85 0.31 Allowed 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 33' ' ' VAL . . . . . 0.715 HG12 ' C ' ' C' ' 42' ' ' GLY . 9.4 p -128.21 150.13 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.858 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -146.72 91.8 2.07 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 94.1 t -67.63 130.88 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.93 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 36' ' ' ILE . . . . . 0.444 HG22 ' O ' ' C' ' 36' ' ' ILE . 5.6 mm -76.17 74.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.508 0.67 . . . . 0.0 109.934 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.72 -119.77 0.5 Allowed Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.73 -17.94 27.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.121 -0.539 . . . . 0.0 109.966 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.21 41.72 3.66 Favored Glycine 0 N--CA 1.465 0.588 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 40' ' ' HIS . . . . . 0.622 ' ND1' HD11 ' C' ' 62' ' ' LEU . 64.8 m170 -75.4 147.37 40.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 110.694 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.4 ptm180 -134.77 163.18 30.38 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.748 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 42' ' ' GLY . . . . . 0.715 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 157.56 -127.25 1.88 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -178.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 98.6 m -131.89 142.85 49.79 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 120.912 0.386 . . . . 0.0 111.845 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 95.9 t -77.83 132.31 32.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.043 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 45' ' ' ALA . . . . . 0.507 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -85.77 -158.72 0.41 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.486 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 81.8 t80 -64.41 143.48 57.87 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 47' ' ' VAL . . . . . 0.559 HG22 HG22 ' C' ' 58' ' ' VAL . 89.9 t -119.64 131.75 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.613 -178.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.0 -176.09 19.45 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 49' ' ' ALA . . . . . 0.746 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -70.3 142.92 52.18 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-O 120.937 0.399 . . . . 0.0 110.015 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 69.6 p -138.6 169.58 17.54 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.473 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 97.1 mt -60.86 -38.82 86.88 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.993 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.0 t80 -59.06 -46.14 89.01 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.523 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.18 143.98 29.63 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.1 p -85.14 166.95 16.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.538 179.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 55' ' ' GLY . . . . . 0.746 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 94.17 -140.54 15.1 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -134.38 96.04 3.51 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.403 -0.469 . . . . 0.0 110.464 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -113.89 171.12 7.78 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.105 0.479 . . . . 0.0 109.785 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 58' ' ' VAL . . . . . 0.559 HG22 HG22 ' C' ' 47' ' ' VAL . 59.9 t -129.77 130.21 66.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.401 -179.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 59' ' ' GLY . . . . . 0.507 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -92.11 134.57 12.3 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 178.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 60' ' ' VAL . . . . . 0.475 HG13 HG21 ' C' ' 33' ' ' VAL . 59.5 t -122.19 132.96 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 CA-C-O 120.906 0.384 . . . . 0.0 111.162 -178.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 7.9 mm -81.39 96.22 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.954 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 62' ' ' LEU . . . . . 0.622 HD11 ' ND1' ' C' ' 40' ' ' HIS . 0.2 OUTLIER -78.17 114.85 17.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.577 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -66.89 -18.07 65.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.66 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 64' ' ' GLU . . . . . 0.655 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.3 mm-40 -60.55 -32.22 71.3 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.341 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 65' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 84.53 46.63 0.02 OUTLIER 'General case' 0 N--CA 1.461 0.09 0 CA-C-O 120.796 0.331 . . . . 0.0 110.772 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 66' ' ' LYS . . . . . 0.538 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.6 ptpt -141.3 110.89 6.44 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.168 0.508 . . . . 0.0 110.238 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 151.31 -143.02 10.02 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 68' ' ' LYS . . . . . 0.428 ' H ' ' HG2' ' C' ' 68' ' ' LYS . 18.3 ptmt -99.4 -171.99 2.18 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 69' ' ' ASN . . . . . 0.455 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 23.0 p-10 -112.07 102.53 10.73 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.603 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -62.41 -15.98 52.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.313 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 71' ' ' GLY . . . . . 0.647 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.42 -45.52 94.27 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.065 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 72' ' ' THR . . . . . 0.647 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.1 p -162.18 120.83 2.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.843 0.354 . . . . 0.0 110.667 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 73' ' ' VAL . . . . . 0.487 ' N ' ' O ' ' C' ' 76' ' ' ARG . 12.7 t -138.69 122.06 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.617 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 74' ' ' GLN . . . . . 0.441 ' C ' ' H ' ' C' ' 76' ' ' ARG . 55.6 tt0 44.78 58.44 3.95 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.275 0.56 . . . . 0.0 110.963 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 60.02 3.88 2.96 Favored Glycine 0 CA--C 1.517 0.186 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 76' ' ' ARG . . . . . 0.487 ' O ' ' N ' ' C' ' 73' ' ' VAL . 17.2 tpp180 -124.75 129.59 50.77 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.862 0.363 . . . . 0.0 110.373 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -113.34 136.43 52.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.271 0.558 . . . . 0.0 111.078 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -88.78 -39.29 14.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.862 178.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -173.33 158.97 3.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.486 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -65.46 96.99 0.27 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.843 0.354 . . . . 0.0 111.001 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.3 t -169.2 144.82 3.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.522 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 49.8 p-10 -84.11 172.16 12.21 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.275 0.56 . . . . 0.0 110.82 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -47.68 151.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.165 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 84' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.03 -6.8 56.8 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 85' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -137.74 128.27 26.61 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 124.73 54.32 0.18 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.736 -0.546 . . . . 0.0 111.736 179.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 87' ' ' ILE . . . . . 0.457 HD12 HD23 ' C' ' 62' ' ' LEU . 96.7 mt -80.43 129.36 37.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 88' ' ' PHE . . . . . 0.569 ' O ' ' CD2' ' C' ' 88' ' ' PHE . 48.6 p90 -74.94 119.35 19.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.087 0.47 . . . . 0.0 111.063 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 89' ' ' VAL . . . . . 0.496 HG21 ' CG2' ' C' ' 94' ' ' ILE . 4.5 m -140.5 162.63 23.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 90' ' ' ARG . . . . . 0.581 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -91.14 163.46 14.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.728 179.732 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' C' C ' 91' ' ' GLN . . . . . . . . . . . . . 55.6 mt-30 -59.31 -42.63 91.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.721 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 67.7 m -63.16 -33.84 76.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.245 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 93' ' ' GLN . . . . . 0.526 ' OE1' ' NH1' ' C' ' 90' ' ' ARG . 72.5 tp60 -64.29 -36.95 85.79 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.655 -178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 94' ' ' ILE . . . . . 0.496 ' CG2' HG21 ' C' ' 89' ' ' VAL . 24.1 pt -99.44 139.3 21.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.051 0.453 . . . . 0.0 110.453 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 59.5 tt0 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.775 -179.655 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 62.7 ttp180 . . . . . 0 N--CA 1.452 -0.339 0 CA-C-O 120.975 0.417 . . . . 0.0 110.798 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 29' ' ' VAL . . . . . 0.467 ' HA ' HG13 ' C' ' 44' ' ' VAL . 1.6 p -55.9 140.62 13.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.059 179.647 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.7 -9.94 62.4 Favored Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . 0.534 ' O ' HG12 ' C' ' 44' ' ' VAL . 67.5 m -92.67 163.76 13.65 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.942 0.401 . . . . 0.0 111.045 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 17.7 ptm180 -61.62 159.11 13.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.318 179.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 33' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' C' ' 42' ' ' GLY . 2.6 m -135.7 160.36 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 34' ' ' GLU . . . . . 0.508 ' N ' ' OXT' ' C' ' 95' ' ' GLN . 77.3 mm-40 -133.2 96.02 3.66 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 177.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 84.9 t -61.07 131.2 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.702 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 36' ' ' ILE . . . . . 0.493 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 6.5 mm -76.68 82.76 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-O 121.426 0.632 . . . . 0.0 110.027 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.28 -125.97 0.79 Allowed Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -64.02 -18.47 64.35 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.306 -0.447 . . . . 0.0 110.454 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.12 55.98 0.59 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 40' ' ' HIS . . . . . 0.526 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 61.0 t-80 -95.44 154.9 16.97 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.799 0.333 . . . . 0.0 110.404 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 41' ' ' ARG . . . . . 0.467 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 37.2 ptt-85 -128.52 157.54 40.89 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.337 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 42' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' C' ' 33' ' ' VAL . . . 176.33 -166.37 37.35 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.5 m -111.11 132.09 54.55 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-O 120.903 0.382 . . . . 0.0 110.667 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 44' ' ' VAL . . . . . 0.534 HG12 ' O ' ' C' ' 31' ' ' SER . 1.5 p -72.26 135.21 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.83 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 45' ' ' ALA . . . . . 0.409 ' O ' HG22 ' C' ' 44' ' ' VAL . . . -87.21 -156.48 0.33 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.801 178.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 46' ' ' TYR . . . . . 0.402 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 91.0 t80 -63.42 140.68 58.9 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.065 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 47' ' ' VAL . . . . . 0.402 ' O ' ' CE2' ' C' ' 46' ' ' TYR . 30.4 m -110.47 153.94 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.063 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.49 -175.3 22.56 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 49' ' ' ALA . . . . . 0.784 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -67.99 153.78 43.0 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.073 0.463 . . . . 0.0 109.971 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 50' ' ' THR . . . . . 0.536 HG23 ' H ' ' C' ' 53' ' ' ALA . 8.1 t -142.45 171.38 14.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.34 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 51' ' ' LEU . . . . . 0.529 HD22 ' N ' ' C' ' 51' ' ' LEU . 3.9 mm? -61.23 -39.27 89.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.471 -179.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 t80 -58.54 -45.72 88.32 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.368 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 53' ' ' ALA . . . . . 0.536 ' H ' HG23 ' C' ' 50' ' ' THR . . . -148.98 146.4 27.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.297 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 11.0 t -87.92 171.94 9.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 55' ' ' GLY . . . . . 0.784 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 96.14 -156.8 21.38 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 -179.479 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -119.27 106.83 12.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.091 0.472 . . . . 0.0 110.607 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 57' ' ' TRP . . . . . 0.58 ' HE1' ' NE ' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -135.22 170.67 15.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.825 179.466 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' C' C ' 58' ' ' VAL . . . . . 0.522 ' CG1' HG23 ' C' ' 44' ' ' VAL . 57.4 t -131.37 132.36 62.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.56 -0.746 . . . . 0.0 111.343 -179.305 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.46 132.94 11.37 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 72.9 t -127.35 134.28 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.556 0.693 . . . . 0.0 111.42 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.6 pt -85.06 119.93 34.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.964 178.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 62' ' ' LEU . . . . . 0.565 HD22 ' CD1' ' C' ' 87' ' ' ILE . 3.8 tp -92.24 122.21 34.5 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.093 -178.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 63' ' ' ASP . . . . . 0.526 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.3 m-20 -67.46 -14.15 62.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.375 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 64' ' ' GLU . . . . . 0.658 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 77.7 mm-40 -62.66 -31.05 71.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.561 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 65' ' ' ALA . . . . . 0.658 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.8 42.28 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.142 0 CA-C-O 120.958 0.409 . . . . 0.0 110.556 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 66' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' C' ' 84' ' ' GLY . 18.9 ptmt -140.4 120.16 13.43 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.978 179.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 146.21 -148.25 19.8 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 68' ' ' LYS . . . . . 0.501 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 40.8 tttt -97.4 -166.55 1.4 Allowed 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 69' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' C' ' 69' ' ' ASN . 1.2 m-20 -104.18 95.94 6.31 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.227 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 70' ' ' ASP . . . . . 0.557 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 5.4 t70 -60.48 -23.07 64.2 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.681 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 71' ' ' GLY . . . . . 0.53 ' O ' HG23 ' C' ' 72' ' ' THR . . . -59.06 -40.28 95.38 Favored Glycine 0 C--O 1.224 -0.482 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 72' ' ' THR . . . . . 0.53 HG23 ' O ' ' C' ' 71' ' ' GLY . 38.1 p -158.5 116.47 2.95 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.807 0.337 . . . . 0.0 110.52 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 73' ' ' VAL . . . . . 0.448 HG23 ' O ' ' C' ' 69' ' ' ASN . 58.6 t -129.88 126.78 62.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.511 179.705 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 47.58 45.93 17.73 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.21 0.529 . . . . 0.0 110.704 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.64 3.13 39.77 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 76' ' ' ARG . . . . . 0.419 ' N ' ' O ' ' C' ' 73' ' ' VAL . 20.3 tpp85 -124.81 129.79 51.12 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.873 0.368 . . . . 0.0 110.371 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -109.44 138.92 45.08 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.883 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -105.35 -26.97 11.77 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.464 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 79' ' ' PHE . . . . . 0.557 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 31.3 t80 -169.84 142.21 2.39 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.232 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 80' ' ' THR . . . . . 0.451 ' H ' HG22 ' C' ' 80' ' ' THR . 0.0 OUTLIER -64.27 106.3 1.07 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.054 0.454 . . . . 0.0 111.363 -179.731 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.1 t -169.19 145.07 3.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.299 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -82.26 171.14 14.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.261 0.553 . . . . 0.0 110.686 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -44.81 155.28 0.11 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.292 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 84' ' ' GLY . . . . . 0.526 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 95.45 -3.73 66.22 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 85' ' ' HIS . . . . . 0.572 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.3 OUTLIER -139.58 140.29 37.02 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.339 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.38 60.0 0.32 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 87' ' ' ILE . . . . . 0.565 ' CD1' HD22 ' C' ' 62' ' ' LEU . 95.9 mt -94.25 130.32 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -75.6 120.47 21.05 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.506 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 89' ' ' VAL . . . . . 0.52 HG21 HG21 ' C' ' 94' ' ' ILE . 20.8 m -139.48 162.53 26.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.443 179.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 90' ' ' ARG . . . . . 0.58 ' NE ' ' HE1' ' C' ' 57' ' ' TRP . 5.5 mpt_? -93.89 150.71 20.13 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.024 0.44 . . . . 0.0 110.249 -179.256 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 91' ' ' GLN . . . . . 0.693 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 1.3 pm0 -51.57 -39.39 57.78 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.142 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 78.9 p -69.99 -28.33 65.43 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.053 0.454 . . . . 0.0 110.368 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 93' ' ' GLN . . . . . 0.493 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.6 tt0 -70.69 -20.19 62.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.501 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 94' ' ' ILE . . . . . 0.52 HG21 HG21 ' C' ' 89' ' ' VAL . 48.1 pt -128.38 163.09 33.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.074 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 95' ' ' GLN . . . . . 0.508 ' OXT' ' N ' ' C' ' 34' ' ' GLU . 59.8 tt0 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.453 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 86.0 mtp180 . . . . . 0 CA--C 1.52 -0.206 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 29' ' ' VAL . . . . . 0.442 ' HA ' HG23 ' C' ' 44' ' ' VAL . 2.1 p -52.68 144.4 3.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.257 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.51 -9.71 75.43 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . 0.501 ' O ' HG22 ' C' ' 44' ' ' VAL . 74.2 m -86.5 165.07 16.55 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.458 . . . . 0.0 111.275 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -58.28 151.14 20.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.881 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 33' ' ' VAL . . . . . 0.706 HG12 ' C ' ' C' ' 42' ' ' GLY . 14.0 p -121.76 150.94 25.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.835 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 34' ' ' GLU . . . . . 0.402 ' N ' HG22 ' C' ' 33' ' ' VAL . 85.2 tt0 -147.43 97.3 2.83 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.29 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -70.7 132.35 33.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.697 -178.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 36' ' ' ILE . . . . . 0.487 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 5.9 mm -71.95 80.3 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.509 179.674 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.29 -126.86 0.84 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -62.99 -21.12 65.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.355 -0.423 . . . . 0.0 110.77 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 107.87 55.49 0.61 Allowed Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 40' ' ' HIS . . . . . 0.544 ' CE1' ' O ' ' C' ' 41' ' ' ARG . 41.8 t-80 -84.93 140.17 31.3 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 121.158 0.504 . . . . 0.0 111.681 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 41' ' ' ARG . . . . . 0.544 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 11.6 ptm85 -119.73 169.73 9.84 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.285 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 42' ' ' GLY . . . . . 0.706 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 150.48 -131.2 3.48 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -178.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 12.3 t -142.67 154.2 44.11 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 111.56 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 44' ' ' VAL . . . . . 0.501 HG22 ' O ' ' C' ' 31' ' ' SER . 3.2 m -88.18 138.88 18.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.024 179.058 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.19 -158.79 0.49 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.962 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 75.1 t80 -64.8 142.53 58.4 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.122 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 47' ' ' VAL . . . . . 0.496 HG23 HG22 ' C' ' 58' ' ' VAL . 8.7 p -113.17 131.98 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.688 -178.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.14 -173.81 24.03 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 49' ' ' ALA . . . . . 0.566 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -66.79 145.78 55.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.079 0.466 . . . . 0.0 110.222 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 50' ' ' THR . . . . . 0.452 ' O ' ' O ' ' C' ' 53' ' ' ALA . 19.5 m -126.64 159.37 33.81 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.862 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 51' ' ' LEU . . . . . 0.44 ' N ' HG22 ' C' ' 50' ' ' THR . 88.8 mt -60.28 -39.54 87.23 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -59.16 -46.48 88.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 0.0 109.943 179.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 53' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -141.72 141.61 33.29 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 110.149 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 9.9 t -89.17 162.12 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.937 -179.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 55' ' ' GLY . . . . . 0.566 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 108.78 -145.95 16.52 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 64.6 mttp -123.68 116.4 23.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.993 0.425 . . . . 0.0 110.359 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -141.55 164.2 30.86 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.326 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 58' ' ' VAL . . . . . 0.496 HG22 HG23 ' C' ' 47' ' ' VAL . 75.2 t -122.54 128.51 75.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.755 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.48 141.74 19.88 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 70.8 t -127.09 133.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 120.879 0.371 . . . . 0.0 110.531 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 11.7 mm -82.2 95.01 3.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 62' ' ' LEU . . . . . 0.564 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -74.57 104.86 5.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.132 -178.865 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 63' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' C' ' 64' ' ' GLU . 54.0 p30 -65.88 -9.88 33.27 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.992 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 64' ' ' GLU . . . . . 0.649 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 75.9 mm-40 -63.21 -32.15 73.47 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.475 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 65' ' ' ALA . . . . . 0.649 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 91.08 39.44 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.042 0.449 . . . . 0.0 110.555 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 66' ' ' LYS . . . . . 0.543 ' N ' ' O ' ' C' ' 84' ' ' GLY . 23.1 pttp -140.75 140.87 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.18 178.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 121.89 -150.15 17.07 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 9.4 mmtt -95.81 -171.51 2.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.39 0.614 . . . . 0.0 111.149 -179.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 69' ' ' ASN . . . . . 0.541 ' ND2' ' O ' ' C' ' 72' ' ' THR . 46.9 p-10 -106.09 102.01 11.46 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.543 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 70' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 7.3 t0 -62.06 -23.73 66.66 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.461 -0.791 . . . . 0.0 108.969 179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 71' ' ' GLY . . . . . 0.531 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.07 -41.83 94.76 Favored Glycine 0 C--O 1.226 -0.38 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 72' ' ' THR . . . . . 0.541 ' O ' ' ND2' ' C' ' 69' ' ' ASN . 32.7 p -158.55 118.31 3.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.922 0.392 . . . . 0.0 110.838 179.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 73' ' ' VAL . . . . . 0.466 ' O ' ' N ' ' C' ' 76' ' ' ARG . 39.6 t -126.43 122.96 62.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.685 179.225 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 68.7 tp60 45.05 49.99 9.36 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.074 0.464 . . . . 0.0 111.544 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.56 1.79 31.8 Favored Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 76' ' ' ARG . . . . . 0.466 ' N ' ' O ' ' C' ' 73' ' ' VAL . 76.3 ttt180 -124.78 126.09 45.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.374 -0.413 . . . . 0.0 110.325 -179.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -107.34 137.92 44.5 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-O 121.363 0.601 . . . . 0.0 111.19 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 78' ' ' TYR . . . . . 0.425 ' OH ' ' OG1' ' C' ' 50' ' ' THR . 1.7 m-85 -98.57 -32.94 11.18 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.371 178.343 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 79' ' ' PHE . . . . . 0.539 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 86.0 t80 -169.55 151.73 4.48 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.373 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 44.0 p -64.9 108.87 1.9 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.745 0.307 . . . . 0.0 111.349 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -172.63 148.32 1.92 Allowed 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.329 179.032 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -86.0 169.87 12.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.153 0.501 . . . . 0.0 111.179 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -50.57 145.05 7.06 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.002 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 84' ' ' GLY . . . . . 0.543 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 104.05 -4.34 45.2 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 85' ' ' HIS . . . . . 0.564 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 4.0 m-70 -140.97 136.2 31.93 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.145 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.95 49.79 0.32 Allowed Glycine 0 N--CA 1.47 0.907 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.331 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 97.4 mt -83.78 135.18 25.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -84.16 119.11 24.62 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.528 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 89' ' ' VAL . . . . . 0.455 HG21 HG23 ' C' ' 94' ' ' ILE . 16.2 m -136.51 162.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 178.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 90' ' ' ARG . . . . . 0.586 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -90.78 155.04 19.09 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.599 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 91' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' C' ' 94' ' ' ILE . 29.2 pt20 -53.22 -38.97 63.4 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.733 -179.545 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 66.6 m -63.18 -37.19 86.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.223 0.535 . . . . 0.0 110.172 178.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 93' ' ' GLN . . . . . 0.487 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.9 tt0 -65.02 -30.05 71.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.109 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 94' ' ' ILE . . . . . 0.455 HG23 HG21 ' C' ' 89' ' ' VAL . 17.1 pt -108.93 145.43 15.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.975 0.417 . . . . 0.0 110.461 179.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.745 179.98 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 78.0 mtp85 . . . . . 0 N--CA 1.465 0.287 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 29' ' ' VAL . . . . . 0.44 ' H ' HG13 ' C' ' 29' ' ' VAL . 6.1 m -50.66 143.21 2.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 30' ' ' GLY . . . . . 0.447 ' N ' HG23 ' C' ' 44' ' ' VAL . . . 91.92 -8.27 78.27 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . 0.527 ' O ' HG22 ' C' ' 44' ' ' VAL . 45.7 t -89.05 163.73 15.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.982 0.42 . . . . 0.0 111.426 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -59.23 149.15 29.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.156 179.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 33' ' ' VAL . . . . . 0.791 HG12 HG13 ' C' ' 44' ' ' VAL . 2.5 m -126.81 159.78 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.013 0.435 . . . . 0.0 110.035 -179.261 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -140.52 93.64 2.64 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 35' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' C' ' 37' ' ' GLY . 84.2 t -56.54 126.54 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 36' ' ' ILE . . . . . 0.618 HG22 ' O ' ' C' ' 36' ' ' ILE . 4.6 mm -67.18 77.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 CA-C-O 121.582 0.706 . . . . 0.0 109.333 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' C' ' 35' ' ' VAL . . . -163.17 -126.61 0.83 Allowed Glycine 0 CA--C 1.519 0.311 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -64.48 -17.31 63.74 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.274 179.396 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.11 58.07 0.89 Allowed Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 40' ' ' HIS . . . . . 0.73 ' HE2' ' H ' ' C' ' 63' ' ' ASP . 75.7 t60 -89.82 138.95 31.05 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 111.124 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 41' ' ' ARG . . . . . 0.517 ' O ' ' CD2' ' C' ' 40' ' ' HIS . 87.6 mtm-85 -89.87 162.71 15.33 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.675 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 42' ' ' GLY . . . . . 0.47 ' C ' HG22 ' C' ' 33' ' ' VAL . . . 171.64 -172.4 44.58 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 85.4 m -124.71 131.95 53.42 Favored 'General case' 0 C--O 1.24 0.569 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 44' ' ' VAL . . . . . 0.791 HG13 HG12 ' C' ' 33' ' ' VAL . 0.2 OUTLIER -72.58 121.14 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.671 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.07 -157.5 0.12 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.934 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -63.61 142.0 58.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.569 -179.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 47' ' ' VAL . . . . . 0.511 HG23 HG22 ' C' ' 58' ' ' VAL . 7.2 p -117.59 135.93 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.176 -179.055 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.99 -177.73 19.5 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 49' ' ' ALA . . . . . 0.567 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -70.45 141.44 52.06 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.974 0.416 . . . . 0.0 110.245 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 47.7 p -139.43 168.58 19.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.293 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 83.3 mt -60.78 -39.35 88.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.974 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 82.8 t80 -59.42 -46.28 89.17 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.215 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -145.94 142.38 28.66 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.012 0.434 . . . . 0.0 110.526 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 60.3 p -85.44 169.12 13.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.914 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 55' ' ' GLY . . . . . 0.567 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 89.66 -146.06 18.67 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -125.77 101.62 6.94 Favored 'General case' 0 N--CA 1.464 0.262 0 O-C-N 122.603 -0.351 . . . . 0.0 110.237 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -121.32 166.45 14.04 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 58' ' ' VAL . . . . . 0.511 HG22 HG23 ' C' ' 47' ' ' VAL . 51.2 t -127.03 129.41 71.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.298 -179.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.61 129.72 9.9 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.6 t -123.81 131.63 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 121.244 0.545 . . . . 0.0 110.805 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 10.1 pt -82.19 126.08 39.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.907 179.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 62' ' ' LEU . . . . . 0.6 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 3.5 tp -102.33 111.48 23.8 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 63' ' ' ASP . . . . . 0.73 ' H ' ' HE2' ' C' ' 40' ' ' HIS . 42.8 t0 -59.71 -11.1 4.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.127 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 64' ' ' GLU . . . . . 0.64 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.6 mm-40 -62.01 -34.01 75.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.286 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 65' ' ' ALA . . . . . 0.64 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.67 46.28 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.858 0.361 . . . . 0.0 110.546 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 66' ' ' LYS . . . . . 0.546 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.7 ptpt -149.79 104.09 3.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.355 0.597 . . . . 0.0 110.105 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.43 -143.19 8.64 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -179.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -96.62 -167.48 1.57 Allowed 'General case' 0 C--O 1.241 0.624 0 CA-C-O 121.104 0.478 . . . . 0.0 109.933 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -117.48 98.72 6.55 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.412 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 76.2 m-20 -62.7 -14.96 50.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.76 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 71' ' ' GLY . . . . . 0.671 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.69 -42.75 96.45 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.069 -1.063 . . . . 0.0 110.63 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 72' ' ' THR . . . . . 0.671 HG23 ' O ' ' C' ' 71' ' ' GLY . 18.9 p -163.22 117.75 1.66 Allowed 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.978 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 73' ' ' VAL . . . . . . . . . . . . . 26.1 t -134.72 122.75 39.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.583 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 51.11 36.37 15.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.743 0.306 . . . . 0.0 111.309 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.58 -2.66 66.64 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 76' ' ' ARG . . . . . . . . . . . . . 16.8 tpp180 -116.11 120.68 39.82 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.351 -0.425 . . . . 0.0 109.937 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -103.14 126.26 50.23 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.375 0.607 . . . . 0.0 110.633 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 83.3 m-85 -79.89 -37.61 34.4 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.861 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 56.8 t80 -171.04 151.74 3.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.392 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.5 p -64.92 98.48 0.28 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.955 0.407 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 6.1 t -167.56 146.86 4.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -81.72 170.67 15.48 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.264 0.555 . . . . 0.0 110.983 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -49.57 155.33 0.8 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.174 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 84' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.8 -7.22 62.92 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 85' ' ' HIS . . . . . 0.6 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 18.5 m-70 -138.39 130.49 28.5 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 123.88 59.49 0.19 Allowed Glycine 0 C--N 1.341 0.856 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.236 179.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 87' ' ' ILE . . . . . 0.427 ' CD1' HD22 ' C' ' 62' ' ' LEU . 97.9 mt -90.62 125.5 43.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.609 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 88' ' ' PHE . . . . . 0.553 ' O ' ' CD2' ' C' ' 88' ' ' PHE . 49.4 p90 -70.79 120.34 16.24 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 120.973 0.416 . . . . 0.0 110.587 -179.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 89' ' ' VAL . . . . . . . . . . . . . 20.5 m -139.01 160.58 29.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 90' ' ' ARG . . . . . 0.495 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -92.91 155.15 17.77 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -179.701 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 91' ' ' GLN . . . . . 0.525 ' NE2' ' OG ' ' C' ' 92' ' ' SER . 2.9 pp0? -52.74 -39.83 62.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.081 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 92' ' ' SER . . . . . 0.525 ' OG ' ' NE2' ' C' ' 91' ' ' GLN . 57.7 m -64.71 -37.14 86.59 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.996 0.427 . . . . 0.0 110.403 178.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 93' ' ' GLN . . . . . 0.495 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.2 tt0 -64.75 -19.23 65.68 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.912 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 94' ' ' ILE . . . . . 0.471 ' O ' ' O ' ' C' ' 91' ' ' GLN . 47.1 pt -123.46 153.79 29.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.668 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 95' ' ' GLN . . . . . 0.447 ' OXT' ' O ' ' C' ' 94' ' ' ILE . 69.2 tp60 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.06 -0.971 . . . . 0.0 110.907 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 . . . . . 0 C--O 1.233 0.23 0 CA-C-O 120.976 0.417 . . . . 0.0 110.636 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 29' ' ' VAL . . . . . 0.432 ' HA ' HG13 ' C' ' 44' ' ' VAL . 2.6 p -62.12 138.07 23.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.014 0.435 . . . . 0.0 110.115 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.27 63.68 Favored Glycine 0 CA--C 1.533 1.202 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . 0.442 ' O ' HG12 ' C' ' 44' ' ' VAL . 70.9 m -89.76 163.1 15.21 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.7 0.286 . . . . 0.0 111.16 179.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -62.18 150.41 38.88 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.087 0.47 . . . . 0.0 111.19 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m -131.14 155.51 41.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.07 100.44 4.28 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 35' ' ' VAL . . . . . 0.471 ' HA ' HG22 ' C' ' 94' ' ' ILE . 88.0 t -64.94 130.1 29.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.876 -178.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 36' ' ' ILE . . . . . 0.453 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 8.4 mm -82.97 75.43 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.72 -121.37 0.57 Allowed Glycine 0 CA--C 1.522 0.478 0 N-CA-C 110.696 -0.961 . . . . 0.0 110.696 -178.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -58.17 -29.4 65.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.041 -0.58 . . . . 0.0 109.951 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.68 59.78 0.51 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 40' ' ' HIS . . . . . 0.419 ' CE1' ' CG ' ' C' ' 64' ' ' GLU . 94.4 m-70 -103.5 150.55 23.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.038 0.447 . . . . 0.0 110.635 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 53.1 ptt85 -137.76 154.78 49.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.744 -179.155 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.94 -122.7 0.94 Allowed Glycine 0 C--O 1.226 -0.351 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 43' ' ' THR . . . . . 0.605 ' CG2' HD12 ' C' ' 61' ' ' ILE . 5.3 t -141.02 154.62 46.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.843 179.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 44' ' ' VAL . . . . . 0.506 HG23 ' CG1' ' C' ' 58' ' ' VAL . 1.2 p -91.72 141.57 14.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.997 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 45' ' ' ALA . . . . . 0.46 ' O ' HG22 ' C' ' 44' ' ' VAL . . . -88.85 -154.31 0.29 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.549 179.062 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -62.69 141.95 58.32 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.115 0.483 . . . . 0.0 110.645 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 72.9 t -112.59 129.84 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.688 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 127.37 -172.97 18.66 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 49' ' ' ALA . . . . . 0.713 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.16 146.98 52.91 Favored 'General case' 0 C--N 1.334 -0.071 0 CA-C-O 120.914 0.387 . . . . 0.0 110.019 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 50' ' ' THR . . . . . 0.412 ' O ' ' O ' ' C' ' 53' ' ' ALA . 69.7 p -133.26 167.12 20.95 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.121 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.84 -40.78 89.68 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -57.87 -46.6 84.62 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.359 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 53' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -143.76 144.4 31.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.819 0.342 . . . . 0.0 110.285 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 10.0 t -90.12 165.29 14.07 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.385 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 55' ' ' GLY . . . . . 0.713 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 101.22 -152.81 18.96 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 60.6 mtpt -119.94 112.07 18.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.551 -179.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -139.12 171.51 14.19 Favored 'General case' 0 CA--C 1.517 -0.296 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 58' ' ' VAL . . . . . 0.506 ' CG1' HG23 ' C' ' 44' ' ' VAL . 50.4 t -131.3 133.16 62.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.637 -178.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -91.4 139.16 14.64 Favored Glycine 0 CA--C 1.532 1.134 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.69 136.85 59.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-O 121.085 0.469 . . . . 0.0 111.287 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 61' ' ' ILE . . . . . 0.605 HD12 ' CG2' ' C' ' 43' ' ' THR . 41.5 mt -88.45 99.87 9.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.182 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.1 118.78 20.69 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -67.53 -13.05 61.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.239 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 64' ' ' GLU . . . . . 0.653 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.3 mm-40 -62.28 -36.16 81.23 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.42 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 65' ' ' ALA . . . . . 0.653 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.79 44.05 0.01 OUTLIER 'General case' 0 C--N 1.342 0.269 0 CA-C-O 120.911 0.386 . . . . 0.0 110.748 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 66' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' C' ' 84' ' ' GLY . 14.4 ptpt -139.58 119.12 13.04 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.771 178.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 144.73 -146.0 15.97 Favored Glycine 0 CA--C 1.518 0.232 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 68' ' ' LYS . . . . . 0.444 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 36.6 tttt -98.01 -168.75 1.71 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.992 0.425 . . . . 0.0 109.973 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 69' ' ' ASN . . . . . 0.444 ' H ' ' HG2' ' C' ' 68' ' ' LYS . 10.9 p30 -112.65 95.74 5.59 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.157 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 70' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' C' ' 70' ' ' ASP . 3.9 p-10 -65.26 -10.21 30.29 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.469 -0.493 . . . . 0.0 110.245 178.57 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 71' ' ' GLY . . . . . 0.663 ' O ' HG23 ' C' ' 72' ' ' THR . . . -60.34 -41.78 98.58 Favored Glycine 0 C--O 1.224 -0.489 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 72' ' ' THR . . . . . 0.663 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.6 p -162.36 109.7 1.32 Allowed 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.879 0.371 . . . . 0.0 110.662 179.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 73' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' C' ' 76' ' ' ARG . 43.7 t -125.94 122.36 61.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.3 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 51.69 35.74 15.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.124 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.88 -1.67 72.71 Favored Glycine 0 CA--C 1.52 0.399 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 76' ' ' ARG . . . . . 0.425 ' N ' ' O ' ' C' ' 73' ' ' VAL . 60.2 ttm-85 -116.01 125.51 52.57 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.096 -0.552 . . . . 0.0 109.768 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.7 pttp -112.29 137.47 50.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.658 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -96.52 -36.11 10.88 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 79' ' ' PHE . . . . . 0.56 ' CD1' HD11 ' C' ' 61' ' ' ILE . 22.4 t80 -164.68 145.76 7.92 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.299 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 30.6 p -64.29 104.45 0.76 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.922 0.391 . . . . 0.0 111.306 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 10.7 t -171.3 144.95 2.09 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.527 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -79.93 169.19 18.24 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.342 0.591 . . . . 0.0 111.143 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -45.67 153.71 0.25 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.864 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 84' ' ' GLY . . . . . 0.535 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 99.03 -5.24 59.32 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 85' ' ' HIS . . . . . 0.543 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -138.27 143.36 40.0 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.36 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.09 58.19 0.36 Allowed Glycine 0 C--N 1.337 0.615 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -88.96 134.55 28.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -82.64 119.71 24.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.087 0.47 . . . . 0.0 110.413 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 89' ' ' VAL . . . . . 0.589 HG21 HG21 ' C' ' 94' ' ' ILE . 20.5 m -139.46 165.31 23.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 90' ' ' ARG . . . . . 0.463 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -97.36 159.25 15.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.839 0.352 . . . . 0.0 110.436 -179.688 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 91' ' ' GLN . . . . . 0.49 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.7 pt20 -55.9 -40.7 73.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.929 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 88.0 p -70.73 -28.37 64.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.98 0.419 . . . . 0.0 110.4 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 93' ' ' GLN . . . . . 0.453 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 73.2 tp60 -66.9 -29.0 68.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.576 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 94' ' ' ILE . . . . . 0.589 HG21 HG21 ' C' ' 89' ' ' VAL . 49.4 pt -125.98 164.15 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.245 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 89.2 mt-30 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.399 179.755 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 85.9 mtp180 . . . . . 0 C--O 1.237 0.426 0 CA-C-O 121.361 0.6 . . . . 0.0 110.335 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 29' ' ' VAL . . . . . 0.498 HG23 ' O ' ' C' ' 45' ' ' ALA . 3.6 p -64.22 146.45 13.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.354 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.75 -17.74 57.88 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.26 -0.736 . . . . 0.0 111.26 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . 0.453 ' O ' HG22 ' C' ' 44' ' ' VAL . 85.0 p -78.28 165.13 24.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.008 0.432 . . . . 0.0 111.553 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -54.48 155.56 3.91 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 33' ' ' VAL . . . . . 0.634 HG12 ' C ' ' C' ' 42' ' ' GLY . 7.6 p -123.65 149.52 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.032 0.444 . . . . 0.0 110.804 -179.386 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -151.45 94.47 2.02 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.388 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 85.5 t -70.36 131.23 34.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.581 -179.335 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 36' ' ' ILE . . . . . 0.563 HG22 ' O ' ' C' ' 36' ' ' ILE . 88.3 mt -72.91 74.06 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-O 121.311 0.577 . . . . 0.0 109.671 179.707 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.24 -121.9 0.59 Allowed Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -59.13 -29.93 67.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.596 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.18 46.65 0.92 Allowed Glycine 0 N--CA 1.466 0.691 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -71.72 136.22 47.11 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.877 0.37 . . . . 0.0 110.409 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -114.51 175.91 5.28 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.196 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 42' ' ' GLY . . . . . 0.634 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 134.43 -137.95 9.68 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -179.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 99.0 m -134.25 142.34 47.3 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 120.978 0.418 . . . . 0.0 111.47 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 44' ' ' VAL . . . . . 0.453 HG22 ' O ' ' C' ' 31' ' ' SER . 16.0 m -75.29 144.89 11.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.612 179.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 45' ' ' ALA . . . . . 0.498 ' O ' HG23 ' C' ' 29' ' ' VAL . . . -91.3 -157.2 0.48 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.334 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -62.69 140.01 58.69 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.306 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 47' ' ' VAL . . . . . 0.518 HG22 HG22 ' C' ' 58' ' ' VAL . 70.1 t -110.77 129.61 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.717 -178.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 126.47 -171.16 18.21 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 49' ' ' ALA . . . . . 0.635 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.6 147.11 52.39 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.062 0.458 . . . . 0.0 109.928 179.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 50' ' ' THR . . . . . 0.434 ' O ' ' O ' ' C' ' 53' ' ' ALA . 82.3 p -132.02 165.17 24.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.232 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.5 tp -60.27 -40.95 92.2 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -58.28 -46.18 86.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.451 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 53' ' ' ALA . . . . . 0.434 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -144.81 147.38 32.81 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.853 0.359 . . . . 0.0 110.447 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -88.38 173.16 8.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 55' ' ' GLY . . . . . 0.635 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 97.01 -151.2 19.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 16.5 ptmt -128.28 102.93 6.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.137 0.494 . . . . 0.0 110.064 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -131.68 161.79 31.94 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 58' ' ' VAL . . . . . 0.518 HG22 HG22 ' C' ' 47' ' ' VAL . 57.4 t -121.36 128.68 75.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.904 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.8 134.52 12.51 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 60' ' ' VAL . . . . . 0.562 HG13 HG21 ' C' ' 33' ' ' VAL . 85.1 t -126.7 130.38 71.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.431 0 O-C-N 122.507 -0.408 . . . . 0.0 111.214 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 4.8 pt -80.23 96.13 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.357 -0.537 . . . . 0.0 110.469 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 62' ' ' LEU . . . . . 0.629 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -73.14 118.06 15.63 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.862 179.907 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.5 p-10 -65.53 -9.22 24.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.51 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 64' ' ' GLU . . . . . 0.648 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.9 mm-40 -62.12 -33.64 74.85 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.212 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 65' ' ' ALA . . . . . 0.648 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.83 46.47 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.679 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 66' ' ' LYS . . . . . 0.56 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.2 ptmt -147.22 114.5 6.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.296 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 147.12 -142.74 10.57 Favored Glycine 0 CA--C 1.516 0.149 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 16.6 mmtt -97.18 -172.69 2.49 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 110.275 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 69' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.7 p-10 -114.07 98.22 6.84 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.979 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -60.17 -17.28 39.77 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.104 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 71' ' ' GLY . . . . . 0.653 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.59 -41.85 95.79 Favored Glycine 0 C--O 1.225 -0.44 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 72' ' ' THR . . . . . 0.653 HG23 ' O ' ' C' ' 71' ' ' GLY . 21.4 p -162.21 111.74 1.49 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.761 0.315 . . . . 0.0 110.591 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 73' ' ' VAL . . . . . 0.476 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.3 t -126.32 124.76 66.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.305 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 53.8 tt0 46.24 47.87 13.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.38 0.61 . . . . 0.0 111.029 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.69 3.61 42.55 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.174 -1.17 . . . . 0.0 110.174 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 76' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' C' ' 73' ' ' VAL . 29.2 tpt180 -125.23 125.93 44.37 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.971 0.415 . . . . 0.0 110.416 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -106.94 138.2 43.57 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.516 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -102.84 -29.98 11.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -170.54 147.41 2.91 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.349 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 80' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' C' ' 80' ' ' THR . 9.7 p -63.93 97.06 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.979 0.419 . . . . 0.0 110.955 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 2.2 t -165.02 145.19 7.14 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.312 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -83.14 171.42 13.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.104 0.478 . . . . 0.0 110.695 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -50.18 151.88 1.91 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.341 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 84' ' ' GLY . . . . . 0.56 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 98.91 -6.16 60.05 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 -179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 85' ' ' HIS . . . . . 0.629 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 19.3 m-70 -136.5 131.34 33.83 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.14 59.42 0.17 Allowed Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.4 mm -86.6 132.79 31.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -82.83 118.5 23.46 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 89' ' ' VAL . . . . . 0.48 HG21 HG23 ' C' ' 94' ' ' ILE . 17.8 m -139.62 159.52 27.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.703 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 90' ' ' ARG . . . . . 0.585 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.1 mpt_? -82.5 154.22 25.19 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.251 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 91' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' C' ' 94' ' ' ILE . 16.0 pt20 -54.3 -39.71 67.24 Favored 'General case' 0 C--N 1.33 -0.255 0 O-C-N 123.299 0.374 . . . . 0.0 111.106 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 74.2 m -63.22 -37.34 86.86 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.983 0.421 . . . . 0.0 110.299 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 73.6 tp60 -63.86 -34.79 78.73 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.029 -178.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 94' ' ' ILE . . . . . 0.48 HG23 HG21 ' C' ' 89' ' ' VAL . 15.9 pt -100.92 140.14 20.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.655 -179.65 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 . . . . . 0 C--O 1.235 0.295 0 CA-C-O 121.376 0.608 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 29' ' ' VAL . . . . . 0.51 ' CG2' HG12 ' C' ' 47' ' ' VAL . 71.6 t -66.19 135.83 27.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.439 179.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.21 -18.83 47.81 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.0 t -73.1 154.04 40.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 117.044 0.422 . . . . 0.0 110.528 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 48.0 ptt85 -46.54 161.62 0.06 Allowed 'General case' 0 N--CA 1.461 0.114 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 33' ' ' VAL . . . . . 0.517 HG12 ' C ' ' C' ' 42' ' ' GLY . 11.3 p -128.99 151.56 35.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.72 -179.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -149.81 95.42 2.31 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 87.1 t -72.11 131.3 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.403 -179.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 36' ' ' ILE . . . . . 0.516 HG22 ' O ' ' C' ' 36' ' ' ILE . 90.2 mt -75.12 76.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-O 121.28 0.562 . . . . 0.0 109.543 179.453 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.14 -122.5 0.63 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -59.35 -25.7 64.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.212 -0.494 . . . . 0.0 109.966 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.8 42.77 1.29 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -73.79 145.74 44.8 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.275 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 52.6 ptt85 -141.75 165.1 28.4 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.963 0.411 . . . . 0.0 110.564 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 42' ' ' GLY . . . . . 0.517 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 155.73 -109.39 0.4 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 43' ' ' THR . . . . . 0.485 ' CG2' HD12 ' C' ' 61' ' ' ILE . 6.8 t -145.4 154.27 42.1 Favored 'General case' 0 C--O 1.243 0.726 0 CA-C-O 120.828 0.347 . . . . 0.0 111.257 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 92.8 t -90.93 122.44 42.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.196 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 45' ' ' ALA . . . . . 0.457 ' O ' HG13 ' C' ' 29' ' ' VAL . . . -80.21 -159.12 0.2 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.953 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -64.35 145.05 56.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.346 0.593 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 47' ' ' VAL . . . . . 0.67 ' CG2' HE21 ' C' ' 91' ' ' GLN . 9.3 p -124.17 141.2 45.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.485 -178.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 120.66 -171.01 14.57 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 49' ' ' ALA . . . . . 0.564 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.01 141.89 56.09 Favored 'General case' 0 C--O 1.23 0.066 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 71.1 p -134.81 164.63 27.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.235 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.6 tp -59.16 -39.27 81.95 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.51 -45.66 84.68 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.871 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -149.27 145.69 27.2 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 110.865 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 63.6 p -83.13 168.04 17.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.682 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 55' ' ' GLY . . . . . 0.564 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 98.65 -143.4 16.62 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 40.5 pttt -136.59 106.79 6.37 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.47 0.652 . . . . 0.0 110.624 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 85.5 m95 -130.73 168.26 17.48 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.808 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 58' ' ' VAL . . . . . 0.609 HG22 HG23 ' C' ' 47' ' ' VAL . 64.6 t -125.57 130.61 72.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.574 -178.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 59' ' ' GLY . . . . . 0.436 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -89.82 129.09 9.53 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 178.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 60' ' ' VAL . . . . . 0.418 HG13 HG21 ' C' ' 33' ' ' VAL . 66.9 t -122.47 132.56 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.135 0.493 . . . . 0.0 110.921 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 61' ' ' ILE . . . . . 0.514 HD11 ' CG ' ' C' ' 79' ' ' PHE . 45.7 mt -85.22 104.16 12.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.361 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 62' ' ' LEU . . . . . 0.442 ' O ' ' CD2' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -84.83 115.67 22.87 Favored 'General case' 0 C--O 1.232 0.174 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.923 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -67.08 -9.08 35.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.289 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 64' ' ' GLU . . . . . 0.646 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.76 -37.54 87.04 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.296 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 65' ' ' ALA . . . . . 0.646 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 86.59 44.34 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 110.672 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 66' ' ' LYS . . . . . 0.568 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.4 ptmt -146.68 106.95 4.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.076 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.96 -140.57 7.36 Favored Glycine 0 CA--C 1.52 0.352 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 68' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' C' ' 85' ' ' HIS . 7.9 mmtm -95.88 -174.74 3.21 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.277 0.56 . . . . 0.0 110.447 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -112.02 96.72 6.21 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 114.688 -1.142 . . . . 0.0 110.68 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -60.78 -15.05 25.55 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.986 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 71' ' ' GLY . . . . . 0.659 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.4 -45.09 94.81 Favored Glycine 0 N--CA 1.449 -0.5 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 72' ' ' THR . . . . . 0.659 HG23 ' O ' ' C' ' 71' ' ' GLY . 21.2 p -163.25 115.19 1.49 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.012 0.435 . . . . 0.0 110.711 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 73' ' ' VAL . . . . . 0.5 ' N ' ' O ' ' C' ' 76' ' ' ARG . 38.8 t -129.53 123.73 58.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.355 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 56.4 tt0 42.86 56.61 3.92 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.214 0.531 . . . . 0.0 111.336 179.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.3 4.76 6.85 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 76' ' ' ARG . . . . . 0.5 ' O ' ' N ' ' C' ' 73' ' ' VAL . 26.0 tpt180 -125.41 127.44 46.56 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 26.7 pttm -112.56 137.97 50.02 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.213 0.53 . . . . 0.0 111.158 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -93.13 -37.18 12.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.814 178.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 79' ' ' PHE . . . . . 0.514 ' CG ' HD11 ' C' ' 61' ' ' ILE . 50.5 t80 -172.6 153.39 2.8 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.323 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 80' ' ' THR . . . . . 0.45 ' N ' ' CD1' ' C' ' 79' ' ' PHE . 28.7 p -64.58 95.57 0.15 Allowed 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.48 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 81' ' ' CYS . . . . . 0.456 ' SG ' ' CG ' ' C' ' 85' ' ' HIS . 9.9 t -163.43 142.26 8.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.561 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -79.14 168.22 19.92 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.334 0.588 . . . . 0.0 110.819 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -46.36 150.47 0.63 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.879 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 84' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 105.06 -8.54 45.57 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 85' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -136.06 136.04 39.89 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.8 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.75 59.61 0.2 Allowed Glycine 0 C--N 1.337 0.596 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.0 mm -85.74 133.0 30.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.561 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -82.28 119.06 23.63 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.156 0.503 . . . . 0.0 110.064 -179.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 89' ' ' VAL . . . . . 0.496 HG21 ' CG2' ' C' ' 94' ' ' ILE . 5.0 m -139.73 164.86 23.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.104 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 90' ' ' ARG . . . . . 0.568 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -97.12 166.71 11.45 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.939 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 91' ' ' GLN . . . . . 0.67 HE21 ' CG2' ' C' ' 47' ' ' VAL . 26.1 mp0 -59.61 -42.88 93.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.764 0.316 . . . . 0.0 110.735 -178.653 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 64.2 m -62.79 -36.03 81.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.379 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 16.8 tt0 -63.96 -35.93 82.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.444 -178.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 94' ' ' ILE . . . . . 0.496 ' CG2' HG21 ' C' ' 89' ' ' VAL . 35.4 pt -101.27 144.41 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.881 0.372 . . . . 0.0 110.59 179.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.946 -1.026 . . . . 0.0 111.113 -179.61 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 80.1 mtp85 . . . . . 0 N--CA 1.464 0.257 0 CA-C-O 121.239 0.542 . . . . 0.0 110.354 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -57.01 141.92 13.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.217 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.75 -18.04 55.58 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 83.8 p -81.54 163.13 22.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.964 0.411 . . . . 0.0 110.923 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -50.66 153.36 1.7 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.935 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 33' ' ' VAL . . . . . 0.722 HG12 ' C ' ' C' ' 42' ' ' GLY . 12.3 p -125.39 149.77 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.939 0.399 . . . . 0.0 111.047 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -150.43 92.79 1.9 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 80.2 t -67.47 131.28 33.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.06 -179.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 36' ' ' ILE . . . . . 0.47 HG22 ' O ' ' C' ' 36' ' ' ILE . 42.5 mm -75.62 74.57 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.293 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -120.47 0.54 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.819 -0.913 . . . . 0.0 110.819 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.61 -27.19 66.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.021 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.14 44.98 1.04 Allowed Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -75.34 141.73 43.29 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 40.0 ptt180 -129.3 165.78 20.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.174 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 42' ' ' GLY . . . . . 0.722 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 151.37 -130.28 3.11 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.129 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.4 m -131.91 140.98 49.22 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.119 0.485 . . . . 0.0 111.56 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 44' ' ' VAL . . . . . 0.441 HG13 ' CG1' ' C' ' 58' ' ' VAL . 97.2 t -75.78 133.16 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.839 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 45' ' ' ALA . . . . . 0.596 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -85.59 -159.6 0.46 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.967 0.413 . . . . 0.0 110.519 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 46' ' ' TYR . . . . . 0.426 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 84.6 t80 -65.34 144.89 56.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.171 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 47' ' ' VAL . . . . . 0.534 HG12 HG22 ' C' ' 58' ' ' VAL . 19.2 m -118.42 154.15 20.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.969 -179.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.93 179.4 20.88 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 49' ' ' ALA . . . . . 0.613 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.53 149.36 49.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.089 0.471 . . . . 0.0 110.366 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 50' ' ' THR . . . . . 0.463 HG23 ' H ' ' C' ' 53' ' ' ALA . 7.6 t -149.22 174.98 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.698 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 86.3 mt -60.96 -39.45 89.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.603 -179.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 52' ' ' PHE . . . . . 0.495 ' CD2' ' CZ ' ' C' ' 88' ' ' PHE . 91.9 t80 -59.22 -46.59 88.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.612 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 53' ' ' ALA . . . . . 0.463 ' H ' HG23 ' C' ' 50' ' ' THR . . . -149.28 140.16 22.82 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.789 0.328 . . . . 0.0 110.412 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 72.7 p -83.74 168.91 15.78 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.405 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 55' ' ' GLY . . . . . 0.613 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 89.14 -153.51 23.63 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 56.6 mtmt -110.88 108.78 18.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.881 0.372 . . . . 0.0 110.478 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 83.8 m95 -134.0 161.38 34.97 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.021 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 58' ' ' VAL . . . . . 0.534 HG22 HG12 ' C' ' 47' ' ' VAL . 87.6 t -128.82 130.57 68.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.311 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 59' ' ' GLY . . . . . 0.596 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -90.43 136.15 13.27 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 60' ' ' VAL . . . . . 0.413 ' CG1' HG21 ' C' ' 33' ' ' VAL . 92.3 t -130.42 134.47 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.269 0.557 . . . . 0.0 111.334 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 6.3 pt -85.22 114.59 25.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.603 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 62' ' ' LEU . . . . . 0.614 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.7 OUTLIER -92.23 125.56 36.95 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.936 0.398 . . . . 0.0 110.666 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -67.53 -11.56 58.29 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.618 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 64' ' ' GLU . . . . . 0.651 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.8 mm-40 -61.16 -32.7 72.42 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.436 179.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 65' ' ' ALA . . . . . 0.651 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 86.9 35.85 0.02 OUTLIER 'General case' 0 C--N 1.34 0.185 0 O-C-N 123.504 0.503 . . . . 0.0 110.658 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 66' ' ' LYS . . . . . 0.537 ' N ' ' O ' ' C' ' 84' ' ' GLY . 65.0 pttt -134.98 136.46 42.21 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.12 -146.54 17.15 Favored Glycine 0 N--CA 1.461 0.313 0 N-CA-C 110.689 -0.965 . . . . 0.0 110.689 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 4.3 mmtm -97.5 -170.16 1.96 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.186 0.517 . . . . 0.0 110.351 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 69' ' ' ASN . . . . . 0.462 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.2 p-10 -114.46 99.47 7.58 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.749 -179.501 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -60.31 -16.99 39.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 71' ' ' GLY . . . . . 0.655 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.7 -43.14 96.52 Favored Glycine 0 C--O 1.226 -0.359 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 72' ' ' THR . . . . . 0.655 HG23 ' O ' ' C' ' 71' ' ' GLY . 18.8 p -161.9 112.62 1.62 Allowed 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.713 0.292 . . . . 0.0 110.765 179.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 73' ' ' VAL . . . . . 0.509 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.6 t -127.53 123.26 61.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.233 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 74' ' ' GLN . . . . . 0.404 ' C ' ' H ' ' C' ' 76' ' ' ARG . 71.2 tp60 43.5 57.01 4.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.365 0.602 . . . . 0.0 110.601 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 61.78 4.81 6.08 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 76' ' ' ARG . . . . . 0.509 ' N ' ' O ' ' C' ' 73' ' ' VAL . 46.7 tpt85 -125.16 126.8 45.83 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 110.172 -0.306 . . . . 0.0 110.172 -179.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 77' ' ' LYS . . . . . 0.491 ' O ' ' NH1' ' C' ' 76' ' ' ARG . 63.2 pttt -108.93 137.98 46.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.879 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 51.8 m-85 -99.91 -31.24 11.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.8 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -171.58 151.0 2.85 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.388 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.0 p -64.19 98.16 0.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.942 0.401 . . . . 0.0 110.822 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 81' ' ' CYS . . . . . 0.412 ' O ' ' N ' ' C' ' 71' ' ' GLY . 4.1 t -168.91 142.92 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.432 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -84.07 170.56 13.75 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.525 0.679 . . . . 0.0 110.591 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -44.82 152.64 0.22 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.989 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 84' ' ' GLY . . . . . 0.537 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.18 -7.76 56.95 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 85' ' ' HIS . . . . . 0.614 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 7.0 m-70 -140.02 134.23 31.13 Favored 'General case' 0 C--O 1.24 0.564 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.7 58.47 0.16 Allowed Glycine 0 C--N 1.337 0.633 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -83.27 131.23 34.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 88' ' ' PHE . . . . . 0.495 ' CZ ' ' CD2' ' C' ' 52' ' ' PHE . 97.4 m-85 -79.42 118.99 21.81 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.79 -178.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 89' ' ' VAL . . . . . 0.475 ' O ' ' N ' ' C' ' 58' ' ' VAL . 12.1 m -141.52 163.47 20.34 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.262 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 90' ' ' ARG . . . . . 0.572 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -90.29 154.33 19.79 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.116 0.484 . . . . 0.0 110.841 179.788 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 91' ' ' GLN . . . . . 0.407 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.1 pt20 -52.54 -38.65 60.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.467 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 89.2 p -67.7 -33.32 74.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.096 0.474 . . . . 0.0 110.657 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -66.66 -21.21 66.11 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.594 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 94' ' ' ILE . . . . . 0.432 ' CG2' HG21 ' C' ' 89' ' ' VAL . 39.0 pt -117.24 146.65 21.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.642 -179.814 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 . . . . . 0 C--O 1.235 0.329 0 CA-C-O 121.418 0.627 . . . . 0.0 110.57 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 29' ' ' VAL . . . . . 0.423 HG23 ' O ' ' C' ' 45' ' ' ALA . 2.9 p -57.63 142.5 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.257 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.2 -18.78 47.99 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.114 -0.794 . . . . 0.0 111.114 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . 0.742 ' O ' HG23 ' C' ' 44' ' ' VAL . 37.0 t -90.36 164.63 14.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.475 0.179 . . . . 0.0 110.523 179.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -60.75 161.03 8.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.207 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 33' ' ' VAL . . . . . 0.541 ' HB ' HG22 ' C' ' 44' ' ' VAL . 0.2 OUTLIER -133.67 151.09 32.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.806 -179.419 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -141.98 91.39 2.34 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.302 177.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.7 t -61.82 131.8 27.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 CA-C-O 121.116 0.484 . . . . 0.0 110.633 -179.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -77.61 88.65 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.416 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.95 -126.1 0.8 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -67.03 -12.58 60.31 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.927 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.04 60.34 0.53 Allowed Glycine 0 CA--C 1.52 0.395 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -105.68 143.68 33.49 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.982 0.42 . . . . 0.0 110.6 179.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -145.78 165.94 27.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.755 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 175.11 -125.76 1.11 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 96.4 m -127.8 136.39 51.4 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 120.715 0.293 . . . . 0.0 111.057 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 44' ' ' VAL . . . . . 0.742 HG23 ' O ' ' C' ' 31' ' ' SER . 43.1 t -72.51 128.89 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 45' ' ' ALA . . . . . 0.462 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -94.82 -159.04 0.68 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.314 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -65.49 141.34 58.52 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.133 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 47' ' ' VAL . . . . . 0.519 HG23 HG22 ' C' ' 58' ' ' VAL . 6.2 p -121.03 133.32 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.394 -179.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.05 -174.05 21.6 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 49' ' ' ALA . . . . . 0.436 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -71.21 152.23 43.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.874 0.369 . . . . 0.0 110.272 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 50' ' ' THR . . . . . 0.669 HG23 ' H ' ' C' ' 53' ' ' ALA . 1.7 t -146.19 166.56 25.84 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.827 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 51' ' ' LEU . . . . . 0.518 HD12 ' N ' ' C' ' 51' ' ' LEU . 10.5 mp -60.67 -38.58 85.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.167 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 52' ' ' PHE . . . . . 0.529 ' N ' ' OE1' ' C' ' 74' ' ' GLN . 92.4 t80 -59.89 -44.76 94.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.206 179.148 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 53' ' ' ALA . . . . . 0.669 ' H ' HG23 ' C' ' 50' ' ' THR . . . -145.5 144.28 30.47 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.511 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 99.1 m -98.44 132.83 43.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.546 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 55' ' ' GLY . . . . . 0.436 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 136.98 -147.69 19.37 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -124.26 96.17 4.82 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 36.6 m95 -122.94 162.98 21.25 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.986 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 58' ' ' VAL . . . . . 0.519 HG22 HG23 ' C' ' 47' ' ' VAL . 59.2 t -125.15 128.27 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.773 -179.252 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 59' ' ' GLY . . . . . 0.462 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -84.54 136.85 15.08 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 109.691 -1.363 . . . . 0.0 109.691 179.003 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.4 t -123.39 133.9 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.037 0.446 . . . . 0.0 111.038 -178.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 16.4 mm -87.06 93.28 4.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.811 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 62' ' ' LEU . . . . . 0.617 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.6 OUTLIER -76.03 120.14 20.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.546 -179.409 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -67.85 -11.94 59.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.837 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 64' ' ' GLU . . . . . 0.657 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.7 mm-40 -63.37 -34.25 77.32 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.476 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 65' ' ' ALA . . . . . 0.657 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 83.42 47.18 0.02 OUTLIER 'General case' 0 C--N 1.338 0.105 0 O-C-N 123.322 0.389 . . . . 0.0 110.748 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 66' ' ' LYS . . . . . 0.552 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.4 ptpt -146.84 109.21 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.387 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.53 -140.5 7.25 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.449 -1.061 . . . . 0.0 110.449 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -97.19 -173.36 2.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.919 0.39 . . . . 0.0 110.125 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 42.3 p-10 -113.95 98.01 6.73 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.576 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 -61.65 -17.37 55.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.375 179.246 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 71' ' ' GLY . . . . . 0.66 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.93 -43.1 97.0 Favored Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 72' ' ' THR . . . . . 0.66 HG23 ' O ' ' C' ' 71' ' ' GLY . 19.1 p -161.41 118.09 2.2 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 120.513 0.197 . . . . 0.0 110.636 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 73' ' ' VAL . . . . . 0.623 ' O ' ' N ' ' C' ' 76' ' ' ARG . 12.7 t -128.31 125.68 64.53 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 74' ' ' GLN . . . . . 0.529 ' OE1' ' N ' ' C' ' 52' ' ' PHE . 3.4 pt20 39.55 36.79 0.25 Allowed 'General case' 0 C--N 1.328 -0.364 0 O-C-N 123.148 0.28 . . . . 0.0 111.323 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 89.03 -19.56 37.78 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 76' ' ' ARG . . . . . 0.623 ' N ' ' O ' ' C' ' 73' ' ' VAL . 59.9 ttt85 -101.96 126.25 48.83 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 pttt -106.83 132.32 52.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.491 0.662 . . . . 0.0 111.209 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 78' ' ' TYR . . . . . 0.546 ' OH ' HG21 ' C' ' 50' ' ' THR . 3.1 m-85 -84.26 -40.65 17.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.063 178.268 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 79' ' ' PHE . . . . . 0.409 ' CG ' ' N ' ' C' ' 80' ' ' THR . 86.8 t80 -170.87 158.19 5.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.467 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 80' ' ' THR . . . . . 0.409 ' N ' ' CG ' ' C' ' 79' ' ' PHE . 82.7 p -64.12 96.95 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.975 0.417 . . . . 0.0 111.029 -179.499 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.31 144.9 4.65 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.305 179.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -86.57 169.45 12.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.191 0.519 . . . . 0.0 110.887 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -46.71 149.93 0.77 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.185 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 84' ' ' GLY . . . . . 0.552 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.36 -7.11 56.14 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -178.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 85' ' ' HIS . . . . . 0.617 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 6.3 m-70 -139.15 132.82 30.56 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.093 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.9 58.57 0.16 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.9 mm -82.34 132.39 31.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -83.66 116.68 22.76 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.482 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 89' ' ' VAL . . . . . 0.482 HG21 ' CG2' ' C' ' 94' ' ' ILE . 4.3 m -140.21 160.01 25.76 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.911 178.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 90' ' ' ARG . . . . . 0.658 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -85.97 162.62 18.44 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 120.791 0.329 . . . . 0.0 110.758 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 91' ' ' GLN . . . . . 0.455 ' O ' ' O ' ' C' ' 94' ' ' ILE . 96.0 mt-30 -59.31 -41.2 88.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.597 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 40.0 t -61.53 -37.99 85.78 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.432 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -63.2 -33.88 76.44 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.565 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 94' ' ' ILE . . . . . 0.482 ' CG2' HG21 ' C' ' 89' ' ' VAL . 34.1 pt -105.01 149.13 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 121.082 0.468 . . . . 0.0 110.799 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.596 179.826 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 96.1 mtm-85 . . . . . 0 C--O 1.234 0.251 0 CA-C-O 120.969 0.414 . . . . 0.0 110.369 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -67.14 140.32 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 CA-C-O 121.361 0.601 . . . . 0.0 111.058 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.07 -16.38 57.23 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.032 -178.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . 0.778 ' O ' HG12 ' C' ' 44' ' ' VAL . 81.5 p -80.36 165.38 22.32 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.918 0.39 . . . . 0.0 111.606 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 32' ' ' ARG . . . . . 0.684 ' NE ' HH21 ' C' ' 41' ' ' ARG . 99.7 mtt180 -68.67 156.21 38.61 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.473 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 33' ' ' VAL . . . . . 0.451 HG22 ' C ' ' C' ' 42' ' ' GLY . 2.2 m -130.82 156.3 42.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.321 0 CA-C-O 121.216 0.531 . . . . 0.0 110.445 -179.707 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -139.39 99.41 3.73 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 177.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 35' ' ' VAL . . . . . 0.412 ' HA ' HG22 ' C' ' 94' ' ' ILE . 74.1 t -62.37 130.3 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.419 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.943 -178.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 36' ' ' ILE . . . . . 0.471 HG22 ' O ' ' C' ' 36' ' ' ILE . 96.9 mt -75.0 76.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.804 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -125.36 0.77 Allowed Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 65.4 pttt -60.01 -20.02 55.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.592 -0.304 . . . . 0.0 110.579 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.44 54.99 0.81 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 40' ' ' HIS . . . . . 0.431 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 66.7 t-80 -87.32 137.4 32.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.218 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 41' ' ' ARG . . . . . 0.684 HH21 ' NE ' ' C' ' 32' ' ' ARG . 78.0 ttt-85 -110.09 139.43 45.22 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.13 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 42' ' ' GLY . . . . . 0.451 ' C ' HG22 ' C' ' 33' ' ' VAL . . . -172.14 -170.8 36.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 95.1 m -114.18 131.55 56.41 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 44' ' ' VAL . . . . . 0.778 HG12 ' O ' ' C' ' 31' ' ' SER . 1.3 p -69.49 139.6 20.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.294 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -96.17 -156.88 0.55 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.375 -0.829 . . . . 0.0 109.274 178.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -63.66 142.37 58.42 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.201 0.524 . . . . 0.0 110.221 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 47' ' ' VAL . . . . . 0.625 HG12 HG22 ' C' ' 58' ' ' VAL . 19.7 m -118.8 153.58 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.285 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 116.96 -175.83 15.91 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 49' ' ' ALA . . . . . 0.715 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.13 141.2 56.14 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 60.3 p -137.69 167.7 21.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.289 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.5 tp -59.86 -41.16 90.84 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 52' ' ' PHE . . . . . 0.462 ' CE1' ' NZ ' ' C' ' 68' ' ' LYS . 88.8 t80 -58.74 -46.0 88.41 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.274 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.39 140.94 32.2 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.964 0.412 . . . . 0.0 110.677 179.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.3 p -84.44 167.63 16.25 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.745 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 55' ' ' GLY . . . . . 0.715 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 87.1 -133.35 11.74 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -131.18 114.68 15.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.524 0.678 . . . . 0.0 110.513 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -137.52 156.04 48.57 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.45 179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 58' ' ' VAL . . . . . 0.625 HG22 HG12 ' C' ' 47' ' ' VAL . 82.1 t -119.36 130.06 74.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.441 -179.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.37 135.49 12.91 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 75.1 t -125.94 132.69 70.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.07 0.462 . . . . 0.0 111.374 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.5 pt -83.5 95.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.561 0.696 . . . . 0.0 110.196 178.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 62' ' ' LEU . . . . . 0.579 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -70.12 120.82 16.38 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.335 -179.321 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 63' ' ' ASP . . . . . 0.431 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.0 m-20 -67.61 -11.1 57.39 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.4 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 64' ' ' GLU . . . . . 0.657 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.19 -35.79 79.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.179 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 65' ' ' ALA . . . . . 0.657 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 87.05 39.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.962 0.41 . . . . 0.0 110.397 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 66' ' ' LYS . . . . . 0.512 ' N ' ' O ' ' C' ' 84' ' ' GLY . 21.3 ptmt -135.6 135.56 40.34 Favored 'General case' 0 CA--C 1.521 -0.155 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.59 179.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.21 -146.79 16.45 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 68' ' ' LYS . . . . . 0.462 ' NZ ' ' CE1' ' C' ' 52' ' ' PHE . 17.5 ptpt -98.47 -168.0 1.58 Allowed 'General case' 0 C--O 1.238 0.452 0 CA-C-O 120.941 0.4 . . . . 0.0 110.736 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 69' ' ' ASN . . . . . 0.422 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 40.6 p-10 -111.8 105.42 13.89 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.56 -179.468 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 70' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' C' ' 85' ' ' HIS . 0.9 OUTLIER -63.93 -11.46 28.44 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.899 178.515 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 71' ' ' GLY . . . . . 0.667 ' O ' HG23 ' C' ' 72' ' ' THR . . . -60.29 -42.92 98.97 Favored Glycine 0 N--CA 1.45 -0.383 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 72' ' ' THR . . . . . 0.667 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.4 p -163.91 115.38 1.36 Allowed 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 123.838 0.376 . . . . 0.0 110.683 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 73' ' ' VAL . . . . . 0.422 ' CG2' ' O ' ' C' ' 69' ' ' ASN . 16.8 t -131.12 119.02 43.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.8 mm-40 52.35 35.16 16.52 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.558 0.218 . . . . 0.0 111.441 179.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.62 -1.7 81.71 Favored Glycine 0 CA--C 1.517 0.195 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 76' ' ' ARG . . . . . 0.405 ' O ' ' N ' ' C' ' 73' ' ' VAL . 28.1 tpt180 -115.98 123.85 49.04 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.244 -0.478 . . . . 0.0 109.75 179.494 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -109.7 136.33 49.22 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-O 121.272 0.558 . . . . 0.0 110.645 -179.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -93.66 -37.23 11.95 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.597 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -170.56 149.18 3.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.279 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 31.0 p -64.3 101.48 0.43 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.888 0.375 . . . . 0.0 111.615 -178.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.0 t -171.19 146.97 2.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.307 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -78.65 168.63 19.47 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.432 0.634 . . . . 0.0 110.717 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -43.57 157.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.307 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 84' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.86 -8.15 63.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 85' ' ' HIS . . . . . 0.579 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 30.7 m-70 -137.61 144.49 41.97 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.6 60.4 0.49 Allowed Glycine 0 N--CA 1.467 0.718 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 50.7 mm -93.77 127.37 45.86 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 88' ' ' PHE . . . . . 0.537 ' O ' ' CD2' ' C' ' 88' ' ' PHE . 49.0 p90 -77.34 119.7 21.33 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.276 0.56 . . . . 0.0 110.091 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 89' ' ' VAL . . . . . 0.412 ' O ' ' HB ' ' C' ' 58' ' ' VAL . 4.0 p -143.44 140.41 26.24 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.728 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 90' ' ' ARG . . . . . 0.651 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -65.59 151.52 46.28 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.954 -0.298 . . . . 0.0 110.925 -177.774 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 91' ' ' GLN . . . . . 0.599 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 3.8 pm0 -57.87 -33.75 69.02 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.836 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 81.7 p -64.95 -36.81 85.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.349 . . . . 0.0 110.849 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -67.59 -20.68 65.4 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.021 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 94' ' ' ILE . . . . . 0.455 ' O ' ' O ' ' C' ' 91' ' ' GLN . 24.3 pt -117.65 148.72 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.88 0.371 . . . . 0.0 110.142 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.583 -179.608 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo . . . . . 0 N--CA 1.483 0.885 0 N-CA-C 109.062 -1.168 . . . . 0.0 109.062 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' LEU . . . . . 0.523 ' H ' HD23 ' C' ' 27' ' ' LEU . 0.1 OUTLIER -85.24 170.37 12.9 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.877 179.85 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 35.1 ptt-85 -122.25 149.2 44.02 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 121.456 0.646 . . . . 0.0 110.839 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' VAL . . . . . 0.475 HG23 ' O ' ' C' ' 45' ' ' ALA . 3.4 p -57.28 145.0 8.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.206 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.34 -20.69 47.53 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -83.67 159.5 21.52 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.861 0.363 . . . . 0.0 110.791 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 39.4 ptt180 -50.72 161.85 0.31 Allowed 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' VAL . . . . . 0.715 HG12 ' C ' ' C' ' 42' ' ' GLY . 9.4 p -128.21 150.13 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.858 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -146.72 91.8 2.07 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 94.1 t -67.63 130.88 33.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.93 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' ILE . . . . . 0.444 HG22 ' O ' ' C' ' 36' ' ' ILE . 5.6 mm -76.17 74.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.508 0.67 . . . . 0.0 109.934 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.72 -119.77 0.5 Allowed Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -58.73 -17.94 27.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.121 -0.539 . . . . 0.0 109.966 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 96.21 41.72 3.66 Favored Glycine 0 N--CA 1.465 0.588 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' HIS . . . . . 0.622 ' ND1' HD11 ' C' ' 62' ' ' LEU . 64.8 m170 -75.4 147.37 40.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 110.694 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.4 ptm180 -134.77 163.18 30.38 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.748 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 42' ' ' GLY . . . . . 0.715 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 157.56 -127.25 1.88 Allowed Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 -178.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 98.6 m -131.89 142.85 49.79 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 120.912 0.386 . . . . 0.0 111.845 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 95.9 t -77.83 132.31 32.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.043 179.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 45' ' ' ALA . . . . . 0.507 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -85.77 -158.72 0.41 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.952 0.406 . . . . 0.0 110.486 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 81.8 t80 -64.41 143.48 57.87 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.29 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 47' ' ' VAL . . . . . 0.559 HG22 HG22 ' C' ' 58' ' ' VAL . 89.9 t -119.64 131.75 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.613 -178.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 132.0 -176.09 19.45 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 49' ' ' ALA . . . . . 0.746 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -70.3 142.92 52.18 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-O 120.937 0.399 . . . . 0.0 110.015 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 69.6 p -138.6 169.58 17.54 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.473 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 97.1 mt -60.86 -38.82 86.88 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.993 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.0 t80 -59.06 -46.14 89.01 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.523 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -146.18 143.98 29.63 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.1 p -85.14 166.95 16.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.538 179.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 55' ' ' GLY . . . . . 0.746 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 94.17 -140.54 15.1 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -134.38 96.04 3.51 Favored 'General case' 0 C--N 1.326 -0.45 0 O-C-N 122.403 -0.469 . . . . 0.0 110.464 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -113.89 171.12 7.78 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.105 0.479 . . . . 0.0 109.785 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 58' ' ' VAL . . . . . 0.559 HG22 HG22 ' C' ' 47' ' ' VAL . 59.9 t -129.77 130.21 66.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.401 -179.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 59' ' ' GLY . . . . . 0.507 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -92.11 134.57 12.3 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 178.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 60' ' ' VAL . . . . . 0.475 HG13 HG21 ' C' ' 33' ' ' VAL . 59.5 t -122.19 132.96 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 CA-C-O 120.906 0.384 . . . . 0.0 111.162 -178.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 7.9 mm -81.39 96.22 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.954 -179.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 62' ' ' LEU . . . . . 0.622 HD11 ' ND1' ' C' ' 40' ' ' HIS . 0.2 OUTLIER -78.17 114.85 17.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.577 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -66.89 -18.07 65.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.66 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 64' ' ' GLU . . . . . 0.655 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.3 mm-40 -60.55 -32.22 71.3 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.341 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 65' ' ' ALA . . . . . 0.655 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 84.53 46.63 0.02 OUTLIER 'General case' 0 N--CA 1.461 0.09 0 CA-C-O 120.796 0.331 . . . . 0.0 110.772 179.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 66' ' ' LYS . . . . . 0.538 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.6 ptpt -141.3 110.89 6.44 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.168 0.508 . . . . 0.0 110.238 179.417 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 151.31 -143.02 10.02 Favored Glycine 0 CA--C 1.52 0.385 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 68' ' ' LYS . . . . . 0.428 ' H ' ' HG2' ' C' ' 68' ' ' LYS . 18.3 ptmt -99.4 -171.99 2.18 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 69' ' ' ASN . . . . . 0.455 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 23.0 p-10 -112.07 102.53 10.73 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.603 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.0 m-20 -62.41 -15.98 52.2 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.313 178.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 71' ' ' GLY . . . . . 0.647 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.42 -45.52 94.27 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.357 -0.925 . . . . 0.0 111.065 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 72' ' ' THR . . . . . 0.647 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.1 p -162.18 120.83 2.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.843 0.354 . . . . 0.0 110.667 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 73' ' ' VAL . . . . . 0.487 ' N ' ' O ' ' C' ' 76' ' ' ARG . 12.7 t -138.69 122.06 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.617 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 74' ' ' GLN . . . . . 0.441 ' C ' ' H ' ' C' ' 76' ' ' ARG . 55.6 tt0 44.78 58.44 3.95 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.275 0.56 . . . . 0.0 110.963 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 60.02 3.88 2.96 Favored Glycine 0 CA--C 1.517 0.186 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 76' ' ' ARG . . . . . 0.487 ' O ' ' N ' ' C' ' 73' ' ' VAL . 17.2 tpp180 -124.75 129.59 50.77 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-O 120.862 0.363 . . . . 0.0 110.373 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -113.34 136.43 52.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.271 0.558 . . . . 0.0 111.078 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -88.78 -39.29 14.02 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.862 178.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -173.33 158.97 3.67 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.486 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 70.3 p -65.46 96.99 0.27 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.843 0.354 . . . . 0.0 111.001 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.3 t -169.2 144.82 3.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.522 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 49.8 p-10 -84.11 172.16 12.21 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.275 0.56 . . . . 0.0 110.82 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -47.68 151.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.165 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 84' ' ' GLY . . . . . 0.538 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.03 -6.8 56.8 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 85' ' ' HIS . . . . . 0.577 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -137.74 128.27 26.61 Favored 'General case' 0 C--O 1.239 0.545 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 179.334 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 124.73 54.32 0.18 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.736 -0.546 . . . . 0.0 111.736 179.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 87' ' ' ILE . . . . . 0.457 HD12 HD23 ' C' ' 62' ' ' LEU . 96.7 mt -80.43 129.36 37.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 88' ' ' PHE . . . . . 0.569 ' O ' ' CD2' ' C' ' 88' ' ' PHE . 48.6 p90 -74.94 119.35 19.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.087 0.47 . . . . 0.0 111.063 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 89' ' ' VAL . . . . . 0.496 HG21 ' CG2' ' C' ' 94' ' ' ILE . 4.5 m -140.5 162.63 23.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 90' ' ' ARG . . . . . 0.581 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -91.14 163.46 14.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.728 179.732 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 91' ' ' GLN . . . . . . . . . . . . . 55.6 mt-30 -59.31 -42.63 91.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.721 -179.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 67.7 m -63.16 -33.84 76.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.245 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 93' ' ' GLN . . . . . 0.526 ' OE1' ' NH1' ' C' ' 90' ' ' ARG . 72.5 tp60 -64.29 -36.95 85.79 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.655 -178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 94' ' ' ILE . . . . . 0.496 ' CG2' HG21 ' C' ' 89' ' ' VAL . 24.1 pt -99.44 139.3 21.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.051 0.453 . . . . 0.0 110.453 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 59.5 tt0 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.775 -179.655 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo . . . . . 0 N--CA 1.481 0.759 0 N-CA-C 108.735 -1.294 . . . . 0.0 108.735 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.85 122.81 20.16 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.948 -0.389 . . . . 0.0 109.948 179.566 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 62.7 ttp180 -73.36 139.59 46.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.798 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 29' ' ' VAL . . . . . 0.467 ' HA ' HG13 ' C' ' 44' ' ' VAL . 1.6 p -55.9 140.62 13.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.059 179.647 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.7 -9.94 62.4 Favored Glycine 0 CA--C 1.53 0.974 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . 0.534 ' O ' HG12 ' C' ' 44' ' ' VAL . 67.5 m -92.67 163.76 13.65 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.942 0.401 . . . . 0.0 111.045 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 17.7 ptm180 -61.62 159.11 13.84 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.318 179.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 33' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' C' ' 42' ' ' GLY . 2.6 m -135.7 160.36 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 34' ' ' GLU . . . . . 0.508 ' N ' ' OXT' ' C' ' 95' ' ' GLN . 77.3 mm-40 -133.2 96.02 3.66 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 177.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 84.9 t -61.07 131.2 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.702 -178.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 36' ' ' ILE . . . . . 0.493 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 6.5 mm -76.68 82.76 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.209 0 CA-C-O 121.426 0.632 . . . . 0.0 110.027 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.28 -125.97 0.79 Allowed Glycine 0 CA--C 1.52 0.357 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -64.02 -18.47 64.35 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.306 -0.447 . . . . 0.0 110.454 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.12 55.98 0.59 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 40' ' ' HIS . . . . . 0.526 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 61.0 t-80 -95.44 154.9 16.97 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.799 0.333 . . . . 0.0 110.404 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 41' ' ' ARG . . . . . 0.467 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 37.2 ptt-85 -128.52 157.54 40.89 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.337 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 42' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' C' ' 33' ' ' VAL . . . 176.33 -166.37 37.35 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.5 m -111.11 132.09 54.55 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-O 120.903 0.382 . . . . 0.0 110.667 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 44' ' ' VAL . . . . . 0.534 HG12 ' O ' ' C' ' 31' ' ' SER . 1.5 p -72.26 135.21 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.333 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.83 179.571 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 45' ' ' ALA . . . . . 0.409 ' O ' HG22 ' C' ' 44' ' ' VAL . . . -87.21 -156.48 0.33 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.801 178.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 46' ' ' TYR . . . . . 0.402 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 91.0 t80 -63.42 140.68 58.9 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.065 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 47' ' ' VAL . . . . . 0.402 ' O ' ' CE2' ' C' ' 46' ' ' TYR . 30.4 m -110.47 153.94 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.063 -179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.49 -175.3 22.56 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 49' ' ' ALA . . . . . 0.784 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -67.99 153.78 43.0 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.073 0.463 . . . . 0.0 109.971 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 50' ' ' THR . . . . . 0.536 HG23 ' H ' ' C' ' 53' ' ' ALA . 8.1 t -142.45 171.38 14.13 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.34 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 51' ' ' LEU . . . . . 0.529 HD22 ' N ' ' C' ' 51' ' ' LEU . 3.9 mm? -61.23 -39.27 89.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.471 -179.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 94.7 t80 -58.54 -45.72 88.32 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.368 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 53' ' ' ALA . . . . . 0.536 ' H ' HG23 ' C' ' 50' ' ' THR . . . -148.98 146.4 27.79 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.297 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 11.0 t -87.92 171.94 9.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 55' ' ' GLY . . . . . 0.784 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 96.14 -156.8 21.38 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 -179.479 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -119.27 106.83 12.7 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.091 0.472 . . . . 0.0 110.607 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 57' ' ' TRP . . . . . 0.58 ' HE1' ' NE ' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -135.22 170.67 15.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.825 179.466 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 58' ' ' VAL . . . . . 0.522 ' CG1' HG23 ' C' ' 44' ' ' VAL . 57.4 t -131.37 132.36 62.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.56 -0.746 . . . . 0.0 111.343 -179.305 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.46 132.94 11.37 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 72.9 t -127.35 134.28 66.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.556 0.693 . . . . 0.0 111.42 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.6 pt -85.06 119.93 34.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.964 178.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 62' ' ' LEU . . . . . 0.565 HD22 ' CD1' ' C' ' 87' ' ' ILE . 3.8 tp -92.24 122.21 34.5 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.093 -178.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 63' ' ' ASP . . . . . 0.526 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.3 m-20 -67.46 -14.15 62.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.375 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 64' ' ' GLU . . . . . 0.658 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 77.7 mm-40 -62.66 -31.05 71.85 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.561 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 65' ' ' ALA . . . . . 0.658 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.8 42.28 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.142 0 CA-C-O 120.958 0.409 . . . . 0.0 110.556 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 66' ' ' LYS . . . . . 0.526 ' N ' ' O ' ' C' ' 84' ' ' GLY . 18.9 ptmt -140.4 120.16 13.43 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.978 179.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 146.21 -148.25 19.8 Favored Glycine 0 CA--C 1.52 0.378 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 68' ' ' LYS . . . . . 0.501 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 40.8 tttt -97.4 -166.55 1.4 Allowed 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 69' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' C' ' 69' ' ' ASN . 1.2 m-20 -104.18 95.94 6.31 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.227 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 70' ' ' ASP . . . . . 0.557 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 5.4 t70 -60.48 -23.07 64.2 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.681 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 71' ' ' GLY . . . . . 0.53 ' O ' HG23 ' C' ' 72' ' ' THR . . . -59.06 -40.28 95.38 Favored Glycine 0 C--O 1.224 -0.482 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 -179.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 72' ' ' THR . . . . . 0.53 HG23 ' O ' ' C' ' 71' ' ' GLY . 38.1 p -158.5 116.47 2.95 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.807 0.337 . . . . 0.0 110.52 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 73' ' ' VAL . . . . . 0.448 HG23 ' O ' ' C' ' 69' ' ' ASN . 58.6 t -129.88 126.78 62.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.511 179.705 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 65.9 tp60 47.58 45.93 17.73 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.21 0.529 . . . . 0.0 110.704 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.64 3.13 39.77 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 76' ' ' ARG . . . . . 0.419 ' N ' ' O ' ' C' ' 73' ' ' VAL . 20.3 tpp85 -124.81 129.79 51.12 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.873 0.368 . . . . 0.0 110.371 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -109.44 138.92 45.08 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.883 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 17.1 m-85 -105.35 -26.97 11.77 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.464 179.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 79' ' ' PHE . . . . . 0.557 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 31.3 t80 -169.84 142.21 2.39 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.739 -0.384 . . . . 0.0 110.232 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 80' ' ' THR . . . . . 0.451 ' H ' HG22 ' C' ' 80' ' ' THR . 0.0 OUTLIER -64.27 106.3 1.07 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.054 0.454 . . . . 0.0 111.363 -179.731 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.1 t -169.19 145.07 3.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.299 179.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -82.26 171.14 14.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.261 0.553 . . . . 0.0 110.686 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -44.81 155.28 0.11 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.292 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 84' ' ' GLY . . . . . 0.526 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 95.45 -3.73 66.22 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 85' ' ' HIS . . . . . 0.572 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.3 OUTLIER -139.58 140.29 37.02 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.339 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.38 60.0 0.32 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 87' ' ' ILE . . . . . 0.565 ' CD1' HD22 ' C' ' 62' ' ' LEU . 95.9 mt -94.25 130.32 43.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -75.6 120.47 21.05 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.506 -178.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 89' ' ' VAL . . . . . 0.52 HG21 HG21 ' C' ' 94' ' ' ILE . 20.8 m -139.48 162.53 26.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.443 179.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 90' ' ' ARG . . . . . 0.58 ' NE ' ' HE1' ' C' ' 57' ' ' TRP . 5.5 mpt_? -93.89 150.71 20.13 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.024 0.44 . . . . 0.0 110.249 -179.256 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 91' ' ' GLN . . . . . 0.693 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 1.3 pm0 -51.57 -39.39 57.78 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.142 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 78.9 p -69.99 -28.33 65.43 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.053 0.454 . . . . 0.0 110.368 179.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 93' ' ' GLN . . . . . 0.493 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.6 tt0 -70.69 -20.19 62.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.501 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 94' ' ' ILE . . . . . 0.52 HG21 HG21 ' C' ' 89' ' ' VAL . 48.1 pt -128.38 163.09 33.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.074 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 95' ' ' GLN . . . . . 0.508 ' OXT' ' N ' ' C' ' 34' ' ' GLU . 59.8 tt0 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.453 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo . . . . . 0 N--CA 1.482 0.812 0 N-CA-C 108.86 -1.246 . . . . 0.0 108.86 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 27' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -136.28 163.65 29.91 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.377 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 86.0 mtp180 -125.27 148.44 48.68 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.742 179.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 29' ' ' VAL . . . . . 0.442 ' HA ' HG23 ' C' ' 44' ' ' VAL . 2.1 p -52.68 144.4 3.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.257 -179.762 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.51 -9.71 75.43 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . 0.501 ' O ' HG22 ' C' ' 44' ' ' VAL . 74.2 m -86.5 165.07 16.55 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.061 0.458 . . . . 0.0 111.275 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -58.28 151.14 20.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.881 179.353 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 33' ' ' VAL . . . . . 0.706 HG12 ' C ' ' C' ' 42' ' ' GLY . 14.0 p -121.76 150.94 25.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.835 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 34' ' ' GLU . . . . . 0.402 ' N ' HG22 ' C' ' 33' ' ' VAL . 85.2 tt0 -147.43 97.3 2.83 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.29 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -70.7 132.35 33.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.697 -178.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 36' ' ' ILE . . . . . 0.487 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 5.9 mm -71.95 80.3 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.509 179.674 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.29 -126.86 0.84 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 25.9 pttm -62.99 -21.12 65.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.355 -0.423 . . . . 0.0 110.77 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 107.87 55.49 0.61 Allowed Glycine 0 CA--C 1.529 0.912 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 40' ' ' HIS . . . . . 0.544 ' CE1' ' O ' ' C' ' 41' ' ' ARG . 41.8 t-80 -84.93 140.17 31.3 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 121.158 0.504 . . . . 0.0 111.681 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 41' ' ' ARG . . . . . 0.544 ' O ' ' CE1' ' C' ' 40' ' ' HIS . 11.6 ptm85 -119.73 169.73 9.84 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.285 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 42' ' ' GLY . . . . . 0.706 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 150.48 -131.2 3.48 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -178.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 12.3 t -142.67 154.2 44.11 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 111.56 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 44' ' ' VAL . . . . . 0.501 HG22 ' O ' ' C' ' 31' ' ' SER . 3.2 m -88.18 138.88 18.28 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.024 179.058 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.19 -158.79 0.49 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.477 -0.783 . . . . 0.0 109.962 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 75.1 t80 -64.8 142.53 58.4 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.122 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 47' ' ' VAL . . . . . 0.496 HG23 HG22 ' C' ' 58' ' ' VAL . 8.7 p -113.17 131.98 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.688 -178.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 143.14 -173.81 24.03 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 49' ' ' ALA . . . . . 0.566 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -66.79 145.78 55.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.079 0.466 . . . . 0.0 110.222 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 50' ' ' THR . . . . . 0.452 ' O ' ' O ' ' C' ' 53' ' ' ALA . 19.5 m -126.64 159.37 33.81 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.862 -179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 51' ' ' LEU . . . . . 0.44 ' N ' HG22 ' C' ' 50' ' ' THR . 88.8 mt -60.28 -39.54 87.23 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 89.1 t80 -59.16 -46.48 88.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.242 -0.435 . . . . 0.0 109.943 179.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 53' ' ' ALA . . . . . 0.452 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -141.72 141.61 33.29 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 110.149 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 9.9 t -89.17 162.12 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.937 -179.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 55' ' ' GLY . . . . . 0.566 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 108.78 -145.95 16.52 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 64.6 mttp -123.68 116.4 23.02 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.993 0.425 . . . . 0.0 110.359 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.3 m-90 -141.55 164.2 30.86 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.326 179.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 58' ' ' VAL . . . . . 0.496 HG22 HG23 ' C' ' 47' ' ' VAL . 75.2 t -122.54 128.51 75.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.755 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -84.48 141.74 19.88 Favored Glycine 0 CA--C 1.529 0.909 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 179.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 70.8 t -127.09 133.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 120.879 0.371 . . . . 0.0 110.531 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 11.7 mm -82.2 95.01 3.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 62' ' ' LEU . . . . . 0.564 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -74.57 104.86 5.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.132 -178.865 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 63' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' C' ' 64' ' ' GLU . 54.0 p30 -65.88 -9.88 33.27 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.992 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 64' ' ' GLU . . . . . 0.649 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 75.9 mm-40 -63.21 -32.15 73.47 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.475 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 65' ' ' ALA . . . . . 0.649 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 91.08 39.44 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.042 0.449 . . . . 0.0 110.555 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 66' ' ' LYS . . . . . 0.543 ' N ' ' O ' ' C' ' 84' ' ' GLY . 23.1 pttp -140.75 140.87 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.18 178.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 121.89 -150.15 17.07 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -178.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 9.4 mmtt -95.81 -171.51 2.37 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.39 0.614 . . . . 0.0 111.149 -179.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 69' ' ' ASN . . . . . 0.541 ' ND2' ' O ' ' C' ' 72' ' ' THR . 46.9 p-10 -106.09 102.01 11.46 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.543 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 70' ' ' ASP . . . . . 0.539 ' OD1' ' N ' ' C' ' 79' ' ' PHE . 7.3 t0 -62.06 -23.73 66.66 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.461 -0.791 . . . . 0.0 108.969 179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 71' ' ' GLY . . . . . 0.531 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.07 -41.83 94.76 Favored Glycine 0 C--O 1.226 -0.38 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 72' ' ' THR . . . . . 0.541 ' O ' ' ND2' ' C' ' 69' ' ' ASN . 32.7 p -158.55 118.31 3.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.922 0.392 . . . . 0.0 110.838 179.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 73' ' ' VAL . . . . . 0.466 ' O ' ' N ' ' C' ' 76' ' ' ARG . 39.6 t -126.43 122.96 62.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.685 179.225 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 68.7 tp60 45.05 49.99 9.36 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.074 0.464 . . . . 0.0 111.544 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.56 1.79 31.8 Favored Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.251 -1.139 . . . . 0.0 110.251 179.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 76' ' ' ARG . . . . . 0.466 ' N ' ' O ' ' C' ' 73' ' ' VAL . 76.3 ttt180 -124.78 126.09 45.07 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.374 -0.413 . . . . 0.0 110.325 -179.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -107.34 137.92 44.5 Favored 'General case' 0 CA--C 1.512 -0.499 0 CA-C-O 121.363 0.601 . . . . 0.0 111.19 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 78' ' ' TYR . . . . . 0.425 ' OH ' ' OG1' ' C' ' 50' ' ' THR . 1.7 m-85 -98.57 -32.94 11.18 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.371 178.343 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 79' ' ' PHE . . . . . 0.539 ' N ' ' OD1' ' C' ' 70' ' ' ASP . 86.0 t80 -169.55 151.73 4.48 Favored 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.373 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 44.0 p -64.9 108.87 1.9 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.745 0.307 . . . . 0.0 111.349 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -172.63 148.32 1.92 Allowed 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.329 179.032 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -86.0 169.87 12.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.153 0.501 . . . . 0.0 111.179 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -50.57 145.05 7.06 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.002 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 84' ' ' GLY . . . . . 0.543 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 104.05 -4.34 45.2 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 85' ' ' HIS . . . . . 0.564 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 4.0 m-70 -140.97 136.2 31.93 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.145 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.95 49.79 0.32 Allowed Glycine 0 N--CA 1.47 0.907 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.331 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 97.4 mt -83.78 135.18 25.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 178.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -84.16 119.11 24.62 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.528 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 89' ' ' VAL . . . . . 0.455 HG21 HG23 ' C' ' 94' ' ' ILE . 16.2 m -136.51 162.52 35.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 178.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 90' ' ' ARG . . . . . 0.586 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -90.78 155.04 19.09 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.599 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 91' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' C' ' 94' ' ' ILE . 29.2 pt20 -53.22 -38.97 63.4 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.733 -179.545 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 66.6 m -63.18 -37.19 86.24 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.223 0.535 . . . . 0.0 110.172 178.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 93' ' ' GLN . . . . . 0.487 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.9 tt0 -65.02 -30.05 71.0 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.109 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 94' ' ' ILE . . . . . 0.455 HG23 HG21 ' C' ' 89' ' ' VAL . 17.1 pt -108.93 145.43 15.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.975 0.417 . . . . 0.0 110.461 179.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 64.8 tt0 . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.745 179.98 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo . . . . . 0 N--CA 1.48 0.703 0 N-CA-C 109.051 -1.173 . . . . 0.0 109.051 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 27' ' ' LEU . . . . . 0.688 ' CD1' HG11 ' C' ' 44' ' ' VAL . 0.1 OUTLIER -78.3 168.39 19.9 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.287 -0.415 . . . . 0.0 109.949 179.987 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 78.0 mtp85 -117.51 139.35 51.05 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.964 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 29' ' ' VAL . . . . . 0.44 ' H ' HG13 ' C' ' 29' ' ' VAL . 6.1 m -50.66 143.21 2.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 30' ' ' GLY . . . . . 0.447 ' N ' HG23 ' C' ' 44' ' ' VAL . . . 91.92 -8.27 78.27 Favored Glycine 0 CA--C 1.528 0.896 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . 0.527 ' O ' HG22 ' C' ' 44' ' ' VAL . 45.7 t -89.05 163.73 15.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.982 0.42 . . . . 0.0 111.426 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 80.1 ttt180 -59.23 149.15 29.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.156 179.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 33' ' ' VAL . . . . . 0.791 HG12 HG13 ' C' ' 44' ' ' VAL . 2.5 m -126.81 159.78 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.013 0.435 . . . . 0.0 110.035 -179.261 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -140.52 93.64 2.64 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 35' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' C' ' 37' ' ' GLY . 84.2 t -56.54 126.54 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -178.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 36' ' ' ILE . . . . . 0.618 HG22 ' O ' ' C' ' 36' ' ' ILE . 4.6 mm -67.18 77.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 CA-C-O 121.582 0.706 . . . . 0.0 109.333 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' C' ' 35' ' ' VAL . . . -163.17 -126.61 0.83 Allowed Glycine 0 CA--C 1.519 0.311 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -64.48 -17.31 63.74 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.969 -0.615 . . . . 0.0 110.274 179.396 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 100.11 58.07 0.89 Allowed Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 40' ' ' HIS . . . . . 0.73 ' HE2' ' H ' ' C' ' 63' ' ' ASP . 75.7 t60 -89.82 138.95 31.05 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.051 0.453 . . . . 0.0 111.124 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 41' ' ' ARG . . . . . 0.517 ' O ' ' CD2' ' C' ' 40' ' ' HIS . 87.6 mtm-85 -89.87 162.71 15.33 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.675 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 42' ' ' GLY . . . . . 0.47 ' C ' HG22 ' C' ' 33' ' ' VAL . . . 171.64 -172.4 44.58 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 85.4 m -124.71 131.95 53.42 Favored 'General case' 0 C--O 1.24 0.569 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 44' ' ' VAL . . . . . 0.791 HG13 HG12 ' C' ' 33' ' ' VAL . 0.2 OUTLIER -72.58 121.14 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.671 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.07 -157.5 0.12 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.593 -0.73 . . . . 0.0 109.934 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -63.61 142.0 58.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.569 -179.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 47' ' ' VAL . . . . . 0.511 HG23 HG22 ' C' ' 58' ' ' VAL . 7.2 p -117.59 135.93 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.176 -179.055 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.99 -177.73 19.5 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 49' ' ' ALA . . . . . 0.567 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -70.45 141.44 52.06 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.974 0.416 . . . . 0.0 110.245 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 47.7 p -139.43 168.58 19.51 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.293 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 83.3 mt -60.78 -39.35 88.52 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.974 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 82.8 t80 -59.42 -46.28 89.17 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.215 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -145.94 142.38 28.66 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.012 0.434 . . . . 0.0 110.526 179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 60.3 p -85.44 169.12 13.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.914 179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 55' ' ' GLY . . . . . 0.567 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 89.66 -146.06 18.67 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -125.77 101.62 6.94 Favored 'General case' 0 N--CA 1.464 0.262 0 O-C-N 122.603 -0.351 . . . . 0.0 110.237 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -121.32 166.45 14.04 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 58' ' ' VAL . . . . . 0.511 HG22 HG23 ' C' ' 47' ' ' VAL . 51.2 t -127.03 129.41 71.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.298 -179.338 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.61 129.72 9.9 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.6 t -123.81 131.63 72.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 121.244 0.545 . . . . 0.0 110.805 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 10.1 pt -82.19 126.08 39.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.907 179.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 62' ' ' LEU . . . . . 0.6 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 3.5 tp -102.33 111.48 23.8 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 63' ' ' ASP . . . . . 0.73 ' H ' ' HE2' ' C' ' 40' ' ' HIS . 42.8 t0 -59.71 -11.1 4.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.127 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 64' ' ' GLU . . . . . 0.64 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.6 mm-40 -62.01 -34.01 75.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.286 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 65' ' ' ALA . . . . . 0.64 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.67 46.28 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.858 0.361 . . . . 0.0 110.546 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 66' ' ' LYS . . . . . 0.546 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.7 ptpt -149.79 104.09 3.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.355 0.597 . . . . 0.0 110.105 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.43 -143.19 8.64 Favored Glycine 0 N--CA 1.448 -0.537 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -179.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 31.2 tttt -96.62 -167.48 1.57 Allowed 'General case' 0 C--O 1.241 0.624 0 CA-C-O 121.104 0.478 . . . . 0.0 109.933 -179.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -117.48 98.72 6.55 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.412 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 76.2 m-20 -62.7 -14.96 50.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.76 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 71' ' ' GLY . . . . . 0.671 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.69 -42.75 96.45 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.069 -1.063 . . . . 0.0 110.63 -179.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 72' ' ' THR . . . . . 0.671 HG23 ' O ' ' C' ' 71' ' ' GLY . 18.9 p -163.22 117.75 1.66 Allowed 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.978 179.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 73' ' ' VAL . . . . . . . . . . . . . 26.1 t -134.72 122.75 39.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.583 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 51.11 36.37 15.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.743 0.306 . . . . 0.0 111.309 179.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.58 -2.66 66.64 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 76' ' ' ARG . . . . . . . . . . . . . 16.8 tpp180 -116.11 120.68 39.82 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.351 -0.425 . . . . 0.0 109.937 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 60.9 pttt -103.14 126.26 50.23 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-O 121.375 0.607 . . . . 0.0 110.633 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 83.3 m-85 -79.89 -37.61 34.4 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.861 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 56.8 t80 -171.04 151.74 3.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.392 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.5 p -64.92 98.48 0.28 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.955 0.407 . . . . 0.0 110.954 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 6.1 t -167.56 146.86 4.99 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 57.5 p30 -81.72 170.67 15.48 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 121.264 0.555 . . . . 0.0 110.983 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -49.57 155.33 0.8 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.174 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 84' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.8 -7.22 62.92 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 85' ' ' HIS . . . . . 0.6 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 18.5 m-70 -138.39 130.49 28.5 Favored 'General case' 0 C--O 1.24 0.58 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 123.88 59.49 0.19 Allowed Glycine 0 C--N 1.341 0.856 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.236 179.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 87' ' ' ILE . . . . . 0.427 ' CD1' HD22 ' C' ' 62' ' ' LEU . 97.9 mt -90.62 125.5 43.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 178.609 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 88' ' ' PHE . . . . . 0.553 ' O ' ' CD2' ' C' ' 88' ' ' PHE . 49.4 p90 -70.79 120.34 16.24 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-O 120.973 0.416 . . . . 0.0 110.587 -179.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 89' ' ' VAL . . . . . . . . . . . . . 20.5 m -139.01 160.58 29.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 179.03 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 90' ' ' ARG . . . . . 0.495 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.0 OUTLIER -92.91 155.15 17.77 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 -179.701 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 91' ' ' GLN . . . . . 0.525 ' NE2' ' OG ' ' C' ' 92' ' ' SER . 2.9 pp0? -52.74 -39.83 62.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.081 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 92' ' ' SER . . . . . 0.525 ' OG ' ' NE2' ' C' ' 91' ' ' GLN . 57.7 m -64.71 -37.14 86.59 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.996 0.427 . . . . 0.0 110.403 178.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 93' ' ' GLN . . . . . 0.495 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 58.2 tt0 -64.75 -19.23 65.68 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.912 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 94' ' ' ILE . . . . . 0.471 ' O ' ' O ' ' C' ' 91' ' ' GLN . 47.1 pt -123.46 153.79 29.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.668 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 95' ' ' GLN . . . . . 0.447 ' OXT' ' O ' ' C' ' 94' ' ' ILE . 69.2 tp60 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.06 -0.971 . . . . 0.0 110.907 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo . . . . . 0 N--CA 1.485 1.012 0 N-CA-C 109.291 -1.08 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 27' ' ' LEU . . . . . 0.487 ' H ' HD23 ' C' ' 27' ' ' LEU . 0.1 OUTLIER -81.29 130.13 34.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.11 -179.868 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -76.18 147.72 38.24 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.976 0.417 . . . . 0.0 110.636 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 29' ' ' VAL . . . . . 0.432 ' HA ' HG13 ' C' ' 44' ' ' VAL . 2.6 p -62.12 138.07 23.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.014 0.435 . . . . 0.0 110.115 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.71 -8.27 63.68 Favored Glycine 0 CA--C 1.533 1.202 0 N-CA-C 111.436 -0.665 . . . . 0.0 111.436 -179.093 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . 0.442 ' O ' HG12 ' C' ' 44' ' ' VAL . 70.9 m -89.76 163.1 15.21 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.7 0.286 . . . . 0.0 111.16 179.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -62.18 150.41 38.88 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.087 0.47 . . . . 0.0 111.19 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m -131.14 155.51 41.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.353 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.682 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.07 100.44 4.28 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 178.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 35' ' ' VAL . . . . . 0.471 ' HA ' HG22 ' C' ' 94' ' ' ILE . 88.0 t -64.94 130.1 29.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.876 -178.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 36' ' ' ILE . . . . . 0.453 ' CG1' ' O ' ' C' ' 93' ' ' GLN . 8.4 mm -82.97 75.43 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.72 -121.37 0.57 Allowed Glycine 0 CA--C 1.522 0.478 0 N-CA-C 110.696 -0.961 . . . . 0.0 110.696 -178.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -58.17 -29.4 65.59 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.041 -0.58 . . . . 0.0 109.951 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.68 59.78 0.51 Allowed Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 40' ' ' HIS . . . . . 0.419 ' CE1' ' CG ' ' C' ' 64' ' ' GLU . 94.4 m-70 -103.5 150.55 23.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.038 0.447 . . . . 0.0 110.635 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 53.1 ptt85 -137.76 154.78 49.55 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.744 -179.155 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.94 -122.7 0.94 Allowed Glycine 0 C--O 1.226 -0.351 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 43' ' ' THR . . . . . 0.605 ' CG2' HD12 ' C' ' 61' ' ' ILE . 5.3 t -141.02 154.62 46.09 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 120.963 0.411 . . . . 0.0 110.843 179.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 44' ' ' VAL . . . . . 0.506 HG23 ' CG1' ' C' ' 58' ' ' VAL . 1.2 p -91.72 141.57 14.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.997 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 45' ' ' ALA . . . . . 0.46 ' O ' HG22 ' C' ' 44' ' ' VAL . . . -88.85 -154.31 0.29 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.549 179.062 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -62.69 141.95 58.32 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.115 0.483 . . . . 0.0 110.645 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 47' ' ' VAL . . . . . . . . . . . . . 72.9 t -112.59 129.84 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.688 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 127.37 -172.97 18.66 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 49' ' ' ALA . . . . . 0.713 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.16 146.98 52.91 Favored 'General case' 0 C--N 1.334 -0.071 0 CA-C-O 120.914 0.387 . . . . 0.0 110.019 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 50' ' ' THR . . . . . 0.412 ' O ' ' O ' ' C' ' 53' ' ' ALA . 69.7 p -133.26 167.12 20.95 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.121 179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.2 tp -59.84 -40.78 89.68 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -57.87 -46.6 84.62 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.359 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 53' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -143.76 144.4 31.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.819 0.342 . . . . 0.0 110.285 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 10.0 t -90.12 165.29 14.07 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.385 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 55' ' ' GLY . . . . . 0.713 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 101.22 -152.81 18.96 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 60.6 mtpt -119.94 112.07 18.73 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.824 0.345 . . . . 0.0 110.551 -179.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 1.2 m-90 -139.12 171.51 14.19 Favored 'General case' 0 CA--C 1.517 -0.296 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 58' ' ' VAL . . . . . 0.506 ' CG1' HG23 ' C' ' 44' ' ' VAL . 50.4 t -131.3 133.16 62.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.637 -178.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -91.4 139.16 14.64 Favored Glycine 0 CA--C 1.532 1.134 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.69 136.85 59.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-O 121.085 0.469 . . . . 0.0 111.287 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 61' ' ' ILE . . . . . 0.605 HD12 ' CG2' ' C' ' 43' ' ' THR . 41.5 mt -88.45 99.87 9.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 179.182 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.1 118.78 20.69 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -67.53 -13.05 61.71 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.239 -179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 64' ' ' GLU . . . . . 0.653 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.3 mm-40 -62.28 -36.16 81.23 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.42 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 65' ' ' ALA . . . . . 0.653 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.79 44.05 0.01 OUTLIER 'General case' 0 C--N 1.342 0.269 0 CA-C-O 120.911 0.386 . . . . 0.0 110.748 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 66' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' C' ' 84' ' ' GLY . 14.4 ptpt -139.58 119.12 13.04 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.771 178.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 144.73 -146.0 15.97 Favored Glycine 0 CA--C 1.518 0.232 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 68' ' ' LYS . . . . . 0.444 ' HG2' ' H ' ' C' ' 69' ' ' ASN . 36.6 tttt -98.01 -168.75 1.71 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.992 0.425 . . . . 0.0 109.973 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 69' ' ' ASN . . . . . 0.444 ' H ' ' HG2' ' C' ' 68' ' ' LYS . 10.9 p30 -112.65 95.74 5.59 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.157 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 70' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' C' ' 70' ' ' ASP . 3.9 p-10 -65.26 -10.21 30.29 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.469 -0.493 . . . . 0.0 110.245 178.57 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 71' ' ' GLY . . . . . 0.663 ' O ' HG23 ' C' ' 72' ' ' THR . . . -60.34 -41.78 98.58 Favored Glycine 0 C--O 1.224 -0.489 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 72' ' ' THR . . . . . 0.663 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.6 p -162.36 109.7 1.32 Allowed 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 120.879 0.371 . . . . 0.0 110.662 179.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 73' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' C' ' 76' ' ' ARG . 43.7 t -125.94 122.36 61.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.3 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.0 mt-30 51.69 35.74 15.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.124 179.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 78.88 -1.67 72.71 Favored Glycine 0 CA--C 1.52 0.399 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 76' ' ' ARG . . . . . 0.425 ' N ' ' O ' ' C' ' 73' ' ' VAL . 60.2 ttm-85 -116.01 125.51 52.57 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.096 -0.552 . . . . 0.0 109.768 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 22.7 pttp -112.29 137.47 50.38 Favored 'General case' 0 CA--C 1.51 -0.596 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.658 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 13.9 m-85 -96.52 -36.11 10.88 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 179.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 79' ' ' PHE . . . . . 0.56 ' CD1' HD11 ' C' ' 61' ' ' ILE . 22.4 t80 -164.68 145.76 7.92 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.299 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 30.6 p -64.29 104.45 0.76 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.922 0.391 . . . . 0.0 111.306 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 10.7 t -171.3 144.95 2.09 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.527 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -79.93 169.19 18.24 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 121.342 0.591 . . . . 0.0 111.143 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -45.67 153.71 0.25 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.864 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 84' ' ' GLY . . . . . 0.535 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 99.03 -5.24 59.32 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 -179.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 85' ' ' HIS . . . . . 0.543 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -138.27 143.36 40.0 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.36 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.09 58.19 0.36 Allowed Glycine 0 C--N 1.337 0.615 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -88.96 134.55 28.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -82.64 119.71 24.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.087 0.47 . . . . 0.0 110.413 -179.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 89' ' ' VAL . . . . . 0.589 HG21 HG21 ' C' ' 94' ' ' ILE . 20.5 m -139.46 165.31 23.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 90' ' ' ARG . . . . . 0.463 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -97.36 159.25 15.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.839 0.352 . . . . 0.0 110.436 -179.688 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 91' ' ' GLN . . . . . 0.49 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.7 pt20 -55.9 -40.7 73.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.929 -179.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 88.0 p -70.73 -28.37 64.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.98 0.419 . . . . 0.0 110.4 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 93' ' ' GLN . . . . . 0.453 ' O ' ' CG1' ' C' ' 36' ' ' ILE . 73.2 tp60 -66.9 -29.0 68.77 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.576 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 94' ' ' ILE . . . . . 0.589 HG21 HG21 ' C' ' 89' ' ' VAL . 49.4 pt -125.98 164.15 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.245 -178.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 89.2 mt-30 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.399 179.755 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo . . . . . 0 N--CA 1.481 0.788 0 N-CA-C 109.066 -1.167 . . . . 0.0 109.066 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 27' ' ' LEU . . . . . 0.624 HD23 ' N ' ' C' ' 28' ' ' ARG . 1.5 tt -117.01 119.33 34.97 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 28' ' ' ARG . . . . . 0.624 ' N ' HD23 ' C' ' 27' ' ' LEU . 85.9 mtp180 -83.89 132.58 34.77 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-O 121.361 0.6 . . . . 0.0 110.335 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 29' ' ' VAL . . . . . 0.498 HG23 ' O ' ' C' ' 45' ' ' ALA . 3.6 p -64.22 146.45 13.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.354 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.75 -17.74 57.88 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 111.26 -0.736 . . . . 0.0 111.26 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . 0.453 ' O ' HG22 ' C' ' 44' ' ' VAL . 85.0 p -78.28 165.13 24.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.008 0.432 . . . . 0.0 111.553 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -54.48 155.56 3.91 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 33' ' ' VAL . . . . . 0.634 HG12 ' C ' ' C' ' 42' ' ' GLY . 7.6 p -123.65 149.52 27.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 121.032 0.444 . . . . 0.0 110.804 -179.386 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -151.45 94.47 2.02 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.388 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 85.5 t -70.36 131.23 34.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.581 -179.335 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 36' ' ' ILE . . . . . 0.563 HG22 ' O ' ' C' ' 36' ' ' ILE . 88.3 mt -72.91 74.06 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-O 121.311 0.577 . . . . 0.0 109.671 179.707 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.24 -121.9 0.59 Allowed Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 69.1 mttm -59.13 -29.93 67.77 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 114.92 -0.64 . . . . 0.0 109.596 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.18 46.65 0.92 Allowed Glycine 0 N--CA 1.466 0.691 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -71.72 136.22 47.11 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 120.877 0.37 . . . . 0.0 110.409 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -114.51 175.91 5.28 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.196 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 42' ' ' GLY . . . . . 0.634 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 134.43 -137.95 9.68 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 -179.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 99.0 m -134.25 142.34 47.3 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 120.978 0.418 . . . . 0.0 111.47 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 44' ' ' VAL . . . . . 0.453 HG22 ' O ' ' C' ' 31' ' ' SER . 16.0 m -75.29 144.89 11.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.612 179.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 45' ' ' ALA . . . . . 0.498 ' O ' HG23 ' C' ' 29' ' ' VAL . . . -91.3 -157.2 0.48 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.334 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -62.69 140.01 58.69 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.306 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 47' ' ' VAL . . . . . 0.518 HG22 HG22 ' C' ' 58' ' ' VAL . 70.1 t -110.77 129.61 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.247 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.717 -178.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 126.47 -171.16 18.21 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 49' ' ' ALA . . . . . 0.635 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.6 147.11 52.39 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 121.062 0.458 . . . . 0.0 109.928 179.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 50' ' ' THR . . . . . 0.434 ' O ' ' O ' ' C' ' 53' ' ' ALA . 82.3 p -132.02 165.17 24.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.232 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.5 tp -60.27 -40.95 92.2 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -58.28 -46.18 86.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.451 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 53' ' ' ALA . . . . . 0.434 ' O ' ' O ' ' C' ' 50' ' ' THR . . . -144.81 147.38 32.81 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.853 0.359 . . . . 0.0 110.447 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 14.4 t -88.38 173.16 8.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 55' ' ' GLY . . . . . 0.635 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 97.01 -151.2 19.77 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 16.5 ptmt -128.28 102.93 6.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.137 0.494 . . . . 0.0 110.064 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 64.9 m95 -131.68 161.79 31.94 Favored 'General case' 0 CA--C 1.514 -0.437 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 58' ' ' VAL . . . . . 0.518 HG22 HG22 ' C' ' 47' ' ' VAL . 57.4 t -121.36 128.68 75.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.904 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.8 134.52 12.51 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 60' ' ' VAL . . . . . 0.562 HG13 HG21 ' C' ' 33' ' ' VAL . 85.1 t -126.7 130.38 71.59 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.431 0 O-C-N 122.507 -0.408 . . . . 0.0 111.214 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 4.8 pt -80.23 96.13 2.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 C-N-CA 120.357 -0.537 . . . . 0.0 110.469 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 62' ' ' LEU . . . . . 0.629 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -73.14 118.06 15.63 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.862 179.907 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.5 p-10 -65.53 -9.22 24.37 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.51 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 64' ' ' GLU . . . . . 0.648 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.9 mm-40 -62.12 -33.64 74.85 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.212 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 65' ' ' ALA . . . . . 0.648 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 85.83 46.47 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.938 0.399 . . . . 0.0 110.679 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 66' ' ' LYS . . . . . 0.56 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.2 ptmt -147.22 114.5 6.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.296 179.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 147.12 -142.74 10.57 Favored Glycine 0 CA--C 1.516 0.149 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 16.6 mmtt -97.18 -172.69 2.49 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.271 0.558 . . . . 0.0 110.275 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 69' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.7 p-10 -114.07 98.22 6.84 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.979 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -60.17 -17.28 39.77 Favored 'General case' 0 C--N 1.321 -0.634 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.104 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 71' ' ' GLY . . . . . 0.653 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.59 -41.85 95.79 Favored Glycine 0 C--O 1.225 -0.44 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 72' ' ' THR . . . . . 0.653 HG23 ' O ' ' C' ' 71' ' ' GLY . 21.4 p -162.21 111.74 1.49 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.761 0.315 . . . . 0.0 110.591 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 73' ' ' VAL . . . . . 0.476 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.3 t -126.32 124.76 66.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.305 179.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 53.8 tt0 46.24 47.87 13.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.38 0.61 . . . . 0.0 111.029 179.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.69 3.61 42.55 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.174 -1.17 . . . . 0.0 110.174 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 76' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' C' ' 73' ' ' VAL . 29.2 tpt180 -125.23 125.93 44.37 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.971 0.415 . . . . 0.0 110.416 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -106.94 138.2 43.57 Favored 'General case' 0 CA--C 1.507 -0.705 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.516 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 43.8 m-85 -102.84 -29.98 11.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -170.54 147.41 2.91 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.349 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 80' ' ' THR . . . . . 0.43 ' O ' ' OG1' ' C' ' 80' ' ' THR . 9.7 p -63.93 97.06 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.979 0.419 . . . . 0.0 110.955 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 2.2 t -165.02 145.19 7.14 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.312 179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 52.5 p-10 -83.14 171.42 13.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.104 0.478 . . . . 0.0 110.695 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -50.18 151.88 1.91 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.341 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 84' ' ' GLY . . . . . 0.56 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 98.91 -6.16 60.05 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 -179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 85' ' ' HIS . . . . . 0.629 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 19.3 m-70 -136.5 131.34 33.83 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.14 59.42 0.17 Allowed Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.4 mm -86.6 132.79 31.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 178.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -82.83 118.5 23.46 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.478 -178.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 89' ' ' VAL . . . . . 0.48 HG21 HG23 ' C' ' 94' ' ' ILE . 17.8 m -139.62 159.52 27.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.703 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 90' ' ' ARG . . . . . 0.585 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.1 mpt_? -82.5 154.22 25.19 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.251 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 91' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' C' ' 94' ' ' ILE . 16.0 pt20 -54.3 -39.71 67.24 Favored 'General case' 0 C--N 1.33 -0.255 0 O-C-N 123.299 0.374 . . . . 0.0 111.106 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 74.2 m -63.22 -37.34 86.86 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.983 0.421 . . . . 0.0 110.299 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 73.6 tp60 -63.86 -34.79 78.73 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.029 -178.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 94' ' ' ILE . . . . . 0.48 HG23 HG21 ' C' ' 89' ' ' VAL . 15.9 pt -100.92 140.14 20.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.655 -179.65 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo . . . . . 0 N--CA 1.485 0.998 0 N-CA-C 109.328 -1.066 . . . . 0.0 109.328 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 27' ' ' LEU . . . . . 0.598 ' CD2' ' H ' ' C' ' 27' ' ' LEU . 0.1 OUTLIER -71.45 148.87 46.43 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.323 -179.574 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 79.5 mtp85 -81.07 148.39 29.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.861 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 29' ' ' VAL . . . . . 0.51 ' CG2' HG12 ' C' ' 47' ' ' VAL . 71.6 t -66.19 135.83 27.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.439 179.837 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.21 -18.83 47.81 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.0 t -73.1 154.04 40.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 117.044 0.422 . . . . 0.0 110.528 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 48.0 ptt85 -46.54 161.62 0.06 Allowed 'General case' 0 N--CA 1.461 0.114 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 33' ' ' VAL . . . . . 0.517 HG12 ' C ' ' C' ' 42' ' ' GLY . 11.3 p -128.99 151.56 35.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.72 -179.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 49.7 tp10 -149.81 95.42 2.31 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 87.1 t -72.11 131.3 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.403 -179.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 36' ' ' ILE . . . . . 0.516 HG22 ' O ' ' C' ' 36' ' ' ILE . 90.2 mt -75.12 76.47 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-O 121.28 0.562 . . . . 0.0 109.543 179.453 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.14 -122.5 0.63 Allowed Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.714 -0.954 . . . . 0.0 110.714 -178.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -59.35 -25.7 64.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.212 -0.494 . . . . 0.0 109.966 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 108.8 42.77 1.29 Allowed Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 88.6 m-70 -73.79 145.74 44.8 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.275 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 52.6 ptt85 -141.75 165.1 28.4 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.963 0.411 . . . . 0.0 110.564 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 42' ' ' GLY . . . . . 0.517 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 155.73 -109.39 0.4 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 43' ' ' THR . . . . . 0.485 ' CG2' HD12 ' C' ' 61' ' ' ILE . 6.8 t -145.4 154.27 42.1 Favored 'General case' 0 C--O 1.243 0.726 0 CA-C-O 120.828 0.347 . . . . 0.0 111.257 179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 44' ' ' VAL . . . . . . . . . . . . . 92.8 t -90.93 122.44 42.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.196 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 45' ' ' ALA . . . . . 0.457 ' O ' HG13 ' C' ' 29' ' ' VAL . . . -80.21 -159.12 0.2 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.953 179.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -64.35 145.05 56.67 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.346 0.593 . . . . 0.0 110.572 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 47' ' ' VAL . . . . . 0.67 ' CG2' HE21 ' C' ' 91' ' ' GLN . 9.3 p -124.17 141.2 45.17 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.485 -178.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 120.66 -171.01 14.57 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 49' ' ' ALA . . . . . 0.564 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.01 141.89 56.09 Favored 'General case' 0 C--O 1.23 0.066 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 71.1 p -134.81 164.63 27.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.235 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 58.6 tp -59.16 -39.27 81.95 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 52' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -57.51 -45.66 84.68 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.871 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -149.27 145.69 27.2 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 110.865 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 63.6 p -83.13 168.04 17.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.682 179.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 55' ' ' GLY . . . . . 0.564 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 98.65 -143.4 16.62 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 40.5 pttt -136.59 106.79 6.37 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.47 0.652 . . . . 0.0 110.624 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 85.5 m95 -130.73 168.26 17.48 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.808 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 58' ' ' VAL . . . . . 0.609 HG22 HG23 ' C' ' 47' ' ' VAL . 64.6 t -125.57 130.61 72.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.574 -178.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 59' ' ' GLY . . . . . 0.436 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -89.82 129.09 9.53 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 178.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 60' ' ' VAL . . . . . 0.418 HG13 HG21 ' C' ' 33' ' ' VAL . 66.9 t -122.47 132.56 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-O 121.135 0.493 . . . . 0.0 110.921 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 61' ' ' ILE . . . . . 0.514 HD11 ' CG ' ' C' ' 79' ' ' PHE . 45.7 mt -85.22 104.16 12.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.361 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 62' ' ' LEU . . . . . 0.442 ' O ' ' CD2' ' C' ' 85' ' ' HIS . 0.5 OUTLIER -84.83 115.67 22.87 Favored 'General case' 0 C--O 1.232 0.174 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.923 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 49.4 p30 -67.08 -9.08 35.68 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.289 -179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 64' ' ' GLU . . . . . 0.646 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.76 -37.54 87.04 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.296 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 65' ' ' ALA . . . . . 0.646 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 86.59 44.34 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.858 0.361 . . . . 0.0 110.672 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 66' ' ' LYS . . . . . 0.568 ' N ' ' O ' ' C' ' 84' ' ' GLY . 16.4 ptmt -146.68 106.95 4.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.076 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 155.96 -140.57 7.36 Favored Glycine 0 CA--C 1.52 0.352 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 -179.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 68' ' ' LYS . . . . . 0.43 ' O ' ' O ' ' C' ' 85' ' ' HIS . 7.9 mmtm -95.88 -174.74 3.21 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.277 0.56 . . . . 0.0 110.447 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -112.02 96.72 6.21 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 114.688 -1.142 . . . . 0.0 110.68 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -60.78 -15.05 25.55 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.986 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 71' ' ' GLY . . . . . 0.659 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.4 -45.09 94.81 Favored Glycine 0 N--CA 1.449 -0.5 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 72' ' ' THR . . . . . 0.659 HG23 ' O ' ' C' ' 71' ' ' GLY . 21.2 p -163.25 115.19 1.49 Allowed 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 121.012 0.435 . . . . 0.0 110.711 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 73' ' ' VAL . . . . . 0.5 ' N ' ' O ' ' C' ' 76' ' ' ARG . 38.8 t -129.53 123.73 58.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.355 179.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 56.4 tt0 42.86 56.61 3.92 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.214 0.531 . . . . 0.0 111.336 179.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.3 4.76 6.85 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 76' ' ' ARG . . . . . 0.5 ' O ' ' N ' ' C' ' 73' ' ' VAL . 26.0 tpt180 -125.41 127.44 46.56 Favored 'General case' 0 N--CA 1.462 0.164 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 -179.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 26.7 pttm -112.56 137.97 50.02 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.213 0.53 . . . . 0.0 111.158 -179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 63.4 m-85 -93.13 -37.18 12.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.814 178.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 79' ' ' PHE . . . . . 0.514 ' CG ' HD11 ' C' ' 61' ' ' ILE . 50.5 t80 -172.6 153.39 2.8 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.323 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 80' ' ' THR . . . . . 0.45 ' N ' ' CD1' ' C' ' 79' ' ' PHE . 28.7 p -64.58 95.57 0.15 Allowed 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.48 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 81' ' ' CYS . . . . . 0.456 ' SG ' ' CG ' ' C' ' 85' ' ' HIS . 9.9 t -163.43 142.26 8.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.561 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -79.14 168.22 19.92 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.334 0.588 . . . . 0.0 110.819 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -46.36 150.47 0.63 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.879 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 84' ' ' GLY . . . . . 0.568 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 105.06 -8.54 45.57 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 85' ' ' HIS . . . . . 0.595 ' ND1' ' N ' ' C' ' 85' ' ' HIS . 0.2 OUTLIER -136.06 136.04 39.89 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.8 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.75 59.61 0.2 Allowed Glycine 0 C--N 1.337 0.596 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 51.0 mm -85.74 133.0 30.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 178.561 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -82.28 119.06 23.63 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.156 0.503 . . . . 0.0 110.064 -179.204 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 89' ' ' VAL . . . . . 0.496 HG21 ' CG2' ' C' ' 94' ' ' ILE . 5.0 m -139.73 164.86 23.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.104 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 90' ' ' ARG . . . . . 0.568 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -97.12 166.71 11.45 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.939 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 91' ' ' GLN . . . . . 0.67 HE21 ' CG2' ' C' ' 47' ' ' VAL . 26.1 mp0 -59.61 -42.88 93.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.764 0.316 . . . . 0.0 110.735 -178.653 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 64.2 m -62.79 -36.03 81.79 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.379 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 16.8 tt0 -63.96 -35.93 82.29 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.444 -178.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 94' ' ' ILE . . . . . 0.544 ' CD1' HD11 ' C' ' 27' ' ' LEU . 35.4 pt -101.27 144.41 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.881 0.372 . . . . 0.0 110.59 179.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 95' ' ' GLN . . . . . 0.458 ' OE1' HD13 ' C' ' 27' ' ' LEU . 96.9 mt-30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.946 -1.026 . . . . 0.0 111.113 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo . . . . . 0 N--CA 1.485 1.02 0 N-CA-C 109.094 -1.156 . . . . 0.0 109.094 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 27' ' ' LEU . . . . . 0.635 ' H ' HD23 ' C' ' 27' ' ' LEU . 0.2 OUTLIER -81.92 168.25 18.1 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.771 179.857 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 80.1 mtp85 -120.85 147.34 45.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.354 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -57.01 141.92 13.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.217 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 100.75 -18.04 55.58 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 83.8 p -81.54 163.13 22.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.964 0.411 . . . . 0.0 110.923 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -50.66 153.36 1.7 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.935 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 33' ' ' VAL . . . . . 0.722 HG12 ' C ' ' C' ' 42' ' ' GLY . 12.3 p -125.39 149.77 30.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.939 0.399 . . . . 0.0 111.047 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -150.43 92.79 1.9 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 80.2 t -67.47 131.28 33.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.06 -179.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 36' ' ' ILE . . . . . 0.47 HG22 ' O ' ' C' ' 36' ' ' ILE . 42.5 mm -75.62 74.57 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.293 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -120.47 0.54 Allowed Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.819 -0.913 . . . . 0.0 110.819 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -59.61 -27.19 66.09 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.021 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.14 44.98 1.04 Allowed Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 93.3 m-70 -75.34 141.73 43.29 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 40.0 ptt180 -129.3 165.78 20.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.174 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 42' ' ' GLY . . . . . 0.722 ' C ' HG12 ' C' ' 33' ' ' VAL . . . 151.37 -130.28 3.11 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.129 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 94.4 m -131.91 140.98 49.22 Favored 'General case' 0 C--O 1.244 0.78 0 CA-C-O 121.119 0.485 . . . . 0.0 111.56 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 44' ' ' VAL . . . . . 0.441 HG13 ' CG1' ' C' ' 58' ' ' VAL . 97.2 t -75.78 133.16 31.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.839 179.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 45' ' ' ALA . . . . . 0.596 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -85.59 -159.6 0.46 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.967 0.413 . . . . 0.0 110.519 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 46' ' ' TYR . . . . . 0.426 ' CE2' ' O ' ' C' ' 47' ' ' VAL . 84.6 t80 -65.34 144.89 56.82 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.171 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 47' ' ' VAL . . . . . 0.534 HG12 HG22 ' C' ' 58' ' ' VAL . 19.2 m -118.42 154.15 20.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.969 -179.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 109.93 179.4 20.88 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 49' ' ' ALA . . . . . 0.613 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.53 149.36 49.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.089 0.471 . . . . 0.0 110.366 179.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 50' ' ' THR . . . . . 0.463 HG23 ' H ' ' C' ' 53' ' ' ALA . 7.6 t -149.22 174.98 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.698 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 86.3 mt -60.96 -39.45 89.6 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.603 -179.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 52' ' ' PHE . . . . . 0.495 ' CD2' ' CZ ' ' C' ' 88' ' ' PHE . 91.9 t80 -59.22 -46.59 88.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.612 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 53' ' ' ALA . . . . . 0.463 ' H ' HG23 ' C' ' 50' ' ' THR . . . -149.28 140.16 22.82 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.789 0.328 . . . . 0.0 110.412 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 72.7 p -83.74 168.91 15.78 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.405 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 55' ' ' GLY . . . . . 0.613 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 89.14 -153.51 23.63 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 56.6 mtmt -110.88 108.78 18.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.881 0.372 . . . . 0.0 110.478 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 83.8 m95 -134.0 161.38 34.97 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.021 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 58' ' ' VAL . . . . . 0.534 HG22 HG12 ' C' ' 47' ' ' VAL . 87.6 t -128.82 130.57 68.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.311 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 59' ' ' GLY . . . . . 0.596 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -90.43 136.15 13.27 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 60' ' ' VAL . . . . . 0.413 ' CG1' HG21 ' C' ' 33' ' ' VAL . 92.3 t -130.42 134.47 62.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.269 0.557 . . . . 0.0 111.334 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 6.3 pt -85.22 114.59 25.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 120.058 -0.657 . . . . 0.0 110.603 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 62' ' ' LEU . . . . . 0.614 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.7 OUTLIER -92.23 125.56 36.95 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.936 0.398 . . . . 0.0 110.666 -179.997 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -67.53 -11.56 58.29 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.618 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 64' ' ' GLU . . . . . 0.651 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 79.8 mm-40 -61.16 -32.7 72.42 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.436 179.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 65' ' ' ALA . . . . . 0.651 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 86.9 35.85 0.02 OUTLIER 'General case' 0 C--N 1.34 0.185 0 O-C-N 123.504 0.503 . . . . 0.0 110.658 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 66' ' ' LYS . . . . . 0.537 ' N ' ' O ' ' C' ' 84' ' ' GLY . 65.0 pttt -134.98 136.46 42.21 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.12 -146.54 17.15 Favored Glycine 0 N--CA 1.461 0.313 0 N-CA-C 110.689 -0.965 . . . . 0.0 110.689 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 4.3 mmtm -97.5 -170.16 1.96 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.186 0.517 . . . . 0.0 110.351 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 69' ' ' ASN . . . . . 0.462 ' ND2' ' O ' ' C' ' 72' ' ' THR . 23.2 p-10 -114.46 99.47 7.58 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.749 -179.501 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 75.4 m-20 -60.31 -16.99 39.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 179.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 71' ' ' GLY . . . . . 0.655 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.7 -43.14 96.52 Favored Glycine 0 C--O 1.226 -0.359 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 72' ' ' THR . . . . . 0.655 HG23 ' O ' ' C' ' 71' ' ' GLY . 18.8 p -161.9 112.62 1.62 Allowed 'General case' 0 CA--C 1.517 -0.302 0 CA-C-O 120.713 0.292 . . . . 0.0 110.765 179.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 73' ' ' VAL . . . . . 0.509 ' O ' ' N ' ' C' ' 76' ' ' ARG . 41.6 t -127.53 123.26 61.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.233 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 74' ' ' GLN . . . . . 0.404 ' C ' ' H ' ' C' ' 76' ' ' ARG . 71.2 tp60 43.5 57.01 4.11 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.365 0.602 . . . . 0.0 110.601 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 61.78 4.81 6.08 Favored Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 76' ' ' ARG . . . . . 0.509 ' N ' ' O ' ' C' ' 73' ' ' VAL . 46.7 tpt85 -125.16 126.8 45.83 Favored 'General case' 0 CA--C 1.518 -0.27 0 N-CA-C 110.172 -0.306 . . . . 0.0 110.172 -179.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 77' ' ' LYS . . . . . 0.491 ' O ' ' NH1' ' C' ' 76' ' ' ARG . 63.2 pttt -108.93 137.98 46.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.879 179.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 51.8 m-85 -99.91 -31.24 11.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.8 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -171.58 151.0 2.85 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.388 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 43.0 p -64.19 98.16 0.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.942 0.401 . . . . 0.0 110.822 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 81' ' ' CYS . . . . . 0.412 ' O ' ' N ' ' C' ' 71' ' ' GLY . 4.1 t -168.91 142.92 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.432 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -84.07 170.56 13.75 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.525 0.679 . . . . 0.0 110.591 179.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -44.82 152.64 0.22 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.989 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 84' ' ' GLY . . . . . 0.537 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.18 -7.76 56.95 Favored Glycine 0 CA--C 1.522 0.48 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -179.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 85' ' ' HIS . . . . . 0.614 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 7.0 m-70 -140.02 134.23 31.13 Favored 'General case' 0 C--O 1.24 0.564 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.7 58.47 0.16 Allowed Glycine 0 C--N 1.337 0.633 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 179.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.7 mm -83.27 131.23 34.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 88' ' ' PHE . . . . . 0.495 ' CZ ' ' CD2' ' C' ' 52' ' ' PHE . 97.4 m-85 -79.42 118.99 21.81 Favored 'General case' 0 C--N 1.329 -0.314 0 C-N-CA 120.413 -0.515 . . . . 0.0 110.79 -178.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 89' ' ' VAL . . . . . 0.475 ' O ' ' N ' ' C' ' 58' ' ' VAL . 12.1 m -141.52 163.47 20.34 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.262 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 90' ' ' ARG . . . . . 0.572 ' HD3' ' H ' ' C' ' 90' ' ' ARG . 0.2 OUTLIER -90.29 154.33 19.79 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.116 0.484 . . . . 0.0 110.841 179.788 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 91' ' ' GLN . . . . . 0.407 ' O ' ' O ' ' C' ' 94' ' ' ILE . 18.1 pt20 -52.54 -38.65 60.21 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.467 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 89.2 p -67.7 -33.32 74.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.096 0.474 . . . . 0.0 110.657 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -66.66 -21.21 66.11 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.594 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 94' ' ' ILE . . . . . 0.432 ' CG2' HG21 ' C' ' 89' ' ' VAL . 39.0 pt -117.24 146.65 21.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.642 -179.814 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_endo . . . . . 0 N--CA 1.483 0.859 0 N-CA-C 109.03 -1.181 . . . . 0.0 109.03 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 27' ' ' LEU . . . . . 0.797 ' H ' HD23 ' C' ' 27' ' ' LEU . 2.2 pt? -85.8 170.57 12.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.334 179.501 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 28' ' ' ARG . . . . . . . . . . . . . 90.6 mtm-85 -125.73 147.93 49.22 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.418 0.627 . . . . 0.0 110.57 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 29' ' ' VAL . . . . . 0.423 HG23 ' O ' ' C' ' 45' ' ' ALA . 2.9 p -57.63 142.5 13.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.257 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 103.2 -18.78 47.99 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.114 -0.794 . . . . 0.0 111.114 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . 0.742 ' O ' HG23 ' C' ' 44' ' ' VAL . 37.0 t -90.36 164.63 14.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.475 0.179 . . . . 0.0 110.523 179.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 32' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -60.75 161.03 8.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.207 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 33' ' ' VAL . . . . . 0.541 ' HB ' HG22 ' C' ' 44' ' ' VAL . 0.2 OUTLIER -133.67 151.09 32.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.806 -179.419 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -141.98 91.39 2.34 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.302 177.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 35' ' ' VAL . . . . . . . . . . . . . 93.7 t -61.82 131.8 27.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 CA-C-O 121.116 0.484 . . . . 0.0 110.633 -179.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -77.61 88.65 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.416 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.95 -126.1 0.8 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -67.03 -12.58 60.31 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.619 -0.291 . . . . 0.0 110.927 179.066 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 109.04 60.34 0.53 Allowed Glycine 0 CA--C 1.52 0.395 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 40' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -105.68 143.68 33.49 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.982 0.42 . . . . 0.0 110.6 179.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 41' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -145.78 165.94 27.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.755 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 42' ' ' GLY . . . . . . . . . . . . . . . 175.11 -125.76 1.11 Allowed Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 96.4 m -127.8 136.39 51.4 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 120.715 0.293 . . . . 0.0 111.057 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 44' ' ' VAL . . . . . 0.742 HG23 ' O ' ' C' ' 31' ' ' SER . 43.1 t -72.51 128.89 35.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 45' ' ' ALA . . . . . 0.462 ' HB3' ' O ' ' C' ' 59' ' ' GLY . . . -94.82 -159.04 0.68 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.314 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -65.49 141.34 58.52 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.133 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 47' ' ' VAL . . . . . 0.519 HG23 HG22 ' C' ' 58' ' ' VAL . 6.2 p -121.03 133.32 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.394 -179.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 136.05 -174.05 21.6 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 49' ' ' ALA . . . . . 0.436 ' CA ' ' O ' ' C' ' 55' ' ' GLY . . . -71.21 152.23 43.56 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.874 0.369 . . . . 0.0 110.272 179.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 50' ' ' THR . . . . . 0.669 HG23 ' H ' ' C' ' 53' ' ' ALA . 1.7 t -146.19 166.56 25.84 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.827 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 51' ' ' LEU . . . . . 0.518 HD12 ' N ' ' C' ' 51' ' ' LEU . 10.5 mp -60.67 -38.58 85.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.167 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 52' ' ' PHE . . . . . 0.529 ' N ' ' OE1' ' C' ' 74' ' ' GLN . 92.4 t80 -59.89 -44.76 94.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.206 179.148 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 53' ' ' ALA . . . . . 0.669 ' H ' HG23 ' C' ' 50' ' ' THR . . . -145.5 144.28 30.47 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.511 179.651 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 99.1 m -98.44 132.83 43.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.546 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 55' ' ' GLY . . . . . 0.436 ' O ' ' CA ' ' C' ' 49' ' ' ALA . . . 136.98 -147.69 19.37 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -124.26 96.17 4.82 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 36.6 m95 -122.94 162.98 21.25 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.986 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 58' ' ' VAL . . . . . 0.519 HG22 HG23 ' C' ' 47' ' ' VAL . 59.2 t -125.15 128.27 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.773 -179.252 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 59' ' ' GLY . . . . . 0.462 ' O ' ' HB3' ' C' ' 45' ' ' ALA . . . -84.54 136.85 15.08 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 109.691 -1.363 . . . . 0.0 109.691 179.003 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 73.4 t -123.39 133.9 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 121.037 0.446 . . . . 0.0 111.038 -178.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 16.4 mm -87.06 93.28 4.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.811 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 62' ' ' LEU . . . . . 0.617 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.6 OUTLIER -76.03 120.14 20.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.546 -179.409 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 63' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -67.85 -11.94 59.63 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.837 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 64' ' ' GLU . . . . . 0.657 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.7 mm-40 -63.37 -34.25 77.32 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.476 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 65' ' ' ALA . . . . . 0.657 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 83.42 47.18 0.02 OUTLIER 'General case' 0 C--N 1.338 0.105 0 O-C-N 123.322 0.389 . . . . 0.0 110.748 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 66' ' ' LYS . . . . . 0.552 ' N ' ' O ' ' C' ' 84' ' ' GLY . 13.4 ptpt -146.84 109.21 4.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.387 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 156.53 -140.5 7.25 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.449 -1.061 . . . . 0.0 110.449 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 68' ' ' LYS . . . . . . . . . . . . . 15.7 mmtt -97.19 -173.36 2.65 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.919 0.39 . . . . 0.0 110.125 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 69' ' ' ASN . . . . . . . . . . . . . 42.3 p-10 -113.95 98.01 6.73 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.576 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 70' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 -61.65 -17.37 55.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.375 179.246 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 71' ' ' GLY . . . . . 0.66 ' O ' HG23 ' C' ' 72' ' ' THR . . . -58.93 -43.1 97.0 Favored Glycine 0 N--CA 1.451 -0.34 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 72' ' ' THR . . . . . 0.66 HG23 ' O ' ' C' ' 71' ' ' GLY . 19.1 p -161.41 118.09 2.2 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 120.513 0.197 . . . . 0.0 110.636 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 73' ' ' VAL . . . . . 0.623 ' O ' ' N ' ' C' ' 76' ' ' ARG . 12.7 t -128.31 125.68 64.53 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 74' ' ' GLN . . . . . 0.529 ' OE1' ' N ' ' C' ' 52' ' ' PHE . 3.4 pt20 39.55 36.79 0.25 Allowed 'General case' 0 C--N 1.328 -0.364 0 O-C-N 123.148 0.28 . . . . 0.0 111.323 179.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 89.03 -19.56 37.78 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 76' ' ' ARG . . . . . 0.623 ' N ' ' O ' ' C' ' 73' ' ' VAL . 59.9 ttt85 -101.96 126.25 48.83 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.1 pttt -106.83 132.32 52.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.491 0.662 . . . . 0.0 111.209 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 78' ' ' TYR . . . . . 0.546 ' OH ' HG21 ' C' ' 50' ' ' THR . 3.1 m-85 -84.26 -40.65 17.77 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.063 178.268 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 79' ' ' PHE . . . . . 0.409 ' CG ' ' N ' ' C' ' 80' ' ' THR . 86.8 t80 -170.87 158.19 5.75 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.467 -179.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 80' ' ' THR . . . . . 0.409 ' N ' ' CG ' ' C' ' 79' ' ' PHE . 82.7 p -64.12 96.95 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.975 0.417 . . . . 0.0 111.029 -179.499 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 1.6 t -167.31 144.9 4.65 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.305 179.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -86.57 169.45 12.75 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.191 0.519 . . . . 0.0 110.887 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -46.71 149.93 0.77 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.185 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 84' ' ' GLY . . . . . 0.552 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 101.36 -7.11 56.14 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.433 -1.067 . . . . 0.0 110.433 -178.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 85' ' ' HIS . . . . . 0.617 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 6.3 m-70 -139.15 132.82 30.56 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.093 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 125.9 58.57 0.16 Allowed Glycine 0 C--N 1.333 0.408 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 40.9 mm -82.34 132.39 31.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 88' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -83.66 116.68 22.76 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.482 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 89' ' ' VAL . . . . . 0.482 HG21 ' CG2' ' C' ' 94' ' ' ILE . 4.3 m -140.21 160.01 25.76 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.28 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.911 178.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 90' ' ' ARG . . . . . 0.658 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 1.0 OUTLIER -85.97 162.62 18.44 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 120.791 0.329 . . . . 0.0 110.758 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 91' ' ' GLN . . . . . 0.455 ' O ' ' O ' ' C' ' 94' ' ' ILE . 96.0 mt-30 -59.31 -41.2 88.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.597 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 40.0 t -61.53 -37.99 85.78 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.432 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 -63.2 -33.88 76.44 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.565 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 94' ' ' ILE . . . . . 0.627 ' CD1' HD11 ' C' ' 27' ' ' LEU . 34.1 pt -105.01 149.13 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 121.082 0.468 . . . . 0.0 110.799 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.596 179.826 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 26' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 N--CA 1.485 0.976 0 N-CA-C 109.287 -1.082 . . . . 0.0 109.287 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 27' ' ' LEU . . . . . 0.616 HD23 ' N ' ' C' ' 28' ' ' ARG . 1.3 tt -112.41 120.57 42.14 Favored 'General case' 0 CA--C 1.534 0.353 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 28' ' ' ARG . . . . . 0.616 ' N ' HD23 ' C' ' 27' ' ' LEU . 96.1 mtm-85 -73.79 127.01 31.68 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-O 120.969 0.414 . . . . 0.0 110.369 -179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 29' ' ' VAL . . . . . . . . . . . . . 2.0 p -67.14 140.32 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 CA-C-O 121.361 0.601 . . . . 0.0 111.058 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.07 -16.38 57.23 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.032 -178.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . 0.778 ' O ' HG12 ' C' ' 44' ' ' VAL . 81.5 p -80.36 165.38 22.32 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.918 0.39 . . . . 0.0 111.606 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 32' ' ' ARG . . . . . 0.684 ' NE ' HH21 ' C' ' 41' ' ' ARG . 99.7 mtt180 -68.67 156.21 38.61 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.473 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 33' ' ' VAL . . . . . 0.451 HG22 ' C ' ' C' ' 42' ' ' GLY . 2.2 m -130.82 156.3 42.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.321 0 CA-C-O 121.216 0.531 . . . . 0.0 110.445 -179.707 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 34' ' ' GLU . . . . . . . . . . . . . 77.4 mm-40 -139.39 99.41 3.73 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 177.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 35' ' ' VAL . . . . . 0.412 ' HA ' HG22 ' C' ' 94' ' ' ILE . 74.1 t -62.37 130.3 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.419 0 CA-C-N 116.301 -0.409 . . . . 0.0 109.943 -178.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 36' ' ' ILE . . . . . 0.471 HG22 ' O ' ' C' ' 36' ' ' ILE . 96.9 mt -75.0 76.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 C-N-CA 120.021 -0.672 . . . . 0.0 109.804 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -161.37 -125.36 0.77 Allowed Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 38' ' ' LYS . . . . . . . . . . . . . 65.4 pttt -60.01 -20.02 55.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.592 -0.304 . . . . 0.0 110.579 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 39' ' ' GLY . . . . . . . . . . . . . . . 103.44 54.99 0.81 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 40' ' ' HIS . . . . . 0.431 ' CE1' ' H ' ' C' ' 63' ' ' ASP . 66.7 t-80 -87.32 137.4 32.38 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.218 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 41' ' ' ARG . . . . . 0.684 HH21 ' NE ' ' C' ' 32' ' ' ARG . 78.0 ttt-85 -110.09 139.43 45.22 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.13 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 42' ' ' GLY . . . . . 0.451 ' C ' HG22 ' C' ' 33' ' ' VAL . . . -172.14 -170.8 36.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 43' ' ' THR . . . . . . . . . . . . . 95.1 m -114.18 131.55 56.41 Favored 'General case' 0 C--O 1.24 0.602 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 44' ' ' VAL . . . . . 0.778 HG12 ' O ' ' C' ' 31' ' ' SER . 1.3 p -69.49 139.6 20.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.294 -179.768 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 45' ' ' ALA . . . . . . . . . . . . . . . -96.17 -156.88 0.55 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.375 -0.829 . . . . 0.0 109.274 178.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 46' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -63.66 142.37 58.42 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.201 0.524 . . . . 0.0 110.221 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 47' ' ' VAL . . . . . 0.625 HG12 HG22 ' C' ' 58' ' ' VAL . 19.7 m -118.8 153.58 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.285 -178.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 48' ' ' GLY . . . . . . . . . . . . . . . 116.96 -175.83 15.91 Favored Glycine 0 CA--C 1.53 1.017 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 49' ' ' ALA . . . . . 0.715 ' HB2' ' O ' ' C' ' 55' ' ' GLY . . . -68.13 141.2 56.14 Favored 'General case' 0 CA--C 1.529 0.154 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 50' ' ' THR . . . . . . . . . . . . . 60.3 p -137.69 167.7 21.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.289 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 51' ' ' LEU . . . . . . . . . . . . . 59.5 tp -59.86 -41.16 90.84 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 52' ' ' PHE . . . . . 0.462 ' CE1' ' NZ ' ' C' ' 68' ' ' LYS . 88.8 t80 -58.74 -46.0 88.41 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.274 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 53' ' ' ALA . . . . . . . . . . . . . . . -142.39 140.94 32.2 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.964 0.412 . . . . 0.0 110.677 179.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 54' ' ' THR . . . . . . . . . . . . . 68.3 p -84.44 167.63 16.25 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.745 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 55' ' ' GLY . . . . . 0.715 ' O ' ' HB2' ' C' ' 49' ' ' ALA . . . 87.1 -133.35 11.74 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 56' ' ' LYS . . . . . . . . . . . . . 20.4 pttp -131.18 114.68 15.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.524 0.678 . . . . 0.0 110.513 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 57' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -137.52 156.04 48.57 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.45 179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 58' ' ' VAL . . . . . 0.625 HG22 HG12 ' C' ' 47' ' ' VAL . 82.1 t -119.36 130.06 74.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.441 -179.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.37 135.49 12.91 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.395 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 60' ' ' VAL . . . . . . . . . . . . . 75.1 t -125.94 132.69 70.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.07 0.462 . . . . 0.0 111.374 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 61' ' ' ILE . . . . . . . . . . . . . 9.5 pt -83.5 95.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.561 0.696 . . . . 0.0 110.196 178.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 62' ' ' LEU . . . . . 0.579 ' O ' ' ND1' ' C' ' 85' ' ' HIS . 0.4 OUTLIER -70.12 120.82 16.38 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.335 -179.321 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 63' ' ' ASP . . . . . 0.431 ' H ' ' CE1' ' C' ' 40' ' ' HIS . 98.0 m-20 -67.61 -11.1 57.39 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.4 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 64' ' ' GLU . . . . . 0.657 ' O ' ' HB3' ' C' ' 65' ' ' ALA . 80.4 mm-40 -62.19 -35.79 79.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.179 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 65' ' ' ALA . . . . . 0.657 ' HB3' ' O ' ' C' ' 64' ' ' GLU . . . 87.05 39.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.962 0.41 . . . . 0.0 110.397 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 66' ' ' LYS . . . . . 0.512 ' N ' ' O ' ' C' ' 84' ' ' GLY . 21.3 ptmt -135.6 135.56 40.34 Favored 'General case' 0 CA--C 1.521 -0.155 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.59 179.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.21 -146.79 16.45 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 68' ' ' LYS . . . . . 0.462 ' NZ ' ' CE1' ' C' ' 52' ' ' PHE . 17.5 ptpt -98.47 -168.0 1.58 Allowed 'General case' 0 C--O 1.238 0.452 0 CA-C-O 120.941 0.4 . . . . 0.0 110.736 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 69' ' ' ASN . . . . . 0.422 ' O ' ' CG2' ' C' ' 73' ' ' VAL . 40.6 p-10 -111.8 105.42 13.89 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.56 -179.468 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 70' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' C' ' 85' ' ' HIS . 0.9 OUTLIER -63.93 -11.46 28.44 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.899 178.515 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 71' ' ' GLY . . . . . 0.667 ' O ' HG23 ' C' ' 72' ' ' THR . . . -60.29 -42.92 98.97 Favored Glycine 0 N--CA 1.45 -0.383 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 72' ' ' THR . . . . . 0.667 HG23 ' O ' ' C' ' 71' ' ' GLY . 20.4 p -163.91 115.38 1.36 Allowed 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 123.838 0.376 . . . . 0.0 110.683 179.641 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 73' ' ' VAL . . . . . 0.422 ' CG2' ' O ' ' C' ' 69' ' ' ASN . 16.8 t -131.12 119.02 43.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 74' ' ' GLN . . . . . . . . . . . . . 96.8 mm-40 52.35 35.16 16.52 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.558 0.218 . . . . 0.0 111.441 179.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.62 -1.7 81.71 Favored Glycine 0 CA--C 1.517 0.195 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 76' ' ' ARG . . . . . 0.405 ' O ' ' N ' ' C' ' 73' ' ' VAL . 28.1 tpt180 -115.98 123.85 49.04 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.244 -0.478 . . . . 0.0 109.75 179.494 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 77' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -109.7 136.33 49.22 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-O 121.272 0.558 . . . . 0.0 110.645 -179.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 78' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -93.66 -37.23 11.95 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.597 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 79' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -170.56 149.18 3.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.279 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 80' ' ' THR . . . . . . . . . . . . . 31.0 p -64.3 101.48 0.43 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.888 0.375 . . . . 0.0 111.615 -178.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 81' ' ' CYS . . . . . . . . . . . . . 4.0 t -171.19 146.97 2.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.307 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 82' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -78.65 168.63 19.47 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.432 0.634 . . . . 0.0 110.717 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 83' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -43.57 157.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.307 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 84' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' C' ' 66' ' ' LYS . . . 97.86 -8.15 63.29 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 85' ' ' HIS . . . . . 0.579 ' ND1' ' O ' ' C' ' 62' ' ' LEU . 30.7 m-70 -137.61 144.49 41.97 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.6 60.4 0.49 Allowed Glycine 0 N--CA 1.467 0.718 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 87' ' ' ILE . . . . . . . . . . . . . 50.7 mm -93.77 127.37 45.86 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 88' ' ' PHE . . . . . 0.537 ' O ' ' CD2' ' C' ' 88' ' ' PHE . 49.0 p90 -77.34 119.7 21.33 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.276 0.56 . . . . 0.0 110.091 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 89' ' ' VAL . . . . . 0.412 ' O ' ' HB ' ' C' ' 58' ' ' VAL . 4.0 p -143.44 140.41 26.24 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.728 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 178.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 90' ' ' ARG . . . . . 0.651 ' H ' ' HD2' ' C' ' 90' ' ' ARG . 0.7 OUTLIER -65.59 151.52 46.28 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.954 -0.298 . . . . 0.0 110.925 -177.774 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 91' ' ' GLN . . . . . 0.599 ' CD ' ' H ' ' C' ' 91' ' ' GLN . 3.8 pm0 -57.87 -33.75 69.02 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.836 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 92' ' ' SER . . . . . . . . . . . . . 81.7 p -64.95 -36.81 85.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.349 . . . . 0.0 110.849 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 93' ' ' GLN . . . . . . . . . . . . . 21.1 mm-40 -67.59 -20.68 65.4 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.021 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 94' ' ' ILE . . . . . 0.455 ' O ' ' O ' ' C' ' 91' ' ' GLN . 24.3 pt -117.65 148.72 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.88 0.371 . . . . 0.0 110.142 179.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 95' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.583 -179.608 . . . . . . . . 0 0 . 1 stop_ save_